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Siempre han intentado sacarme una sonrisa en los peores momentos, haciéndome sentir 
querida, valorada y apoyada. Aunque no entendierais porque tenía que trabajar los fines 
de semana o porque no podía ir a las quedadas o a los festivales que tanto nos gustan, 
siempre me comprendíais y teníais una propuesta alternativa para poder vernos. Después 
de mil horas en el laboratorio, sentir que tus amigos van a estar para lo que necesites, ya 
sea en persona o por teléfono (no me olvido de las personas que se han preocupado por 
mí a km de distancia), es algo que os agradeceré eternamente. Mil veces gracias. 
Y por último, me gustaría dar las gracias a mis grandes pilares durante este largo camino... 
En primer lugar, gracias a mis padres, por estar siempre a mi lado y apoyarme en todas 
mis decisiones. Por aguantarme y reconfortarme en mis peores momentos. Nunca os 
podré agradecer tanta dedicación y cariño. Desde pequeña me habéis hecho sentir lo 
orgullosos que estabais de mí y que podía conseguir todo lo que me propusiera. Gracias 
por vuestro esfuerzo para abrirme las puertas de mi futuro.  
 
En segundo lugar, gracias a Fran. Gracias por aparecer en mis peores momentos, quedarte 
y cambiar mi mundo. Has sido mi vía de escape durante este largo camino. Tus palabras 
de ánimo, cariño, paciencia, comprensión y tus abrazos interminables son algo que no 
olvidaré nunca…"si no confías en ti, confía en el mí que cree en ti". Te debo muchísimo. 
Gracias por ser mi calma en la tempestad. 
 
Y por último, esta tesis se la quiero dedicar a mi hermana, a mi ejemplo a seguir. Gracias 
por agarrarme fuerte de la mano y no soltarme nunca. Desde pequeña siempre me has 
enseñado que con esfuerzo, dedicación y trabajo todo se puede conseguir, y por eso una 
parte de esta tesis es tuya. Eres ese ave fénix que resurge de sus cenizas con más fuerza 
todavía. Hasta en tus peores momentos te sigues preocupando por mí y sigues haciéndome 
sentir la persona más fuerte y con más suerte del mundo. Nunca dudes de todo lo que eres 





































Aa = Amino acid 
ACN = Acetonitrile 
AGM = Aminoglutethimide 
AMI = Acute myocardial infarction 
AMM = Activated monomer mechanism  
APIs = Active pharmaceutical ingredients 
Ar = Argon 
Asp = Aspartate 
ATRA = All-trans retinoic acid 
Au-3MPS = Sodium 3-mercapto-1-propane sulfonate  
BBB = Blood-brain barrier 
BG = Benzyl-L-glutamate 
BSA = Bovine serum albumin  
CAC = Critical aggregation concentration 
cAMP = Cyclic adenosine monophosphate 
Cat. B = Cathepsin B  
CD = Circular dichroism  
Ck = Cytokeratin 
CMC = Critical micelle concentration 
COX-2 = Cyclooxygenase-II  
CVD = Cardiovascular diseases 
Cy5.5 = Cyanine 5.5 
Ð = Polydispersity 
Da = Dalton 
DC = Diffusion coefficient 
DCM = Dichloromethane 
DCs = Dendritic cells  
ddH2O = MilliQ water 
DHA = Docosahexaenoic acid  
diDHA = Didocosahexaenoic acid  
DIEA = N,N-Diisopropylethylamine  
Dil = 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine Perchlorate 
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DLS = Dynamic light scattering  
DMAP = 4-Dimethylaminopyridine 
DMEM = Dulbecco's Modified Eagle's Medium 
DMF = N,N'-Dimethyl formamide  
DMSO = Dimethyl sulphoxide  
DMTMM = 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4- methylmorpholinium  
dn/dc = Refractive index increment 
DNA = Deoxyribonucleic acid  
Dox = Doxorubicin 
DP = Degree of polymerization  
E.E = Encapsulation efficiency 
ECM = Extracellular matrix 
EDC = 1-Ethyl-3-(-3-dimethylaminopropyl) carbodiimide  
EGF = Epidermal growth factor 
EGFR = Epidermal growth factor receptor  
EPA = Eicosapentaenoic acid  
EPR = Enhanced permeability and retention 
eq. = Equivalents 
FBS = Fetal bovine serum  
FD = Free drug 
FDA = Food and drug administration 
FLUO = Fluocinolone acetonide 
F-NALP = Fusogenic nucleic acid lipid particle  
FPLC = Fast protein liquid chromatography 
GAU = Glutamic acid units 
G-CSF = Granulocyte-colony stimulating factor 
GFLG = Gly-Phe-Leu-Gly 
GLFG = Gly-Leu-Phe-Gly 
Gly = Glycine 
GPC = Gel permeation chromatography  
GPR120 = G-protein-coupled receptor 120 
H&E = Hematoxilin-Eosin 
HA = Hyaluronic acid 
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HAase = Hyaluronidase 
HaCaT= Human immortalized non-tumorigenic keratinocyte cell line 
HA-CP = Hyaluronic acid-poly-L-glutamate cross-polymer 
hGH = Human growth hormone 
HIH = National institute of health 
HIV-1 = Human immunodeficiency virus type 1 
HPLC = High pressure liquid chromatography  
HPMA = Poly-N-hydroxypropyl methacrylamide  
I/R = Ischemia-reperfusion  
ICAM-1 = Intercellular adhesion molecule 1 
Ig = Immunoglobulin 
IKK = IkB kinase (IKK) 
IL = Interleukin 
IMQ = Imiquimod 
INF-γ = Interferon gamma 
IPA = Isopropanol 
K = Keratins 
kDa = Kilodalton  
kHz = Kilohertz  
LbL = Layer-by-layer  
LCMS = Liquid chromatography–mass spectrometry 
Leu = Leucine 
LPS = Lipopolysaccharide 
Lys = L-lysine 
MDA = Malondialdehyde 
mDCs = Dermal myeloid DCs  
MeOH = Methanol 
moDCs = Monocyte derived denditric cells 
MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium  
Mw = Molecular weight 
MWCO = Molecular weight cut-off 
N2  = Nitrogen  
NAM = Normal amine mechanism 
NCA = N-carboxyanhydride 
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NCS = Neocarzinostatin 
NF-kB = Nuclear factor kappa beta 
nm = Nanometer 
NMR = Nuclear Magnetic Resonance  
OCT = Optimum cutting temperature 
OG = Oregon green 488 cadaverine 
PAMAM = Polyamidoamine 
PASI = Psoriasis Area Severity Index 
PB = Phosphate buffer  
PBG = Poly-benzyl-L-glutamate  
PBS = Phosphate-buffered saline 
pDC = Plasmacytoid dendritic cells 
PDEPT = Polymer-directed enzyme prodrug therapy 
PDI = Polydispersity index 
PDT = Photodynamic therapy  
PEG = Polyethylene glycol 
PELT = Polymer-enzyme liposome therapy 
PFA = Paraformaldehyde 
PGA = Poly(L-glutamic acid) 
Phe = Phenylalanine 
PLGA = Poly-lactic-co-glycolic acid 
PPhe = Poly-L-phenylalanine  
PPP = Palmoplantar pustulosis 
PTS = Polypeptide Therapeutic Solutions S.L. 
PTX = Paclitaxel 
PUFAs = Polyunsaturated fatty acids 
PUVA = Ultraviolet A plus psoralen 
PVA = Polyvinyl alcohol 
PVP = Polyvinyl pyrrolidone 
r.t. = Room temperature  
Rf = Retention factor  
Rh = Hydrodynamic radius 
RI = Refraction Index 
RMN = Nuclear Magnetic Resonance  
25 
 
RNA = Ribonucleic acid 
ROP = Ring opening polymerization 
SANS = Small-angle neutron scattering  
SAXS = Small-angle X-ray scattering 
SC = Stratum corneum 
SEC = Size exclusion chromatography  
SEM = Standard error of the mean  
siRNA = Small interfering RNA 
SMA = Styrene-co-maleic acid 
ST = Star polymer 
STAT = Signal transducer and activator of transcription  
TBA = Thiobarbituric acid 
TBARS = Thiobarbituric acid reactive substance 
TDL = Total drug loading 
TEM = Transmission electron microscopy 
TFA-d1 = Deuterated trifluoroacetic acid 
TG = Total tryglyceride 
TLC = Thin-layer chromatography  
TLR = Toll-like receptors  
TNBSA = 2,4,6-Trinitrobenzene Sulfonic Acid 
TNF = Tumor necrosis factor 
TNFR1 = TNF receptor 1 (TNFR1) 
TTC = 2,3,5 Triphenyltetrazolium chloride 
UVA = Ultraviolet A 
UVB = Ultraviolet B 
UV-Vis = Ultraviolet-visible 
VCAM-1 = Vascular cell adhesion molecule 1 
w/w = Weight/weight  
w/v = Weight/volume 
WAXS = Wide angle X-ray scattering 



































Topical administration represents the main route to attain local therapeutic activity 
of bioactive agents in several organs, such as the skin or the heart by means of devices 
that enhance drug transport through the endothelium acting as a reservoir. 
The complex structure of the skin protects the human body against potentially 
harmful external agents; however, this protective mechanism inhibits the penetration of 
topically administering bioactive agents employed for the treatment of skin diseases. 
Unfortunately, many of the topical drugs currently used or under evaluation in clinical 
trials lack the appropriate physico-chemical characteristics required for delivery through 
the skin. However, various rational strategies have been employed in an attempt to 
improve the physico-chemical properties of bioactive agents according to the features of 
the desired site of action, thereby improving topical delivery and stability.  
The research carried out in this thesis describes the application of polymer 
therapeutics, a nanomedicinal approach, to improve the physico-chemical properties and 
increase both the penetration of bioactive agents through the skin and retention time at 
the desired site of action. Well-defined polypeptide-based polymer therapeutic 
approaches offer particular advantages for dermal applications such as biodegradability, 
versatility, multivalence, and high drug loading capacity. The development of new 
polypeptide-drug conjugates employing stimuli-responsive linking moieties can enhance 
transdermal drug delivery into the skin, thereby improving the effectiveness of topical 
treatments for skin diseases such as psoriasis. Furthermore, we believe that our newly 
developed platforms may find wider use, and we also explore polypeptide-drug 
combinations as an approach to enhance wound healing and treat ischemia/reperfusion 
injury following myocardial infarction. 
Psoriasis, a common and chronic inflammatory disease mediated by the immune 
system with predominantly cutaneous involvement, affects 2-3% of the adult population 
and 0.5-1% of children. Plaque psoriasis, the most prevalent type of psoriasis, is 
characterized by scaly skin, erythematous plaques, and inflammatory cell infiltration. 
Approximately 80% of patients are affected by mild to moderate disease, and topical 
treatment with corticosteroids remains a widely employed therapeutic approach. 
However, many topical corticosteroids that are currently employed or under assessment 
in clinical trials lack adequate physico-chemical properties and suffer from local 
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cutaneous and systemic side effects that correlate with the high doses required. Therefore, 
we propose the implementation of polymer conjugation approaches to overcome these 
limitations. 
The knowledge base regarding the pathogenesis of human psoriasis has recently 
widened thanks to the development of accurate ex vivo and in vivo models. We now 
present the detailed characterization of an inflammatory ex vivo human skin model, 
including the assessment of tissue viability, immunohistopathology, and the 
quantification of pro-inflammatory cytokine release. Additionally, we developed an in 
vivo preclinically relevant imiquimod (IMQ)-induced model of psoriasis that reflects the 
critical features of the human disease. Our findings demonstrated the suitability of this 
murine model to mimic the main hallmarks of human psoriasis, including inflamed skin 
and the presence of increased levels of psoriasis-associated inflammatory cytokines in 
tissue and serum.  
Furthermore, our newly described models permitted the evaluation of both the 
safety and therapeutic efficacy of our novel polypeptide-based therapeutics. To this end, 
we present the development of a biodegradable vehicle, comprising a cross-linked matrix 
of hyaluronic acid and poly-L-glutamic acid (hyaluronic acid-poly-L-glutamate cross-
polymer or HA-CP), for the topical delivery of the advanced therapeutic agents. We 
exhaustively characterized and biologically evaluated our HA-CP vehicle in vitro, ex 
vivo, and in vivo revealing multiple advantageous properties regarding the topical 
administration of therapeutics. Our HA-CP vehicle functioned as a penetration enhancer, 
using a family of amphiphilic block copolymers of different nature (using PPhe and PBG 
with different degree of polymerization) and physico-chemical properties, significantly 
promoting the penetration into the viable epidermis while avoiding the systemic 
absorption and any associated adverse effects. 
We also present a straightforward methodology for the synthesis of well-defined 
polypeptide-based drug conjugates based on poly-L-glutamic acid, or PGA, as the 
polymeric carrier. We synthesized and characterized a PGA-conjugated corticosteroid 
(fluocinolone acetonide) via a pH-responsive ester linker. PGA conjugation targeted the 
corticosteroid to the appropriate skin layer, and the implementation of bioresponsive 
polymer-drug linking moieties permitted the sustained release of the drug at the required 
site of action. Both these characteristics promote optimal drug release kinetics and the 
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attainment of a therapeutically relevant concentration of an active agent within the 
epidermis for the required period of time. We demonstrated that polymer conjugation 
significantly improved the pharmacological activity of the drug due to greater 
bioavailability in the required skin layer in vitro, ex vivo, and in vivo. Moreover, the 
combination of our polypeptide-conjugated corticosteroid within the HA-CP vehicle 
resulted in synergistic anti-psoriatic activity in vivo, providing a significant reduction in 
inflammation. Therefore, our novel combinatorial polymer-based approach represents a 
possible palliative treatment of inflammatory skin diseases.  
Finally, we applied the knowledge acquired from the development of polymer-
drug conjugates for the treatment of skin inflammation to the development of novel 
wound healing approaches via the PGA-conjugation of the omega-3 polyunsaturated fatty 
acid didocosahexaenoic acid (diDHA). PGA conjugation enhanced diDHA stability and 
decreased degradation, which promoted improved therapeutic activity for the conjugate 
when compared to free diDHA both in skin wound healing and in the treatment of 
ischemia-reperfusion injury in the mouse heart following myocardial infarction. 
Overall, our findings highlight the suitability of polymer therapeutic approaches, 
and polypeptide conjugation in particular, to form drug delivery systems for dermal 
applications. Specifically, PGA-drug conjugates enhance the skin penetration of drugs, 
while bioresponsive linkers promote the specific release of the drug in the desired skin 
layer. Moreover, PGA conjugation of fatty acids has also demonstrated the improvement 
of both safety and effectiveness of the treatment in skin wound healing and in ischemia-






















OBJECTIVES OF THE RESEARCH 
The present thesis dissertation focuses on the development of polymeric platforms 
for drug delivery as novel treatment approaches for skin diseases or disorders, such as 
psoriasis and wound healing. The development of polymer-drug conjugates must follow 
well-established synthetic approaches and employ rational design; furthermore, polymer-
drug conjugates require exhaustive physico-chemical characterization and biological 
evaluation in relevant models. 
The general aims can be summarized as the following specific objectives: 
1. The development and exhaustive characterization of healthy and 
inflammatory ex vivo human skin models and a psoriatic mouse model as 
platforms to evaluate advanced treatment approaches (Chapter II) 
 
2. The synthesis, full physico-chemical characterization, and biological 
evaluation of novel crosslinked hyaluronic acid and poly-L-glutamic acid-
based materials that function as vehicles that enhance penetration through 
the skin (Chapter III) 
 
3. The design, synthesis, and exhaustive physico-chemical characterization of 
poly-L-glutamic acid-drug conjugates incorporating bioresponsive linkers as 
a treatment for psoriasis and the in vitro, ex vivo, and in vivo biological 
evaluation of said conjugates to assess enhanced anti-inflammatory/anti-
psoriatic activities (Chapter IV)  
 
4. The design, synthesis, and exhaustive physico-chemical characterization of a 
family of poly-L-glutamic acid-drug conjugates for wound healing disorders 
and the biological evaluation of said conjugate to assess enhanced wound 















































































I.1. Biological Barriers to the Administration of Therapeutic Agents 
The term “biological barriers” encompasses a group of protective mechanisms 
present throughout the body. These biological barriers, such as the blood-brain barrier 
(BBB), the skin, and the nasal and mouth mucosa, protect the body from unwanted 
exogenous material (including chemicals, viruses, bacteria), while selectively allowing 
molecules with specific characteristics to cross. However, the restrictive nature of these 
barriers also impedes the passage of a range of therapeutic agents, as in the case of the 
topical administration, thereby lowering overall effectiveness. This delivery “challenge” 
requires novel and rationally designed therapeutics, such as polymer therapeutics 
(discussed in detail in Section I.4.), that can conform to the different characteristics 
required to pass through specific biological barriers to reach disease sites, specific tissue 
and cell types, or even specific subcellular locations.  
Biological barriers that inhibit the passage of therapeutic agents to their desired 
site of action can be categorized into five levels (Figure I. 1) and will be discussed below. 
Level 1: Reaching the Bloodstream 
Reaching the bloodstream is generally the first biological barrier faced by a given 
therapeutic. Intravenous injection represents the easiest and most direct administration 
route; however, alternative routes of administration, including topical [1, 2], inhalatory 
[3], and oral [4] administration involve different types of barriers [5, 6]. 
For the treatment of skin diseases/disorders, a given therapeutic agent may require 
targeting to specific skin layers, rather than the bloodstream, thereby requiring the rational 
design of delivery systems that can reach the desired site of action and avoid unwanted 
systemic side effects. 
Level 2: Circulatory System Barriers 
When a given therapeutic agent enters the bloodstream, various plasma proteins, 
including serum albumin, apolipoproteins, and immunoglobulins, adsorb to the surface 
of a therapeutic agent in a process known as opsonization [7]. This process promotes the 
recognition of foreign agents by phagocytes (immune cells) resulting in their removal 
from the bloodstream. Opsonization depends on specific physico-chemical and surface 
properties of the therapeutic agents, including size, surface charge and chemistry, and 
hydrophobicity [8].  
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Level 3: Tissue-specific Barriers  
Several biological barriers separate the blood from the interstitial fluid that 
encloses tissues (including the blood-brain, blood-ocular, and blood-thymus barriers). 
The most selective and controlled of these barriers is the blood-brain barrier, or BBB, 
located in the central nervous system [9]. As an example, certain omega-3 fatty acids 
(including didocosahexaenoic acid [diDHA]) can attenuate neuroinflammation in the 
brain [10, 11], thereby demonstrating its capacity to cross the BBB. Of note, we will 
explain in detail how diDHA can enhance to cross biological barriers in Chapter V of 
this thesis. 
Level 4: Cellular Barriers 
The passive diffusion of molecules represents the main pathway used to cross 
cellular barriers. Therapeutic agents can be uptaken through endocytotic, 
macropinocytotic, or phagocytotic mechanisms [12, 13]. Cell internalization can be 
enhanced by modifying the physico-chemical characteristics of the therapeutic agent, 
including shape, charge, and/or the addition of different ligands. 
Level 5: Subcellular Barriers 
Some therapeutic agents have been designed to target the specific intracellular 
locations/organelles implicated in cellular dysfunction [14]; however, optimal delivery 
through membranes delineating each type of organelle represents a significant challenge. 
Of note, the mechanism employed for the internalization of a given therapeutic agent will 
influence subcellular targeting. Hence, a global understanding of these processes will 
provide relevant information for the rational design of therapeutic agents [15]. 
 
Figure I. 1: General representation of biological barriers present in the body. Adapted from [16]. 
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I.2. Skin as a Barrier 
I.2.1. Skin Structure and Function 
The skin is the largest and most physiologically complex organ of the human 
body; it accounts for ~10% of total body mass and has a surface area of approximately 2-
3 m2, thereby representing the main biological barrier of the body [17]. The skin performs 
multiple functions, including the regulation of temperature, control of water 
ingress/egress, self-maintenance/self-repair, and protection against external threats [18, 
19]. The skin also possesses a sizeable sensory surface containing three categories of skin 
sensory receptors: mechanoreceptors, thermoreceptors, and nociceptors. Therefore, the 
skin transmits sensory information, such as temperature, touch, pressure, and pain 
throughout the body. The skin displays a multilayer structure consisting of two main 
histological layers: the epidermis and the dermis. 
I.2.1.1. The Epidermis 
The epidermis is the outermost layer of the skin, whose thickness varies according 
to body area [19]. The ongoing production of lipids, glycosaminoglycans, and ceramides 
[20] in this layer contributes to the creation of the protective barrier. The epidermis lacks 
blood vessels and diffusion across the dermis supplies nutrients to cells in deeper layers. 
Although is composed mostly of keratinocytes, the epidermis also hosts other cell types, 
such as Langerhans cells (antigen-presenting cells), melanocytes (melanin-producing 
cells), and Merkel cells (mechanoreceptors). The epidermis comprises a stratified 
epithelium formed by several layers of keratinocytes that display increased levels of 
keratinization as the layers approach the skin surface (stratum corneum), creating five 
distinct layers or strata (Figure I. 2).  
The stratum basale 
Commonly known as the basal layer, the stratum basale is considered the deepest 
layer of the epidermis. In this layer, keratinocytes are interconnected and form further 
connections with the dermo-epidermal membrane via desmosomes and 
hemidesmosomes, respectively [21, 22]. The innermost metabolically active layer is 
formed by epidermal stem cells that continually provide keratinocytes from the inner 
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epidermis for the outer epidermis [23]. Interestingly, other cell types, such as 
melanocytes, Langerhans cells, and Merkel cells, are also found in this layer. 
The stratum spinosum 
This stratum spinosum (or spinous layer/prickle cell layer) is located above the 
stratum basale and comprises an average of two to six layers of keratinocytes that flatten 
as they approach the next layer towards the skin surface. These keratinocytes contain 
cytosol prolongations similar to prickles and are often called spiny cells [24]. The prickles 
of adjacent keratinocytes provide improved structural rigidity and increase the resistance 
of the skin to abrasion. Studies have also reported keratin production in this layer [25].  
The stratum granulosum 
The stratum granulosum is composed of one or more layers of flattened 
keratinocytes. The cytoplasm of these keratinocytes contains characteristic granules of 
keratohyalin, the precursor of keratin synthesis [26]. The apoptosis of keratinocytes 
begins in this layer, with cells beginning to lose their nucleus. 
The stratum lucidum 
The stratum lucidum is present only in thicker skin, such as that of the palms of 
the hands and the soles of the feet [27], and consists of a single layer of flattened 
homogeneous keratinocytes that lack a nucleus and display a consistent increase in 
keratinization compared to deeper stratum. 
The stratum corneum 
The stratum corneum is the last and outermost layer of the epidermis with protein 
(mainly keratin) and lipids (predominately triglycerides, cholesterol, and phospholipids) 
[28] representing major components. Both the stratum lucidum and the stratum corneum 
also contain dead keratinocytes that are replaced thanks to the upward migration of cells 
from the deepest epidermal layers - a renewal process known as desquamation [29]. The 
stratum corneum presents as a compacted, dehydrated, and keratinized multilayer whose 
keratinocytes transform into corneocytes (terminally differentiated, anucleated cells of 
the keratinocyte lineage). 
In healthy skin, the rate of stratum corneum desquamation is generally similar to 
the ratio of epidermal cell synthesis, taking approximately 28 days; however, in skin 
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diseases such as psoriasis, the keratinocyte renewal cycle decreases from 28 to 7 days, 
leading to interrupted maturation and incorrect completion [30]. 
 
Figure I. 2: Structure of the epidermis separated into different strata. Adapted from [31].  
I.2.1.2. The Dermis 
The dermis, which constitutes the most significant proportion of the skin as a 
whole, lies directly below the epidermis and is considered as the support of the skin. The 
epidermal and dermal layers meet at the dermal-epidermal junction [32], a matrix of 
mechanically strong fibrous proteins (mainly collagen) immersed in a mixture of proteins, 
glucose, electrolytes, and water (generally known as the ground substance) [33]. 
Additionally, blood vessels, nerve tissues, and skin appendages such as sebaceous glands 
and hair follicles lie within this matrix. While the vasculature provides nutrients for the 
epidermis, it also transports substances absorbed across the skin barrier into the systemic 
circulation.  
I.2.2. Penetrating the Skin Barrier  
The skin represents an alternative route for the administration of therapeutic 
agents due to its sizeable available surface area, allowing for sustained and continuous 
delivery to the circulatory system. This approach enables wider spacing of doses than 
intravenous delivery, for example, while avoiding the unwanted side effects of other 
administration routes [34]. Transdermal delivery also promotes patient compliance due 
to the ease of administration and the option of safe self-administration. Importantly, the 
transdermal route represents an alternative for certain therapeutic agents where there 
exists a significant first-pass effect in the liver, which can lead to premature 
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metabolization, therefore avoiding systemic administration is advisable [35]. However, 
the barrier role of the multilayer stratum corneum makes transdermal delivery a 
challenging prospect. Transdermally administered therapeutic agents can reach the 
bloodstream if said therapeutic can perform three steps: i) penetration, entry into a 
specific skin layer, ii) permeation, penetration from one layer to another, and iii) 
resorption, entry into the vascular system [36]. 
 There exist three proposed penetration pathways through the skin [37]: i) the 
intercellular penetration pathway, ii) the transcellular penetration pathway, and iii) the 
follicular penetration pathway [38, 39] (Figure I. 3). The intercellular route represents 
the most common pathway for permeation [40] - the therapeutic agent penetrates through 
the stratum corneum by passing between corneocytes. However, the transcellular pathway 
is more direct and rapid, with the therapeutic in question crossing the skin by directly 
passing through the lipid structures of the stratum corneum and the cytoplasm of 
keratinocytes. Significant resistance to permeation represents the major limitation to this 
route, given that therapeutic agents must cross both lipophilic and hydrophilic structures 
[41]. Studies had suggested a meager contribution of the follicular pathway (0.15%) in 
comparison to intercellular/transcellular penetration, given the relatively small area of 
skin covered by hair [34]. Nevertheless, recent studies have demonstrated that follicular 
penetration can create a reservoir of drugs that can be released slowly; therefore, this route 
may still have relevance to the delivery of therapeutic agents [42-46]. 
 
Figure I. 3: Representative image of the three penetration pathways: intracellular, intercellular, 
and follicular. Adapted from [34].  
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I.2.3. Penetrant Characteristics 
The physico-chemical properties of the penetrant (the therapeutic agent in 
question) significantly influence the penetration route across the skin, with lipophilicity 
and molecular size representing critical parameters [47-49].  Other critical parameters that 
influence penetration include hydrogen bond acidity and basicity, excess molar 
refractivity, polarizability, molar refractivity, melting point, and molar volume [50, 51]. 
Penetrant properties influence skin permeation through two possible mechanisms: 
increasing absorption into or lowering the diffusion resistance through the stratum 
corneum lipid phase [52]. 
I.2.4. Methods to Improve Penetration through Skin 
The structure of the skin provides resistance to permeation of therapeutic agents; 
however, different methodologies have been developed to increase transdermal 
penetration. 
I.2.4.1. Formulation Optimization 
Effective penetration through the skin not only depends on skin conditions and the 
characteristics of the therapeutic agent but also depends on the transport vehicle employed 
[53]. The vehicle plays a vital role in therapeutic potency and success since the 
characteristics of the vehicle can influence the rate and extent of therapeutic agent 
penetration and absorption, thereby modifying its bioavailability [54].  
The application of hydrophilic and hydrophobic therapeutics to the skin requires 
the application of varying vehicles or formulations, including creams, gels, and patches. 
The vehicle must be selected and formulated with the characteristics of each therapeutic 
agent in mind to promote maximal release and penetration through the skin to ensure 
enhanced transdermal delivery. The vehicle should facilitate the rapid but controlled 
therapeutic release by permitting sustained release over time. 
I.2.4.2. Chemical Enhancers  
Chemicals can be incorporated into topical formulations to promote the 
penetration and enhance therapeutic agent release within skin layers. These chemicals 
must exhibit specific properties for their inclusion in different formulations [55]. 
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Chemical enhancers must: 
 Be pharmacologically inert 
 Be non-toxic, non-irritating, and non-allergenic 
 Allow immediate penetration of the therapeutic agent after application 
 Allow the rapid and complete recovery of full barrier properties after use 
 Be chemically and physically compatible with associated therapeutics and 
adjuvants 
 Be suitable solvents for therapeutic agents 
 Be well-tolerated by patients, organoleptically acceptable  
 Be readily formulated into dermatological preparations, transdermal devices, and 
skin adhesives. 
Chemical enhancers can increase the penetration of therapeutic agents through 
various mechanisms [56]: 
 By increasing the diffusion coefficient of the therapeutic agent 
 By increasing the effective concentration of the therapeutic agent in the vehicle 
 By improving partitioning between formulation and stratum corneum 
 By decreasing skin thickness 
Several types of chemical enhancers have been studied and evaluated: 
1. Water 
The application of water represents one of the most used and safest means to 
improve skin permeation and permeability. The water content of human stratum corneum 
is typically around 15–20% [57]. Despite extensive research in the area, the mechanism 
of action involved remains unclear, although many hypothesize that water increases the 
hydration of the stratum corneum and also controls the transepidermal water loss.   
2. Sulfoxides 
Sulfoxides can aid both hydrophilic and hydrophobic permeants. One of the most 
widely used penetration enhancer is dimethyl sulfoxide or DMSO, also known as the 
“universal solvent” in pharmaceutical sciences. DMSO can denature proteins, changing 
the intercellular keratin configuration in human skin from helical to beta sheet [58]. 
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Although DMSO has proven to be an excellent penetration accelerant, studies have 
encountered adverse effects at high concentrations of DMSO, such as erythema [56]. 
3. Azones 
Azone (1-dodecylazacycloheptan-2-one or laurocapram), a colorless and odorless 
liquid with a melting point of -7°C, is considered as the first molecule exclusively 
designed as a skin penetration enhancer [57]. The mechanism of action comprises the 
fluidization of the intercellular lipid bilayers of the stratum corneum, thereby reducing 
the diffusional resistance of the skin barrier to permeation [59]. The application of azone 
has improved the skin penetration of a variety of drugs, including steroids, antibiotics, 
and antiviral agents [60, 61]. 
4. Pyrrolidones 
Pyrrolidones have been employed as permeation enhancers for a wide range of 
molecules, including hydrophilic and lipophilic drugs. Treatment with pyrrolidones can 
generate drug reservoirs within skin layers, as pyrrolidones partition into the lipids of the 
stratum corneum and increase their fluidity, thereby permitting the release of an active 
agent from the stratum corneum over time [57, 58]. N-methyl-2-pyrrolidone is one of the 
most used enhancers of skin penetration, and has been applied with several drugs and 
active agents, such as caffeine [62]. 
5. Fatty Acids 
Several long-chain fatty acids have been employed as enhancers of therapeutic 
agents penetration through the skin. Oleic acid, one of the principal long-chain fatty acids 
used for this purpose, increases the diffusivity of therapeutics through the skin by 
interacting and interfering with lipids within the stratum corneum [63]. Lauric acid, 
myristic acid, and capric acid can also enhance the delivery of various drugs [64]. 
6. Alcohols 
Ethanol is the most used alcohol in transdermal formulations, often employed as 
a component of transdermal patches. Obtaining the desired effect depends on the 
concentration used, as high levels cause dehydration of biological membranes and 
therefore decrease permeation [56]. Fast evaporation of ethanol increases drug 
concentration, thereby altering solubility in the skin, and providing a supersaturated state 




Surfactants in formulations help to form micelles that solubilize the therapeutic 
agent in question and promote effective skin permeation. Surfactants are generally 
classified into three types: anionic (e.g., sodium lauryl sulfate), cationic (e.g., 
cetyltrimethylammonium bromide), and non-ionic (e.g., dodecyl betaine). Anionic and 
cationic surfactants can have adverse effects on human skin; for example, sodium lauryl 
sulfate is a powerful irritant and can increase transepidermal water loss in vivo [65]. In 
contrast, non-ionic surfactants tend to be considered safe for application to human skin.  
8. Urea 
Urea is regarded as a hydrating agent (a hydrotrope) and has been widely applied 
in the treatment of diseases such as psoriasis [57]. Urea induces transdermal permeation 
by facilitating significant stratum corneum hydration and the formation of hydrophilic 
diffusion channels [66]. Moreover, salicylic acid provides keratolytic properties to urea, 
allowing application in skin diseases characterized by an increment of epidermis 
thickening (e.g., keratosis, sometimes associated with the development of psoriasis) [67]. 
Several analogs containing more potent enhancing moieties have been developed to 
improve the penetration-enhancing activity of urea, including cyclic, alkyl, and aryl urea 
analogs [68]. 
9. Essential oils, Terpenes, and Terpenoids 
Terpenes are found in essential oils and have been employed as medicines, 
flavorings, and fragrance agents. The size of terpenes influences their activity; smaller 
terpenes tend to be more active permeation enhancers than larger terpenes (such as 
sesquiterpenes) [57]. Terpenes can transform the solvent nature of the stratum corneum, 
thereby modifying and enhancing diffusivity through the skin [56]. Essential oils of 
eucalyptus, chenopodium, and ylang-ylang have been shown to improve the penetration 
of 5-fluorouracil in human skin [69].  
10. Phospholipids 
Several pharmaceutical formulations have employed phospholipids to carry 
therapeutic agents into and through human skin due to their capacity to create vesicles 
(liposomes) that surround and protect said therapeutic agent. The application of the 
phospholipids as vesicles promotes fusion with stratum corneum lipids, while 
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phospholipids also alter the solvent nature of the human skin and improve the permeation 
of different drugs, demonstrating the most significant positive effect on hydrophilic drugs 
[70, 71]. 
I.2.4.3. Physical Enhancers 
Physical enhancers can improve the penetration of therapeutic agents by physical 
disruption of the structure of the skin, using for this purpose different techniques. 
1. Iontophoresis  
Permeation is enhanced by the application of a low-level electric current directly 
over the skin [72-74], a strategy which can be adapted to each case [75]. Modifiable 
parameters include electrode type, system pH, current intensity, competitive ion effect, 
and permeant type [76]. Several mechanisms can increase permeability: i) the anode-
cathode charge directs the therapeutic agent towards specific layers of skin [77]; ii) the 
electric current itself deconstructs skin layers and inhibits barrier function [78]; and iii) 
the accumulation of water increases by electroosmosis, which improves the hydration of 
the skin and favors penetration [79]. 
2. Sonophoresis or Phonophoresis 
This technique involves the usage of high- or low-frequency ultrasound waves. 
Sonophoresis enlarges existing skin pores and also creates more pores in the skin leading 
to the disruption of the stratum corneum [80]. Parameters that can affect the effectiveness 
of this technique include the duration, intensity, and frequency of the treatment [75]. 
Several studies have demonstrated the improvement of insulin delivery using ultrasound 
[81, 82].  
3. Magnetophoresis  
Magnetophoresis, the application of a magnetic field, represents a novel approach 
to improve therapeutic agent permeation across the skin. The presence of a magnetic field 
induces structural alterations, thereby modifying the protective properties of the skin and 
increasing permeability. This technique has been used to improve the penetration of a 




4. Electroporation  
Electroporation is the transitory structural modification of the lipid bilayer 
membranes due to the application of short and high voltage pulses to the skin [85], which 
leads to transient pore formation allowing the transit of compounds into cells [58]. The 
electrical parameters and physico-chemical properties of the drugs determine the 
effectiveness of transport. 
5. Thermophoresis  
Thermophoresis employs higher than physiological temperature to favor 
percutaneous absorption [86] thanks to induced vasodilation of the subcutaneous blood 
vessels [87] and increased drug diffusivity through the vehicle and skin because of 
improved lipid fluidity [88]. In vitro [89] and in vivo [90] studies have demonstrated the 
contribution of this technique to the improvement of drug permeation.  
6. Radiofrequency  
Radiofrequency is a versatile technology employed for generating therapeutic 
intensities of heat, thereby producing structural and biological responses. This technique 
focuses on the exposure of skin to high-frequency alternating current (preferably from 
100 to 500 kHz), which induces the formation of membrane microchannels in response 
to the heat caused by electrical current application, facilitating the penetration of 
hydrophilic drugs [91].  
7. Microneedles  
Microneedle devices facilitate the penetration by piercing the stratum corneum to 
deliver therapeutic agents into the epidermis. Microneedles have been fabricated with 
different size, shape, geometry, and materials [92] for applications with a wide range of 
molecules and nanoparticles [93, 94]. 
I.2.5. Techniques to Evaluate Skin Penetration 
The assessment of skin penetration represents a critical challenge in the evaluation 
of the suitability and effectiveness of a given therapeutic agent as a treatment for skin 
diseases. The development of real skin models that can better mimic the characteristic 
features of disease has generated an ever-expanding knowledge base regarding 
penetration. Furthermore, the development of new specific techniques that can track the 
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drug through the skin will allow a better understanding of the processes that mediate the 
localization of a given therapeutic agent. 
I.2.5.1. Skin Models 
Widely accepted models for skin-permeation studies include ex vivo human or 
animal skin either frozen or in culture; however, several alternative in vitro models to in 
vivo animal models have been developed applying the 3R principle (replace, reduce and 
refine [95]) (Table I. 1).  
The latest advances comprise the creation of skin models through artificial 
membranes or reconstructed skin models. 
Table I. 1: Different skin models. Adapted from [96]. 
 
Artificial and reconstructed skin models represent suitable tools for the evaluation 
of transdermal absorption. Artificial skin models are particularly convenient for the study 
of the underlying mechanisms of passive transport through a membrane [97-99]. The 
development of these models is reproducible and straightforward due to the elimination 
of the complexity of human or animal skin [96]. Although simplicity represents one of 
the main advantages of these models, oversimplification also represents a limitation, as 




Reconstructed skin models are created from layers of different human cells 
cultured on a polymeric matrix, thereby obtaining the desired organization and a degree 
of complexity. Reconstructed human epidermis models can be generated to mimic the 
epidermis or the entire human skin (living skin equivalents) [101, 102]. Interestingly, 
these models also mimic the physiopathology of various diseases states, such as psoriasis 
or atopic dermatitis [96]. Therefore, reconstructed skin models can be used not only to 
understand the molecular pathways responsible for specific diseases but also to examine 
the penetration, delivery, and effects of topical therapies.  
I.2.5.2. Monitoring Penetration in the Skin 
Several advanced physicochemical techniques have been used to investigate skin 
penetration pathways, which allow the study of the internal structure of skin layers and 
their physiological behavior, as well as the penetration of different drugs through the skin, 
and the interactions between therapeutic agents and skin components [103-105]. 
Techniques employed to detect penetration include infrared and Raman spectroscopy, 
confocal microscopy, and mass spectrometry. 
 Fourier transform infrared spectroscopy permits the investigation of stratum 
corneum lipids under controlled conditions [106] and the evaluation of changes in stratum 
corneum barrier function in vivo after the application of compounds, such as sucrose 
oleate and sucrose laurate [107]. Also, Fourier-transform infrared spectroscopy represents 
a useful screening tool for the evaluation of guidelines in the design of chemical 
enhancers to increase skin permeability [108]. 
Raman spectroscopy provides specific vibrational signatures of chemical bonds, 
allowing the precise skin layer-location of the studied therapeutic agent [109, 110], while 
confocal microscopy permits the visualization and localization of fluorescent compounds 
in the skin [111]. Recent studies have employed a novel technique based on confocal-
Raman microspectroscopy [112], demonstrating its suitability in assessing the effect of 
skin penetration enhancers [113, 114], the penetration of different compounds [115, 116], 
and the status of skin features and conditions, such as hydration [117, 118]. 
Recently, mass spectrometry methods have been used to image the spatial 
distribution of compounds in various skin layers, providing high chemical specificity 
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[119]; as an example, mass spectrometry has allowed the observation of differences in 
penetration profiles for four different drugs [120]. 
I.2.6. Skin Penetration as a Challenge 
The complex structure of the skin provides the necessary protection to the human 
body against external agents; however, this protection also has a negative consequence 
when topically administering drugs or active agents, as the skin prevents penetration. 
Many of the topical drugs currently used or under clinical trials lack appropriate 
physico-chemical characteristics for adequate delivery through the skin. Various rational 
strategies have been evolved to improve the physico-chemical properties of 
drug/therapeutic agents according to the features of the desired site of action, improving 
topical delivery and stability. Some methods include the development of the prodrug 
approach [121] or the development of nanomedicines via the conjugation of therapeutic 
agents to carriers with different characteristics [122]. Said nanomedicines protect the 
therapeutic agent against premature degradation and interact with various components of 
the skin, increasing the penetration of the therapeutic agents through the different layers 
of the skin, and increase retention time in the desired site of action [123, 124].  
We will detail the main characteristics and advantages of nanomedicine in the 
field of topical applications in the next section. 
I.3. Nanomedicine 
Nanotechnology involves controlling the properties and structures with particle 
sizes in the nanometer range, typically ranging from less than 100 to 1000 nm [125, 126]. 
Nanomedicines are nano-sized agents employed for the diagnosis, prevention, and 
treatment of diseases/disorders, and have allowed a deeper understanding of the complex 
pathophysiology of disease [127]. Nanomedicinal advances, mainly in cancer, have 
demonstrated huge potential and utility as systemic treatment approaches [128].  
The first classes of nanomedicinal platforms present distinct physico-chemical 
properties (Figure I. 4) and can be classified into separate groups depending on size 
ranges in the nanoscale: liposomes (80 - 200 nm), nanoparticles (20 - 1000 nm), polymer 
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therapeutics (5 - 25 nm), block copolymer micelles (50 - 200 nm), gold nanoparticles (5 
- 50 nm), and nanosized drug crystals (100 - 1000 nm). 
 
Figure I. 4. Schematic illustration of established first generation nanomedicines platforms. 
Adapted from [127].  
Different nanoparticle-based formulations are used in clinics as a potential 
strategy to deliver a range of therapeutic agents [129], including polymeric nanoparticles 
[130], micelles [131], liposomes [132], antibody-drug conjugates [133], virosomes as 
nanoparticles [134], nanocrystals [135], gene therapy and immunotherapy-based 
treatment [129]. 
I.3.1. Nanomedicine Applications to the Skin  
The improvement of transdermal delivery remains the main target of current 
research. The nanomedicinal approaches in topical applications hope to overcome many 
of the limitations of current transdermal delivery formulations. Nanosized carriers, or 
nanocarriers, are especially useful for the passive delivery of therapeutic agents, inducing 
transit through the skin without the need for energy input or specific receptors.  
Nanocarriers offer several advantages over conventional carriers, including higher 
solubility, controlled size, delivery to specific targets, controlled and sustained release of 
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therapeutic agents, delivery of hydrophilic and lipophilic molecules, weakened skin 
irritancy, protection from degradation, increased loading, and enhanced permeation 
through the skin [136-138]. Due to these advantages, nanocarriers can enhance the 
pharmacokinetic profile and effectiveness of therapeutic agents when compared to “free” 
forms [139]. Moreover, nanocarriers interact with the skin and can modify barrier 
properties, contributing to penetration [140].  
Some of the most used nanocarriers include nanoparticles (e.g., nanocapsules and 
nanospheres), liposomes, microparticles (e.g., microcapsules and microspheres), 
nanocrystals, polymersomes, niosomes, cubosomes, dendrimers, and fullerenes, amongst 
notable others [141, 142]. Of these, nanoparticles represent the most promising systems 
due to their high physico-chemical stability and ability to incorporate different therapeutic 
agents. 
 The application of nanocarriers as treatment approaches for skin diseases has 
given rise to the field of “nanodermatology”. First introduced by the Nanodermatology 
Society [143], nanodermatology consists of the application of nanotechnology to the skin 
for diagnostic, therapeutic, or cosmetic purposes (Table I. 2). 
Table I. 2: Promising areas in nanodermatology research. Adapted from [144]. 
 
This new area of research allows the development of delivery systems to transport 
therapeutic agents through the epidermis and direct them towards their required site of 
action [145, 146]. Therefore, the features of the delivery systems in the skin not only 
depend on the therapeutic agents but also the transporting nanocarrier.  
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This thesis describes a particular nanomedicinal approach, polymer therapeutics, 
to increase the penetrability of bioactive agents through the skin and improve the physico-
chemical properties. 
I.4. Polymer Therapeutics: The First Polymeric Nanomedicines 
Polymer therapeutics represent exciting first-generation nanomedicines and are 
generally considered as the first polymeric nanomedicines [147, 148]. The term “Polymer 
Therapeutics”, coined by Prof. Ruth Duncan, includes an extensive family of nano-sized 
medicines (5 - 100 nm in diameter). More than twenty polymer therapeutics have found 
in routine clinical use [149] with two polymer therapeutics becoming top-selling drugs in 
the USA in the last decade: the polymeric drug glatiramer acetate for the treatment of 
multiple sclerosis (Copaxone®, Teva Pharm) and a polyethylene glycol (PEG)-filgrastim 
polymer conjugate for the treatment of neutropenia (Neulasta®, Amgen) [148].  
Polymer therapeutics-based treatments have demonstrated suitability in a range of 
disease/disorders, including cancer [150-152], neurodegenerative disorders [153, 154], 
hepatitis [155], and autoimmune diseases [156], thereby reflecting the huge potential of 
this nanomedicinal approach. 
I.4.1. Definition and Classification 
Polymer therapeutics fall into five distinct families: polymeric drugs (polymers 
with inherent activity) [157], polymer-protein conjugates [158], polymer-drug conjugates 
[159], polyplexes (multi-component systems used as non-viral vectors for gene/small 
interfering RNA delivery) [160], and polymeric micelles (where drug attachment occurs 
via covalent bonding) [161] (Figure I. 5).  
This thesis focuses most of its attention on the development of polymer-drug 




Figure I. 5: Schematic representation of the polymer therapeutics family. Redrawn from [159].  
Polymer therapeutics employ specific water-soluble polymers, a crucial factor for 
systemic administrations of these systems, acting as an inert structural component or as 
an active agent (polymeric drug) [159]. While most polymer therapeutics in the clinics 
employ intravenous administration, other options include oral, intramuscular, 
subcutaneous, and local administration routes [162]. Of particular interest to this thesis, 
polymer therapeutics have been clinically developed as a topical administration; as an 
example, VivaGel® (Starpharma), a lysine-based dendrimer (a type of branched polymer) 
that acts as microbiocide is currently in Phase III clinical trials [163, 164] as an HIV-1 
preventative agent. 
When used as a delivery system for an active agent, be it a small molecule drug, 
protein, targeting moiety, etc., polymer therapeutic-based approaches allow for targeted 
release at the desired site of action and controlled and sustained release within a suitable 
therapeutic window [165]. The conjugation of a therapeutic agent to a polymer backbone 
offers several advantages over other nanomedicines, including (1) increased water 
solubility; (2) controlled size and size-dependent properties; (3) protection of the 
therapeutic agent against degradation by proteolytic enzymes or unspecific cellular 
uptakes; (4) enhanced plasma half-life due to the increase in hydrodynamic volume and 
the decrease in kidney clearance; (5) prevention or reduction of aggregation, 
immunogenicity, and antigenicity; (6) modified pharmacokinetics both at cellular and 
even subcellular level. 
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The design of nanosized medicines like polymer therapeutics has been inspired by 
the “enhanced permeability and retention (EPR) effect” first described by Matsumura and 
Maeda [166]. After intravenous administration, nanomedicines of specific sizes can 
passively extravasate from the bloodstream and accumulate in the tumor interstitium due 
to the enhanced permeability of the angiogenic tumor vasculature and defective lymphatic 
drainage (Figure I. 6). 
 
Figure I. 6: Enhanced permeability and retention (EPR) effect and passive targeting. Adapted 
from [167]. 
The EPR effect also plays a vital role in inflammatory tissues, as in the case of 
psoriatic skin, supporting and justifying the design and use of this class of nanocarriers 
in infectious and inflammatory conditions [168]. However, studies have shown that the 
EPR effect is a complex phenomenon with a heterogeneous presentation, which in the 
case of cancer is also affected by tumor type, tumor region, and tumor vascularization. 
As tumor vascularization represents an important factor regarding the uptake of 
nanomedicines, poorly-vascularized damaged tissues are less susceptible passively-
targeted nanosized therapeutics [169], thereby highlighting the need for the integration of 
targeting strategies into polymer therapeutics-based approaches.  
Following accumulation around the tumor or target tissue, endocytic mechanisms 
promote the cellular uptake of polymer-based nanomedicines through invaginations of 
the cell membrane, creating vesicles called endosomes that undergo a complex succession 
of fusion events until the formation of the lysosome. Lysosomes contain a high 
concentration of proteolytic enzymes and display an acidic pH (5.5) [170] that can aid the 
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degradation of the polymer-based nanomedicines with degradable linkers or the polymer 
backbone, and release the therapeutic agent from the polymer (Figure I. 7). 
 
Figure I. 7: Lysosomotropic intracellular drug delivery process followed by polymer-drug 
conjugates. Adapted from [171]. 
I.4.2. Polymer Conjugates as Therapeutics 
Polymer conjugates fall into two groups: polymer-protein and polymer-drug 
conjugates. The choice of an adequate polymeric carrier and a suitable linker(s) or 
spacer(s) depends on the physico-chemical properties of the bioactive agents(s) to deliver 
to the molecular target and also the biological activity or aim pursued in each case.  
The exponential increase in the number of polymer conjugates on the market for 
different medical applications reflects the enormous future potential for polymer 








Table I. 3: Marketed polymer conjugates. PEG: polyethylene glycol; G-CSF: granulocyte-colony 
stimulating factor. 
  
I.4.2.1. Polymer-Protein Conjugates 
Most therapeutics that contain peptides, proteins, or antibodies present limitations 
such as short circulation times, low stability, limited therapeutic effects, and possible 
immunogenic responses. Protein conjugation addresses these limitations by increasing 
stability in serum and decreasing immunogenicity. Although the development of 
polymer-protein conjugates began in the 1990s with the appearance of SMANCS, a poly-
(styrene-co-maleic acid) (SMA) conjugate of neocarzinostatin (NCS) for hepatocellular 
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carcinoma treatment [172], polymer-protein conjugates only became relevant following 
the description of the US Food and Drug Administration (FDA)-approved PEGylation 
technique [173, 174]. The mechanism comprises the covalent attachment of polyethylene 
glycol (PEG) to proteins, and examples abound in the market [147]. 
PEG, an artificial non-biodegradable polymer that displays flexibility, extreme 
water-solubility, and a lack of charge, has found common use in the pharmaceutical 
industry as an excipient and a starting product. PEG conjugation to proteins improves 
immunogenicity and solubility, and prolongs blood plasma half-life [175]. The 
hydrophilic character of PEG contributes to steric stability and protects the system against 
degradation, thereby allowing a reduction in the required dosing frequency, which 
enhances the safety profile of the therapeutic in question.  
Encouragingly, PEGylation has had substantial clinical impact in the treatment of 
various pathologies, including hepatitis C and rheumatoid arthritis. As a consequence, 
this impact has encouraged the clinical approval of PEG-protein conjugates by the FDA 
(Table I. 3), and several products are in clinical development since 2018 (Table I. 4).  
However, reported toxic effects limit the application of PEG [176] as the non-
biodegradable nature of PEG provokes progressive accumulation following continuous 
administration, leading to adverse side effects [177]. Also, the functional molecular 
weight (Mw) used has limits; studies have demonstrated that oligomers with < 400 Da 
are toxic due to oxidation into diacid and hydroxyl acid metabolites by alcohol and 
























I.4.2.2. Polymer-Drug Conjugates 
Polymer-drug conjugates, a term coined by Ringsdorf in 1975 [180], are 
composed of three main components: a water-soluble polymer, a bioresponsive linker, 
and a bioactive agent (Figure I. 8). Polymer-drug conjugates are formulated to influence 
drug pharmacokinetics at the whole body and cellular level, and to aid passage through 
various biological barriers. Moreover, conjugation improves cellular specificity, controls 
drug release rate in specific targets, and therefore, decreases non-specific toxicities.  
Importantly, inherent polymer multivalency permits the conjugation of more than 
one compound to the polymeric backbone, allowing the introduction of targeting residues 
(promoting receptor-mediated endocytosis) [181], diagnostic moieties [182], or more 
than one drug (polymer-based combination therapy) [183]. 
 
Figure I. 8: Schematic illustration of polymer-drug conjugates. Adapted from [184]. 
In general, the development and application of polymer-drug conjugates have 
generally focused on cancer treatment. In 1994, Kopecek and Duncan developed the first 
polymer-anti-cancer drug conjugate clinically evaluated, the poly-N-hydroxypropyl 
methacrylamide (HPMA) copolymer-doxorubicin (DOX) conjugate (HPMA-DOX or 
PK1, FCE 28068), which employed a lysosomally-cleavable peptidyl linker [159]. 
Although PK1 displayed a 15-fold improvement in plasma half-life, an enhanced safety 
profile, and higher anti-tumor efficacy in comparison with free DOX in preclinical animal 
models [185], clinical trials demonstrated low efficacy, thereby halting PK1 
development.  
Overall, only a small fraction of the first generation of polymer-drug conjugates 
have had success in clinical trials: 
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 Poly (N-hydroxypropyl methacrylamide) (polyHPMA)-DOX [186-189]. 
 Poly (glutamic acid) (PGA) conjugates of paclitaxel (XyotaxTM or OpaxioTM) 
or camptothecin (CT-2106) [190-192]. 
 PEG-cyclodextrin-camptothecin nanoparticulate conjugates (CRLX101 or IT-
101) [193, 194]. 
 PEG-polypeptide block copolymer conjugated with SN-38 (NK-012), 
Doxorubicin (NK-911) or Cisplatin (NC-6004) [195-197]. 
 
And currently, only one polymer-drug conjugate is already in the market, 
MovantikTM (PEGylated derivative of naloxol, a metabolite of naloxone) used to treat 
opioid-induced constipation [198], and more than 20 products are in clinical development 
(Table I. 5).   
 
OpaxioTM [199] (previously called XyotaxTM), a PGA-conjugate form of 
paclitaxel (PTX) using an ester linker (PGA-PTX), represents one of the most advanced 
polymer-drug conjugate and is currently in Phase III clinical trials for the treatment of 
ovarian, prostate and esophageal cancer, which can be applied in combination with 
cisplatin or radiotherapy. OpaxioTM has an average Mw of 38.5 kDa and a drug loading 
between 36 - 37% w/w (1 drug molecule in each 11 glutamic acid (GA) units). In 
comparison with other nanosystems with PTX, OpaxioTM has higher drug loading (37 
wt% vs. 5 wt% for the discontinued HPMA-PTX conjugate [200] and therefore presents 
with enhanced stability in blood.  
Interestingly, the OpaxioTM clinical trial results demonstrated a relationship 
between polymer-drug conjugate therapeutic effect and patient hormone status: pre-
menopausal women with higher estrogen levels responded, while post-menopausal 
women and men did not. The current hypothesis states that higher estrogen levels increase 
cathepsin B activity, with cathepsin B responsible for the PTX release from the PGA 
backbone. Hence, cathepsin B activity represents one of the few examples of biomarker 
assessment in nanomedicine clinical trial patient selection [150]. In 2012, the FDA 
awarded OpaxioTM orphan drug designation for the treatment of glioblastoma multiforme 
in combination with temozolomide and radiotherapy. OpaxioTM development has been a 
reference for the expansion of PGA and polypeptide-based conjugates alone or in 
combination therapy, revealing the huge potential of these systems as therapeutics [16, 
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201]. One of the major strategies to move forward with polymer conjugates is the use of 
biodegradable nanocarriers, such as polypeptides, to avoid undesired side effect as those 
observed with PEG related with vacuolization and lysosomal storage diseases [13, 183].  












I.4.2.2.1. Rational Design of Polymer-Drug Conjugates 
The design of polymer-drug conjugates for the treatment of a given disease or 
disorder must follow a rational stepwise design in consideration of the different processes 
that the conjugate faces following patient administration [202]. The physico-chemical 
characteristics of the polymer-drug conjugates will determine its capacity to cross the 
required biological barriers, such as the skin, and, therefore, the biological activity. The 
successful activity of the conjugate depends mainly on its response to the specific 
physiological environments found in the whole body. The essential components studied 
for the effective development of polymer-drug conjugates are the biodegradable polymer 
carrier itself and the bioresponsive linker between the polymer and the therapeutic agent 
involved.  
I.4.2.2.1.1. Polymeric Carrier 
In general, the polymeric carrier of choice should present the following properties: 
(1) Biodegradability or a suitably small molecular weight, thereby facilitating 
excretion in vivo. 
(2) Low polydispersity, providing homogeneity of the final conjugate. 
(3) Prolonged half-life in the blood, enhancing adequate biodistribution and 
accumulation in body compartments, thus promoting optimal activity. 
(4) Multivalency, allowing adequate drug loading, combinatorial drug loading, or 
the application of targeting/diagnostic moieties. 
Biodegradability represents one of the most important characteristics of potential 
carriers, as this avoids accumulations in the body and possible related adverse side effects. 
The non-biodegradability and molecular weight restrictions of the first-generation 
conjugates of PEG and HPMA revealed limitations to pharmacokinetics and systemic 
toxicity. Thus, current research focuses on developing new and advanced biodegradable 
and biocompatible water-soluble polymers [203]. Polymer carriers include natural 
polymers as dextran (α-1,6 polyglucose), dextrin (α-1,4 polyglucose), cyclodextrin, and 
hyaluronic acid, and synthetic polymers such as PEG, HPMA copolymers (a polymer 
derived from more than one types of monomer), polyacetals, and polypeptides.  
Moreover, polymer structural versatility has allowed the synthesis of a massive 
number of different systems, from linear or branched homopolymers to block 
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copolymers. Branched polymers involve several types, such as star, hyperbranched and 
dendritic-like polymers, dendrimers, graft, brush, and comb-like polymers, and polymer 
networks [204]. The high multifunctionality of branched polymers provides several 
advantages compared to their linear analogs, such as enhanced stimuli-responsiveness 
and the conjugation of a vast amount of different bioactive agents [205]. Moreover, 
branched polymers have demonstrated superior biodistribution, pharmacokinetic profiles 
[206], and in vivo biodistribution in healthy mice. Overall, the required functionality will 
drive the final use of linear or branched polymers.  
I.4.2.2.1.2. Bioresponsive Linkers 
The choice of the bioresponsive linker represents another critical parameter in the 
rational design of polymer-drug conjugates [207]. The application of stimuli-responsive 
materials, both endogenous (e.g., pH, redox environments or reactive oxygen species) 
and exogenous (e.g., magnetic field, temperature, light), has exponentially grown in 
recent times. Linker chemistry can optimize drug release profiles in specific 
microenvironments or the presence of particular enzymes, thereby ensuring the release of 
the active agent(s) within the target area and improving biological activity. 
Different types of linkers have been described according to their susceptibility 
[16]: 
(i) pH-responsive linkers: including acetal or ester bonds, N-cis-aconityl acid, or 
hydrazone linkers [208, 209]. 
(ii) Lysosomal enzyme-responsive linkers: normally oligopeptides cleaved by 
lysosomal enzymes such as cathepsin B or D, or metalloproteinases. Examples 
of such linkers include GFLG (Gly-Phe-Leu-Gly) and GLFG (Gly-Leu-Phe-
Gly) [210]. 
(iii) Self-immolative linkers: These linkers can disassemble into constituent 
fragments, provoking the rapid disassembly of the polymer [211, 212].  
(iv) Reductive-sensitive linkers: Drug release is produced in reducing 
environments, mainly due to the presence of glutathione [213]. 
(v) Drug release by anchimeric-assisted hydrolysis: firstly, drug-linkers release 
from the polymer following hydrolysis (first prodrug), activating the linker 
(second prodrug) which releases the free and active form of the drug [214]. 
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I.4.2.2.1.3. Physico-Chemical Properties of Polymer-Drug Conjugates 
 The selection of the polymeric carrier and the linker significantly influences the 
physico-chemical parameters of the polymer-drug conjugate, such as the size 
(hydrodynamic radius), surface charge, and conformation. 
The size of the conjugate determines its ability to cross biological barriers, such 
as the skin, and also the mechanism of cellular uptake. Therapeutic agents with sizes 
larger than 200 nm do not penetrate through the different layers of the epidermis well, 
although conjugates of this size may be captured by other mechanisms, such as through 
hair follicles [215, 216].  
Within the circulatory system, nanosystems with sizes smaller than 5 nm penetrate 
capillary fenestrae and become rapidly eliminated by renal glomerular capillaries; 
however, larger particles exhibit prolonged circulation in the bloodstream, thereby 
increasing the time in which the nanosystem can play an active therapeutic role. Hence, 
nanosized therapeutics suitable for systemic applications should be in the range from 5 to 
200 nm.  
The self-assembly behavior of nanosystems also affects the final size and is 
determined by the characteristics of the assembling polymers and the conjugated drug(s), 
among other driving forces specific for each nanosystem implicated in its regulation 
[206]. Remarkably, several hydrophilic polymers fail to aggregate in the presence of 
water, but conjugation with a hydrophobic drug can induce self-assembly. As an example, 
both PEG-P(L-Asp) and PEG-P(L-Glu) create nanosized systems only after conjugation 
with DOX, resulting in the well-known polymeric micelles, some of them in advanced 
clinical development [217, 218]. 
The type of polymeric carrier employed also influences the surface charge 
(positive, neutral or negative), while after conjugation to different moieties or drugs, the 
zeta (ξ) potential value (the relative magnitude of the charges) of the system can also 
change. The surface charge impacts the in vivo effect of conjugates, conditioning the type 
of interactions with cell membranes and therefore cellular uptake, recognition and 
elimination from the bloodstream, and toxicity [219, 220].  
In terms of cellular uptake, surface charge regulates the interactions between the 
nanosystem and the lipid cell membrane; due to the presence of sulfated proteoglycans in 
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the lipid bilayer, the cellular surface charge is ordinarily negative [221]. Hence, 
nanosystems with positive surface charges, such as poly-lysine, can bind strongly to the 
membrane, enhancing cellular uptake. However, positively charged nanosystems are not 
recommended for direct application in vivo, as these systems interact with negatively 
charged serum proteins (albumin) and red blood cells in the bloodstream and produce a 
precipitate over the cell surface [222], thereby destabilizing the plasma membrane and 
inducing instantaneous toxicity [223]. Thus, nanosystems should be modified with small 
or neutral charges by conjugation or complexation with anionic molecules (e.g., siRNA), 
to decrease the positive charge. Interestingly, surface charge also affects the physical 
stability and aggregation of the nanosystem in the circulatory system. 
Conjugate conformation also represents an important parameter in the design of 
polymer-drug conjugates. Polymer chain conformation can modulate the stability of the 
nanosystem and the interaction with cellular membranes, and therefore, the final 
biological activity. The conformation of polymer-drug conjugates also affects the 
exposure of the therapeutic agent(s) involved to the factors that trigger its release, such 
as pH or specific enzymes, which can significantly influence release rate, activity, and 
effectiveness of the treatment at the desired target. The conformation of the nanosystem 
can also vary according to the type and pH of the solvent. This effect is especially 
significant in the case of polypeptides, where pH changes promote an ionization or 
neutralization of functional groups in the amino acid residues, which then encourages 
conformational transitions [224]. Furthermore, conjugated moieties or drugs can 
introduce extra charged elements that can modify the electrostatic equilibrium of the 
nanosystem, acting as a stabilizing or destabilizing force [225].  
The polymer-drug conjugates synthesized, characterized, and evaluated in this 
thesis are based on the poly-L-glutamic acid (PGA) as polypeptidic carrier (discussed 
below). Ester bond linkers have been used in the majority of the systems due to their 
susceptibility to pH changes, leading to the drug release in the lysosomal compartment or 
in specific tissue areas showing an inflammation or a pathological situation. 
I.4.3. Polypeptide-Based Therapeutics 
Giving the described problems with previously developed non-biodegradable or 
bioaccumulative polymers, the use of natural biodegradable polymers in polymer 
therapeutics has greatly expanded, especially as a component of drug delivery systems 
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[226]. In particular, poly-amino acids or polypeptide-based materials (such as PGA) have 
had the most significant impact in the field of biomedicine as they provide the previously 
described advantages of polymers (see section I.4.2.2.1.1.) while avoiding some of the 
unwanted side effects.  
The intrinsic characteristics of polypeptide-based materials have justified the 
trend to move away from non-natural polymers. Polypeptides mimic natural proteins, 
demonstrating remarkable biocompatibility and biodegradability due to controlled 
sequences and composition of the constitutive monomers. Therefore, the application of 
polypeptide-based materials suits diseases that require prolonged and continuous 
treatment, such as chronic or infectious diseases, neurological disorders, or tissue 
regeneration. Moreover, polypeptides present low immunogenicity [227, 228], thereby 
contributing to their suitability for constant parenteral administration and allowing the 
use of high doses of polymer [127]. The emergence of polymerization techniques, mainly 
ring-opening polymerization of α-amino-N-carboxyanhydrides [229-231], has led to the 
controlled synthesis of polypeptides with narrow polydispersity, high reproducibility, and 
specific functionalization of the polymeric backbone [204, 230]. 
Several important properties must be considered in the design of advanced 
biodegradable polypeptide-based materials [232]. Characteristics include (i) the 
avoidance of a sustained inflammatory response, (ii) a degradation time according to their 
function, (iii) suitable mechanical characteristics for their final use, (iv) the production of 
easily resorbable or excretable non-toxic degradation products, and (v) the possession of 
adequate permeability and processability for the designed purpose. 
Polypeptide-based conjugates have found use in multiple areas of medicine, with 
an ever-increasing number of polypeptide-based compounds reaching preclinical and 
clinical trials [233]. These products include anti-cancer [234, 235], anti-tuberculosis 
[236], anti-diabetic [237], anti-microbial [238, 239], anti-virus [240], and anti-apoptotic 
conjugates [241], alongside magnetic resonance imaging agents [6], and theranostic 
agents (diagnostic and therapeutic applications in the same agent) [242]. These examples 
demonstrate the structural versatility of the polypeptide conjugates, facilitating the 
conjugation of therapeutic agents with different origin and physico-chemical properties 
(e.g., size, hydrophilicity) and diverse loading rates.  
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In this thesis, the synthesized polymer-drug conjugates employed PGA as a 
biodegradable polymer to take advantage of the intrinsic properties explained above. 
I.4.4. Characterization Techniques 
The rational design of drug delivery systems will significantly influence the final 
activity of the drug, and the exhaustive physico-chemical characterization of developed 
systems can provide information regarding structure-activity relationships, safety, and 
efficacy. Characterization contributes to the broader understanding of the conformation, 
dynamics, dimensions, and also the interactions with the biological environment. Purity, 
identity, molecular weight, polydispersity, drug content, free drug content, and 
quantification of targeting units represent just some of the critical characteristics of a 
nanosized drug-delivery system. 
A growing interest in new biodegradable polymeric systems has led to the 
development of complex systems, creating the need for establishing adequate physico-
chemical techniques for their characterization. The application of multiple and 
complementary techniques has provided knowledge on shape, size, and conformation. 
Table I. 6 describes some of the most important techniques used in the physicochemical 
characterization of the nanosystems. Novel physico-chemical techniques such as SAXS 
(small-angle X-ray scattering), SANS (small-angle neutron scattering) [243, 244], wide 
angle X-ray scattering (WAXS), and Cryo-TEM (Transmission Electron Microscopy) 












Table I. 6: Summary of the most relevant techniques used to elucidate physico-chemical 




Table I. 6: Summary of the most relevant techniques used to elucidate physico-chemical 





I.4.5. Polymer Therapeutics for Skin Delivery 
Transdermal drug delivery systems based on polymer therapeutics represent a 
non-invasive administration strategy for both local and systemic therapies. The topical 
route presents several advantages compared to other types of administration, mainly due 
to the reduction of the frequency of dose and bypassing hepatic first-pass elimination 
[248, 249]. 
One of the most widely used polymeric carriers for transdermal delivery of 
bioactive molecules is the biodegradable and biocompatible natural polymer, hyaluronic 
acid (HA) [250], a glycosaminoglycan found in the extracellular matrix that binds and 
retains water molecules [251]. As an example of the potential of HA, Yang et al. assessed 
the penetration capacity of an HA-conjugated form of the human growth hormone (hGH) 
[252]. hGH has been commonly employed for the treatment of short stature by injection 
over months to years. As hGH receptors are distributed throughout the skin, especially in 
fibroblasts, and influence cell proliferation and differentiation [253, 254], topical 
administration of hGH represents an exciting alternative to intravenous injection. The 
topical application of the HA-hGH conjugate led to increased penetration and reached the 
dermis, thereby drastically enhancing the bioavailability of hGH in the bloodstream when 
compared to free hGH.  
The bioresorbable polymer chitosan represents another natural polymer carrier 
that can enhance skin penetration by modifying the secondary structure of keratin in the 
skin, thereby increasing the hydration of the stratum corneum and cell membrane fluidity 
[255]. Chitosan is a type of mucopolysaccharide found in the shell of crustaceans, and 
many other organisms, including insects and fungi [256]. Pawar et al. prepared a chitosan 
hydrogel containing the covalently conjugated antibiotic cefuroxime by an ester linker 
for the treatment of wound infections in the skin. The results revealed a potent 
antibacterial activity using the agar well diffusion method (Kirby-Bauer assay [257]), 
thereby extending the therapeutic time span of the antibiotic [258]. 
The conjugation of various drugs (e.g., retinal [Vitamin A], pyridoxal [Vitamin 
B6], and pyridoxal phosphate [metabolically active coenzyme of vitamin B6]) to a 
polyamidoamine based dendrimer (PAMAM), a type of branched polymer, has also been 
used as a means to effectively penetrate the skin [259]. Due to the intrinsic characteristics 
of these branched polymers, such as monodispersity and a compact spherical structure   
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(1 - 10 nm), the reduced size of the PAMAM dendrimers improved the penetration of the 
conjugates in the skin [260, 261].  
A study by Castleberry et al. reported the conjugation of all-trans retinoic acid 
(ATRA) to a hydrophilic polymer, polyvinyl alcohol (PVA), through a hydrolytically 
degradable ester linkage (PATRA), as a potential means to improve transdermal 
penetration. Franz diffusion cell studies using an explant pig skin model demonstrated 
that topical application of the PATRA conjugate for 12 hours led to the improved dermal 
accumulation of ATRA. In vivo irritation studies demonstrated that PATRA generated a 
more significant reduction in inflammation at the site of application site when compared 
to free ATRA [262].  
In another study, Bonina et al. developed polyoxyethylene ester prodrug 
conjugates of different anti-inflammatory drugs (e.g., ketoprofen, naproxen, and 
diclofenac). Ester synthesis employed the conjugation of drugs with polyoxyethylene 
glycols using a succinic acid spacer. In vitro transdermal absorption studies established 
that esters with elevated levels of ethylene oxide groups displayed an increased flux 
through the skin when compared to the application of the free drugs. The evaluation of 
the anti-inflammatory activity of the conjugates in a methyl nicotinate-induced skin 
erythema model in healthy human volunteers demonstrated the appreciable and sustained 
activity of ketoprofen and diclofenac esters with higher PEG molecular mass compared 
with the free drugs [263].  
Polymer therapeutic approaches have also been employed to develop a topical 
chemotherapy strategy for the treatment of melanoma. Capanema et al. developed a 
carbohydrate-based prodrug composed of a carboxymethylcellulose polymer conjugated 
with the anticancer drug DOX via covalent amide bonds. Additionally, cross-linking of 
the polymer with citric acid produced advanced hydrogels. The results established the 
influence of the carboxymethylcellulose structure (different degree of substitution) on 
DOX release kinetics in vitro and its cytotoxicity towards melanoma cancer cells in vitro 
[264]. 
Overall, polymer therapeutics offer particular advantages that can enhance 
transdermal drug delivery. Although the skin presents certain challenges to the delivery 
of therapeutic agents, such as the stratum corneum barrier and constant cell shedding, 
polymer therapeutics can overcome barrier properties and promote drug penetration to 
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deeper skin layers. The use of polymer therapeutic-based formulations for various skin 
diseases could revolutionize current therapeutic strategies employed in dermatology by 
overcoming old challenges and offering new perspectives for the treatment and 
prevention of dermatological diseases. 
To this end, we will discuss the skin disorder psoriasis in the following section as 
one of the main focuses of this thesis. 
I.5. Psoriasis as a Target Pathology 
Damage to the skin barrier function leads to the development of several skin 
diseases or disorders [265]. Skin barrier integrity is essential for the protection of the 
whole body, and its dysfunction can enhance the risk of developing infective and 
inflammatory disorders [266]. In some disorders, such as psoriasis, the inflammatory 
process impedes the correct synthesis and maintenance of skin barrier elements and 
prevents or diminishes the effectiveness of topical treatments. Our challenge is to develop 
a suitable and effective topical treatment for our target pathology, psoriasis, through the 
application of a polymer therapeutic-based approach.  
Psoriasis is a common and chronic inflammatory disease mediated by the immune 
system with predominantly cutaneous involvement. Psoriasis is characterized by the 
unpredictable nature of pathological evolution, presenting with periods free of disease 
followed by periods of outbreaks with highly variable appearance and duration. There are 
several clinical phenotypes of psoriasis, which can be classified based on the 
characteristics of the disease, including patient age at disease onset, degree of skin 
involvement, morphologic pattern, and anatomic location [267]. While the most common 
manifestation of psoriasis is plaque psoriasis or psoriasis vulgaris (90% of psoriatic 
patients [268]), other forms of this disease include psoriasis-like pustular psoriasis, 
erythrodermic psoriasis, and guttate psoriasis (Figure I. 9) [269, 270]. Psoriasis can have 
a considerable impact on patient quality of life, due, in most cases, to the perceived 
embarrassment regarding the appearance of the skin, therefore affecting both the physical 




Figure I. 9: Clinical presentation of psoriasis. Adapted from [272, 273]. 
I.5.1. Prevalence and Morbidity 
Psoriasis is a relatively common disease, affecting 2 - 3% of the adult population 
and 0.5 - 1% of children [274]. Studies have indicated that the incidence of psoriasis 
doubled between the years 1970 and 2000 [275] and can appear at any age, although 
normally between the ages of 15 - 30 and 50 - 60 [276]. According to the National Institute 
of Health (NIH), as many as 7.5 million Americans suffer from some form of psoriasis, 
with more than 150,000 new diagnoses of psoriasis reported every year; however, most 
new cases are in persons under 30 years of age [277]. These numbers translate to annual 
health care costs of around $135 billion in the USA alone [278].  
Recently, the importance of gender in psoriasis prevalence has been demonstrated 
[279] in a study that demonstrated a significantly higher presence of the disease in male 
than in female in the Japanese and Thai populations (Figure I. 10) [280, 281]. 
 
Figure I. 10: Prevalence of psoriasis and the palmoplantar pustulosis (PPP) (localized forms of 
pustular psoriasis) in the Japanese (left) and Thai (right) population. Adapted from [280, 281]. 
The onset of psoriasis usually leads to the development of new associated 
disorders, as the chronic systemic inflammation associated with psoriasis leads to an 
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increased risk of suffering from cardiovascular diseases [271] such as hypertension, 
diabetes mellitus, and obesity [282]. Furthermore, psoriasis can trigger the appearance of 
other autoimmune diseases, such as psoriatic arthritis and Crohn’s disease [283]. 
I.5.2. Etiology 
Psoriasis is a complex disease that involves a range of factors or causes. The 
development of the disease has a genetic predisposition, along with several factors that 
can trigger its appearance. 
I.5.2.1. Triggering Factors 
1. Trauma and Infection 
In 1872, Koebner discovered that psoriatic skin lesions appeared in unaffected 
areas following trauma in patients [284]. The “Koebner phenomenon” describes the 
characteristic distribution of psoriatic lesions on extensor surfaces, such as the elbows, 
knees, and sacral region. Additionally, infections can induce and/or exacerbate the onset 
of psoriasis by triggering a cascade of internal alterations. Infections by Streptococcus, 
Staphylococcus aureus, Malassezia fungi, Candida, and some viruses can all induce 
psoriasis [285]. 
2. Obesity 
Psoriasis can represent both the cause and consequence of the appearance of 
obesity, along with other cardiovascular diseases. Recent studies have shown that patients 
with obesity have a high risk of developing psoriasis. For instance, the Nurses’ Health 
Study followed around 100,000 women over 12 years, assessing if obesity was a potential 
triggering factor. The authors demonstrated the presence of a significant association 
between increasing body mass index and the risk of suffering psoriasis [286]. 
3. Medication 
Certain medications can cause the appearance of psoriasis in patients with a 
genetic predisposition and can also intensify or exacerbate existing disease. Some of the 
drugs evaluated as potential triggers of the disease include beta-blockers, lithium, 
hydroxychloroquine, some antibiotics (penicillin, amoxicillin, ampicillin, and 
doxycycline), and non-steroidal anti-inflammatory drugs [285, 287, 288]. 
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4. Stress, Alcohol, and Smoking 
Periods of stress can lead to the appearance of psoriasis, and while the exact 
mechanisms involved have yet to be clarified, one study established that stress produces 
alterations in the hypothalamic-pituitary-adrenal axis that provokes changes in the 
expression of some hormones [289, 290]. Furthermore, unhealthy habits such as smoking 
or the excessive consumption of alcohol can trigger the disease, with studies directly 
linking tobacco/alcohol consumption to the appearance of psoriasis [291, 292]. 
5. Endocrine factors 
Some hormones related to the hypothalamic-pituitary-adrenal axis, such as 
androgens, prolactin, and thyroid hormone, influence psoriasis directly [293]. Abrupt 
changes in hormonal levels, such as those that occur during pregnancy, can produce the 
appearance of psoriasis or worsen preexisting disease [294]. 
I.5.2.2. Genetic Factors 
 Psoriasis is also related to a strong hereditary character, involved a complex 
genetic basis [295]. Multiple genes are involved in the molecular genetic basis of 
psoriasis, confirming the complexity of the disease [296]. Although there exists 
heterogeneity between different populations, previous studies identified ten loci as 
common potential psoriasis susceptibility regions [297] (Table I. 9).  




The primary susceptibility locus for psoriasis is at 6p21, referred to as PSORS1, 
which is over-expressed in all populations tested [298-301]. Additional studies found a 
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relationship between psoriasis and other genes implicated in inflammatory pathways, 
including nuclear factor kappa beta (NF-kB), tumor necrosis factor (TNF), and 
interleukin (IL)-23/17 pathways [297] demonstrating a central role of both the innate and 
the adaptive immune system. 
I.5.3. Immunopathological Features 
While initial analyses suggested that the aberrant activity of keratinocytes and the 
associated uncontrolled proliferation of the epidermal cell layers causes psoriasis, recent 
studies have demonstrated that the evolution of psoriatic skin inflammation seems to be 
influenced by the presence of immune cells, especially dendritic cells and T cells [274]. 
Therefore, psoriasis is no longer considered merely as a disease caused by an ineffective 
skin barrier, but rather a more complex and systemic disease. Moreover, studies have 
established a dependence on the interaction between systemic pro-inflammatory factors 
and keratinocyte overproliferation [302-304]. Alterations to the immune system are now 
considered the primary inducing factor for psoriasis [293]. 
 Psoriasis vulgaris is characterized by aberrant keratinocyte hyperproliferation in 
the basal layer when compared with healthy skin, causing the increment in epidermal 
thickening (acanthosis) that produces the plaques that characterize this subtype [305, 
306]. Additionally, the premature maturation of keratinocytes produces the incomplete 
conversion of keratinocytes into corneocytes, with the retention of nuclei in the stratum 
corneum (parakeratosis) [307]. Inflammatory infiltration, consisting mainly of dendritic 
cells, macrophages, and T cells (Figure I. 11), is also observed in psoriatic lesions. 
Psoriasis also affects the regulation of the synthesis of essential keratins (K) for the 
correct functioning of keratinocytes; one study found that hyperproliferation-associated 





Figure I. 11: (A) Characteristics plaques together with erythema, in different sizes and shapes. 
(B) Histopathological features characterized by increased epidermis thickness, parakeratosis, 
elongated rete ridges, and a mixed cellular infiltrate CD3+ T cells (C) and CD8+ T cells (D). 
Adapted from [307].  
I.5.4. Immunopathogenesis: Central Role of the Immune System 
The contributions of dysfunctional skin cells and the immune system establish a 
pro-inflammatory environment within the skin that prevents the normal functioning of 
the skin barrier. During the development of psoriasis, there exists a close relationship 
between the innate and adaptive immune system; the innate immune system provides an 
early response mechanism, and after its activation, the adaptive immunity becomes 
involved. 
As described Nestle et al. [307] (Figure I. 12), the onset of psoriasis begins with 
the activation of the innate immune system, in particular, the activation of dendritic cells 
(DCs), which are antigen-presenting cells that connect innate and adaptive immunity. 
Different types of DCs can be found in the skin, expressing different surface markers and 
immune mediators. Following inflammation, studies have revealed an increase in the 
numbers of specific DC populations, including plasmacytoid DCs (pDCs) and dermal 
myeloid DCs (mDCs) [274]. During disease initiation, pDCs become activated in huge 
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numbers. Following a disease trigger, keratinocytes respond by producing LL-37, an 
antimicrobial peptide, that complexes with self-DNA and RNA. LL-37/DNA and LL-
37/RNA complexes can be uptaken by dendritic cells and activate them, stimulating two 
Toll-like receptors (TLR) types, TLR-9, and TLR-7, respectively.  
Adaptive immunity-related mechanisms begin to function following the activation 
of the innate immune system. Activated dendritic cells produce the synthesis of pro-
inflammatory cytokines such as IL-12 and IL-23 [310] to promote T-cell induction of Th1 
and Th17 class expansion, respectively. This interaction begins a cascade of inflammation 
and the synthesis of proinflammatory cytokines such as IL-17A, IL-17F, IL-22, IL-26, 
IL-6, IL-21, TNF-α, and interferon gamma (INF-γ) [274, 310]. The cytokine IL-17 plays 
an essential role in the amplification of the inflammatory signal, and several studies have 
indicated that the development of psoriasis occurs primarily through the IL-23/IL-17 axis, 
which, therefore, represents a primary therapeutic target. Binding of IL-17 to receptors 




Figure I. 12: Evolution of a psoriatic lesion from initiation to maintenance of disease. Adapted 
from [307]. 
Other than the activation of Th17 cells, IL-23 has been implicated in several other 
effects related to the development of psoriasis [312]. IL-23 receptor complex is formed 
by IL-12Rb1 and IL-23R subunits, which are associated with the Jak family members. 
IL-23 stimulation activates receptor-associated Jaks [310], which, in turn, phosphorylate 
tyrosine residues that serve as docking sites for the signal transducer and activator of 
transcription (STAT) molecules, with STAT3 the most relevant member in the IL-23 
signaling pathway. After activation, STAT3 homodimers translocate into the nucleus and 
bind DNA promoter regions of target genes, thereby promoting the synthesis of cytokines 
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related with psoriasis (IL-17A, IL-17F, and INF-γ) (Figure I. 13). Moreover, IL-23 alters 
the expression of TNF-α by stimulating macrophages [293] and has a direct impact in 
keratinocytes by promoting keratin 16 (K16) gene expression, which is associated with 
epidermal hyperplasia [308, 313]. 
 
Figure I. 13: IL-23 signaling pathway. Adapted from [310]. 
Other cytokines with essential roles in the development of psoriasis include TNF-
α and INF-γ. A multitude of cells involved in the pathophysiology of psoriasis produce 
TNF-α, including keratinocytes, DCs, and Th1, Th17 and Th22 cells [314], which 
participates in both acute and chronic phase disease. The pro-inflammatory functions of 
TNF-α include the initiation of several secondary mediators and the induction of adhesion 
molecules [315]. 
INF-γ also represents a crucial mediator that prolongs the inflammatory process. 
Type I IFNs play various roles in the antiviral host defense, due to their ability to prevent 
viral replication and promote immune system activation [316]. Activated pDCs secrete 
large amounts of INF-γ in response to the release of nucleic acids, which induces 
epidermal regeneration. This type of interferon is mainly involved in the acute phase of 
psoriasis (appearance of skin lesions), where pDCs infiltrate into early developing lesions 
[317]. INF-γ also affects the expression levels of IL-17, contributes to cytokine release 
[318], and induces the expression of the IL-22 receptor by acting indirectly on 
keratinocytes [314]. Moreover, continuous type I IFNs activity prevents wounds healing, 
thereby enhancing the development of psoriatic lesions [319, 320]. 
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 In summary, psoriasis is a complex disease based on interconnected 
immunological mechanisms. Although there are several pathways implied in the onset of 
the disease, the IL-23/IL-17 axis plays an essential role in the beginning, development, 
and maintenance of the disease. 
I.5.5. Current Therapeutic Approaches for Psoriasis 
The complexity of psoriasis has prompted the development of a multitude of 
treatments against the various mechanisms involved in psoriasis. Treatment approaches 
are generally patient-specific, factoring in the severity of the disease (critical factor to 
select the most adequate therapeutic), comorbidities, patient compliance, and safety. 
Furthermore, the body surface area affected must be taken into account, and while topical 
treatment suit mild to moderate psoriasis, moderate to severe psoriasis may require 
systemic medications and/or phototherapy. 
Currently developed therapeutics for psoriasis are classified into three types: 
topical, systemic, and phototherapy-based approaches. 
I.5.5.1. Topical Approaches 
Topical therapies are the most widely employed treatment for psoriasis and can 
be combined with systemic therapies in patients with more severe forms of the disease. 
Topical anti-psoriatic drugs typically aim to diminish local epidermal inflammation and 
thereby reduce both the epidermal layer thickness and desquamation in the stratum 
corneum. This approach can avoid or slow down the formation of characteristic skin 
plaques. Furthermore, decreasing inflammation through topical therapies eliminates the 
red coloration characteristic of erythema, and can, therefore, improve patient quality of 
life from an emotional health point of view.  
Recommended topicals treatments include corticosteroids, vitamin D analogs, 
calcineurin inhibitors, retinoids, and their combination [293]. Topical corticosteroids 
represent the most common and effective topical treatments, with the variety of 
vehicles/formulations (such as ointment, cream, lotion, gel, foams, etc.) allowing patient-
specific approaches based on location and severity of lesions [321].  
Of note, the correct selection of the vehicle for drug delivery is a critical parameter 
controlling the effectiveness and acceptability of topical formulations. As previously 
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mentioned, drug permeability through the different layers of the skin is modulated and 
related by the properties of the vehicle used [322]. The main parameters that ensure 
successful topical treatment, such as drug release, drug penetration through the stratum 
corneum and drug permeation through the skin layers, are determined by the interaction 
between the vehicle, the skin, and the drug [323]. The formulation of therapeutic agents 
includes ointments, creams, lotions, gels, foams, and a range of other similar examples.  
The physico-chemical properties of the vehicle condition the effect of the 
therapeutic agents on the skin. Paraffin, fats, and oils are occlusive and lipophilic vehicles, 
which enhance the moisture content in the skin, and hence increase drug penetration. The 
term occlusion refers to skin coverage by impermeable films or substances that are widely 
utilized to enhance the penetration of applied drugs [324]. In contrast, hydrogels 
consisting mainly of water do not display an occlusive effect but can improve the 
hydration level of the skin, thereby promoting drug penetration and preventing additional 
symptoms related to dry skin.  
The combination of aqueous and oily solutions results in emulsions; water-in-oil 
emulsions have a less occlusive nature than the lipid solutions but are more occlusive than 
the oil-in-water emulsions [322]. Recently, the development of Pickering emulsions, 
emulsions stabilized by solid particles in place of surfactants, has improved such vehicles. 
Adsorbed solid particles avoid coalescence to a greater degree than surfactants, a process 
in which two or more droplets merge to form a single larger droplet, stabilizing the 
emulsions. The elimination of surfactants in these vehicles allows for long term skin 
applications, where surfactants often cause irritancy [325]. Importantly, formulations that 
increase patient compliance will improve outcomes thanks to the stricter adherence to 
treatment regimens. 
I.5.5.2. Systemic Approaches 
Systemic therapies are generally the most effective treatments for psoriasis. An 
increase in our understanding of the mechanisms and mediators involved in psoriasis has 
prompted the development of new systemic therapies specifically targeting various 
critical pathways, thereby increasing the effectiveness of the treatment. These therapies 




I.5.5.2.1. Biologic Therapeutics 
  The discovery of biologic drugs has supposed a revolution in the therapeutic 
management of patients suffering psoriasis. A multitude of research articles have revealed 
the efficacy and safety profile in the long term of the biologic treatments. Therefore, this 
treatment represents an excellent therapeutic tool for chronic diseases like psoriasis [326, 
327]. Living organisms can be employed to generate biological therapeutics [328], which 
include monoclonal antibodies, cytokines, kinase inhibitors, etc [329]. The involved 
mechanisms of action focus on attacking specific targets of the immune system, and so 
have colossal relevance and potential for the treatment of autoimmune diseases. 
Biological therapeutics are classified according to the therapeutic target on which 
they act, although each one will have a different mechanism of action. Based on the 
immunopathogenesis of psoriasis, therapeutic targets with the best clinical results are the 
primary mediators of the inflammatory process of the disease, such as TNF-α, IL-17, and 
IL-23. Schadler et al. [293] described some of the most effective biologic treatments 
approved by the FDA, according to the target on which they act: 
1. TNF-α inhibitors 
Etanercept (Enbrel®, Amgen): a TNF-receptor fusion protein that acts by 
competitively inhibiting the binding of TNF-α to TNF receptors 1 and 2. Etanercept was 
approved for the treatment of psoriatic arthritis in 2002 and the treatment of plaque 
psoriasis in adults in 2005. 
Adalimumab (Humira®, AbbVie): a monoclonal antibody against TNF-α that acts 
by binding host TNF ligands, thereby inhibiting interaction with TNF receptors. 
Adalimumab was approved for the treatment of moderate to severe plaque psoriasis in 
adults in 2008. 
Infliximab (Remicade®, Janssen Pharmaceutica): a monoclonal anti-TNF-α 
antibody that acts through the same mechanism of action as Adalimumab, and was 
approved for the treatment of psoriatic arthritis in 2005 and chronic plaque psoriasis in 
2006. 
Certolizumab Pegol (Cimzia®, UCB): a Polymer Therapeutic, specifically a PEG-
TNF-α antibody fragment conjugate first approved for use in Crohn’s disease, rheumatoid 
arthritis, psoriatic arthritis, and ankylosing spondylitis. The PEG moiety induces 
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improvements to the activity of the drug, due to the increment lifetime of the molecule in 
circulation. Certolizumab Pegol received approval for the treatment of moderate to severe 
plaque psoriasis in adults in 2018. 
2. IL-17 inhibitors 
Secukinumab (Cosentyz®, Novartis): a humanized IgG monoclonal antibody that 
specifically targets IL-17A. Secukinumab was the first anti-IL-17 antibody on the market 
for the treatment of psoriasis in adults and was approved in 2015.  
Ixekizumab (Taltz®, Eli Lilly and Company): a humanized monoclonal antibody 
which targets IL-17A to inhibit interaction with its receptor that was approved in 2016 
for the treatment of adults with plaque psoriasis.  
Brodalumab (Siliq®; Valeant Pharmaceuticals): a monoclonal antibody targeted 
against IL-17 receptor A. The IL-17 receptor is a dimer complex of which receptor A is 
a shared subunit and binding of this subunit by Brodalumab prevents IL-17 from 
complexing with the receptor. Brodalumab was approved in 2017 for use in adults with 
chronic plaque psoriasis. 
3. IL-23 Inhibitors 
Guselkumab (Tremfya®; Janssen Pharmaceutica): a monoclonal antibody that 
specifically targets the p19 subunit of IL-23. Guselkumab was approved in 2017 for use 
in adults and became the first selective IL-23 inhibitor on the market.  
Tildrakizumab (Ilumya®, Sun Pharmaceutical Industries Ltd.): An IgG 
humanized antibody that also targets the p19 subunit of IL-23. In 2018, Tildrakizumab 
received approval for treatment of adults with moderate to severe plaque psoriasis. 
New drugs in phase III clinical trials for the treatment of moderate to severe plaque 
psoriasis and psoriatic arthritis, including bimekizumab (IL-17 inhibitors) and 
risankizumab (IL-23 inhibitor) [293, 330]. 
I.5.5.2.2. Non-Biologic Therapeutics 
Non-biologic therapeutics for moderate to severe psoriasis represent less specific 
systemic treatments with generally lower efficacy than biologic therapeutics. Commonly 
employed non-biologic therapeutics include methotrexate, a dihydrofolate reductase 
inhibitor that reduces the synthesis of purines and pyrimidines required for DNA 
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synthesis. However, methotrexate also displays anti-inflammatory, anti-proliferative, and 
immunosuppressive activities in psoriatic patients [331].  
Apremilast, a phosphodiesterase 4 inhibitor, inhibits the breakdown of cyclic 
adenosine monophosphate and the decreased production of inflammatory cytokines and 
clinical trials have established Apremilast as an effective treatment for plaque, nail, scalp, 
and palmoplantar psoriasis [332, 333].  
Cyclosporine, an immunosuppressive drug that inhibits calcineurin and decreases 
the synthesis of IL-2, is a conventional oral treatment for psoriasis treatment alongside 
methotrexate [334].  
Finally, Acitretin, a vitamin-A-derived retinoid that interferes with epidermal cell 
growth and differentiation [335], is used in combination with topical or systemic 
treatments as alone it presents only weak effects on outcomes in psoriasis patients [336]. 
I.5.5.3. Phototherapy 
Phototherapy consists of repeated exposure of the skin to ultraviolet (UV) 
radiation as a treatment and is often employed following the failure of topical 
medications. While recent improvements have improved utility and accessibility, the 
mechanism of action has yet to be fully delineated [337]. However, studies have 
discovered that phototherapy intensifies cutaneous immunosuppression, mainly by 
altered cytokine expression and lymphocyte apoptosis [338].  
Different types of radiation have been used; ultraviolet B (UVB), ultraviolet A 
plus psoralen (PUVA), and photodynamic therapy (PDT) [339]. Ultraviolet B radiation 
at 311 nm represents the most common and effective phototherapeutic modality in 
psoriasis patients; however, the strategy of employing ultraviolet A plus psoralen (PUVA) 
is no longer used to the heightened associated risk of skin cancer [293]. To improve 
patient compliance, home UV units were developed to allow patients to avoid medical 
facilities, and this has improved access to treatment and increased patient satisfaction 
[340].  
I.5.6. Nanomedicine-Polymer Therapeutic Approaches to Psoriasis Treatment 
Several polymer-based nanocarriers have been employed as drug delivery systems 
for the treatment of skin diseases such as psoriasis, as they permit the sustained diffusion 
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of the drug into the skin following the formation of a high drug concentration gradient at 
the skin surface [341]. These advantages allow the sustained and controlled drug release 
at the target site for prolonged periods when compared to the free drug [342, 343]. 
Furthermore, polymer-based nanocarriers can also reduce the number of doses and 
spacing times, producing higher levels of patient acceptability and treatment compliance 
[344]. In the following section, we will discuss the few studies that have directly 
addressed psoriasis.  
In 2016, Bessar et al. employed gold nanoparticles functionalized by sodium 3-
mercapto-1-propane sulfonate (Au-3MPS) to encapsulate methotrexate and studied the 
absorption behavior in a C57BL/6 mouse normal skin model. They discovered that this 
formulation reached the epidermis, with a lower amount also reaching the dermis [345]. 
Ultraviolet-visible spectroscopy after 24 hours of skin application revealed the presence 
of the conjugate in the mouse skin, with higher delivery of methotrexate to the epidermis 
and dermis using the gold nanoparticles when compared to treatment with the free drug. 
The authors confirmed their findings in vitro by scanning transmission electron 
microscopy images, observing gold nanoparticles distribution inside the keratinocytes 
from primary cell cultures.  
Another study developed by Crisan et al. employed silver and gold nanoparticles 
to carry polyphenols-rich extracts from the Cornus mas. shrub recently revealed to have 
promising anti-inflammatory activity in vivo [346]. The application of nanoparticle-based 
ointments in psoriatic patients for six weeks prompted a considerable improvement of 
psoriasis plaques, with reduced peeling, erythema, and plaque thickness. 
Immunofluorescence of skin biopsies demonstrated that nanoparticles significantly 
reduced CD68-positive macrophages and TNF-α production in the psoriasis plaques. 
Nemati et al. developed novel nanoparticles conjugating the epidermal growth 
factor receptor (EGFR) siRNAs to gold nanoparticles. Treatment (three times per week 
for three weeks) with EGFR-siRNA gold nanoparticles mixed with Aquaphor®, a 
marketed ointment for skin application of active agents, in an acute imiquimod-induced 
psoriasis murine model revealed reduced epidermal thickness when compared free 
EGFR-siRNA [347].  
Thapa et al. studied the effect of tacrolimus (immunosuppressive drug)-loaded 
liquid crystalline nanoparticles in a psoriatic mice model, finding the retention of 65% of 
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the total drug when applied as a nanoparticle formulation at 24 hours when compared to 
only 25% when used as a solution [348].  
However, the use of non-biodegradable gold, silver or liquid crystalline 
nanoparticles can provoke local and/or systemic accumulation, producing adverse effects 
in the body. Currently, lipidic and polymeric nanoparticles represent the most applied 
type of nanoparticle for the treatment of skin diseases. As an example, the encapsulation 
of capsaicin [349] or a combination of methotrexate and etanercept [350] in lipidic 
nanoparticles increases the amount of drug that reaches the viable epidermis when 
compared to the application of the drug alone. The controlled synthesis of polymeric 
nanoparticles also allows more controllable development of chemical and physical 
characteristics and can help the nanoparticle (and hence the associated drug(s)) to 
penetrate through the skin and improve therapeutic outcomes.  
The application of polymersomes [351, 352] has led to further improvements in 
drug treatment for psoriasis. As an example, Marepally et al. developed a polymersome 
based on a fusogenic nucleic acid lipid particle (F-NALP) system, encapsulating two 
therapeutic nucleic acids, anti-STAT3 and anti-TNF-α siRNA. Results revealed that F-
NALPs efficiently carried both therapeutics into the dermis and synergistically functioned 
to improve psoriatic-like plaques in an imiquimod-induced psoriatic-like plaque mouse 
model.  
Several studies revealed the potential of drug encapsulation in polymeric 
nanoparticles as a delivery system. For instance, the use of curcumin-loaded poly-lactic-
co-glycolic acid) (PLGA) nanoparticles in a psoriasis-like mouse model prompted a 
reduction of psoriasis symptoms, mainly due to the higher penetration through the skin 
of the PLGA nanoparticles in comparison with free curcumin in gel [353]. In studies 
carried out by Mao et al. aiming to increase the encapsulation efficiency of curcumin, 
researchers synthesized new self-assembled nanoparticles formed by a new amphiphilic 
polymer, RRR-α-tocopheryl succinate-grafted-ε-polylysine. The application of these 
curcumin-loaded nanoparticles in gel in an imiquimod-induced psoriatic mouse revealed 
that the nanoparticles displayed better activity than the free curcumin in gel, with a higher 
therapeutic effect and significant inhibition of the expression of inflammatory cytokines 
(TNF-α, NF-kB, and IL-6) [354]. 
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Gurny and co-workers developed a new formulation for tacrolimus encapsulation, 
using a methoxy-poly (ethylene glycol)-hexyl substituted poly (lactic acid)-based 
nanocarrier and subsequently loaded it into a carbopol hydrogel. The authors compared 
the activity of the developed formulation with the commercial formulation Protopic™, 
an ointment containing free tacrolimus used as a benchmark. The results revealed that the 
skin delivery of tacrolimus composite hydrogel in an imiquimod-induced psoriasis mouse 
model was twice as high as for the Protopic™. Furthermore, the tacrolimus composite 
hydrogel showed significant enhancements on both the histopathological score in the 
mice model as well as the in vivo clinical score (erythema and skin thickness) [355]. 
In 2017, Wan et al. synthesized a novel hybrid system based on self-assembling 
nanoparticles of HA-conjugated cholesterol for the encapsulation of nicotinamide and 
tacrolimus. Antipsoriatic activity assessed in an imiquimod-induced psoriasis mouse 
model found that the newly developed nanoparticles functioned as well as a positive 
control for psoriasis treatment (clobetasol propionate) and better than a commercial 
ointment Protopic® [356]. 
To the best of our knowledge, there exist only a few reports of the development 
of polymer-conjugated psoriatic drugs. Jin et al. conjugated zinc phthalocyanine (core) to 
a biocompatible amphiphilic polymer called Brij 58 (a type of polyoxyethylene acyl 
ether) (shell), to create a novel compound for photodynamic therapy of psoriasis. Anti-
psoriatic activity assessments in guinea pig psoriasis model suggested that treatment with 
the conjugate prompted an almost complete disappearance of the signs of psoriasis 
according to the histopathological investigation, compared to groups treated with saline, 
light alone, zinc phthalocyanine polymer conjugate alone, and the combination of light 
and zinc phthalocyanine polymer conjugate [357].  
Summarising, although not many examples of nanomedicine and in particular 
Polymer Therapeutics have been so far reported for the topical treatment of psoriasis it is 
clear that a rational design and a control drug release at the adeaquate skin layer and 
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CHAPTER II  
EX VIVO AND IN VIVO MODELS OF PSORIASIS: 





























II.1. Antecedents and Background 
Psoriasis, a human-specific and genetically heterogeneous autoimmune chronic 
inflammatory skin disease, currently lacks effective treatment options. At the histological 
level, psoriatic lesions present with acanthosis (thickened epidermis due to rapid 
keratinocyte proliferation), elongated epidermal rate ridges (epithelial extensions that 
project into the underlying connective tissue in both skin and mucous membranes), 
aberrant differentiation of keratinocytes, dilation of blood vessels in papillary dermis 
causing visible erythema (redness of the skin or mucous membranes), and elevated levels 
of inflammatory cell infiltration [1, 2]. During the last decade, our knowledge base 
regarding psoriasis pathogenesis has widened, leading to the development of accurate ex 
vivo and in vivo models. 
Ex vivo models represent valuable research tools for investigations into psoriasis 
and are considered more relevant than in vitro research involving cell lines. Reconstructed 
epidermal models and ex vivo human skin models are the most relevant, and although 
both can test the topical application of different active agents at similar concentrations to 
real dosage conditions [3], the use of human skin from different types of surgeries (e.g., 
abdominal) is considered the most representative model to mimic the complexity and 
interactions in human physiology [4]. Reconstructed epidermal models do not include all 
human skin cell types as they develop from specific cell lines (keratinocytes and 
fibroblasts) and present with a more permeable stratum corneum [5, 6].  
During the development of this thesis, we employed both models to evaluate the 
safety of the synthesized conjugates and their anti-inflammatory activity. We developed 
healthy reconstructed epidermal models following well-established methodologies that 
employed primary human keratinocytes and fibroblasts from juvenile foreskin [7, 8] 
through a collaboration with Prof. Sarah Hedtrich (University of British Columbia, 
Vancouver, Canada). To develop an inflammatory phenotype in the reconstructed 
epidermal models emulating characteristics of psoriatic skin, such as hyperproliferation 
[9], we added recombinant TNF-α to the culture medium to induce the release of pro-
inflammatory cytokines to the culture medium. The assessment of the conjugates in these 
reconstructed epidermal models will be detailed in Chapter IV. We anticipate that the 




Concurrently, in our laboratory, we have developed ex vivo human skin models 
from skin explants from patients. The methodology involved in the development of ex 
vivo human skin model comprises the culture of skin samples in wells containing metal 
grid supports held over liquid culture medium, allowing epidermal exposure to air and 
contact of the dermis with the culture medium for several days. This approach enables 
the study of several parameters, including tissue viability, drug penetration, intradermal 
vaccination, photosafety evaluation, skin barrier repair, and genotoxicity [3, 6, 10-13]. 
Of note, ex vivo human skin models allow the development of inflammatory 
models through the application of bacterial lipopolysaccharide (LPS) and pro-
inflammatory cytokines or mediators.  
Inflammatory ex vivo skin models allow us to monitor the processes involved 
following activation of the immune system in healthy human skin [14], such as the release 
of pro-inflammatory cytokines or the increment in the thickness of the epidermis due to 
inflammatory processes. These models mimic the physiological characteristics of 
inflammatory skin diseases, such as psoriasis [15, 16], and therefore, allow the screening 
of anti-psoriatic drugs in topical treatments. Ex vivo human skin models also enable the 
testing of pharmaceutical products without the need for animals [17-19], thereby abiding 
by the 3R principle [20]: replacement (replace the use of animals), reduction (reduce the 
number of animals), and refinement (minimize animal suffering). However, limited 
accessibility to skin biopsies, donor variability [4], and the lack a real immune system to 
mimic the features of an autoimmune disease such as psoriasis represent significant 
problems with ex vivo human skin models. Therefore, the application of in vivo models 
will complement the information obtained from the ex vivo models. 
The development of in vivo preclinical mouse models may help us to understand 
the genetic and immune mechanisms contributing to disease development. Thus, any 
animal model developed must reflect the critical features of the human disease and 
respond similarly to previously developed psoriasis treatments [21]. 
 Recent decades have seen the development and characterization of a wide range 
of mouse models of psoriasis, as described in Figure II. 1. The most representative 
models for the study of psoriasis are classified into three types: i) acute (inducible) [22-
24], ii) genetically engineered (transgenic) [25-28], and iii) xenograft (humanized) 
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models [29, 30]. The advantages and limitations associated with each type of model 
highlight the complexity of mimicking multifactorial human diseases in animals [31].   
 We have developed and studied the features of an imiquimod (IMQ)-induced 
model of acute skin inflammation in immunocompetent (BALB/c) mice for the 
preclinical study of psoriasis. IMQ (or 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-
4-amine) is an imidazoquinoline derivative with a small size and high hydrophobicity 
[32]. IMQ has displayed antiviral and antitumor activity in animal models, enhancing 
both the innate and the adaptive immune system [33].  
Drugs like IMQ represent a new therapeutic approach to modify and enhance the 
immune response [34]. The first formulation of IMQ (AldaraTM cream) was developed by 
3M Pharmaceuticals, with IMQ 5% cream clinically applied to treat genital and perianal 
warts commonly caused by different viruses. Overall, patients tolerated this treatment 
well, with some measure of effectiveness observed [35, 36]. 
 
 
Figure II. 1: Summary of the major types of preclinical mouse models currently employed to 
study psoriasis. Adapted from [10]. 
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Van der Fits et al. described the first use of IMQ to generate a psoriasis mouse 
model, establishing that the repeated application of IMQ produced phenotypic changes in 
the skin similar to psoriasis and modulated the IL-23/17 axis [37]. The primary mode of 
action of IMQ occurs through the activation of the Toll-like receptors (TLRs), with TLR7 
specifically involved in psoriatic disease [38-40]. The TLR family is composed of ten 
human pathogen-recognition receptors (TLR-1-10) and represents a central component 
of the innate immune response, allowing cytokine synthesis in response to different 
stimuli [41]. Nevertheless, several studies have demonstrated that IMQ can activate other 
mechanisms independently of TLR7 signaling. For example, IMQ can antagonize A2A 
adenosine receptors to diminish the activation of adenylyl cyclase and the accumulation 
of cyclic adenosine monophosphate (cAMP), thereby decreasing immunosuppression and 
promoting inflammation [42].  
 The IMQ mouse model of acute skin inflammation presents several advantages 
when compared to other model systems, including the straightforward application of IMQ 
(directly to the back of the mouse), the low costs compared to xenograft or knockout 
models, and the rapid induction of inflammation that reduces the treatment duration 
required to produce acute skin inflammation. However, there do exist limitations to this 
model, as the topical application of IMQ can produce a systemic inflammatory response 
and dehydration [39]. Moreover, the establishment of certain aspects of human psoriasis 
is limited due to the acute and non-chronic induction of the disease. Even given these 
limitations, the IMQ-induced psoriasis mouse model has rapidly become one of the most 
widely employed for the study of human psoriasis [43-45]. 
 In this chapter, we focus on fully characterizing disease progression using an 
inflammatory ex vivo human skin model and an in vivo mice model of psoriasis. In the ex 
vivo model, we focus on the histopathological characteristics of the inflamed skin and the 
release of pro-inflammatory cytokines into the culture medium. The in vivo model 
provides information regarding disease progression during the seven days of IMQ 
application in immunocompetent mice, concentrating on the identification of functional 
features in the skin and the expression of pro-inflammatory cytokines considered crucial 
for disease development. Due to the fact that the application of IMQ cream produces acute 
rather than chronic inflammation, we also study the maintenance and progression of the 
disease for a further ten days after the IMQ application ceases to determine the optimum 
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time for subsequent studies into the application of different anti-psoriatic treatments 
(without the disappearance of the main features of the disease). 
II.2. Results 
II.2.1 Ex Vivo Human Skin Model 
II.2.1.1. Characterization of Ex Vivo Human Skin Model  
II.2.1.1.1. Tissue Viability Maintenance 
We developed and characterized an ex vivo human skin model [46] and then 
assessed skin viability over 11 days using the MTT cell metabolic activity assay. The 
results revealed constant tissue viability from day 0 to day 4 in culture medium (Figure 
II. 2) [18]; however, we observed a marked decrease in tissue viability from day 4 to 7, 
after which point, tissue viability remained constant until day 11. These results indicate 
that keratinocytes within the ex vivo human skin model maintain their metabolic activity 
for the first 4 days, therefore mirroring the properties of healthy human body skin.  
 
Figure II. 2: Tissue viability of skin samples in culture medium for 11 days by MTT assay (n=3). 
II.2.1.1.2. Histological Features 
Analysis of the histological features of the ex vivo human skin model also 
confirmed tissue viability during the experimental time in culture (Figure II. 3). 
Hematoxylin-Eosin (H&E) staining of skin samples (Figure II. 3 – Top Row) revealed 
the maintenance of skin structure and physiology for the 11 days in culture medium; 
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overall, the different skin layers appeared similar to day 0 at all other experimental time 
points. Furthermore, we observed a clear differentiation between the epidermis and the 
dermis layer at all times studied, without unwanted alterations such as tears or epidermal 
thickening. 
Additionally, we established the presence of the Ki67 marker in keratinocytes at 
all studied times (Figure II. 3 – Middle Row), indicating the proliferative nature of these 
cells. Finally, we studied the expression of the cytokeratin (Ck) 5/6 basal cell marker in 
the epidermis (Figure II. 3 – Bottom Row) (Ck5 stabilizes the epidermis and Ck6 is 
considered as a hyperproliferative cytokeratin [47]), finding positive staining at all times 
under investigation. Again, this reinforces the adequate maintenance of morphology, 
proliferation, and the capacity for cytokeratin synthesis. 
 
Figure II. 3: Histological features of the ex vivo human skin model by H&E staining (first row), 
Ki67 marker (second row) and Ck5/6 marker (third row). Original magnification displayed in 
each image was 10x. One representative picture is shown for each time point. 
II.2.1.2. Characterization of Inflammatory Ex Vivo Human Skin Model 
A combination of epidermal growth factor (EGF) and bacterial LPS in the culture 
medium in contact with the skin ex vivo can mimic the histological and biochemical 
features of psoriatic lesions [48]. Although this system lacks an immune system, the 
epidermal keratinocytes in such inflammatory model can produce and release pro-
inflammatory cytokines to the culture medium in response to triggers, such as LPS. 
Moreover, the activity of EGF and the local inflammation produced by LPS produces an 
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increment of epidermal thickness, thereby imitating the typical ridges and hyperkeratosis 
that occur in psoriasis. Also, this inflammatory model offers complementary information 
to in vitro experiments and can provide results similar to those obtained from in vivo 
experiments. 
Importantly, this model allows for the extensive evaluation of anti-psoriatic 
therapeutics after application on the skin. For example, penetrative capacity can be 
studied qualitatively and quantitatively with techniques including confocal microscopy, 
high-performance liquid chromatography (HPLC), or liquid chromatography-mass 
spectrometry (LCMS). Also, the model permits both the histological evaluation of 
epidermal thickness modulation and the assessment of anti-inflammatory capacity via 
quantification of the pro-inflammatory cytokines released to the culture medium. 
In the following sections, we report the results of our exhaustive characterization 
of the developed inflammatory model to ensure the presence of psoriasis-like 
characteristics. 
II.2.1.2.1. Maintenance of Tissue Viability Following Inflammation  
We evaluated tissue viability after the addition of a combination of LPS and EGF 
in the culture medium to induce inflammation at 24 and 48 h by MTT assay. We 
maintained a constant concentration of EGF (2.5 ng/mL) but varied the level of LPS from 
10 to 30 µg/mL at 24 h and from 10 to 15 µg/mL at 48 h (Figure II. 4).  
 
Figure II. 4: Tissue viability after the treatments with different concentrations of LPS (10 - 30 
µg/mL) and a constant concentration of EGF (2.5 ng/mL) at 24 (A) and 48 h (B) in culture medium 




The results obtained suggest that tissue remains viable, with no significant 
differences observed between any combination of inflammatory insults and control. 
However, we do note the overall trend for a reduction in cell viability with the increasing 
levels of LPS at 24 h. 
II.2.1.2.2. Inflammatory Features  
We next assessed tissue viability after inflammatory insult by monitoring the 
histological modification of tissue over time. H&E staining for histomorphologic analysis 
revealed that the skin maintained its structure in response to the various inflammatory 
insults (Figure II. 5A). However, we observed a general increase in epidermal thickness 
in response to the combined action of the LPS and EGF, therefore suggesting that this 
inflammatory model mimics the features of skin suffering from inflammatory diseases as 
psoriasis.  
We immunohistochemically studied keratinocyte viability (Ck5/6 marker) and 
proliferation (Ki67 marker) and assessed inflammation through the detection of typical 
pro-inflammatory cytokines and mediators, such as the IL-1b, INF-γ, and NF-kB. 
Analyses of Ck5/6 and Ki67 confirmed the viability and proliferation of the keratinocytes 
at all the concentrations of LPS and EGF tested. However, we failed to find significantly 
different levels of inflammation between the control and the treatments, perhaps due to 
the induction of inflammation in the control samples following the surgical procedures 
employed to isolate the samples (Figure II. 5A). 
While keratinocytes are present in considerable numbers in the skin, there also 
exist other cell types such as fibroblasts (synthesis of fibers and maintenance of the 
extracellular tissue matrix), Langerhans cells (initiation and regulation of the immune 
response) and melanocytes (melanin synthesis). After treatment with the lowest 
concentrations (10 and 15 µg/mL of LPS) for 24 and 48 h, immunostaining with Hsp47 
(fibroblasts) [49], langerin (Langerhans cells) and melanin A (melanocytes) markers 
revealed the presence of all three cell types described above in the skin. This finding 
suggests that treatment with LPS and EGF failed to influence other cells of the skin 
significantly, and therefore, the cellular viability of these cell types is not affected (Figure 
II. 5B).  
Histologically, these findings indicate that the inflammatory insults employed do 





Figure II. 5: (A) H&E stained images (first row) of representative skin sections showing intact 
skin structure. Immunohistochemical staining of skin for Ck5/6 (second row) and Ki67 (third 
row) demonstrates the viability and proliferative capacity of keratinocytes. Positive cells for IL-
1b (fourth row), INF-γ (fifth row), and NF-kB (sixth row) demonstrated the induction of 
inflammation (10x magnification). (B) Immunohistochemical staining of fibroblasts (first row), 
Langerhans cells (second row) and melanocytes (third row) provides evidence that the 






II.2.1.2.3. Quantification of Cytokine Release following Inflammatory Insult 
To confirm the results obtained by histology, we assessed cytokine release after 
inflammatory insult to corroborate the establishment of the inflammatory model. We 
quantified the release of cytokines to the culture medium using a LUMINEX kit after 
inflammatory insult at 24 and 48 h. As shown in Figure II. 6A, the application of LPS at 
10 and 15 µg/mL for 24 h led to a significant increase in the levels of the pro-
inflammatory cytokines IL-1b and TNF-α, and the granulocyte macrophage colony 
stimulating factor (GM-CSF). In contrast, higher concentrations of LPS (20 and 30 
µg/mL) failed to produce further increases in the release of pro-inflammatory cytokines 
and so studies at 48 h only employed 10 and 15 µg/mL of LPS (Figure II. 6B). 
Interestingly, we observed a trend for the increased expression of the INF-γ pro-
inflammatory cytokine at 24 h, but we failed to observe a similar induction using 10 and 
15 µg/mL of LPS at 48 h. At 48 h, as for 24 h, we observed a marked increase in the levels 
of IL-1b, TNF-α, and GM-CSF.  
 
Moreover, we also assessed the release of IL-6, a key cytokine involved in the 
inflammatory processes, after induction with specific concentrations of LPS: 10, 15 and 
20 µg/mL at 24 h and 15 µg/mL at 48 h (Figure II. 6C). Each inflammatory insult led 
to an increase in IL-6 when compared to the control – 4 times larger than control at 24 h 
and 15 - 20 times at 48 h.  
Of note, we evaluated the levels of IL-10 anti-inflammatory cytokine [50] in the 
culture medium (Figure II. 7); the increased expression of the IL-10 after the 
inflammatory insult at 24 and 48 h indicates the development of inflammation in the skin, 
as the release of this cytokine counteracts the inflammatory response. 
Summarizing, these results revealed that low concentrations of LPS lead to acute 
inflammation in the proposed ex vivo model without affecting tissue viability and 
morphology. Therefore, we performed further studies in this model using a final 
concentration of 15 µg/mL of LPS and 2.5 ng/mL of EGF. 
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Figure II. 6: Quantification of pro-inflammatory cytokines released to the culture medium after 
24 (A) and 48 h (B) of treatment with different concentrations of LPS (10 - 30 µg/mL)  and a 
constant concentration of EGF (2.5 ng/mL). (C) Quantification of IL-6 released to the culture 
medium after 24 and 48 h of treatment with varying levels of LPS (10 - 20 µg/mL) and EGF (2.5 
ng/mL). Asterisks indicate statistically significant differences after ANOVA analyses followed 
Bonferroni’s post hoc tests, mean ± SEM. In all cases, we considered differences to be significant 
when p***<0.001; p**<0.01; p*<0.05. 
 
Figure II. 7: Quantification of IL-10 released to the culture medium after 24 (A) and 48 h (B) of 
treatment with different concentrations of LPS (10 - 30 µg/mL) and a constant concentration of 
EGF (2.5 ng/mL). Asterisks indicate statistically significant differences after ANOVA analyses 
followed Bonferroni’s post hoc tests, mean ± SEM. In all cases, we considered differences to be 
significant when p***<0.001; p**<0.01; p*<0.05. 
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II.2.2 In Vivo Model of Psoriasis 
II.2.2.1. Monitoring Safety during Disease Induction via Animal Weight 
We applied IMQ cream for seven consecutive days to the mouse dorsal region and 
on the right ear, and then sacrificed animals at day 7, 10, 12, 14, and 17 following the first 
day of treatment with IMQ (Figure II. 8A). We evaluated IMQ cream safety by 
monitoring body weight and comparing observed values to those derived from healthy 
animals. We discovered that the application of IMQ cream for seven days produced a 
slight decrease in animal weight, whereas we observed a recovery in weight after the 
administration of the drug had terminated, eventually reaching the values observed at day 
0 (Figure II. 8B). 
 
Figure II. 8: (A) General scheme of the establishment of the psoriatic model. (B) Mouse body 
weight measurement over time with no significant alterations in body weight. Animals recovered 
weight following the last day of application of the IMQ cream (day 7) with a 100% survival rate.  
II.2.2.2. Evaluation of Inflammation: Back Morphology and PASI Score 
Several studies have demonstrated that IMQ produces a robust immune response, 
inducing psoriasis-like inflammation by activating the production of immune cells via 
TLR activation and thereby mimicking the development of psoriatic features observed in 
mice [51, 52]. In our model, we stopped IMQ cream application after seven consecutive 
days of application and then monitored main psoriatic features.  
At the gross morphological level, we observed the maximum level of erythema, 
scaling, and skin thickness on the back at day 7, which remained for up to 5 days later 
(day 12). After day 12, we observed a decrease in these characteristic disease parameters 




Figure II. 9: Morphological changes observed on the dorsal skin of the animals from 7 days of 
treatment with IMQ (day 7), in comparison with day 10, 12, 14 and 17 after the first dose of IMQ. 
 
We assessed other key psoriatic features, including erythema, scaling, itching, and 
skin epidermal thickening, with the Psoriasis Area Severity Index (PASI) score. Doctors 
use this score to record psoriasis severity in the patients and is the most widely employed 
tool for measuring the psoriasis stage and evaluating the progress of people receiving 
psoriasis treatment. During the optimization stage of the psoriatic mice model, this score 
allowed us to appraise the appearance of the characteristics of the disease while applying 
IMQ cream (7 days) and their subsequent disappearance over time following the cessation 
of IMQ cream application. 
PASI scoring from day 0 to day 17 revealed the expected progressive increase in 
score until 7 days of IMQ application (Figure II. 10). Examination of the back of the 
mouse every two days following the termination of IMQ treatment revealed a reduction 
in the signs of psoriasis, especially from day 12. 
Overall, both the morphological and PASI parameters provided similar results in 




Figure II. 10: Severity of dorsal skin inflammation of the mouse indicted by PASI scoring 
(itching, thickness, scaling, and erythema) using a scale from 0 to 4. Asterisks indicate statistically 
significant differences after ANOVA analyses followed Bonferroni’s post hoc tests (mean ± SEM 
displayed). In all cases, we considered differences to be significant when p***<0.001; p**<0.01; 
p*<0.05. 
II.2.2.3. Increase in Ear Thickness 
We measured ear thickness with a caliper every two days, discovering an increase 
in the thickness during the application of IMQ up to day seven (Figure II. 11). We found 
a significantly increased ear thickness at day five and day seven of IMQ treatment, and 
this remained until five days after the last application of IMQ (day 12) when compared 
to the contralateral untreated control ear. From day 12, we observed a decrease in the 
thickness of the IMQ-treated ear due to the disappearance of the inflammation produced 




Figure II. 11: Ear thickness measurements every two days demonstrate IMQ-induced epidermal 
thickening. Asterisks indicate statistically significant differences after ANOVA analyses followed 
Bonferroni’s post hoc tests (mean ± SEM displayed). In all cases, we considered differences to 
be significant when p***<0.001; p**<0.01; p*<0.05. 
II.2.2.4. Histology of Ear and Back  
Histological examination of the ears and back sections via H&E staining revealed 
a marked difference in epidermal thickening between the healthy control and the IMQ-
treated mice (Figure II. 12). Right ear samples treated with IMQ cream displayed an 
increase in epidermal thickness that was maintained up to 12 days after the first 
application of IMQ (five days after the termination of IMQ treatment). However, analysis 
of samples from day 14 and day 17 revealed a slight decrease in epidermal thickness, 






Figure II. 12: H&E staining of the ears in IMQ-treated mice. Original magnification displayed 
in each image was 10x. One representative picture is shown for each time point. 
 
The histological examination of the dorsal skin of the IMQ-treated mouse revealed 
a similar pattern to the treated right ear. Analysis of back skin samples treated with IMQ 
until day seven revealed a considerable increase in epidermal thickness in comparison 
with healthy control. The thickening was maintained up to five days after the termination 
of treatment (day 12), although we observed decreases in epidermal thickness on days 14 
and day 17 as the mouse recovered (Figure II. 13). 
 Both the ear and the back of the mice displayed marked epidermal hyperplasia and 
hyperkeratosis, evidencing increased epidermal growth in these lesions and thereby 







Figure II. 13: H&E staining of the dorsal skin in IMQ-treated mice. Original magnification 
displayed in each image is 10x. One representative picture is shown for each time point. 
II.2.2.5. Increase in Spleen Weight 
Several studies have reported that IMQ produces significant spleen enlargement 
and a general increase in weight due to the release of pro-inflammatory cytokines [37, 54, 
55]. Our analyses revealed a considerable increase in spleen weight when compared to 
healthy control at days 7, 10, and 12 (0, 3, and 5 days after IMQ treatment termination) 
(Figure II. 14). The results demonstrated that the application of the IMQ cream in our 
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model produced a significant increase in spleen weight even at our experimental endpoint 
17 days after the first application and 10 days after removal of IMQ treatment. This 
increase in spleen weight correlates to the known increase in the synthesis of pro-
inflammatory cytokines in psoriasis. 
 
Figure II. 14: Spleen weight determined after treatment with IMQ cream. Analysis demonstrated 
significant increase when compared to the untreated control group. Asterisks indicate statistically 
significant differences after ANOVA analyses followed Bonferroni’s post hoc tests, (results 
displayed as mean ± SEM). In all cases, we considered differences to be significant when 
p***<0.001; p**<0.01; p*<0.05. 
II.2.2.6. Increased Pro-Inflammatory Cytokines Release in Serum and Tissue 
IL-1b, IL-23, IL-17, INF-γ, and TNF-α act as major inflammatory mediators of 
psoriasis and are induced upon IMQ treatment [37, 56, 57]. We employed proteins 
extracted from frozen dorsal tissue and blood serum from IMQ treated and control 
animals to study IL-23 and INF-γ protein expression using a LUMINEX Kit according to 
the manufacturer’s instructions.  
Figure II. 15 depicts the levels of cytokines in dorsal tissue over the 17 days of 
the experiment. We observed a trend for maximal induction of cytokines levels on day 
seven (seven days of IMQ treatment) in comparison with healthy control mice. Following 


















































levels except for IL-23, whose expression increased significantly over time. Of note, IL-
23 is a crucial cytokine for disease progression and maintenance in humans. 
 
Figure II. 15: Induction of the synthesis of pro-inflammatory cytokines related to psoriasis in 
mouse dorsal skin tissue as measured by LUMINEX kit. Asterisks indicate statistically 
significant differences after ANOVA analyses followed Bonferroni’s post hoc tests, results 
displayed as mean ± SEM. In all cases, we considered differences to be significant when 
p***<0.001; p**<0.01; p*<0.05. 
We also assessed the levels of pro-inflammatory cytokines in serum only in the 
last day of the experiment (day 17). While we failed to observe the induction of IL-1b or 
IL-17a synthesis when compared to healthy controls, we observed significantly higher 
values of IL-23, INF-γ, and TNF-α in IMQ-treated animals when compared to healthy 
controls (Figure II. 16).  
 
Figure II. 16: Induction of the synthesis of pro-inflammatory cytokines in serum related to 
psoriasis measured by LUMINEX kit. Asterisks indicate statistically significant differences after 
ANOVA analyses followed Bonferroni’s post hoc tests, results displayed as mean ± SEM. In all 
cases, we considered differences to be significant when p***<0.001; p**<0.01; p*<0.05. 

































































These results corroborate a robust immune response not only at the local level in the skin 
but also at the systemic level. 
II.2.2.7. Hematological Parameters 
The assessment of various hematological parameters can contribute to the 
detection of the systemic pathology development in psoriasis. We evaluated the levels of 
leukocytes, platelets, lymphocytes, and monocytes throughout the experimental time 
course. We observed specific alterations related to immune system status with 
significantly higher levels of leukocytes and monocytes after seven days of IMQ 
treatment (Figure II. 17).  
 
Figure II. 17: Complete hemogram of IMQ-induced psoriasis model. Asterisks indicate 
statistically significant differences after ANOVA analyses followed Bonferroni’s post hoc tests, 
results displayed as mean ± SEM. In all cases, we considered differences to be significant when 
p***<0.001; p**<0.01; p*<0.05. 
 
Both cell types are actively involved in the immune system [58] and, interestingly, 
monocyte-derived cells play a role in psoriasis development through the production of 
pro-inflammatory cytokines that increase the activation of skin-resident T cells [59]. 
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However, we failed to observe significantly higher lymphocyte levels as expected from 
an autoimmune disease such as psoriasis. 
Following the withdrawal of IMQ treatment, levels of leukocytes and monocytes 
reduced over time; however, we observed a peak in platelet production at day 12 (five 
days after IMQ withdrawal), perhaps due to the increase in the number of wounds that 
occur due to scaling and dryness of psoriatic skin.  
II.3. Discussion 
II.3.1. Inflammatory Ex Vivo Human Skin Model Mimics the Features of Psoriasis 
The development of new models that lie between in vitro and in vivo methods 
allow the investigation of the structure and functions of healthy and diseased skin under 
conditions close to the in vivo situation. We have developed healthy and inflammatory ex 
vivo human skin models that ensure the maintenance of skin architecture and properties. 
The implementation of this inflammatory model plays a vital role throughout this thesis, 
as we can simulate the characteristics of the human psoriasis disease and, therefore, 
evaluate different therapeutic agents developed before moving to in vivo models.  
Culturing skin with stimuli such as bacterial LPS and EGF represents a suitable 
means to induce skin inflammation. Histologically, we observed a marked increment in 
epidermal thickening, similar to that which occurs in psoriasis, without altering cell 
viability (including keratinocytes, fibroblasts, melanocytes, and Langerhans cells) and 
proliferation. Also, we failed to observe disruption to the stratum corneum, suggesting 
that the barrier function of the skin remains intact, thereby simulating the properties of 
human skin. Of note, LPS/EGF stimulation induced the secretion of pro-inflammatory 
cytokines to the culture medium, and depending on the concentration of LPS used, we 
can modulate the release of different cytokines involved in the pathology of psoriasis 
(e.g., IL-1b, IL-6, and GM-CSF) [14]. 
This ex vivo model provides a straightforward method for using human skin in 
tissue viability and drug penetration studies. Furthermore, this approach will also allow 
the rapid screening of drugs employed for the treatment of a range of skin diseases, 
including psoriasis, by evaluating the decrease in epidermal thickness and pro-
inflammatory cytokines released to the culture medium. 
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II.3.2. Suitability of Imiquimod Cream for Psoriasis Development 
While psoriasis is a uniquely human disease, a wide range of mouse models have 
been developed to mimic the main characteristics of the human condition, and these have 
allowed for the ever-widening understanding of disease pathology [21, 60]. However, the 
absence of animal models that reflect the intrinsic characteristics of the disease in humans 
remains a significant challenge to the development of new anti-psoriatic therapies [61]. 
Taking into consideration all currently available models, the in vivo IMQ-induced model 
[37, 43] has become the most straightforward model with the greatest potential for 
assessing the development of inflammatory skin diseases in humans [44, 51, 62, 63]. 
Although this model does not represent a chronic disease model, but rather an 
acute model of inflammation, IMQ-induced psoriasis in mice provides a powerful model 
with relevance to human psoriatic disease due to its simplicity, rapidity, and general 
applicability to different mouse strains [32, 64]. This simple model presents several 
features of human psoriatic skin lesions, such as the activation of plasmacytoid dendritic 
cells (pDCs) and the production of pro-inflammatory cytokines (IL-23, INF-γ, and TNF-
α) [65]. 
 However, we do note certain limitations of IMQ application; results following 
IMQ in different mouse strains have reached contradictory conclusions regarding the 
inflammatory and cellular mediators as well as the disease mechanism leading to the 
development of the psoriasis form phenotype [66]. 
II.3.3. H&E Staining as a Tool to Evaluate Skin Inflammation 
The daily topical application of IMQ cream in mice for seven days led to inflamed 
skin lesions similar to psoriatic plaques and inflammatory cell activation, mimicking 
human psoriasis, in agreement with other studies [67]. IMQ functions through the ligation 
of TLR7 in mice [38] or TLR7 and TLR8 in humans [68], which then activates the STAT1 
and STAT3 pathways required for optimal cytokine production by dendritic cells (DCs) 
[69]. The importance of STAT3 pathway activation in the pathogenesis of psoriasis was 
initially assessed through the use of transgenic mice [70]. The overexpression of STAT3 
in keratinocytes through activation with IMQ triggered a psoriatic phenotype reproducing 
characteristic features of the disease, including parakeratosis, hyperkeratosis, and 
inflammatory cell infiltration. Moreover, the epidermal thickening caused by increased 
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keratinocyte proliferation reflects the increased mitotic activity within the basal layer [71, 
72].  
Histologically, the characteristics of our model include many hallmarks of human 
psoriasis, including acanthosis, hyperkeratosis, erythema, and desquamation, a 
phenomenon related to the hyperkeratosis that occurs in the stratum corneum after the 
application of IMQ cream. This phenotype has shown to be critically dependent on the 
IL-23/IL-17 axis in human psoriasis [37, 73] as in our mouse model. 
II.3.4. Interleukin Levels as a Critical Biomarker of Psoriatic Progression 
IMQ application affects both innate and acquired immunity [34], and our IMQ 
model displayed alterations to key immunological pathways and inflammatory cellular 
mediators present in the human disease [32]. As discussed above, IMQ is a ligand for 
TLR of macrophages, monocytes, and pDCs in mice [10], and therefore, TLR7 
overexpression in macrophages and DCs can influence the development of an IMQ-
induced mouse model of psoriasis. 
Consequently, IMQ contributes to the strong activation of the immune system. 
Monocyte-derived cells (moDCs) and macrophages located in the dermis [74, 75] play a 
decisive role in the production of pro-inflammatory cytokines that increase the activation 
of skin T cells and epidermal thickening [59, 62, 76]. Hence, IMQ-treated mice exhibited 
increased tissue levels of several inflammatory cytokines characteristic of psoriasis (IL-
1b, IL-23, INF-γ, TNF-α, and IL-17) by activating moDCs, in good agreement with 
several studies [59, 77]. 
Studies have demonstrated that IL-23 present in serum and tissue acts 
preferentially on memory T cells to trigger psoriasis followed by the production and 
proliferation of IFN-γ [78-81]. While there exist contradictory studies regarding the 
presence of IFN-γ [82-85], we have demonstrated the elevated presence of IFN-γ, 
together with TNF-α and IL-23, both in serum and tissue in our disease model in 
comparison with healthy animals. Several studies observed the overexpression of TNF-α 
in lesioned psoriatic skin [86, 87] and plasma [88, 89] from human patients, in agreement 
with our discoveries within our mouse model. 
 Importantly, we emphasize the enlarged spleen (splenomegaly) detected in our 
model after the topical application of IMQ cream, with an increase in weight of two-fold 
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encountered. Studies have demonstrated that IMQ induces systemic effects on the cellular 
composition of the spleen, with a shift from lymphoid to myeloid cells, with an increased 
number of Th17 cells [37]. This finding supports a role for IMQ in the induction of the 
synthesis of pro-inflammatory cytokines. As previously mentioned, psoriasis induction 
occurs in an acute and non-chronic manner, so once the action of the IMQ cream ceases, 
we observed a recovery of normal weight levels. 
 Based on the observations described above, analysis of IMQ treatment of mouse 
skin confirms its suitability in the development of a mouse model of psoriasis by 
mimicking many of the described features of the human disease [32, 37, 59] with regards 
to immunological pathways and inflammatory cellular mediators. 
II.4. Conclusions 
Within this chapter, we have developed and fully characterized ex vivo human 
skin models that can maintain tissue viability after four days in the culture medium, as 
evidenced by tissue viability assays and histological characteristics. The inflammatory 
skin model allows us to understand the peculiarities of inflammatory skin diseases, such 
as psoriasis. Also, ex vivo models permit drug screening as well as the evaluation of both 
drug penetration and anti-inflammatory activity of the desired drug before starting in vivo 
studies. 
Moreover, we have described psoriasis progression in a preclinical mouse model 
widely employed for the appraisal of anti-psoriatic or anti-inflammatory therapies. We 
evaluated disease progression for 10 days after 7 days of disease induction by IMQ cream 
treatment (day 17 as endpoint). We focused our study on the pathological features that 
characterize the disease and compromise patient health. The exhaustive and detailed 
characterization of the psoriatic model over time has allowed us to assess the moment 
where the animals recover to a basal healthy-like state close to the endpoint studied.  
 We also discovered that five days after the termination of IMQ treatment (day 12), 
animals maintained the immune system activation and thickening of the epidermis, 
together with the ongoing presence of hyperkeratosis and acanthosis. Finally, after the 
optimization of our IMQ-induced psoriasis model, we confirmed the maintenance of the 
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main characteristics of the disease for five days after the last application of IMQ, thereby 
allowing us to evaluate the activity of anti-psoriatic therapeutic agents in further steps. 
II.5. Materials and Methods  
II.5.1. Ex Vivo Models 
II.5.1.1. Development of Ex Vivo Human Skin Model 
Breast skin samples were obtained with informed consent from healthy women 
undergoing plastic surgery (kindly donated from Hospital la Fe, Valencia, Spain). The 
skin was cut to approximately 1 cm2 and placed in 6-well plates so that the dermal side 
was in contact with Dulbecco’s modified Eagle medium (DMEM) supplemented with 50 
mL fetal bovine serum (FBS), 5.5 mL penicillin/streptomycin, and 50 µL amphotericin 
B (all from Gibco, Spain). The epidermis was exposed to the air. After each time point 
(1, 4, 7, 11 days) in culture medium, skin samples were washed twice with 0.1 % PBS-
BSA (PBS supplemented with bovine serum albumin (BSA)) and kept in 4% 
paraformaldehyde (PFA) for 24 h at room temperature (r.t.). Then, the samples were 
washed with 30% sucrose in PBS solution and stored in this solution for 24 h at 4ºC. 
Finally, skin samples were washed twice with PBS and preserved in a cryopreservation 
solution (40% 0.1M PB, 30% ethylene glycol, and 30% glycerol) at 4ºC until use.  
II.5.1.1.1 Tissue Viability Assay 
The skin pieces were incubated at 37ºC under 5% CO2 for 11 days, and the media 
was changed every day. Tissue viability after 1, 4, 7, 11 days was evaluated by MTT 
assay. Skin samples were washed twice with PBS and were introduced in 4 mL of MTT 
solution (2 mg/mL) at 37ºC. MTT assay is a colorimetric assay for assessing cell 
metabolic activity; the activity of NAD(P)H-dependent cellular oxidoreductase enzymes 
reflect the number of viable cells present. These enzymes are capable of reducing the 
tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to 
insoluble formazan (Sigma, Spain). After 4 h of incubation, skin samples were washed 
twice with PBS and placed in 4 mL of dimethyl sulfoxide (DMSO) to extract the formazan 
from the skin. After 15 h of extraction, the absorbance was read at 490 nm using 
Victor2Wallac™ plate reader (Perkin Elmer, Spain).  
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II.5.1.1.2. Histological Analysis and Imaging  
Tissue samples were processed for histological analysis. Skin fragments preserved 
in a cryopreservation solution were washed with PBS under shaking conditions three 
separate times. A common dehydration and paraffin-inclusion procedure was carried out, 
leading to blocks that were sliced into 5 μm sections.  
H&E staining and immunostaining (Ki67 and Ck5/6) were performed as required 
(Dako Autostainer 48, US) and the slides were observed under the microscope, and those 
of interest were scanned with a Panoramic 250 Flash II slide scanner and processed with 
CaseViewer software (both from 3DHISTECH Ltd, Hungary).  
II.5.1.2. Development of Inflammatory Ex Vivo Human Skin Model  
Breast skin samples were obtained with written informed consent from healthy 
women undergoing plastic surgery (donated from Hospital la Fe, Valencia, Spain). The 
skin samples were cut to approximately 1 cm2 and placed in 6-well plates so that the 
dermal side was in contact with DMEM medium supplemented with 50 mL FBS, 5.5 mL 
penicillin/streptomycin, and 50 µL amphotericin B (all from Gibco, Spain). The 
epidermis remained exposed to the air. The skin was incubated at 37ºC under 5% CO2.  
The inflammatory model was induced by the addition of a constant concentration 
of EGF (2.5 ng/mL) (Sigma, Spain) and different concentrations of LPS from E. coli 
(InvivoGen, US) (10 µg/mL, 15 µg/mL, 20 µg/mL, or 30 µg/mL) to the culture medium 
and further incubation for 24 and 48 h at 37ºC under 5% CO2. After each time point, skin 
samples were washed twice with 0.1 % PBS-BSA and kept in 4% PFA for 24 h at r.t. 
Then, the samples were washed with 30% sucrose in PBS solution and stored in this 
solution for 24 h at 4ºC. Finally, skin samples were washed twice with PBS and preserved 
in a cryopreservation solution (40% 0.1M PB, 30% ethylene glycol, and 30% glycerol) at 
4ºC until use.  
The model was evaluated by MTT assay, histology and immunohistochemistry 
(H&E, Ki67, Ck5/6, INF-γ, IL-1b, NF-kB), and also the quantification of the pro-
inflammatory cytokines released to the culture medium. 
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II.5.1.2.1. Tissue Viability Assay 
Tissue viability after 24 and 48 h was evaluated by MTT assay. Skin pieces were 
washed twice with PBS and introduced into 4 mL of MTT solution (2 mg/mL) at 37ºC. 
After 4 h of incubation, skin samples were washed twice with PBS and introduced into 4 
mL of DMSO, to extract the formazan from the skin. After 15 h of extraction, the 
absorbance was read at 490 nm using Victor2Wallac™ plate reader (Perkin Elmer, Spain). 
II.5.1.2.2. Histological Analysis and Imaging 
Tissue samples were processed for histological analysis. Skin fragments preserved 
in a cryopreservation solution were washed with PBS under shaking conditions three 
separate times. A common dehydration and paraffin-inclusion procedure was carried out, 
leading to blocks that were sliced into 5 μm sections. Then, tissue samples were processed 
for histopathological analysis as described above. 
II.5.1.2.3. Quantification of Pro-Inflammatory Cytokines Released to the Culture 
Medium 
Culture medium was collected under standardized conditions from skin cultures 
after 24 and 48 h of incubation with the inflammatory treatment and kept at -80ºC until 
use. Cytokines concentrations were measured by LUMINEX kit (Affymetrix, 
eBioscience, Spain) and cytokine levels were determined according to standard solutions. 
II.5.2. In Vivo Models  
II.5.2.1. Mouse Strains  
The 6-week-old male inbred immunocompetent BALB/c (BALB/cOlaHsd) mice 
used for all the experimental procedures were purchased from Envigo Laboratories Inc. 
(Spain).  
II.5.2.2. Ethical Considerations  
Animal experiments were performed in accordance with the European 
Communities Council Directive (86/609/ECC) guidelines and by the Spanish Royal 
Decree 1201/2005. All experimental procedures were approved by the Institutional 
Animal Care and Use Committee and accomplished by certified and trained staff, meeting 
the animal care rules. Mice were maintained in a specific-pathogen-free facility, under 
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constant temperature and humidity, using a 12 h light-dark cycle. Food pellets and water 
were provided ad-libitum during all experiments, and general aspect, body weight, 
grooming conduct, and behavior were evaluated daily from the beginning of the 
experiment to ensure animal welfare.  
II.5.2.3. Establishment of the Psoriatic Model 
The back of the mice was shaved one day before the start of the study. Mice at 6 
weeks of age received a daily topical dose of 62.5 mg of commercially available IMQ 
cream (5%) (Imunocare®; Industrial Farmacéutica Cantabria, S.A., Spain) on the shaved 
back and the right ear (left ear acting as control for each animal) for 7 consecutive days, 
translating to a daily dose of 3.125 mg of the active compound. This dose was empirically 
determined to cause optimal and reproducible skin inflammation in mice [37]. Animals 
were sacrificed after different days (day 7, day 10, day 12, day 14, and day 17) after the 
the onset of treatment with IMQ to determine the time to apply the different treatments 
without the disappearance of the disease. 
II.5.2.4. Scoring Severity of Skin Inflammation (PASI Score) 
An objective scoring system was used to score the severity of the disease and the 
inflammation of the dorsal skin based on the clinical Psoriasis Area and Severity Index. 
Erythema, scaling, itching, and thickening were scored independently on a scale from 0 
to 4: 0, none; 1, slight; 2, moderate; 3, marked; 4, very marked.  
II.5.2.5. Ear Thickness 
Ear thickness was evaluated by measuring using a caliper every two days and 
comparing with the healthy ear (control). 
II.5.2.6. Spleen Weight 
At the end of the 7 days of IMQ treatment, mice were sacrificed via CO2 inhalation 
at different days (7, 10, 12, 14, and 17 days), and spleen weight was then measured 




H&E staining was carried out in both ears and the back. All the samples were 
removed from euthanized mice at relevant time points, and then tissues were washed in 
fresh PBS, carefully dried, weighed, and fixed in 4% PFA for 24 h. PFA was eliminated 
by successive washing with PBS, dehydration and paraffin-inclusion procedures were 
carried, and blocks were then sliced into 5 μm sections. The slides were observed under 
the microscope, scanned with a Panoramic 250 Flash III slide scanner, and processed with 
CaseViewer software (both from 3DHISTECH Ltd, Hungary).  
II.5.2.8. Pro-Inflammatory Cytokines Levels in Serum and Tissue 
The pro-inflammatory cytokine levels were measured in serum and dorsal skin 
tissue. Fresh serum was isolated from the blood through centrifugation (4000 rpm, 10 
min, 4ºC), and both were stored at -80oC. To performed protein extraction from frozen 
dorsal tissue, the skin was mixed with PBS (pH 7.4) containing a protease and 
phosphatase inhibitor cocktail and then treated in an ice bath by Ultra Turrax Scatter at 
10000 ref/min for 20 min. Immediately after incubation, the tube was centrifuged at 4000 
rpm for 20 min at 4°C and supernatants were collected and stored at -80oC until use. For 
the LUMINEX assays, IL-1b, IL-23, INF-γ, TNF-α, and IL-17A protein expression in 
skin lysates and serum were quantified with according to the manufacturer’s instruction 
(Invitrogen, Spain). 
II.5.2.9. Hematological Analysis 
Blood was extracted immediately after sacrifice by cardiac puncture with a 1 mL 
heparinized syringe and transferred to a 2 mL Eppendorf tube. Blood was gently 
homogenized and then kept at 4ºC until analysis (within the first 30 min after extraction). 
Serum was isolated by centrifugation (4000 rpm, 10 min, 4ºC) and analyzed using an 
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III.1. Antecedents and Background   
Transdermal drug delivery systems promote the non-invasive delivery of a drug 
or active pharmaceutical ingredients (APIs) through the skin for the localized or systemic 
treatment of various diseases or disorders [1]. This administration route avoids any 
adverse effect associated with hypodermic injection or oral administration [2, 3]. 
Biocompatibility, biodegradability, and high permeation efficiency through the skin 
barrier represent some of the desired characteristics for such delivery systems.  
Hydrogels are commonly employed in nanomedicine for dermal applications and 
cosmetic skincare [4] as many hydrogel-based biomaterials mimic specific properties of 
the skin extracellular matrix [5]. Cross-linking of polymers represents a common 
synthetic approach to obtain hydrogels, providing materials with useful properties when 
compared to linear polymers, including higher viscosity in aqueous solutions, higher 
molecular weights (Mw), and greater resistance to degradation [6]. These advantageous 
properties have promoted the application of cross-polymers in tissue engineering, 
injectable hydrogel formulations, skin delivery, and dermal fillers, among notable others 
[7-9]. 
Polysaccharides, and hyaluronic acid (HA) in particular, represent the most widely 
used biopolymers for dermal applications [8]. HA, a natural heteropolysaccharide with a 
linear structure composed of altered residues of D-glucuronic and N-acetyl-D-
glucosamide, was discovered by Meyer and Palmer in 1934 [10]. HA represents one of 
the primary components of the skin extracellular matrix and disappearance of epidermal 
HA content can occur during natural aging and oxidative processes generated by exposure 
to ultraviolet rays from sunlight [11, 12]. HA has been widely employed in the 
composition of different vehicles for dermal applications [6], wound healing [13, 14], and 
for the penetration of drugs into the skin as part of dermal drug delivery systems [15, 16].  
The characteristics of biodegradable polypeptides have also prompted their 
exploration as part of dermal drug delivery systems [17-19]. Poly-glutamic acid (PGA) 
(specifically poly-γ-glutamic acid – a polymeric chain where the peptide bonds are 
formed between NH2 and gamma COOH at glutamic acid side chain) moisturizes the skin 
and acts as a hydrophilic humectant (a substance that moisturizes and softens the skin) 
due to the creation of a smooth and elastic film after application to the skin [20]. PGA 
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administration also enhances the synthesis of natural moisturizing factors in the skin, such 
as lactic acid, pyrrolidone carboxylic acid, and urocanic acid, and also improves skin 
elasticity when compared with HA or collagen [21, 22]. Of note, studies have reported 
that PGA inhibits the activity of hyaluronidases, a family of enzymes that degrades 
dermal HA, therefore maintaining skin elasticity [23]. Moreover, the free glutamate units 
produced during PGA degradation act as nutrients for the skin [24].  
 Although polyglutamates are mainly used as drug delivery agents itself in 
nanomedicine approaches employed to treat several systemic diseases, such as cancer or 
Alzheimer's disease [25-27], it has also been found to be used as skin penetration 
enhancers for pharmaceuticals such as insulin (through the use of polymer microneedles 
composed by γ-PGA and polyvinyl alcohol/polyvinyl pyrrolidone ([PVA/PVP] 
supporting structures) [24]. PGA can also increase water absorption rates and swelling 
ratios, so it has been widely applied in biomaterials for biological adhesive (natural 
polymeric compounds that can act as adhesives in the skin) and tissue engineering [28, 
29]. Therefore, PGA not only increases the skin penetration of bioactive agents but also 
maintains a moist microenvironment that promotes effective wound healing [30, 31].  
Motivated by the desire to develop an advanced biodegradable platform for the 
topical delivery of drugs and also considering the advantageous properties of PGA as well 
as HA in dermal applications, we decided to rationally design our platform using both 
materials. We based our design on well-established strategies using cross-linked HA and 
γ-PGA for skin applications [32-34], but using the synthetic poly-L-α-glutamic acid 
instead.  
In close collaboration with the company Polypeptide Therapeutic Solutions S.L. 
(PTS, Valencia, Spain) we developed a cross-polymer vehicle composed by HA and PGA 
cross-linked through L-lysine (Lys) residues (hyaluronic-poly-L-glutamate cross-
polymer or HA-CP). This vehicle is a biodegradable and biocompatible material which is 
completely assimilable by the organism and allows the modulation of its rheological 
properties; this viscous gel-like vehicle does not behave as a hydrogel at our working 
concentration (1% w/v) in terms of rheological or mechanical behavior, but can form 
viscoelastic hydrogels at higher concentrations or higher cross-linking degrees. We 
exhaustively characterized HA-CP using a battery of techniques and then evaluated HA-
CP in vitro, ex vivo, in vivo (see Chapter IV) and even in human volunteers. To 
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demonstrate the property of this material as skin penetration enhancer we studied the 
capacity of HA-CP to act as a vehicle of hydrophobic APIs (using fluorescence probes as 
model system) encapsulated in amphiphilic micelles based on polyethylene glycol (PEG)-
polyamino acids (amphiphilic block copolymers). The encapsulation of hydrophobic 
drugs or APIs in aqueous solution by amphiphilic PEG-polyamino acid micelles has been 
widely described in the literature [35], with examples for transdermal skin delivery [2] 
and the treatment of skin diseases such as psoriasis [36, 37].  
The combination of HA-CP with the adequate polymeric nanomicelles could be 
considered an efficient hybrid transdermal delivery system for a variety of therapeutic 
applications where the required drug is not capable to bypass this challenging biological 
barrier, the skin (Figure III. 1). 
 
Figure III. 1: Upper Section: Scheme of the hyaluronic acid-poly-L-glutamate cross-polymer 
(HA-CP) vehicle, the micelle composed by amphiphilic block copolymer encapsulating a 
hydrophobic API, and the hybrid material (composed by micelles embedded into the HA-CP 
matrix). Lower Section: Schematic representation of the developed skin delivery platforms: (i) 
hydrophobic API in micelle applied in water, (ii) hydrophobic API in micelle applied with linear 
hyaluronic acid and (iii) hydrophobic API in micelle applied in HA-CP vehicle. Representative 
confocal microscopy images obtained from the penetration studies with each platform are shown 
next to the skin schema as demonstrative examples. 
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III.2. Results and Discussion 
III.2.1. Development of the Hyaluronic Acid-Poly-L-Glutamate Cross-Polymer 
(HA-CP) Vehicle: Synthesis and Physico-Chemical Characterization 
Cross-linked reactions for HA can use several established methodologies, 
including Schiff-base reaction, thiol-Michael addition, Diels-Alder click cross-linking, 
ionic-crosslinking, amide or ester bond formation, supramolecular-cross-linking, and 
photo-crosslinking [6, 38]. HA possesses various reactive groups, including carboxylic 
acid and hydroxylic groups, which can be easily chemically modified. We selected 
carboxylic acid moieties for cross-linking due to the presence of these groups in PGA. 
Many activating reagents condense carboxyl and amino groups to create amide bonds, 
including carbodiimides, carbonyl diimidazole, 1-ethyl-3-(3-dimethyl aminopropyl)-1-
carbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), and 4-(4,6-
Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM·Cl) [5]. A 
common mechanism of action is the initial activation of the carboxyl group via adduct 
formation, followed by the nucleophilic attack of the amine moiety to create the amide 
bond. This mechanism precludes the activating agent from being incorporated into the 
final product [6].  
Focusing on the development of a biodegradable skin delivery platform, our 
synthetic cross-linking approach employed amide bond formation between carboxylic 
groups of HA and PGA, using the amines of the lysine residue as the cross-linker moiety 
and DMTMM·Cl as the activating coupling agent. The use of DMTMM·Cl for peptidic 
coupling of HA [5, 39] and PGA [40-42] through amine moiety in aqueous solutions is 
reported widely in the literature. 
III.2.1.1. Synthesis and Physico-Chemical Characterization of HA-CP 
We obtained HA-CP through the activation of the carboxylic groups of linear HA 
(50 kDa) and PGA with DMTMM·Cl, employing lysine as coupling moiety. Figure III. 
2 shows the 1H-NMR spectra of HA-CP, demonstrating the presence of HA and PGA 
moieties within the cross-polymer. The low stoichiometric amounts of lysine employed 
for the cross-linking reaction and the fact that epsilon (ε) methylene near to the amino 
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group might experience a significant downfield shift precludes the identification of lysine 
within the HA-CP via NMR after extensive purification by dialysis.  
 
Figure III. 2: NMR studies. (A) 1H-NMR spectra in D2O for starting materials with assigned 
protons. (B) 1H-NMR spectra in D2O for HA-CP and the physical mixture of starting materials, 
showing PGA signals in the HA-CP (A: Signal for PGA; B: No signals for lysine (Lys) in HA-
CP were observed).  
We performed Mw distribution comparing HA-CP with the starting HA material. 
SEC elugrams employing a refractive index (RI) detector revealed higher Mw distribution 
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for HA-CP when compared to starting HA in terms of retention time, yielding a three-
dimensional reticulated HA-CP network of 150 kDa (Figure III. 3A). Mw distribution 
values represented in Table III. 1 obtained by SEC [43] indicated a Mw of our novel HA-
CP cross-polymer three-times higher than the starting HA (145 kDa and 49 kDa, 
respectively). 
Table III. 1: Mw distributions and polydispersity index (PDI) by SEC. 
 
Compound Mw (kDa) by SEC PDI by SEC 
Starting HA  49.1 1.119 
HA-CP 145.2  1.863 
 
We monitored the cross-linking reaction through free amine quantification by 
TNBSA [44, 45] and viscosity assays. Although the cross-linking reactions can produce 
undesired ester bond formation between carboxylic acids and alcohols of HA, the higher 
amine nucleophilic character when compared to the alcohol [42, 46] directs the reaction 
towards amide bond formation. Although NMR studies failed to find evidence for the 
presence of lysine in the cross-polymer, we observed a population of free amines by 
TNBSA assay. Of note, as the reaction progresses, free amine levels fall while viscosity 
increases due to amide bond formation and the promotion of cross-linking. Furthermore, 
the pH decreased as a consequence of the release of protons during the formation of each 
amide bond (Figure III. 3B and C).  
According to the results obtained from the viscosity assay and free amine 
quantification by TNBSA assay, we obtained the desired cross-linked material after 500 
min of reaction. At this point, HA alcohols form undesired cross-linked reactions by the 
formation of ester bonds in the absence of free lysine amines in the reaction media, 
yielding an unstable material with excessive viscosity. Excessively cross-linked HA 
matrices increase collagen deposition and therefore trigger some adverse effects, such as 
inflammatory reactions [43]. For these reasons, we terminated the cross-linked reaction 




Figure III. 3: Molecular weight calculations and cross-linking reaction monitoring. (A) SEC-RI 
elugram for HA-CP and starting HA in aqueous media with 100 mM NaNO3 at pH 5 
demonstrating higher Mw distribution for HA-CP compared to starting HA. (B) Percentage (%) 
of free lysine amines determined by TNBSA assay in the cross-linked reaction media for 500 min, 
including pH values. (C) Viscosity in cP of the cross-linked reaction media, demonstrating an 
exponential increase during the first 500 min, and an excessive viscosity increase after lysine 
consumption. 
In summary, we successfully developed a cross-linking reaction between HA and 
PGA through lysine moieties employing DMTMM·Cl as a coupling agent. As expected, 
analysis of the physico-chemical characteristics demonstrated an increase in the 
molecular size and viscosity of HA-CP due to the cross-linking reaction when compared 
to starting HA. 
III.2.1.2. Development of Fluorescently-labeled HA-based Materials 
To compare the skin permeation of our novel cross-polymer compared to 
conventional HA, we fluorescently labeled both HA-based materials with the Cyanine 5.5 
(Cy5.5) fluorescent dye, generating HA-CP-Cy5.5 and HA-Cy5.5 materials. We based 
the synthetic strategy on peptidic coupling through DMTMM·Cl carboxylic group 
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activation following to Cy5.5 amine nucleophile attack and new amide bond formation. 
We characterized both labeled materials by UV-Vis spectroscopy to determine the 
loading percentage (% w/w) within the materials, and by SEC to determine Mw 
distributions (Table III. 2).  Dye loading by UV-Vis quantification demonstrated an 
enhanced conjugation efficiency for HA-CP (0.63 % molar dye) in comparison to linear 
HA (0.43 % molar dye), with 1% molar the target dye loading in both cases. SEC 
elugrams revealed successful dye moiety conjugation to both HA-based materials, 
showing perfect correlation in terms of retention times, which may be attributed to the 
covalent union between the carboxylic acids (from HA and HA-CP) and Cy5.5 (Figure 
III. 4). We next employed the resultant labeled materials for skin permeation studies. 
Table III. 2: Results of Cy5.5 loading by UV-Vis spectroscopy and Mw distributions by SEC 
Compound % w/w Cy5.5* % Molar Cy5.5* 
Conjugation 
Efficiency* 
Mw (kDa)** PDI** 
HA-CP-Cy5.5 1.18 0.63 63% 145.2 1.863 
HA-Cy5.5 0.81 0.43 43% 205.5 1.442 
*Data obtained by UV-Vis spectroscopy measured at 676 nm.**Data obtained by SEC measurements. 
 
 
Figure III. 4: (A) SEC-RI-UV elugram for HA-CP-Cy5.5. (B) SEC-RI-UV elugram for HA-
Cy5.5. SEC-RI-UV chromatograms were achieved at 3.75 mg/mL in 150 mM NaNO3 adjusted to 






III.2.2. Analysis of the HA-CP as a Biomaterial for Topical Skin Applications 
To fully understand the biological behavior of our newly developed HA-CP 
vehicle for topical skin applications, we studied several properties in comparison to a 
conventional linear HA with a similar Mw distribution (PrimalHyal300; 200 kDa).  
III.2.2.1. Hyaluronidase Degradation Studies 
We studied the degradation of our HA-based materials by assessing Mw 
distribution alterations in the presence of hyaluronidase (HAase), a natural enzyme 
located in the skin that degrades HA [47]. We selected SEC to study the HAase-mediated 
degradation of our HA-based materials, due to its robustness and reproducibility in Mw 
determination. Furthermore, SEC also allows the study of degradation kinetics and 
comparison between samples. Although the effective HAase concentration depends on 
the Mw of the HA [47], we used 5 U/mL according to literature to mimic the 
concentration of HAase present within human skin [48-50]. We evaluated Mw values 
obtained from the kinetics per triplicate from three different degradations at 0, 1, 2, 3, 4, 
6, 8, 10, and 24 h. The results obtained by SEC revealed a rapid degradation for linear 
HA when compared to HA-CP under the same conditions, with HA-CP presenting a more 
constant and sustained degradation over time (Figure III. 5). This effect may be 
explained by the different structural conformation of HA-based materials; a cross-linked 
conformation may possess intrinsic resistance to HAase activity due to the inaccessibility 
of the HA chains in solution while HAase may have free access to the linear HA chains 
and degrade them more rapidly, thereby promoting a rapid decrease in Mw distribution. 
In addition, maybe our PGA might also have some HAase inhibition activity as in the 
case of γ-PGA, but the complete rationale for this phenomenon lies outside the scope of 




Figure III. 5: (A) HAase degradation of HA-CP and linear HA showing Mw values obtained by 
SEC. (B) SEC-RI elugram for linear HA. (C) SEC-RI elugram for HA-CP. SEC conditions 
employed: 100 mM NaNO3 at pH 5 using 5 mM PB in the presence of bovine testicular HAase at 
5 U/mL. 
III.2.2.2 Cell Viability In Vitro 
We carried out cell viability assays after 72 h of treatment to determine the toxicity 
of both HA-based materials in human keratinocytes (HaCaT cells) and human fibroblasts 
[51]. As hoped, both linear HA and the HA-CP vehicle maintained cell viability in both 
cell lines up to the concentrations tested (Figure III. 6). 
 
Figure III. 6: Cell viability by MTS assay of HA-CP and HA in (A) HaCaT keratinocytes and 
(B) human fibroblasts after 72 h of treatment (n = 3).  
161 
 
III.2.2.3. Tissue Viability in an Ex Vivo Human Skin Model 
We also evaluated tissue viability in an ex vivo human skin model (see Chapter 
II for more details) after 24, 48, and 72 h of treatment with 3 µL of 1% w/v solution of 
linear HA and HA-CP. We obtained breast skin samples with informed consent from 
healthy women undergoing plastic surgery (Hospital la Fe, Valencia, Spain). The results 
shown in Figure III. 7 demonstrate that all both treatments allowed the maintenance of 
tissue viability at the concentration tested. Interestingly, the HA-CP vehicle provided 
enhanced results when compared to linear HA at 48 h. This phenomenon may be due to 
an increase in the hydration of the skin after HA-CP application, given the slower 
degradation of HA present in the HA-CP than linear HA. These results agreed with the 
HAase degradation kinetics obtained by SEC.  
 
Figure III. 7: Tissue viability in an ex vivo human skin model after 24, 48, and 72 h of treatment 
with HA and HA-CP (n = 3).  
III.2.2.4. Ex Vivo Human Skin Permeation by Franz Diffusion Cells  
We next performed skin permeation studies by Franz diffusion cells using human 
skin [52, 53]. Again for this experiment, we obtained breast skin samples with informed 
consent from healthy women undergoing plastic surgery (kindly donated from Hospital 
la Fe, Valencia, Spain). We carefully fixed skin between the donor and the receptor 
chambers of the Franz cells so that the stratum corneum faced upwards; we then filled the 
receptor chamber with 8 mL of 0.01 M PBS pH = 7.4. We added 100 µL of 1% w/v 
solution of fluorescently labeled HA-based materials to the donor chamber, which is in 
contact with the upper part of human skin (stratum corneum), incubated the samples for 
8 h, and then studied skin sections by confocal microscopy (Figure III. 8A).  
The levels of detected fluorescence suggested that HA-based materials permeated 
through the stratum corneum; images for HA-CP-Cy5.5 verified successful penetration 
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through the stratum corneum, with a marked diffusion through to the viable epidermis. 
However, images captured for the linear HA-Cy5.5 revealed accumulation mainly in the 
stratum corneum, a finding that agrees with a previous report from Essendoubi et al. that 
employed an HA of 100-300 kDa [54]. Furthermore, pixel quantification of Cy5.5 
fluorescence using Image J software analysis revealed a marked accumulation of HA-CP-
Cy5.5 in the viable epidermis and lower accumulation in the stratum corneum compared 
to linear HA-Cy5.5 (Figure III. 8B).  
Overall, skin permeation experiments demonstrated that HA-CP-Cy5.5 possesses 
an enhanced skin permeation capacity when compared to linear HA-Cy5.5, reaching 
deeper skin layers. 
 
Figure III. 8: Permeation studies using Franz diffusion cells after 8 h of treatment with HA-Cy5.5 
and HA-CP-Cy5.5 at 1% w/v. (A) Confocal microscopy images of Cy5.5-labeled HA and HA-
CP after 8 h of permeation. Original magnification displayed in each image was 40x. (B) 
Quantification of Cy5.5 fluorescence intensity in the stratum corneum (SC) and the viable 
epidermis by Image J software. Asterisks indicate statistically significant differences after 
ANOVA analysis followed Bonferroni’s post hoc tests, mean ± SEM. In all cases, we considered 
differences to be significant when p***<0.001; p**<0.01; p*<0.05. 
We also studied the ability of both systems to penetrate to the deepest skin layer, 
the dermis, which is in contact with the liquid in the receptor chamber (representing the 
circulatory system for our purposes). We employed benzoic acid, a well-known drug that 
can penetrate through the skin [55], as a positive control for skin penetration (Figure III. 
9). As expected, results obtained by HPLC analysis suggested that the positive control 





Figure III. 9: Concentration of benzoic acid in the receptor chamber of the Franz diffusion cells 
at different permeation times analyzed by HPLC. Asterisks indicate statistically significant 
differences after ANOVA analysis followed Bonferroni’s post hoc tests, mean ± SEM. In all 
cases, we considered differences to be significant when p***<0.001; p**<0.01; p*<0.05. 
However, HPLC analysis of aliquots taken from the receptor chamber 
(representing the circulatory system) revealed the absence of Cy5.5 signal in the case of 
HA-based materials (Figure III. 10). Therefore, the results suggest that either HA-based 
materials remain in the epidermis (HA-CP-Cy5.5) or the stratum corneum (HA-Cy5.5) 
without reaching the dermis.  
 
Figure III. 10: Aliquots from the receptor chamber after 8 h of permeation study in human skin 
by Franz diffusion cells analyzed by HPLC. Chromatograms of a standard sample of Cy5.5 at 0.1 
µg/mL, HA-Cy5.5, and HA-CP-Cy5.5. 
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In summary, our novel HA-CP vehicle has demonstrated suitability for topical 
applications, and the avoidance of systemic absorption and any associated undesired 
systemic effects. 
III.2.2.5. Hydration Assays in Human Volunteers 
Finally, through a certified laboratory (Prof. Cortijo Lab. Univ. Valencia, Spain) 
we performed in vivo hydration assays with both HA-based materials in over 15 healthy 
volunteers (Figure III. 11).  The zone of the cheekbone and nasolabial fold were 
measured using a Corneometer®, an instrument used to indicate the hydration level of the 
layers of the skin via measurement of the skin dielectric properties. For the experiment, 
we used two pharmaceutical formulations developed by the company PTS following 
Good Manufacturing Practice (GMP) in compliance with all regulations (ICH guidelines; 
https://www.ich.org/products/guidelines.html) and using as active component HA and 
HA-CP. The formulations were applied to the left zone, while the right zone acted as a 
control, and performed measurements at time 0 (before applying the product) and at 1, 3, 
8, 16, 24, and 40 h post-treatment.  
The results suggest that conventional linear HA provided significant higher skin 
hydration than HA-CP over short times. However, HA-CP administration displayed a 
trend (non-significant) towards prolonged and enhanced skin hydration when compared 
with linear HA and the control from 8 h. These results agree with the results obtained in 
the HAase assay, where HA-CP displayed higher resistance to HAase-mediated 
degradation at 24 h, supporting the hypothesis that the cross-polymer maintains its native 
structure and intrinsic properties for an extended period of time, providing better results 





Figure III. 11: Hydration assay in human volunteers using linear HA and HA-CP over 40 h (n = 
15). Asterisks indicate statistically significant differences after ANOVA analysis followed 
Bonferroni’s post hoc tests, mean ± SEM. In all cases, we considered differences to be significant 
when p***<0.001; p**<0.01; p*<0.05. 
III.2.3. Hybrid Material: HA-CP Vehicle Combined with Polypeptidic Micelles for 
Transdermal Delivery of Hydrophobic APIs 
After the robust physico-chemical characterization and biological evaluation of 
HA-CP and in order to validate its capacity as permeation enhancer, we next analyzed a 
hybrid material, with polymeric micelles embedded within HA-CP, as a novel platform 
system for topical delivery for hydrophobic APIs. The polymeric micelles were 
developed via amphiphilic block copolymer formulation. 
III.2.3.1. Synthesis and Characterization of Block Copolymers 
Firstly, we prepared six amphiphilic PEG-amino acid block copolymers by ring-
opening polymerization (ROP) of N-carboxy anhydride (NCA). Using this material, we 
then prepared micelles using a co-solvent methodology [56]. ROP of NCAs occurs via 
two mechanisms: normal amine mechanism (induced by nucleophilic substitution) and 
activated monomer mechanism (AMM, induced by deprotonation) [57]. The synthesis of 
our block copolymers proceeds by normal amine mechanism, based on the nucleophile 
attack of the initiator PEG (in this case). We employed hydrophilic block copolymers 
composed by PEG of 5 kDa (approx. 114 units of ethylene oxide), and L-phenylalanine 
(Phe) or benzyl-L-glutamate (BG) with different degree of polymerization (DP: 10, 20, 
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and 40) as the hydrophobic component. Synthesis yielded a family of six amphiphilic 
block copolymers: PEG-PPhe10, PEG-PPhe20, PEG-PPhe40, PEG-PBG10, PEG-
PBG20, and PEG-PBG40 (Scheme III. 2).  
 
Scheme III. 2: Synthetic scheme for the preparation of the block copolymer family. 
We synthesized amphiphilic block copolymers as previously described [58-60]. 
We employed a well-controlled polymerization reaction by modifying the initiator PEG 
(MeO-PEG-NH2), as illustrated by the well-defined architecture obtained for poly-L-
benzyl glutamate derivatives in terms of targeted Mw and low PDI derived from GPC 
analysis (Figure III. 12A). In the case of PPhe derivatives, we discovered the hindered 
growth of the polypeptide backbone for a degree of polymerization higher than 10, 
perhaps attributed to the increasing insolubility of the resulting polymers (as evidenced 
by the generation of cloudy suspensions during polymerization). We obtained further 
evidence of low solubility from GPC analysis, where larger aggregates appeared for all 
Phe derivatives as the degree of polymerization increased (Figure III. 12C). We 
employed 1H-NMR spectra to assess purity, identity, and confirm the experimental degree 
of polymerization (Figure III. 12B and D). These findings agreed with data obtained by 





Figure III. 12: (A) SEC-RI elugram for PEG-PBG diblock family in DMF. (B) 1H-NMR spectra 
in deuterated trifluoroacetic acid (TFA) for PEG-PBG family. (C) SEC-RI elugram for PEG-PPhe 
diblock family in DMF. (D) 1H-NMR spectra in deuterated TFA for PEG-PPhe family. 
Table III. 3: Physico-chemical characterization of the family of amphiphilic block copolymers 









DPa DPb Ða 
MeO-PEG-NH
2
 - 6749 -- - - 1.187 
PEG-PBG10 10 8943 7801 10 9 1.146 
PEG-PBG20 20 10931 10931 19 17 1.140 
PEG-PBG40 40 13863 11329 33 38 1.224 
PEG-PPhe10 10 7651 7925 6 8 1.134 
 PEG-PPhe20c 20 8571 8954 13 15 1.149 
 PEG-PPhe40c 40 10759 9248 18 17 1.288 
 
aData obtained by GPC (DMF, LiBr 1 % w/w) at 8 mg/mL. bData obtained by 1H-NMR in 
deuterated TFA by integrating PEG signal of the macroinitiator to α-proton of polypeptide block. 
cPrecipitation observed in the polymerization reaction, GPC data showed bimodal traces pointing 
to strong aggregation. DP: Degree of polymerization. Ð = polydispersity.  
 
III.2.3.2. Characterization of Block Copolymer Micelle Formulation  
We used synthesized block copolymers to create the micelles using the co-solvent 
method [56] developed for efficient encapsulation of hydrophobic APIs, encapsulating 
the fluorophore Dil as an example of a hydrophobic API. We performed a preselection of 
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diblock copolymers at 10 mg/mL based on their micellar formulation stability. Larger 
polypeptidic backbone block copolymers (PEG-PPhe40 and PEG-PBG40) precipitated 
within a few hours of incubation at room temperature (r.t.), probably due to an imbalance 
of the hydrophilic and lipophilic ratio. Therefore, we selected PEG-PBG10, PEG-PBG20, 
PEG-PPhe10, and PEG-PPhe20 for further evaluation. The micelles displayed a small 
hydrodynamic diameter by number, a narrow PDI, and a Z-potential close to 0. Of note, 
we observed smaller encapsulation efficiency for PEG-PPhe (~50%) than PEG-PBG 
(~100%) (Table III. 4).  
Table III. 4: Characteristics of the micelles formed by block copolymers with and without 




















10 28/317e 16 0.316 -0.695 
--- --- 5 30 16 0.251 -0.111 







10 32/173e 15 0.420 -0.781 
5 33/179e 17 0.373 0.230 
1 35/248e 18 0.338 2.040 
PEG-PBG20 --- --- 0.01 
10 30 18 0.149 -0.269 
5 32 19 0.130 -0.157 







10 32 19 0.164 0,184 
5 34 20 0.127 0.384 
1 36 19 0.254 0.771 
PEG-PPhe10 --- --- 0.008 
10 164 25 0.363 0.052 
5 137 31 0.279 0.481 
1 110 27 0.246 1.867 
PEG-PPhe10 
+ Dil 
47 0.47 --- 
10 166 30 0.322 0.390 
5 145 30 0.297 1.103 
1 108 28 0.261 3.36 
PEG-PPhe20 --- --- <0.004 
10 143 28 0.409 2.443 
5 128 30 0.282 3.207 
1 103 21 0.232 5.143 
PEG-PPhe20 
+ Dil 
58 0.58 --- 
10 77/403e 30 0.466 2.683 
5 79/330e 34 0.388 3.170 
1 107 26 0.317 5.110 
E.E = Encapsulation efficiency. a Determined by UV-Vis. b Critical micelle concentration (CMC) 
determined by fluorescence using pyrene as a hydrophobic probe. c Hydrodynamic diameter by intensity.   
d Hydrodynamic diameter by number. e Bimodal size distribution by intensity (values related to each peak 




Moreover, PEG-PBG displayed higher critical micelle concentration (CMC) than 
Phe derivatives, presenting values between 0.04 - 0.01 and 0.004 - 0.008 mg/mL, 
respectively. These results indicate higher propensity for self-assembly of PEG-PPhe in 
aqueous solution, probably due to the strong hydrophobic nature of PPhe (Figure III. 
13A). In agreement with these results, GPC analysis revealed a robust aggregation 
behavior for PEG-PPhe copolymers. 
We next employed circular dichroism (CD) to evaluate the secondary structure of 
the polypeptidic block within the micellar core. As shown in Figure III. 13B, micellar 
aqueous solutions of block copolymers displayed the typical alpha-helix conformation for 
PB and a mixture of beta-sheet and alpha-helix conformation for Phe, both with 
pronounced negative bands for polymers with a larger degree of polymerization (PEG-
PPhe20 and PEG-PBG20). Interestingly, the intensity and the shape of the characteristic 
alpha-helix band changed for PPhe to PBG copolymers, pointing to structurally different 
arrangements of side-chain groups. PPhe derivatives strongly form aggregates; as an 
example, diphenylalanine demonstrates self-assembly behavior generating nanotubes in 
aqueous solutions [61]. Castelletto and Hamley developed a similar system to ours (5 kDa 
PEG and 4 units of Phe) [62], and their CD and fluorescence analysis revealed that self-
assembly behavior relied on π-π* interactions, yielding fibrils at 0.5 mg/mL. Decandio et 
al. analyzed a peptide composed by arginine (Arg) and Phe and discovered the same 
negative band over 200 nm [63]. The negative band for Phe derivatives was also observed 
for triblock PEG-PGA-PPhe micelles at pH 4.5 in aqueous solution [64]. These 
experiments agree with our results and confirm strong aggregation observed for the 
micelles containing Phe residues.  
Size analysis of the micelles by DLS revealed similar mean size distribution (Dh) 
for the selected copolymers, ranging from 12 to 30 nm with no significant variation upon 
changing concentration (1 - 10 mg/mL) in good agreement with reported values for 
similar amphiphilic block copolymers [65-67] (Figure III. 13C). Transmission electron 
microscopy (TEM) images confirmed that micelles displayed a mainly spherical shape 




Figure III. 13: Physico-chemical characterization of micelles. (A) CMC obtained for aqueous 
micellar formulations using a fluorimeter employing an intensity ratio I338/I333. (B) CD spectra of 
micellar solutions at 0.5 mg/mL in water. (C) Size distribution by number obtained from DLS 
measurements at 10 mg/mL of micelles formulation. (D) TEM images of aqueous micellar 
formulations at 2 mg/mL. 
In conclusion, the application of a Phe backbone promoted a more rigid inner core, 
probably very tightly packed. As a result, the Phe-based block copolymers possess a 
higher tendency to form micelles (lower CMC) and lower capacity to encapsulate the dye 
(Dil) than the BG-based block copolymers, as expected due to the modification of the 
hydrophilic-hydrophobic balance. 
III.2.3.3. Cell Viability Studies In Vitro of Selected Micelles 
We performed cell viability assays with the selected micelles (PGA-PPhe10, 
PGA-PPhe20, PGA-PBG10, and PGA-PBG20) to determine any toxicity in HaCaT 
keratinocytes and human fibroblasts by MTS assay. As shown in Figure III. 14, all the 




Figure III. 14: Cell viability by MTS assay of PGA-PPhe10, PGA-PPhe20, PGA-PBG10, and 
PGA-PBG20 in (A) HaCaT keratinocytes and (B) human fibroblasts after 72 h of treatment (n=3).  
III.2.3.4. Characterization of the Hybrid Material 
To study the properties of the HA-CP vehicle as a skin permeation enhancer for 
hydrophobic APIs, we prepared hybrid materials containing HA-CP vehicle and micelles 
loaded with the fluorophore Dil (PEG-PPhe10-Dil, PEG-PPhe20-Dil, PEG-PBG10-Dil, 
and PEG-PBG20-Dil). We dissolved each micelle at 10 mg/mL in a 1% w/v solution of 
HA-CP vehicle. 
We characterized the resultants hybrid materials in terms of size distribution by 
DLS. The micelles composed by the block copolymers formed by 10 units of polypeptides 
(PEG-PPhe10 and PEG-PBG10), displayed lower size distribution by number, with sizes 
close to micelles without HA-CP (Table III. 5); however, the micelles embedded into 
HA-CP with 20 units of polypeptides (PEG-PPhe20 and PEG-PBG20) displayed a broad 
size distribution, maybe presenting fewer but larger aggregates, but the complete 
explanation requires deeper studies (Figure III. 15). By intensity, all the hybrid materials 
revealed higher size distribution, with similar values to micelles formulated in pure water 





Figure III. 15: Size distribution by number obtained from DLS measurements at 10 mg/mL of 
micelle formulations embedded into the HA-CP vehicle at 1% w/v.  
Table III. 5: Size distribution by DLS of the micelles embedded into HA-CP vehicle (1% w/v).  
Hybrid System Size, Ia (nm) Size, Nb (nm) PDI 
PEG-PBG10 in HA-CP (1% w/v) 75/559c 38 0.521 
PEG-PBG20 in HA-CP (1% w/v) 222 189 0.881 
PEG-PPhe10 in HA-CP (1% w/v) 315 35 0.434 
PEG-PPhe20 in HA-CP (1% w/v) 262 214 1.000 
a Hydrodynamic diameter by intensity. b Hydrodynamic diameter by number. c Bimodal size distribution by 
intensity (values related to each peak by DLS). Concentration of micelles was 10 mg/mL embedded in the 
HA-CP vehicle (1% w/v). 
III.2.3.5. Ex Vivo Human Skin Permeation of Hybrid Material by Franz Diffusion 
Cells  
We next undertook skin permeation studies following 8 h of treatment using Franz 
diffusion cells employing human skin. To perform the permeation studies, we added 100 
µL of a 10 mg/mL solution of each micelle with encapsulated Dil (PEG-PPhe10-Dil, 
PEG-PPhe20-Dil, PEG-PBG10-Dil, and PEG-PBG20-Dil) applied in the HA-CP (1% 
w/v) vehicle to the donor chamber, which is in contact with the upper part of human skin 
(stratum corneum). Encouragingly, all micelles formulated in the HA-CP vehicle 
penetrated through the stratum corneum, reaching the viable epidermis (Figure III. 16A).  
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Of note, by Image J analysis we demonstrated that the hybrid material that 
contained the PEG-PBG20-Dil micelle accumulated significantly in the epidermis in 
comparison to the other micelles composed by different block copolymers, perhaps due 
to the physico-chemical differences of each micelle stated above, such as the 
conformation (PEG-PBG20 presented alpha-helix conformation in solution) and a less 
rigid inner core compared to Phe-based micelles (Figure III. 16B).  
 
Figure III. 16: Permeation studies with polypeptide-based micelles formulated in HA-CP (1% 
w/v) after 8 h of permeation using Franz diffusion cells. (A) Confocal microscopy images of Dil-
labeled micelles formulated in HA-CP. Original magnification displayed in each image was 40x. 
(B) Dil fluorescence intensity quantification by Image J software in the stratum corneum (SC) 
and the viable epidermis. Asterisks indicate statistically significant differences after ANOVA 
analysis followed Bonferroni’s post hoc tests, mean ± SEM. In all cases, we considered 
differences to be significant when p***<0.001; p**<0.01; p*<0.05. 
Additionally, HPLC analysis of aliquots taken from the receptor chamber 
following permeation studies demonstrated the absence of Dil signal for all the micelles 
studied after 8 h of treatment (Figure III. 17). Therefore, these findings confirm the 
potential of our novel HA-CP vehicle as a penetration enhancer for topical applications, 
transporting the micelles to the epidermis without reaching the dermis, thereby avoiding 




Figure III. 17: Aliquots from the receptor chamber after 8 h of permeation study in human skin 
by Franz diffusion cells analyzed by HPLC. Chromatograms of a standard sample of Dil at 0.1 
µg/mL and the four formulations PEG-PPhe10-Dil, PEG-PPhe20-Dil, PEG-PBG10-Dil, and 
PEG-PBG20-Dil applied in the HA-CP (1% w/v) vehicle. 
Finally, due to the higher capacity of the hybrid material composed by PEG-
PBG20-Dil and HA-CP to permeate through the epidermis, we selected this formulation 
to carry out comparative permeation studies when the system is applied in water, linear 
HA, and HA-CP vehicle. Confocal microscopy images revealed that HA-CP enhanced 
the permeation of the PEG-PBG20-Dil compared to linear HA or water formulation, 
accumulating mainly in the viable epidermis (Figure III. 18A). Quantification of Dil 
intensity by Image J software suggested that the micelle applied in HA-CP penetrated 
significantly through the epidermis, with an almost two-fold higher intensity when 
compared to the formulations in water or linear HA (Figure III. 18B). The intensity in 
the stratum corneum for the formulation with HA-CP remains low, suggesting that the 
micelle penetrates across the stratum corneum barrier and reaches deeper skin layers. This 
enhancement relates to the resistance of HA-CP vehicle against the HAase degradation, 
which maintains an intact structure over time, thereby permitting sustained activity over 




Figure III. 18: Permeation studies of PEG-PBG20-Dil applied in water, HA (1% w/v), and HA-
CP (1% w/v) after 8 h of permeation using Franz diffusion cells. (A) Confocal microscopy images 
of Dil-labeled micelle PEG-PBG20 in the three formulations. Original magnification displayed 
in each image was 40x. (B) Dil fluorescence intensity quantification by Image J software in the 
stratum corneum (SC) and the viable epidermis. Asterisks indicate statistically significant 
differences after ANOVA analysis followed Bonferroni’s post hoc tests, mean ± SEM. In all 
cases, we considered differences to be significant when p***<0.001; p**<0.01; p*<0.05. 
III.2.3.6. Tissue Viability of Hybrid Material in an Ex Vivo Human Skin 
We also evaluated tissue viability in an ex vivo human skin model (see Chapter 
II for more details) after 24, 48, and 72 h of treatment with 3 µL of a 10 mg/mL solution 
of the three selected formulations due to its higher permeation through the skin: (i) PEG-
PBG20 in water, (ii) PEG-PBG20 applied in linear HA (1% w/v), and (iii) PEG-PBG20 
applied in HA-CP (1% w/v). The results shown in Figure III. 19 demonstrate that all 






Figure III. 19: Tissue viability in an ex vivo human skin model after 24, 48, and 72 h of treatment 
with the selected formulations: (i) PEG-PBG20 in water, (ii) PEG-PBG20 applied in linear HA, 
(iii) PEG-PBG20 applied in HA-CP, with HA and HA-CP as controls.  
III.3. Conclusions 
Encouraged by previous studies that employed polypeptides in skincare products, 
we proposed a novel transdermal drug delivery platform based on a cross-linked 
hyaluronic acid and polyglutamic acid (HA-CP). In close collaboration with the company 
Polypeptide Therapeutic Solution S.L., we synthesized a biodegradable and 
biocompatible cross-polymer composed by cross-linked HA and PGA through lysine 
moieties. We demonstrated the enhanced properties of HA-CP vehicle compared to linear 
HA, including HAase activity resistance and higher long-term hydration skin capacity in 
human volunteers, which promotes human skin tissue compatibility. Permeation studies 
in human skin established that our novel HA-CP vehicle exhibited a marked penetrative 
capacity to the viable epidermis when compared to linear HA.  
To further demonstrate the penetration properties of our vehicle, we developed a 
family of amphiphilic block copolymers of different nature, using PPhe and PBG with 
different degree of polymerization carrying a hydrophobic fluorescent dye (Dil) as a 
hydrophobic API model, and we studied their skin penetration in the presence of HA-CP 
vehicle. We demonstrated that changes in the solution conformation of the nanocarrier 
were driven by the presence of Phe as aminoacid in the polymeric chain. Moreover, the 
type of polypeptide modifies other physico-chemical characteristics of the micelles such 
as the critical micelle concentration (CMC) and the encapsulation efficiency (E.E) of Dil; 
Phe-based block copolymers micelles possess lower CMC and capacity to encapsulate 
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the dye than the BG-based micelles. We observed the enhanced penetration of micelles 
into the viable epidermis, with a marked accumulation in the case of PEG-PBG20-Dil, 
demonstrating the ability of the cross-polymer to enhance the penetration through the 
skin. Of note, all micelles accumulated in the epidermis without reaching the dermis, 
therefore avoiding the possible undesirable adverse effects observed at the systemic level.  
Finally, using the PEG-PBG20-Dil micelle as an example, we studied skin 
penetration when applied alone, in linear HA, or in the HA-CP vehicle. This study 
demonstrated the utility of our HA-CP vehicle to promote the penetration of micelles in 
comparison with linear HA. Also, our HA-CP vehicle revealed enhanced tissue viability 
compared to control in an ex vivo human skin model. 
III.4. Materials and Methods 
III.4.1. Materials 
All reagent grade chemicals were obtained from Sigma Aldrich (Spain) and used 
without further purification unless otherwise indicated. H-L-Glu(OBzl)-OH, L-
Phenylalanine (Phe) and MeO-PEG-NH2 (Mw = 5 kDa, 114 ethylene glycol units) were 
obtained from Iris Biotech (Germany). Sodium hyaluronate PrimalHyal300 (Mw = 200 
kDa) was supplied by Comercial Química Massó S.A. (Spain) and sodium hyaluronate 
(Mw = 50 kDa) by Principium S.A. (Switzerland). Dil dye fluorophore (1,1'-dioctadecyl-
3,3,3',3'-tetramethylindocarbocyanine perchlorate (Dil; DilC18(3)) was purchased from 
Thermo Fisher Scientific (Spain). Cyanine5.5 amine dye fluorophore was purchased from 
Lumiprobe GmbH (Germany). Bovine testicular HAase (Type IV-S) with a specific 
activity of 999 units per milligram was obtained from Sigma Aldrich (Spain). HAase was 
weighed before each experiment because activity in frozen solution did not remain 
constant [47]. Pyrene was obtained from Fluka Analytical (Spain). Deuterated 
trifluoroacetic acid (TFA-d1), chloroform-d1, dimethylsulfoxide-d6, and deuterium oxide 
(D2O) were purchased from Deutero GmbH (Germany). Dialysis was performed in a 
Millipore ultrafiltration device fitted with a 1, 3, 10 or 30 kDa MWCO regenerated 
cellulose membrane (Vivaspin®). 
The human immortalized non-tumorigenic keratinocyte cell line (HaCaT) was 
supplied by CLS Cell Lines Service (Eppelheim, Germany) and human fibroblasts were 
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supplied by Hospital La Fe (Valencia, Spain). High glucose DMEM Glutamax and 
Dulbecco's Modified Eagle's Medium-high glucose were purchased from Fisher (Spain) 
and Sigma Aldrich (Spain), respectively. Phosphate buffer saline (PBS) and fetal bovine 
serum (FBS) Medium 200 were provided from Gibco (Spain). (3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) was 
supplied by Promega (Spain). All solvents were of analytical grade and dried and freshly 
distilled. Ultrapure water (MilliQ water) with a resistivity of 18 MΩ.cm was used in all 
aqueous preparations.  
III.4.2. Physico-Chemical Characterization Methods 
III.4.2.1. Nuclear Magnetic Resonance (NMR) Spectroscopy 
NMR spectra were recorded at 27°C (300 K) on a 300 UltrashieldTM from Bruker 
(Billerica MA, USA). Data were processed with the software Topspin (Bruker GmbH, 
Karlsruhe, Germany). Samples were prepared at a concentration of 5 mg/mL in the 
required solvent.  
III.4.2.2. Gel Permeation Chromatography (GPC) in DMF 
For SEC measurements in DMF containing 1 g/L of lithium bromide as an 
additive, a GPC max (Malvern Instruments, Spain) autosampler was used with a flow rate 
of 0.7 mL/min at 60°C as an integrated instrument, including two columns (105/103/102Å 
porosity) from Tosoh. Viscotec TDATM 302 triple detector was used as an integrated 
detection system (Refractive index and Light Scattering), and the calibration curve was 
obtained with PEG analytical standards kit (Sigma Aldrich, Spain), ReadyCal set Mp 200-
1.200.000 for GPC. 
III.4.2.3. Gel Permeation Chromatography (GPC) in Aqueous Media 
For SEC measurements in aqueous media containing 150 mM NaNO3, 5 mM 
phosphate buffer (PB) at pH 5, and 0.005 % (w/w) sodium azide as an additive were used 
in an AF2000 system from Postnova Analytics (Landsberg, Germany). The system was 
configured to work on SEC mode with an isocratic pump (PN1130) an autosampler 
(PN5300), a refractive index (RI, PN3150), 21 angle-multi angle light scattering (MALS, 
PN3621), and an ultraviolet-visible (UV-Vis) (PN3211) detectors. A working flow rate 
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of 0.8 mL/min at 30°C was employed with one TSKgel G6000PWXL column. Refractive 
index (RI) and multi-angle light scattering (MALS) were used for detection and Mw 
determination, calibration of both RI and MALS detectors was achieved with well-
defined Pullulan (50 kDa) and validation with polymethacrylic acid sodium salt (62.5 
kDa PMASS) standards, purchased from Polymer Standards Service (PSS, Mainz, 
Germany). dn/dc values for cross-linked sodium hyaluronates were determined from 
recovered mass assuming 95 - 100% recovery from the chromatographic column and 
found to be within 0.125 - 0.150 mL/g. 30 μL of a 3.75 mg/mL polymer solution was 
injected each time. For linear sodium hyaluronates, 0.150 mL/g as dn/dc value was used 
according to the values reported in the literature [47].  
Hyaluronidase Degradation Studies by Gel Permeation Chromatography (GPC) 
in Aqueous Media: HA-based materials were degraded by HAase at 37ºC employing the 
thermo conditioning autosampler of AF2000 system from Postnova Analytics 
(Landsberg, Germany). GPC measurements were carried out as described previously in 
the previous point. Concentration for HA materials was 3.75 mg/mL and for HAase was 
5 U/mL. Mw distributions values were achieved per triplicate and represented as the 
average of Mw. 
III.4.2.4. Circular Dichroism (CD) 
CD Spectroscopy was performed with a J-815 CD Spectrometer using a Peltier 
thermostated cell holder (PTC-4230) with a recirculating cooler (JULABO F250) 
(JASCO Corporation, Spain). A nitrogen flow (~2.7 L/min) was led through the 
spectrometer and controlled with a nitrogen flow monitor (Afriso Euro-Index, Germany). 
The samples were dissolved under different conditions at different concentrations in 
MilliQ water. Samples were measured in triplicate in a quartz cuvette with d = 0.1 cm. 
III.4.2.5. Dynamic Light Scattering (DLS) 
DLS measurements were performed using a Malvern Zetasizer NanoZS 
instrument, equipped with a 532 nm laser at a fixed scattering angle of 173° (Malvern 
Instruments Ltd., UK). Polymer solutions were prepared in MilliQ water or 1 mM KCl at 
different concentrations and temperatures, and then solutions were sonicated for 10 min 
and allowed to equilibrate for the required time, filtered through a 0.45 μm cellulose 
membrane filter, and finally measured. Size distribution was measured (radius, nm) for 
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each polymer sample in triplicate and automatic optimization of beam focusing and 
attenuation was applied for each sample.  
 Z-potential measurements were performed at 20°C using a Malvern ZetaSizer 
NanoZS instrument, equipped with a 532 nm laser using disposable folded capillary cells 
(Malvern Instruments Ltd., UK). Polymer solutions were prepared in 1 mM KCl in MilliQ 
water. The solutions were filtered through a 0.45 μm cellulose membrane filter. Z-
potential was measured for each sample in triplicate. 
III.4.2.6. Fluorescence Spectroscopy 
Critical micelle concentration (CMC) determination was carried out through 
fluorescence experiments performed using a JASCO FP-6500 spectrofluorimeter 
(JASCO Corporation, Spain) at 25ºC with 1 cm quartz cells.  The pyrene assay was 
performed as published elsewhere [68]. In brief, several solutions of the compounds were 
prepared to cover a wide range of polymer concentrations (between 2 - 0.004 mg/mL) to 
which 3 µL of the pyrene stock solution (0.02 mg/mL) in acetone were added. Then, all 
solutions were placed in vials and are incubated at 37ºC for 2 h to evaporate the acetone. 
After storing the samples for 24 h, measurements were carried out. Each excitation 
spectrum is recorded from 300 to 360 nm with an emission wavelength of 390 nm. The 
excitation and emission band slits are 5 and 2.5 nm, respectively. Finally, data were 
expressed by plotting the intensity ratio I338/I333 against the polymer concentration in 
order to determine the CMC value. 
III.4.2.7. Ultraviolet-Visible (UV-Vis) Spectroscopy 
UV-Vis measurements were performed using JASCO V-630 spectrophotometer 
(JASCO Corporation, Spain) at 25°C with 1.0 cm matched quartz cells and with a spectral 
bandwidth of 0.5 nm. 
Quantification of Dil Loading: Dye loading was determined by recording the 
absorbance band at 548 nm using a calibration curve in MeOH, giving a concentration 
range between 0.00001 - 0.00014 mg/mL. 
Quantification of Cy5.5 Loading: Dye loading was determined by recording the 
absorbance band at 676 nm using a calibration curve in water containing 0.001% of 
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DMSO to improve the Cy5.5 solubility, giving a concentration range between 0.00005 -
0.00025 mg/mL. 
III.4.2.8. Transmission Electron Microscopy (TEM) 
TEM images were recorded in a transmission electron microscope EM 410, 
Philips operating at 60 - 80 kV. Block copolymers samples (1 - 2 mg/mL) were applied 
directly onto carbon film on 200 mesh copper grids. Any excess of sample was carefully 
removed by capillary action, and the grids were immediately stained with one drop of 
0.1% phosphotungstic acid for 30 s. Excess stain was also removed by capillary action. 
III.4.2.9. Amine Quantification by TNBSA Assay 
0.01% (w/v) solution of TNBSA (2,4,6-trinitrobenzene sulfonic acid) was 
prepared using 0.1 M sodium bicarbonate buffer at pH 8.5 as a diluent (prepared fresh for 
each measurement). A calibration curve was constructed with lysine from 10 to 250 µM. 
HA-CP aliquots were taken at different times and diluted in the sodium bicarbonate buffer 
and then measured. The levels of amine were obtained via interpolation of the calibration 
curve. Measurements were performed with UV-Vis spectrophotometer plate reader for 
96 well plates SPECTROstarNANO (Biogen, Spain) at 335 nm. 
III.4.2.10. High-Performance Liquid Chromatography (HPLC) 
Analytical determination of Dil content in the receptor chamber after permeation 
studies by Franz diffusion cells was performed on a system comprising an Agilent 1260 
Infinity III Quaternary Pump solvent delivery module, a G7115A Diode Array Detector 
WR (Santa Clara, CA, USA), a InfinityLab Poroshell 120 C18 RP-HPLC column (EC-
C18, 4.6 x 100 mm, 4 μm) (Santa Clara, CA, USA), and an Open Lab (Agilent) 
workstation. The composition of the mobile phase was methanol: tetrahydrofuran (8:2) 
with a flow rate of 1.0 mL/min and a column temperature of 25ºC. The injected sample 
volume was 10 µL at a concentration of 0.1 mg/mL of Dil standard, with a retention time 
between 4.5 and 7.5 min. The dye was monitored at 552 nm. 
III.4.2.11. Viscosity Measurements 
 Viscosity values of the HA-based materials were obtained using a Fungilab 
rotational viscosimeter Visco Smart LT20 (Fisher Scientific, Spain) composed by (i) 
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viscometer head, (ii) adapter for small samples and (iii) a spindle. The concentration of 
HA-CP in aqueous solution was 3.4%, and the temperature employed was 25ºC. A 
starting rpm of 100 was fixed until the system stabilized. Then, rpm values were varied 
until reaching a percentage of base scale 40 ± 3 %. When the percentage was stable to 40, 
the value was obtained as long as values remained constant ± 10 cP. 
III.4.3. Synthetic Protocols 
III.4.3.1. Synthesis of Hyaluronic Acid-poly-L-Glutamate Cross-Polymer 
Synthesis of 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride 
(DMTMM·Cl): This coupling agent was obtained according to synthetic procedures 
plentifully described [69]. Yield: 80%. 1H-NMR (300 MHz, D2O) δ 4.70 (d, J = 11.4 Hz, 
2H), 4.22 (d, J = 8.7 Hz, 8H), 4.06 – 3.87 (m, 4H), 3.63 (s, 3H). 
Synthesis of Cross-Linked Hyaluronic-Polyglutamate Vehicle: HA-CP was 
obtained by peptidic amide bond formation between carboxylic glutamate groups and 
both amine of lysine using DMTMM·Cl as coupling agent [41]. HA-CP was synthesized 
using hyaluronic acid (Mw = 50 kDa). Four solutions were prepared in parallel: (A) 
sodium hyaluronate (100 mg, 0.249 mmol, 1 eq.) was dissolved in distilled water; (B) 
sodium poly-L-glutamate (2.6 mg, 0.017 mmol, 0.07 eq.) was dissolved in distilled water; 
(C) DMTMM·Cl (44 mg, 0.159 mmol, 0.6 eq. to total carboxylic acids) was dissolved in 
distilled water. (D) Lysine hydrochloride salt (1.5 mg, 0.008 mmol, 0.03 eq. to total 
carboxylic acids) was dissolved in distilled water. B solution was added into A, and then, 
C was added and mixed, and the pH was adjusted to 7 with a few microliters of 1 M 
NaOH. The solution was stirred for 15 min before D was added, and the pH adjusted to 
8.5 with a few microliters of 1 M NaOH. The reaction was carried out overnight at r.t. 
Then, the product was purified by dialysis using a Vivaspin® centrifugal concentrators 
containing an MWCO membrane of 30 kDa. The product was washed with 5 mM PB at 
pH 7.5 and was then washed with distilled water. The solution was lyophilized, and a 
white powder obtained. 
III.4.3.2. Cyanine5.5 Labeling of HA-based Materials 
Synthesis of Fluorescently Labeled HA-CP with Cy5.5 (HA-CP-Cy5.5): A 
fluorescent HA-CP was obtained through the formation of an amide bond between 
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carboxylic HA groups and Cyanine 5.5 amine, using DMTMM·Cl as a coupling agent. 
HA-CP (100 mg; 0.249 mmol, 1 eq.) was dissolved in distilled water. In parallel, coupling 
agent DMTMM·Cl (3.4 mg; 0.012 mmol, 0.05 eq.) was dissolved in water. The 
DMTMM·Cl solution was added to HA-CP solution, and the pH was adjusted to 7 with 
a few microliters of 1 M NaOH. The coupling activation of carboxylic acid through 
DMTMM·Cl was allowed to proceed for 30 min. After that, a solution of Cy5.5 amine 
(1.8 mg, 0.003 mmol, 0.01 eq.) previously prepared in a mixture of water:DMSO (1:1) 
was added, and the pH was adjusted at 8.5 with a few microliters of 1 M NaOH. The 
resultant blue solution of conjugation reaction was allowed to proceed for 72 h at r.t. 
Then, the product was purified by dialysis using a Vivaspin® centrifugal concentrators 
containing an MWCO membrane of 30 kDa. The product was washed with 5 mM PB at 
pH 7.5 and then was washed with distilled water. The solution was lyophilized, and a blue 
powder was obtained. 
Synthesis of Fluorescently Labeled HA with Cy5.5 (HA-Cy5.5): Fluorescent HA 
was obtained through the same procedure described previously for HA-CP-Cy5.5 using 
a PrimalHyal300 HA (Mw = 200 kDa). 
III.4.3.3. Synthesis of Amphiphilic Block Copolymers 
General Synthesis of Block Copolymers: Synthesis of PEG-polyamino acid block 
copolymers was achieved following well-established protocols described elsewhere [59, 
60], adjusting the feeding ratio [monomer]/[initiator] to obtain the target degree of 
polymerization. The NCA monomer (3.923 mmol, 10 equivalents (eq.)) was weighed in 
a Schlenk tube, which was fitted with a stir bar and dried at 80oC for at least 24 h before 
starting the reaction. The tube was purged with Argon/vacuum cycles, and the monomer 
was dissolved in 4 mL of dry DMF. The MeO-PEG-NH2 macroinitiator was weighed in 
a vial, purged with argon and dissolved in 1 mL of dry DMF. The initiator solution was 
added to monomer solution under an argon atmosphere, and the polymerization media 
was placed at 4oC under vigorous stirring for three to four days. The reaction mixture was 
poured over 50 mL diethyl ether, and the white precipitate was filtered and washed with 
additional diethyl ether. Further purification was carried out by suspension in THF and 
precipitation over excess diethyl ether. Finally, the product was filtered and dried under 
an N2 stream.  
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III.4.3.4. Preparation of the Micelles using the Block Copolymers 
Co-solvent Method: This method was adapted from the literature [56]. The block 
copolymer (20 mg/mL) was dissolved in THF and added dropwise into MilliQ water with 
continuous stirring at r.t. until the evaporation of the organic solvent. The formulations 
were allowed to equilibrate at r.t. for 24 h, followed by centrifugation at 1000 rpm for 10 
min, and the supernatant was dialyzed against MilliQ water, MWCO = 1 kDa. The 
polymers were studied at concentrations of 1, 5, and 10 mg/mL.  
Synthesis of Fluorescently Labeled Micelles with Dil: For the preparation of 
fluorescently labeled micelles, 1% w/w of Dil loading was aimed for by dissolving the 
block copolypeptides and the dye in THF and following the same procedures described 
above.  
III.4.4. Biological Evaluation 
III.4.4.1. In Vitro Evaluation 
III.4.4.1.1. Cell Viability 
To carry out the cytotoxicity studies in vitro two cell lines were used: a human 
immortalized non-tumorigenic keratinocyte cell line (HaCaT) was supplied by CLS Cell 
Lines Service (Eppelheim, Germany) and human fibroblasts were supplied by Hospital 
La Fe (Valencia, Spain). The culture media used was high glucose DMEM Glutamax 
(Fisher, Spain) for HaCaT keratinocytes and DMEM (Sigma-Aldrich Chemical Co., 
Spain) for fibroblasts; both were supplemented with 2% penicillin/streptomycin and 50 
mL of FBS in a humidified incubator (Hucoa-Erlöss S.A., Spain) at 5% CO2 and 37°C. 
Briefly, 50 μL of cells were seeded in 96-well plates at a concentration of 4,000 cells/well 
in the case of HaCaT and 2,000 cells/well for fibroblasts. After 24 h, 50 μL of each 
treatment were added, reaching a final volume of 100 μL in the well. All treatments were 
filtered before adding to the well (pore size 0.45 μm). Cells were incubated with samples 
or controls for 72 h, and then the MTS assay was performed. For this assay, 20 μL of a 
90% phenazine methosulfate minimum (PMS, Sigma, Spain) solution and salt of 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethylphenyl)-2-(4-sulfophenyl)-2H tetrazolium), 
(MTS, Promega, Spain) were added in a ratio 1:20. After 3 h of incubation, the absorbance 
was read at 490 nm using Victor2Wallac™ plate reader (Perkin Elmer, Spain). The 
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concentrations tested were in a range from 0.029 to 0.5 mg/mL for PEG-PPhe10, PEG-
PPhe20, PEG-PBG10, and PEG-PBG20. 
III.4.4.2. Ex Vivo Evaluation 
III.4.4.2.1. Permeation Studies by Franz Diffusion Cells 
Breast skin samples were obtained from healthy women undergoing plastic 
surgery after written informed consent (kindly donated by Hospital la Fe, Valencia, 
Spain). Immediately after excision, the subcutaneous fatty tissue was carefully removed 
using a scalpel. The skin was cut into 4 cm2 pieces, wrapped in aluminum foil and stored 
at -20ºC until use. To reduce inter-individual variability and afford a better comparison 
of results, skin from only one donor was used in all experiments. Before starting each 
experiment, the skin was allowed to equilibrate at r.t. 
Permeation studies employed the modified Franz diffusion cells (Logan 
Instruments Corp., EE. UU) with a diffusional area of 0.95 cm2. The skin was fixed 
carefully between the donor and the receptor chamber, so that stratum corneum was 
placed upwards. The receptor chamber was filled with 8 mL of 0.01 M PBS pH = 7.4 and 
stirred with a magnetic stirring bar at 600 rpm with a thermostated temperature of 37ºC. 
After an equilibration time of 30 min, 100 µL of the formulations using a fixed 
concentration (10 mg/mL) were introduced into the donor chamber using a standard 
pipette. The formulations studied were HA-Cy5.5 (1% w/v), HA-CP-Cy5.5 (1% w/v), 
four types of micelles with encapsulated Dil applied in HA-CP (1% w/v) (PEG-PPhe10-
Dil, PEG-PPhe20-Dil, PEG-PBG10-Dil, and PEG-PBG20-Dil), and finally the PEG-
PBG20-Dil micelle in water and linear HA (1% w/v). Also, benzoic acid as a positive 
control at the same concentration was employed. The donor chamber was then sealed 
with Parafilm®, and aluminum foil and the experiments ran for 8 h. Samples from the 
receptor chamber were taken at times 0, 4, and 8 h and was immediately refilled with 
fresh solution. After the permeation study, skin samples were washed twice with 0.1% 
PBS-BSA and kept in 4% paraformaldehyde (PFA) for 24 h at r.t. Then, the samples were 
washed with 30% sucrose in PBS solution and retained for 24 h at 4ºC. Finally, skin 
samples were washed twice with PBS and preserved in a cryopreservation solution (40% 
0.1 M PB, 30% ethylene glycol and 30% glycerol) at 4ºC until use. Then, skin samples 
were included in the optimum cutting temperature inclusion medium and slides of 5 µm 
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were acquired with the cryostat (version CM1850 UV, Leica, Germany), and samples 
were analyzed by confocal microscopy. Images were captured with an inverted DM IRE2 
microscope equipped with a λ-blue 40x oil immersion objective and handled with a TCS 
SP2 system, equipped with an Acoustic Optical Beam Splitter (AOBS). Dil C18(3) was 
excited at 549 nm, Cy5.5 at 675 nm and DAPI at 405 nm. Images were captured at an 8-
bit greyscale and processed with LCS software (version 2.5.1347a, Leica, Germany) 
containing multicolor, macro and 3D components. Control tissue that follows the same 
incubation time with MilliQ water was also analyzed to establish the autofluorescence. 
Cy5.5 or Dil intensity was quantified five times per sample using Image J software and 
expressed as pixels versus the thickness of the skin (µm). The control intensity was 
subtracted in each case. 
III.4.4.2.2. Evaluation of Tissue Viability in an Ex Vivo Human Skin Model 
Breast skin samples were obtained from healthy women undergoing plastic 
surgery after written informed consent (kindly donated from Hospital la Fe, Valencia, 
Spain). The skin was cut to approximately 1 cm2 and placed in 6-well plates so that the 
dermal side was in contact with DMEM supplemented with 50 mL FBS, 5.5 mL 
penicillin/streptomycin, and 50 µL amphotericin B, and the epidermis was exposed to the 
air. The ex vivo human skin model was incubated at 37ºC under 5% CO2 (see Chapter II 
for more details). After 24 h in culture, the treatments were applied. Tissue viability of 3 
µL of a 10 mg/mL solution of PEG-PBG20 applied in water, applied in linear HA (1% 
w/v), and in the HA-CP (1% w/v) vehicle was evaluated after 24, 48 and 72 h of treatment. 
HA (1% w/v) and HA-CP (1% w/v) vehicles were applied as controls. Tissue viability 
after each treatment was evaluated by MTT assay. Briefly, skin pieces were washed twice 
with PBS and were added to 4 mL of MTT solution (2 mg/mL). After 4 h of incubation 
at 37ºC, skin samples were washed twice with PBS and added to 4 mL of DMSO to 
extract formazan from the skin. After 15 h of extraction, the absorbance was read at 490 
nm using Victor2Wallac™ plate reader (Perkin Elmer, Spain).  
III.4.4.3. In Vivo Evaluation 
III.4.4.3.1. Hydration Assays 
To determine the hydration percent, the Corneometer® CM 825 probe of the 
Cutometer dual MPA 580 (Microcraya S.L., Spain) was used showing the arithmetic 
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mean of five determinations, under the conditions of 22°C ± 2 with relative humidity 
between 40 - 60%. Two pharmaceutical formulations developed following Good 
Manufacturing Practice (GMP) using as active component HA and HA-CP were used. 
The measurement was performed in the corresponding zone between cheekbone and 
nasolabial fold in over 15 human volunteers. HA and HA-CP formulations were applied 
in the left zone, while the right zone was used to carry out the control measures. 
Measurements were performed at time 0 (before applying the product) and at 1, 3, 8, 16, 
24, and 40 h after applying the HA-based materials. Finally, reference values for the 
degree of hydration were collected. 
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IV.1. Antecedents and Background  
Approaches involving nanosized drug delivery systems represent an efficient 
means to treat skin diseases such as psoriasis, a molecularly complex autoimmune 
disease.  
Pharmacotherapy for psoriasis disease is generally divided into systemic or topical 
treatment approaches. The primary topical treatments used in the clinics are 
corticosteroids, which exhibit anti-inflammatory, immunosuppressive, anti-proliferative, 
and vasoconstrictive activities [1]. Corticosteroids act by binding to the α-isoform of the 
nuclear glucocorticoid receptor, which modulates the transcription of anti-inflammatory 
proteins. Glucocorticoid receptors are found in most cells of the human body; in the skin, 
these receptors are located in epidermal keratinocytes and dermal fibroblasts [2, 3]. 
Binding of corticosteroids to their receptor, following uptake via passive diffusion, leads 
to the dissociation of the heat-shock proteins and immunophilins that keep the receptor 
in an inactive form in the cytoplasm, allowing the translocation of the corticosteroid-
receptor complex to the nucleus [4]. In the nucleus, this complex binds to a specific 
sequence of DNA (glucocorticoid-response element) and induces the synthesis of anti-
inflammatory and regulatory proteins. 
While the topical corticosteroids display great potential as anti-inflammatory and 
immunomodulatory drugs, several studies have reported that these drugs can trigger 
immediate and delayed hypersensitivity reactions with continued application, as they can 
behave as allergens [5, 6]. Moreover, cross-reactivity between different topically-
administered corticosteroids has also been reported [7].  
 Fluocinolone acetonide (FLUO), 6-alpha, 9-alpha-difluoro-16-alpha, 17 alpha-
acetonide, is classified by the FDA as a class 6 (mild) topical corticosteroid [8] and is 
currently widely applied in the treatment of eye diseases [9-12]. Several FLUO-
containing implants approved by the FDA are currently on the market, including Retisert® 
for the treatment of uveitis [13] and Iluvien® for the treatment of diabetic macular edema 
[14, 15]. Furthermore, several studies have demonstrated the potential of FLUO as an 
anti-inflammatory and anti-psoriatic drug [16-18]. The anti-psoriatic activity of this drug 
was initially studied by Scholtz et al., in 1961, who revealed its ability to reduce psoriatic 
skin lesions in a study with twelve patients [19]. Since then, many studies have tried to 
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improve the effectiveness of FLUO by modifying the optimal concentration and the type 
of vehicle used (e.g., cream, gel, foam) to enhance the penetration into the skin [20].  
Therefore, the development of new formulations that improve the effectiveness of 
FLUO and increase its concentration in the required skin layer, via a more controlled and 
targeted release, continues as an unmet clinical need. Of note, any formulation developed 
should also aim to diminish the adverse effects caused by the continual topical application 
of corticosteroids, such as stinging, irritation, and photosensitivity, among others [21]. 
 Our proposal to overcome these challenges is the conjugation of FLUO to a 
polymeric backbone using rationally designed covalent bonds to promote sustained drug 
release at the desired site of action in response to specific triggers, such as pH or the 
presence of specific enzymes. Furthermore, control and modification of the specific 
physico-chemical characteristics will allow the synthesis of polymer-drug conjugates that 
can penetrate through the skin via selective pathways of penetration. Polymer conjugation 
will also inhibit the degradation of FLUO, thereby ensuring elevated levels of the drug at 
the desired target cell or tissue. The use of biodegradable polymers such as polypeptides, 
in particular poly-glutamic acid (PGA) [22, 23], can reduce the side-effects derived from 
the continued use of non-degradable polymeric carriers [24]. 
 Therefore, in the present study, we proposed giving FLUO a “new breath of life” 
by developing a PGA-conjugated form (PGA-FLUO) that we hoped would improve 
penetration to specific skin layer as well as its anti-inflammatory activity. The use of an 
ester as covalent bond between the polymer and the drug allows FLUO release in a pH-
responsive manner that could permit selective intracellular release of FLUO allowing its 
binding to the glucocorticoid receptor. Furthermore, the abundant esterase activity 
observed within viable skin (epidermis and dermis) will also facilitate the hydrolysis of 
the ester linker and the release of the drug [25-27]. Additionally, in Chapter III of this 
thesis, the hyaluronic-poly-L-glutamate cross-polymer (HA-CP) vehicle demonstrated 
the improvement of the penetration of several micelles through the skin and provided a 
considerable increase in skin hydration. Therefore, we aimed to improve the topical 
administration of PGA-FLUO conjugate in the skin by embedding the conjugate within 
the HA-CP vehicle. 
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 In this chapter, we present the PGA-FLUO conjugate as a promising treatment for 
psoriasis, highlighting the importance of linker design that would secure a sustained drug 
release. We also emphasize the importance of the use of an adequate vehicle for the 
topical application of the conjugate in order to enhance skin penetration. The use of HA-
CP as vehicle provides additional advantages such as skin hydration (Chapter III). 
Therefore, the improvement of the physiological characteristics of the skin could also 
improve the effectiveness of our conjugate in the psoriasis treatment, expecting a 
synergism of PGA-FLUO conjugate and HA-CP combination. 
IV.2. Results 
IV.2.1. Safety and Skin Penetration of Linear and Star PGAs 
As described in Chapter I, the inherent versatility of the polymers based on 
polypeptides, as poly-glutamic acid (PGA), allows the synthesis of different architectures, 
including simple linear or more complex branched polymers (e.g., star polymers) [28]. 
We first assessed the suitability of linear polymer (PGA) and star polymer (ST-PGA) for 
topical applications. In vitro cell viability assays on keratinocytes (HaCaT cells) and 
human fibroblasts after 72 h of treatment confirmed that both polymers maintained or 
increased cell viability up to the concentration tested (Figure IV. 1).  
 
Figure IV. 1: Cell viability assays in HaCaT cells (left) and human fibroblasts (right) after 72 h 
of treatment of PGA and ST-PGA (n=3). 
After confirming the absence of toxicity in cell lines, we evaluated the penetration 
of 10 mg/mL Oregon Green-labeled PGA (PGA-OG) and ST-PGA (ST-PGA-OG) both 
formulated in water in human skin explants by Franz diffusion cells after 24 h of 
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treatment. After fixation and tissue processing, we took confocal images to evaluate skin 
penetration. The results suggest that both polymers reached the epidermis, although they 
mainly accumulated within the stratum corneum (SC) (Figure IV. 2A). We quantified 
the intensity of OG using Image J software, discovering a slightly higher intensity in the 
SC and viable epidermis for the linear PGA (Figure IV. 2B). Considering these 
preliminary results, we decided to conjugate FLUO to the linear PGA for further studies. 
 
Figure IV. 2: Skin penetration of linear and star polymers labeled with OG. (A) Confocal 
microscopy images of PGA-OG and ST-PGA-OG polymers after 24 h of penetration by Franz 
diffusion cells. (B) Quantification of OG intensity by Image J in the stratum corneum (SC) and 
the viable epidermis (n=5).  
IV.2.2. Synthesis and Characterization of Poly-L-Glutamate Fluocinolone 
Acetonide Conjugates 
Herein we aimed to conjugate the poorly water-soluble corticosteroid 
fluocinolone acetonide (FLUO) to a water-soluble PGA carrier via an ester bond, aiming 
to improve FLUO bioavailability after topical administration in the skin while providing 
a modulated release rate of the drug in the specific skin layer. We chose PGA based on 
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its successful application in the synthesis of polymer-drug conjugates in terms of cargo 
loading capacity due to its multivalcency (carboxylic acid groups in the side chains) [29], 
high hydrophilicity, elevated biodegradability of the polyaminoacid backbone under 
physiologically relevant conditions [30], and the ability of PGA-based nanomedicines to 
bypass biological barriers with a non-toxic and safe biodistribution profile [31-33]. 
Furthermore, PGA is composed of repeating units of glutamic acid, an essential amino 
acid that can provide the skin with the necessary nutrition for proper cellular function, 
and hence, enhances skin hydration, thereby exhibiting a soothing effect on damaged skin 
[34].  
We prepared PGA-FLUO conjugates following well-established synthetic 
procedures [35], attaching FLUO to the polypeptidic backbone through an ester linker 
(Figure IV. 3) by means of a carbodiimide coupling using EDC and 4-
dimethylaminopyridine (DMAP) as a catalyst.  
 
Figure IV. 3: Synthetic route for the preparation of PGA-FLUO conjugates through an ester 
linker: i) EDC, DMAP, DMF, 0ºC, N2 (see synthetic methods section for more details).  
The molecular weight for PGA backbone was determined as 15 kDa by size-
exclusion chromatography (SEC) (100 units of glutamic acid, see Figure IV. 4), and a 





Figure IV. 4: SEC in aqueous conditions (refractive index channel (crosses) vs. molar mass 
(line)) of PGA.  
 
Figure IV. 5: 1H-NMR quantification (mol%) of FLUO (aromatic signals) in the PGA-FLUO 
conjugate in 500 µL of 5 mg/mL solution in D2O. The efficient conjugation was demonstrated by 
achieving around 8 mol% drug loading in all the conjugates. 
We characterized the synthesized conjugates through a battery of techniques to 
ensure identity, purity, total drug loading, and free drug content. The synthetic strategy 
yielded the desired conjugates with excellent purity as revealed via NMR spectroscopy. 
After the conjugation of FLUO to PGA, a broadening of the bands can be observed 
although still retaining the characteristic peaks of the parent drug derivative at 6.5 - 7.5 
ppm. Indeed, the integrity of the acetonide moiety was proven along with the conjugate 
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as shown by the prevalence of the associated peaks at 0.5 and 1.5 ppm respectively within 
the conjugate (Figure IV. 6).  
 
Figure IV. 6: 
1
H-NMR assignment of FLUO signals in the PGA-FLUO conjugate in D2O and 
FLUO in deuterated acetonitrile (5 mg/mL). Aromatic signals that allow the quantification of 
FLUO (6.5 - 7.5 ppm) were maintained after conjugation to PGA. The signals of the acetonide 
group, between 0.5 - 1.5 ppm, were also maintained after conjugation to the polymeric backbone. 
As shown in Figure IV. 7, UV-Vis spectra of PGA-FLUO shows the preservation 
of the characteristic maximum absorbance of the parent drug (239 nm). However, the 
signals of PGA and FLUO overlap at the maximum absorbance, and so we quantified 
total drug loading at 260 nm. UV-Vis analysis allowed us to determine total drug loading 
(TDL) by weight of 16 - 24 wt%, which agreed with the estimated value obtained from 
NMR analysis (6.5 to 8.9 mol%) for the different batches. In the case of the OG-labeled 
conjugates, we also analyzed the loading of OG by UV-Vis spectroscopy, yielding a result 





Figure IV. 7: UV-Vis spectra of PGA-FLUO and PGA-FLUO-OG conjugates. (A) Calibration 
curve of FLUO at 239 nm. (B) Spectra of the calibration curve of FLUO. (C) Spectra of PGA-
FLUO conjugates. (D) Spectra of PGA, FLUO and PGA-FLUO conjugate. 
 
Figure IV. 8: UV-Vis spectra of OG-labeled PGA-FLUO conjugates. (A) Calibration curve of 




We established the homogenous conjugation of the drug throughout the 
polypeptidic backbone, as evidenced by SEC chromatograms obtained from the parent 
PGA and the conjugates, detected by UV-Vis at the absorbance peak of FLUO (260 nm) 
in good agreement with the refractive index chromatograms (note that the peak at 17 min 
comes from the Na+ counter ion from PGA backbone) (Figure IV. 9).  
 
Figure IV. 9: SEC in aqueous conditions (refractive index and UV channel) of PGA and PGA-
FLUO.  
Then, we optimized the synthetic methodology for robust reproducibility and 
scalability (up to multigram scale), yielding the desired products with high purity. Table 
IV. 1 summarizes the most relevant parameters for the physico-chemical characterization 
of our polymer-drug conjugates from three different batches and scales, demonstrating 
batch to batch reproducibility together with the robustness of the synthetic methodology 
followed (Figure IV. 10).  
Table IV. 1: Physico-chemical characterization of PGA-FLUO conjugates. a Determined by UV-
Vis. b Determined by HPLC. c Determined by 1H-NMR. d Hydrodynamic radius (1 mg/mL and 






Figure IV. 10: 1H-NMR spectra in D2O of three different batches of PGA-FLUO demonstrating 
batch-to-batch reproducibility. 
Furthermore, we found a free drug (FD) content of 0.10 - 0.12 wt% in relation to 
the total drug loading in all studied conjugates as determined by high-performance liquid 
chromatography (HPLC). The results obtained demonstrated free drug content below 2 
wt% (relative to total drug loading) after the exhaustive purification of the conjugate, 
thereby providing evidence for the purity and high drug loading of the conjugate (Figure 





Figure IV. 11: (A) Calibration curve of FLUO at 239 nm. (B) HPLC chromatograms of the 
calibration curve of FLUO. (C) HPLC chromatogram of liquid-liquid extraction of FLUO, FLUO 
+ PGA, FLUO + PGA-FLUO conjugate, and FLUO + PGA-FLUO + HA-CP vehicle. (D) HPLC 
chromatogram of free FLUO from PGA-FLUO conjugate (blue) in comparison with a standard 
sample of FLUO at 0.075 mg/mL (black).  
IV.2.3. Self-assembling Behavior of PGA-FLUO 
We next studied the behavior of the PGA-FLUO conjugates in an aqueous 
environment as the conjugation of the corticoid motifs into the hydrophilic PGA 
backbone may result in the generation of an amphiphilic system with appropriate 
hydrophobic-hydrophilic balance, enabling the self-assembly into larger nanometer-sized 
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objects [36]. At the molecular level, we found evidence that the self-assembly of the 
PGA-FLUO proceeded primarily via hydrophobic effect, as evidenced by the pyrene 
assay performed to determine the critical aggregation concentration (CAC) [37]. The 
presence of hydrophobic pockets within the assemblies allowed us to determine the CAC 
via pyrene probe  resulting in a low value of 0.06 mg/mL, in close agreement with other 
anionic polymer amphiphiles reported in the literature [38] (Figure IV. 12A).  
We then employed circular dichroism (CD) to determine the conformation of the 
conjugates as a function of PGA-FLUO conjugate concentration and at different pHs that 
would mimic the different environments to which the conjugates will be exposed after 
topical administration (Figure IV. 12B). At pH 7.4, PGA-FLUO took on a predominantly 
random coil conformation, as revealed by the absolute minimum ellipticity value at 200 
nm. We also recorded a significant redshift evolution of the random coil negative band 
below and above the CAC threshold value, together with the appearance of a cotton effect 
in the 270 - 300 nm region, which is a characteristic change in optical rotatory dispersion 
in the vicinity of an absorption band of a substance, and in this case such bands are 
attributed to the ketones within the FLUO molecules [39]. The increase in the cotton band 
intensity is most likely related to the increasing concentration of the FLUO content rather 
than a supramolecular organization of the inner core of the assembled conjugates, as 
derived by the flat shape of the CD spectra when representing the molar ellipticity and 
hence correcting the concentration effect (Figure IV. 13).  
 
Figure IV. 12: Self-assembly behavior of PGA-FLUO conjugates. (A) Pyrene assay of PGA-
FLUO conjugates by fluorescence spectroscopy. (B) Secondary structure of the conjugates by CD 




Figure IV. 13: Molar ellipticity of PGA-FLUO at different concentrations at pH 7.4 and 5.5.  
At pH 5.5, in contrast, we found a partial alpha-helix characteristic conformation 
that evolved when increasing the concentration above the CAC. Under this condition, the 
random coil to alpha-helix transition is expected to be partial according to the pKa values 
(which indicated the strength of an acid) reported in literature around 4.9 (roughly 50% 
of side chains are protonated at pH 5.5) [28], and the fact that we failed to observe 
precipitation or cloudiness at pH 5.5 [40] as can be observed at pH 3 (Figure IV. 14). 
 
Figure IV. 14: Transmittance measurements by UV-Vis of PGA-FLUO at pH 7.4, 5.5, and 3.  
TEM micrographs confirmed the spherical aspect of the self-assembled carriers 
with geometrical sizes in the range of 50 - 100 nm with no particular evidence for core-
shell morphologies (Figure IV. 15A). The conjugates exhibited a hydrodynamic radius 
208 
 
(Rh) of 40 - 100 nm in aqueous solutions at different pHs and ionic strengths, confirming 
the assembly of multiple PGA-FLUO conjugates molecules within the globular 
nanoassembly (Figure IV. 15B). Z-potential measurements resulted in a highly negative 
value of -50 mV, confirming the assembly of multiple PGA-FLUO molecules within the 
globular nanoassembly. The compaction of the assembled conjugates upon increasing 
ionic strength reinforces the critical character of hydrophobic interactions. These 
interactions can drive the self-assembly process exposing the polyglutamate anionic 
backbone to the surface, and hence experiencing a screening of anionic repulsions upon 
increasing ionic strength and leading to the recorded decrease in Rh [41].  
 
Figure IV. 15: (A) TEM micrographs of PGA-FLUO from a sample prepared in MilliQ water at 
2 mg/mL. (B) Hydrodynamic radius by DLS in different solvents (MilliQ water, PB 10 mM, and 
PBS pH 7.4) with a constant size close to 100 nm.  
In summary, the conjugation of the highly hydrophobic corticoid FLUO to PGA 
results into an amphiphilic PGA-FLUO conjugate that self-assembles into spherical 
nanosized objects driven by the hydrophobic interactions of the FLUO motifs. Although 
we found no clear evidence for a core-shell structure by TEM, spectroscopic analyses 
suggest an unordered arrangement of FLUO within an inner hydrophobic core. At the 
outer layer of the constructs, CD analysis and z-potential values indicate a PGA backbone 
composition with a high anionic carboxylate form at pH 7.4 in a relatively constrained 
random coiled conformation, probably due to electrostatic repulsions, which might 





IV.2.4. FLUO Release Kinetics as a Crucial Feature Driving Sustained Release into 
the Skin 
We subsequently studied drug release kinetics under hydrolytic and proteolytic 
conditions owing to the pH-labile nature of the ester bond and cathepsin B-mediated 
degradation of the polymer backbone. We incubated samples of PGA-FLUO at 37ºC at 
different pHs including 5.5 (lysosome, in presence and absence of cathepsin B) and 7.4 
(blood) up to 72 h. In addition, as we use the HA-CP hydrogel (see Chapter III for more 
details) as a vehicle to administer the conjugate into the skin, we performed drug release 
kinetics in the presence of the HA-CP vehicle. Overall, the data collected suggests a small 
but sustained FLUO release in all the cases (Figure IV. 16 and Figure IV. 17).  
 
Figure IV. 16: Drug release profiles by HPLC at different pH (5.5 and 7.4) and under proteolytic 
conditions (Cat. B) of PGA-FLUO alone and applied in the HA-CP vehicle. Experiments were 




Figure IV. 17: Drug release chromatograms by HPLC. (A) Release of FLUO at pH 5.5 at time 0 
(black) and after 72 h (blue) (B) Release of FLUO at pH 7.4 at time 0 (black) and after 72 h (blue) 
(C) Release of FLUO in presence of cathepsin B at time 0 (black) and after 72 h (blue).  
The results suggest that drug release kinetics from the conjugate at 72 h is 2-fold 
faster at pH 7.4 (5 wt% of free FLUO) than at pH 5.5 (2.4 wt% of free FLUO). Although 
these results might seem counterintuitive, we must consider the conformational and 
spatial arrangement of the drug within the polymer-drug conjugate and the resulting 
assembled nanocarrier. Although acids or bases chemically catalyze ester-bond 
hydrolysis [42-44], these results might be explained in terms of a PGA backbone response 
to pH. At pH 5.5, protonation of PGA side chains represents roughly 50% molar of the 
overall carboxylates as derived from the pKa of linear PGA reported in literature [28]. 
These effects induce a partial random coil to alpha-helix conformation transition as shown 
above, although the system remains fully soluble according to turbidimetric data. At pH 
7.4, 100% molar side chains in PGA are carboxylates, yielding a full random coil 
conformation. Whether the observed change in release kinetics derives from 
conformational aspects (i.e., rigidity, compactness, accessibility to PGA-FLUO bonds) 
or auxiliary effect of vicinal carboxylates, the result observed represents an inverse 
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release profile to that expected. Unfortunately, the complete rationale for this 
phenomenon lies outside the scope of the present work. We also studied drug release in 
the presence of cathepsin B (5 U), a lysosomal cysteine protease that forms a major part 
of the proteolytic conditions faced by the polymer-drug conjugates following cell uptake. 
We found the release of FLUO to be significantly higher following the addition of 
cathepsin B when compared to hydrolytic conditions, with 20 wt% drug released within 
72 h (Figure IV. 16). This significant increase in drug release can be ascribed to the 
digestion of PGA backbone, enabling the heightened accessibility of the PGA-FLUO 
bond to hydrolytic conditions [45]. 
Additionally, the incorporation of the PGA-FLUO conjugate within the HA-CP 
vehicle caused a marked decrease in the release of FLUO under hydrolytic conditions, 
obtaining half of the free FLUO released at pH 7.4 (~2.5 wt% of free FLUO) and pH 5.5 
(~1.2 wt% of free FLUO). However, more importantly, we observed a marked decrease 
under proteolytic conditions, obtaining ~2.5 - 3 wt% of free FLUO in comparison with 
the 20 wt% drug release without the HA-CP vehicle. 
IV.2.5. Compatibility of PGA-FLUO with the HA-CP Vehicle  
As PGA-FLUO will be delivered topically using the HA-CP vehicle (previously 
reported to enhance permeation to the epidermis in Chapter III), we studied the 
compatibility of the intended formulations. The incorporation of PGA-FLUO at a 
working concentration of 10 mg/mL within 1% w/v of HA-CP vehicle established the 
complete solubility and stability of the conjugate in the vehicle. Furthermore, the vehicle 
displayed no effect over nanosized PGA-FLUO in terms of homogenous globular shape 
nanoparticles and an expected size of about 80 - 100 nm, as evidenced in TEM 
micrographs (Figure IV. 18).  
 
Figure IV. 18: Representatives TEM images of PGA-FLUO conjugates in the HA-CP (1% w/v) 
vehicle at 10 mg/mL, scale bar is 100 nm (left) and 500 nm (right).  
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In order to explain the reduction of drug release observed from the PGA-FLUO 
under proteolytic conditions in the presence of the HA-CP, we studied the activity of the 
cathepsin B in vitro with and without the vehicle. We used medium (80 µL of acetate 
buffer 20 mM pH=5, 10 µL of EDTA 2 mM and 10 µL of DTT 5 mM), medium with the 
substrate (Z-Arg-Arg-AMC), and negative control (leupeptin) as controls (Figure IV. 
19). The increase in the viscosity caused sequestering of the nanocarrier structure within 
the gel network contributing to the delayed release of FLUO compared to the aqueous 
dispersion. The decrease of the drug release is more evident under proteolytic conditions, 
where the reduction in the release kinetics is most likely related to the lower mobility of 
enzyme and substrate. Indeed, we discovered a significant decrease of cathepsin B 
activity in the presence of HA-CP vehicle. These results suggest a protective effect of the 
HA-CP vehicle on PGA-FLUO. 
 
Figure IV. 19: Cathepsin B activity in vitro with or without HA-CP vehicle by the quantification 
of the fluorescence intensity. 
IV.2.6. In Vitro Skin Compatibility and Cell Trafficking Studies of PGA-FLUO 
Conjugates 
Cell viability assays performed on HaCaT cells and human fibroblasts after 72 h 
of treatment with increasing doses of free FLUO or PGA-FLUO at the same drug 
equivalents revealed the absence of cell toxicity up to the concentrations tested, 
demonstrating the safety of the conjugation strategy for dermal applications (Figure IV. 




Figure IV. 20: In vitro evaluation of PGA-FLUO conjugates. Cell viability assays in (A) HaCaT 
cells and (B) human fibroblasts after 72 h of treatment with FLUO or PGA-FLUO conjugate 
(n=3). (C) Uptake study by flow cytometry of PGA-FLUO conjugates fluorescently labeled with 
OG in HaCaT cells. Results represented as the average of positive cells (%) ± SEM. t-student, 
comparison of pair of data with control condition, ***p<0.001, **p<0.01, *p<0.05 (n=3). (D) 
Confocal images from the uptake of OG-labeled PGA-FLUO conjugates at 24 h post-treatment 
in HaCaT cells, in which a colocalization with lysotracker red was observed (yellow). 
In addition, we performed flow cytometry (Figure IV. 20C) and fluorescence 
confocal microscopy (Figure IV. 20D) at non-toxic concentrations in keratinocytes as 
our target cell to understand the cell internalization of OG-labeled PGA-FLUO. As 
expected for these macromolecular systems [46, 47], we observed energy-dependent 
endocytic uptake, reaching 30% of positive cells at 24 h post-treatment. In agreement 
with these results, we obtained confocal images to identify the subcellular localization of 
the PGA-FLUO-OG conjugate inside the keratinocytes after 24 h of uptake, 
demonstrating a clear co-localization with the lysosomal marker Lysotracker red. These 
findings indicate the suitability of our polypeptidic nanocarriers for lysosomotropic drug 




IV.2.7. PGA-FLUO Reduces the Release of Pro-Inflammatory Cytokines In Vitro 
Additionally, we evaluated cell viability of murine macrophages (Raw264.7 cell 
line) in response to FLUO after 72 h of treatment, allowing us to select 0.49 ng/mL as 
FLUO concentration for any subsequent pharmacological study in this cell line (Figure 
IV. 21A).  
 
Figure IV. 21: In vitro PGA-FLUO evaluation in macrophages. (A) Cell viability assay in 
Raw264.7 macrophages following treatment with varying concentrations of FLUO for 72 h (n=3, 
mean±SEM). (B) Cell viability assay after 72 h of treatment with FLUO, PGA-FLUO conjugate, 
and vehicles at 0.49 ng/mL FLUO eq. (C) Reduction of pro-inflammatory cytokines release after 
treatment for 72 h in macrophages stimulated with bacterial LPS (n=3). Asterisks indicate 
statistically significant differences after ANOVA analyses followed Tukey’s post hoc tests mean 
± SEM. In all cases, we considered differences to be significant when p***<0.0001; p**<0.01; 
p*<0.05. 
We then assessed cell viability after the treatments with FLUO, PGA-FLUO, and 
vehicles by MTS assay at the selected concentration of FLUO, revealing a non-toxic 
profile when tested at 72 h of incubation (Figure IV. 21B). Finally, we tested the anti-
inflammatory activity of the FLUO derivatives by assessing the reduction of the pro-
inflammatory cytokines release to the culture media from the macrophages treated with 
215 
 
5 ng/mL of bacterial LPS from E. coli, using a LUMINEX multiplex immunoassay for 
the quantification of the cytokines. The results obtained suggested that FLUO not only 
retains its anti-inflammatory activity following incorporation into the polypeptidic 
backbone, but also that the conjugation to PGA promotes the inhibitory effect of FLUO 
on the release of pro-inflammatory cytokines IL-1b and INF-γ (Figure IV. 21C).  
IV.2.8. PGA-FLUO Biocompatibility and Anti-Inflammatory Effect in an 
Inflammatory Skin Equivalents Model and an Inflammatory Ex Vivo Human Skin 
Model 
Ex vivo models represent valuable research tools for investigations into different 
skin diseases such as psoriasis, and are considered more relevant than in vitro research 
involving cell lines. We employed two ex vivo models, from which we can obtain 
complementary information, to evaluate the safety and the anti-inflammatory activity of 
the synthesized conjugates. We explored two ex vivo models to corroborate the data 
obtained in the cell studies: (i) an ex vivo human skin model (Figure IV. 22A) and (ii) a 
skin equivalent model (Figure IV. 22B). 
In an ex vivo human skin model (Figure IV. 22C), tissue viability after the 
treatment with 3 µL of a solution of 10 mg/mL of PGA, FLUO, PGA-FLUO applied in 
water or in the HA-CP vehicle (1% w/v), and the HA-CP (1% w/v) during 24 h revealed 
that all the treatments maintain tissue viability. Additionally, in a skin equivalents model 
the application of two doses of 5 mg/mL of the same treatments on day 11 and 13 of 
culture also demonstrated excellent biocompatibility, as indicated by the absence of 
significant cytotoxic effects (Figure IV. 22D).  
Additionally, we developed inflammatory models to assess the anti-inflammatory 
potential of the FLUO derivatives at the same concentration evaluated in the viability 
assays. We studied IL-6 secretion by ELISA assay in an optimized inflammatory ex vivo 
human skin model after inflammatory insult via the combined treatment with bacterial 
lipopolysaccharide (LPS; 15 µg/mL) and epidermal growth factor (EGF; 2.5 ng/mL) for 




Figure IV. 22: Evaluation of tissue viability and anti-inflammatory activity of FLUO derivatives 
in inflammatory skin models. (A) Establishment on the inflammatory ex vivo human skin model. 
(B) Establishment of the inflammatory skin equivalents model. (C) Tissue viability in an 
inflammatory ex vivo human skin model after 24 h of treatment (10 mg/mL of PGA, FLUO, PGA-
FLUO in water and HA-CP vehicle (1% w/v), and HA-CP (1% w/v)) by MTT assay. (D) Tissue 
viability in the inflammatory skin equivalents model after 2 doses of treatment (5 mg/mL of PGA, 
FLUO, PGA-FLUO in water and HA-CP vehicle (1% w/v), and HA-CP (1% w/v)) by MTT assay. 
(E) IL-6 levels in the inflammatory ex vivo human skin model after the induction with the 
combination of bacterial LPS (15 µg/mL) and EGF (2.5 ng/mL), following treatment (10 mg/mL 
of PGA, FLUO, PGA-FLUO in water and HA-CP vehicle (1% w/v), and HA-CP (1% w/v)) for 
24 h. Values expressed as relative inhibition of IL-6 (%). (F) IL-6 levels in the inflammatory skin 
equivalents model stimulated with TNF-α (20 ng/mL), following two doses of treatment (5 
mg/mL of PGA, FLUO, PGA-FLUO in water and HA-CP vehicle (1% w/v), and HA-CP (1% 
w/v)). Values are expressed as relative inhibition of IL-6 (%). Asterisks indicate statistically 
significant differences after ANOVA analyses followed Bonferroni’s post hoc tests, mean ± SEM. 
In all cases, we considered differences to be significant when p***<0.001; p**<0.01; p*<0.05. 
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Treatment for 24 h revealed that the reduction in IL-6 release following FLUO 
administration was similar to PGA-FLUO treatment (both applied in water or in the HA-
CP vehicle). All treatments reduced IL-6 levels by around 20% compared to the 
corresponding untreated control (Figure IV. 22E). To ratify this data, we also studied  
IL-6 secretion in the second inflammatory skin equivalents model induced by the 
application of 20 ng/mL of recombinant TNF-α in the culture media on days 10 and 12 
of culture [49-52]. Of note, this model provides a more permeable stratum corneum than 
the ex vivo human skin model, given the reconstitution of this skin model from cells. On 
day 11 and 13, we topically applied the same treatments at 5 mg/mL (35 μg/cm2) and 
evaluated the release of IL-6 by ELISA assay. We discovered a significant reduction in 
IL-6 secretion (almost 50%) in the case of PGA-FLUO treatment applied in water or the 
HA-CP vehicle when compared to the free drug, most probably due to the lower amount 
of model variance when compared to the higher variation observed among the human 
skin samples (Figure IV. 22F).  
IV.2.9. FLUO Conjugation and the Use of HA-CP as Vehicle Enhances Skin 
Permeation 
To visualize skin penetration of PGA-FLUO and explore the role of the HA-CP 
on the extent of skin permeation, we performed a qualitative study on human skin using 
Franz diffusion cells comparing the permeation of 100 µL from 10 mg/mL solution of 
OG-labeled PGA-FLUO applied in water or embedded in Cy5.5-labeled HA-CP vehicle 
(1% w/v) for 24 h. After fixation and tissue process, we acquired confocal microscopy 
images that revealed the significant accumulation of the PGA-FLUO within the stratum 
corneum, and a lower accumulation in the epidermis (Figure IV. 23A). However, PGA-
FLUO within the HA-CP vehicle displayed enhanced penetration through the epidermal 
layer (Figure IV. 23B). The quantification of OG intensity in the different skin layers by 
Image J software revealed that the presence of the HA-CP vehicle significantly enhanced 
the epidermal accumulation of PGA-FLUO, proven by the higher fluorescence intensity 
detected in both, the stratum corneum and the viable epidermis (Figure IV. 23C). 
Furthermore, we extracted FLUO from the whole skin at 24 h post-treatment with 
PGA-FLUO (10 mg/mL) in water or embedded in the HA-CP vehicle (1% w/v) and 
analyzed the samples by HPLC (Figure IV. 24). We normalized HPLC data considering 
the amount of FLUO released determined from the release kinetics studies under similar 
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conditions (with or without HA-CP), demonstrating that the amount of FLUO was almost 
two-fold higher in presence of HA-CP as vehicle (Figure IV. 23D). These findings prove 
the ability of the HA-CP vehicle to act as penetration enhancer, being able to promote the 
accumulation of the conjugate in the epidermal layer, thereby creating a source for the 
sustained release of the drug that could reduce the need for the repeated skin 
administration.  
 
Figure IV. 23: Evaluation of skin permeation of PGA-FLUO and FLUO quantification in whole 
skin. (A) Confocal images after permeation studies of OG-labeled conjugates formulated in water. 
(B) Confocal images after permeation studies of OG-labeled conjugates formulated in the HA-
CP vehicle (1% w/v). (C) Quantification of OG intensity by Image J software in the stratum 
corneum (SC) and the viable epidermis (n=5) after permeation studies. (D) Quantification of 
FLUO extracted from the whole skin (see material and methods for details) analyzed by HPLC 
after the permeation studies of PGA-FLUO with and without the HA-CP vehicle (n=3). Asterisks 
indicate statistically significant differences after ANOVA analyses followed Bonferroni’s post 





Figure IV. 24: HPLC chromatograms of FLUO extracted from the skin after the permeation 
studies in Franz diffusion cells for 24 h. (A) Calibration curve of FLUO at 239 nm in DMSO. (B) 
Chromatogram of FLUO extracted when the PGA-FLUO conjugate was applied in water (blue) 
in comparison with a standard sample at 0.075 mg/mL (black) (C) Chromatogram of FLUO 
extracted when the PGA-FLUO conjugate was applied in the HA-CP vehicle (blue) in comparison 
with a standard sample at 0.075 mg/mL (black). 
Additionally, we analyzed the aliquots extracted from the receptor chamber 
obtained during the permeation studies by UV-Vis spectroscopy, in order to detect any 
signal from OG that would suggest the capability of the specific formulation to reach 
systemic circulation, feature to be avoided with corticosteroids in order to prevent 
systemic toxicities. MilliQ water as well as the use of HA-CP-Cy5.5 without the 
conjugate were used as controls. The results revealed the absence of OG signal at 495 nm 
and Cy5.5 at 676 nm (as already demonstrated in Chapter III) at 8 and 24 h of study, 
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suggesting that the conjugate is not capable to reach the dermis, and therefore the receptor 
chamber in contact with the dermis (Figure IV. 25). As the receptor chamber simulates 
the bloodstream, this finding would indicate that the conjugate would not reach the 
systemic circulation avoiding the possible corticosteroids adverse effects and focusing its 
action on the desired epidermis. 
 
Figure IV. 25: UV-Vis spectra of the aliquots extracted from the receptor chamber after 8 (left) 
and 24 h (right) after Franz diffusion cell permeation studies in human skin by using PGA-FLUO-
OG applied in water or in the HA-CP vehicle and HA-CP-Cy5.5 as control.  
IV.2.10. Optimization of In Vivo Experiments  
Several reports have demonstrated that imiquimod (IMQ) can activate immune 
cells via a toll-like receptor to induce psoriasis-like inflammation [53-55]. In Chapter II, 
we optimized our IMQ-psoriasis induced model in order to evaluate the anti-psoriatic 
activity of the conjugates compared to the free drug. 
Firstly, in vivo experiments were conducted to optimize the optimal concentration 
of FLUO equivalents that trigger the maximum anti-psoriatic activity, in order to select 
the adequate therapeutic window. After seven days of application of IMQ cream in the 
back and the right ear, we split mice into representative groups. We employed healthy 
and untreated mice as controls (negative and positive control). Conjugate-based 
treatments at different FLUO equivalents (0.01, 0.15 and 0.3 wt% FLUO eq.) were 
studied, based on the commonly marketed dose of FLUO in the formulations (0.01% w/w) 
[20]. The conjugates were dissolved in the HA-CP vehicle (1% w/v) and immediately 
applied topically in the back and the right ear for five consecutive days. We also applied 
HA-CP vehicle (1% w/v) as control following the same methodology. The safety of the 
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treatments was evaluated by tracking body weight every two days, demonstrating that 
after a slightly decrease in body weight during the application of IMQ, the animals 
maintain and recover body weight during the application of the treatments (Figure IV. 
26).  
 
Figure IV. 26: Relative body weight of the mice during the treatment showing no significant 
alterations, which displayed a 100% survival rate. 
IV.2.10.1. Reduction of Skin Inflammation, Ear Thickness, and Splenomegaly 
We evaluated the evolution and progression of the disease for five days of 
treatment after the last application of IMQ cream. PASI score allowed the assessment of 
several features of psoriasis disease, such as erythema, scaling and thickness (skin 
induration) of the back of the mice after the treatment with the different concentrations 
of PGA-FLUO conjugates (0.01, 0.15, and 0.3 wt% FLUO eq.) (Figure IV. 27A). 
Examination of the back every two days revealed that the groups treated with the different 
concentrations of PGA-FLUO conjugate showed a significant reduction in the studied 
features. In the three parameters evaluated, we observed a progressive improvement by 
increasing the concentration of PGA-FLUO conjugate used, obtaining values close to 0 
in the case of the 0.15 and 0.3 wt% FLUO eq. In addition, in those animals treated with 
HA-CP vehicle, we observed a marked reduction of erythema and scaling at day 13, as a 
possible consequence of the general improvement of the skin features, specifically skin 
hydration. 
Ear thickness was also evaluated every two days using a caliper in comparison 
with the positive control. The results obtained at day 13 revealed that the group treated 
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with 0.01 wt% FLUO eq. reduces ear thickness by 10% compared with the positive 
control. Importantly, a significant decrease in the ear thickness was observed using 0.15 
and 0.3 wt% FLUO eq. reducing ear thickness by almost 20% (Figure IV. 27B). 
 
Figure IV. 27: Reduction of skin inflammation, ear thickness, and splenomegaly in an IMQ-
induce in vivo psoriasis model. (A) Scoring severity of skin inflammation in the dorsal skin with 
PASI score (erythema, scaling, and thickness) every two days during the treatment, scale from 0 
to 4. (B) Relative reduction of ear thickness after the treatments compared to the positive control. 
(C) Spleen weight (mg) determination after five days of treatment. Asterisks indicate statistically 
significant differences after ANOVA analyses followed Bonferroni’s post hoc tests, mean ± SEM. 
In all cases, we considered differences to be significant when p***<0.001; p**<0.01; p*<0.05. 
Of note, as explained in Chapter II, the topical application of IMQ cream for 
seven consecutive days has been reported to induce a significant increase in spleen weight 
[56]. This splenomegaly is correlated with the increment of the synthesis of pro-
inflammatory cytokines which are involved in the onset of the disease. After five days of 
treatment application, we observed a marked reduction in the animals spleen weight with 
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the three concentrations tested. The groups treated with 0.01, 0.15 and 0.3 wt% FLUO 
eq. presented a value of spleen weight around 150, 90 and 85 mg, respectively, reaching 
up to a splenomegaly reduction >70% compared with the positive control (Figure IV. 
27C). These results showed that there is a decrease in the immune response not only at 
the local level but also at the systemic level. Therefore, the reduction in spleen weight 
may be closely related to the decrease of the localized inflammation in the skin and the 
synthesis of pro-inflammatory cytokines. Of note, the group treated with the HA-CP 
vehicle also revealed a reduction in spleen weight, which could be related to an 
improvement of the skin properties at a local level triggering a decrease of the local 
inflammation, which also results in a decrease of the systemic inflammation. 
IV.2.10.2. Reduction of Epidermal Thickness 
We also assessed the reduction of the epidermal thickness of the ear and the back 
by histological examination. Firstly, H&E staining of the right ear treated with IMQ 
cream revealed a marked difference in epidermal thickness when compared to the 
contralateral healthy ear, mimicking the pathophysiology of the psoriasis (Figure IV. 28).  
 
Figure IV. 28: H&E staining of the ears after five days of treatment in the IMQ-induced skin 
inflammation model. Original magnification displayed in each image was 10x. One representative 
picture is shown for each treatment regimen. 
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Although with the three concentrations of FLUO eq. tested we can observe a 
decrease in the epidermal thickness, a more pronounced decrease was revealed in the 
groups treated with 0.15 and 0.3 wt% FLUO eq., even resembling the results of the control 
healthy ear. The control group treated with HA-CP vehicle showed a decrease in 
epidermal thickness, as a possible consequence of improved skin hydration and a decrease 
in the scaling process.  
In addition, we observed the same trend via H&E staining in mouse backs in a 
concentration dependent manner recovering almost completely the skin structure with the 
highest concentration used (Figure IV. 29). Of note, the group treated with the HA-CP 
vehicle also presents a reduction in the epidermal thickness, similar to which occurs with 
the lowest concentration tested (0.01 wt% FLUO eq.). This fact, also observed in the right 
ear, may be explained due to improved dryness and desquamation of the skin, and 
therefore, the improvement of these properties leads to a reduction of the local 
inflammation and the epidermal thickness. 
 
Figure IV. 29: H&E staining of the back of the mice after five days of treatment in the IMQ-
induced skin inflammation model. Original magnification displayed in each image was 10x. One 
representative picture is shown for each treatment regimen. 
IV.2.10.3. Reduction of Pro-Inflammatory Cytokines Levels in Serum 
IL-23, IL-17, INF-γ, and TNF-α act as major pro-inflammatory mediators of 
psoriasis in serum and tissue, and could be induced upon IMQ treatment [56-58]. In this 
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optimization, we will focus on the quantification of pro-inflammatory cytokines in serum 
(specifically IL-1b, IL-23, and INF-γ) detected by LUMINEX assay. 
After five days of treatment with different FLUO eq., the expression of IL-1b, IL-
23, and INF-γ in serum were measured and values compared with controls (Figure IV. 
30). All the concentrations tested and also the HA-CP vehicle revealed a notable decrease 
of the pro-inflammatory cytokine levels compared to the positive control. In the case of 
the IL-1b levels a decrease of 20% respect to the positive control was observed with no 
marked differences between the treatments. For IL-23 levels, the group treated with 0.01 
wt% FLUO eq. showed around a 20% reduction, however, the groups treated with 0.15 
and 0.3 wt% FLUO eq. revealed a higher significant reduction (~55%) compared to the 
positive control. Finally, in the case of INF-γ levels, the best results (40% decrease) was 
obtained with 0.15 wt% FLUO eq. Hence, in general, the group treated with 0.15 wt% 
FLUO eq. exhibited the best results.  
Moreover, the treatment with the HA-CP vehicle also displayed a marked 
reduction of the IL-1b, IL-23, and INF-γ levels. As explained in previous sections, this 
fact is related to the reduction of the systemic inflammation triggered by the reduction of 
the local inflammation present in the skin.  
 
Figure IV. 30: Reduction of pro-inflammatory cytokines IL-1b, IL-23, and INF-γ in serum post-
treatment measured by LUMINEX assay. Asterisks indicate statistically significant differences 
after ANOVA analyses followed Bonferroni’s post hoc tests, mean ± SEM. In all cases, we 
considered differences to be significant when p***<0.001; p**<0.01; p*<0.05. 
Based on these results, further studies in vivo were conducted using the 
intermediate concentration tested, 0.15 wt% FLUO eq. applied in the HA-CP vehicle. 








0.01% PGA-FLUO + HA-CP
0.15% PGA-FLUO + HA-CP



























formulation (0.15 wt% FLUO eq. in the HA-CP vehicle) in comparison with the same 
concentration of the conjugate and the free FLUO both applied in a commercially-
available cream used with current marketed corticosteroids. 
IV.2.11. PGA-FLUO in HA-CP Reduces Imiquimod-Induced Skin Inflammation In 
Vivo 
After the optimization of the experimental condition to perform the in vivo 
experiments (0.15 wt% FLUO eq. applied during 5 days) we carried out the final 
benchmark experiment. We used this concentration to compare the anti-psoriatic activity 
of FLUO applied in a commercially-available cream used for current corticosteroids (due 
to its hydrophobicity and poor water solubility) with PGA-FLUO in the same cream and 
also applied in the HA-CP vehicle due to its adequate hydrophilicity. We applied 
treatments to the back and the right ear of IMQ-treated 6-week-old male BALB/c mice 
for five days. We also applied the cream and the HA-CP vehicle alone as controls. 
Treatment safety was evaluated by tracking body weight every two days and comparing 
results to healthy animals. Encouragingly, we discovered that treatments failed to 
significantly alter body weight (Figure IV. 31).  
 
Figure IV. 31: Relative body weight of the mice measured every two days. During treatments, 
the animals recover body weight and we observed no significant alterations. 
 Histological examination of the mouse ears and back sections revealed a marked 
difference in the extent of epidermal thickening and elongation of epidermal ridges 
between the treated groups. PGA-FLUO treatment resulted in a more significant 
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diminishment of ear thickness and epidermal ridges and, remarkably, the choice of the 
vehicle employed for the administration also influenced overall effects, with the group 
treated with PGA-FLUO in HA-CP providing similar results to those observed in healthy 
control animals. Overall, PGA-FLUO in HA-CP exhibited significant differences 
compared to all other groups, presenting minimal epidermal thickening, an intact stratum 
corneum, and histological features compared to the negative control (Figure IV. 32). 
Importantly, following analysis of the control groups treated with the vehicles, we 
discovered that the group treated with the HA-CP presented a decrease in the epidermis 
thickness, whereas treatment with the commercially available cream failed to elicit any 
anti-psoriatic effect. This finding suggests that the probable increase in skin hydration via 
HA-CP treatment can lead to an improvement in the symptoms (dryness, scaling) 
produced by IMQ application.  
 
Figure IV. 32: H&E staining of the back and right ear of the mice after five days of treatments in 
an IMQ-induced skin inflammation model. Original magnification displayed in each image was 
10x. One representative picture is shown for each treatment regimen. 
Therefore, the use of this HA-CP vehicle offers a synergistic effect with the 
conjugated corticosteroids triggering an enhanced cutaneous anti-psoriatic effect. Signs 
of epidermal thickening due to inflammation were not only evident in the back but also 
by microscopical examination of the ear sections.  
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IV.2.12. Reduction of Skin Inflammation, Ear Thickness, and Splenomegaly 
We also evaluated erythema, scaling, and thickness of the dorsal skin by PASI 
score after five days of treatment (Figure IV. 33A). Whereas examination of the back 
every two days revealed that the group treated with FLUO displayed a reduction in all the 
parameters, this was not enough to restore typical values. Again, FLUO conjugation to 
PGA prompted an enhanced effect when applied in cream and a more marked effect when 
administered in the HA-CP vehicle, presenting significant morphological tissue recovery 
(similar to the negative control, a value of 0 in the PASI score at the end of the experiment 
in the three measured parameters). The group treated with the HA-CP vehicle also 
exhibited a reduction in PASI score, due to its ability to hydrate the skin and diminish 
IMQ-induced skin dryness. Regarding the ear thickness measured every two days during 
the treatments with a caliper, the results corroborate the findings observed by H&E 
staining; all treated groups showed a decrease compared to the positive control group, 
with a maximum reduction (20%) of thickness observed in the group treated with PGA-
FLUO within the HA-CP vehicle (Figure IV. 33B).  
Finally, several studies have reported that IMQ can produce a significant spleen 
enlargement with a weight increase, which is attributed to the release of inflammatory 
cytokines [56]. In our IMQ-induced model, we established an average spleen weight in 
the positive control of 250 mg compared to 100 mg in the negative control (Figure IV. 
33C). All treated groups exhibited a marked decreased in the spleen weight (FLUO 125 
mg and PGA-FLUO applied in cream 100 mg), which was maximal for the group treated 
with PGA-FLUO within the HA-CP vehicle. There was no significant difference in the 
spleen weights between the negative control and the group treated with PGA-FLUO in 
HA-CP, confirming the ability of the vehicle embedded conjugate to reach the epidermal 




Figure IV. 33: Reduction of skin inflammation, ear thickness, and splenomegaly. (A) Scoring 
severity of skin inflammation in the dorsal skin with PASI score (erythema, scaling, and 
thickness) every two days during the treatments using a scale from 0 to 4. (B) Relative reduction 
of ear thickness after the treatments compared to the positive control. (C) Spleen weight (mg) 
determination after five days of treatment. Asterisks indicate statistically significant differences 
after ANOVA analyses followed Bonferroni’s post hoc tests, mean ± SEM. In all cases, we 
considered differences to be significant when p***<0.001; p**<0.01; p*<0.05. 
IV.2.13. PGA-FLUO Conjugates Reduce Pro-Inflammatory Cytokines Levels in 
Serum and Tissue 
TNF-α, IL-17, IL-23, and INF-γ act as major mediators of psoriasis as they mark 
the onset of the IMQ induced psoriasis [56-58]. We discovered the significantly higher 
expression of INF-γ and IL-23 for the positive control compared to the negative control 
in tissue and INF-γ in serum, which confirmed adequate in vivo psoriatic model 
development (Figure IV. 34). In tissue, the levels of INF-γ were reduced by 31% and 
51% in the groups treated with PGA-FLUO in cream and PGA-FLUO in HA-CP, 
respectively, compared to 6% for the free FLUO group. Furthermore, IL-23 levels were 
reduced by 21% and 34% for PGA-FLUO in cream and PGA-FLUO in the HA-CP 
vehicle, respectively, as compared to the free FLUO (24%). Similar reduction values and 
differences among groups were observed when INF-γ levels were studied in serum, 
establishing that PGA-FLUO within the HA-CP vehicle displayed the highest anti-
inflammatory capacity. Of note, the group treated with HA-CP vehicle displayed a 
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reduction in INF-γ levels in tissue and serum by 28% and 27%, respectively. The possible 
explanation can be ascribed to the intrinsic nature of HA-CP as it results from cross-
linking of HA with amino acids which protect its enzymatic degradation by 
hyaluronidases and consequently allows a prolonged moisturizing effect that could trigger 
its impact in reducing inflammation (see Chapter III). 
Figure IV. 34: Reduction of pro-inflammatory cytokines levels related to the disease in (A) tissue 
and (B) serum. Asterisks indicate statistically significant differences after ANOVA analyses 
followed Bonferroni’s post hoc tests, mean ± SEM. In all cases, we considered differences to be 
significant when p***<0.001; p**<0.01; p*<0.05. 
In summary, the topical application of PGA-FLUO within an HA-CP vehicle 
ameliorated IMQ-induced psoriasis, returning indicators of disease back to basal levels. 
We believe that the synergism observed derives from the conjugation of the corticosteroid 
to a polypeptidic carrier and from the application of a highly hydrating vehicle for topical 
administration as a permeation enhancer. The application of FLUO as a water-soluble 
PGA conjugate resulted in higher drug concentration available at the site of application, 
while the inclusion of PGA-FLUO within the HA-CP vehicle results in higher uptake by 
dermal cells and improved skin permeation, leading a deeper penetration of PGA-FLUO 
into the viable epidermis. Furthermore, the incorporation of PGA-FLUO in HA-CP might 
increase skin hydration, an additional factor required for treatment success, while HA-CP 
may also protect the conjugate from enzymatic degradation, thereby allowing it to reach 
the target epidermal layer. We believe that the combination of a polymer-corticosteroid 
conjugate and HA-CP vehicle provides a synergistic effect that may make corticosteroid 







Herein, we have demonstrated that the polypeptide conjugation of a corticosteroid 
used for the topical treatment of psoriasis (PGA-FLUO) provides a significant 
improvement in the pharmacological activity due to greater bioavailability in the require 
skin layer. Polypeptide conjugation may contribute to improve the penetration and drug 
exposure, thereby increasing the amount of corticosteroid in the viable epidermis, and 
therefore, increasing the effectiveness of the treatment. An adequate drug release kinetic 
profile represents a crucial parameter for the achievement of a suitable drug concentration 
in the epidermis, and therefore, polymer-drug linker design represents an essential 
feature. However, the mode of conjugate administration also plays a vital role, as the 
application of the polypeptide-conjugated corticosteroid within a polymeric vehicle (HA-
CP) protected the conjugate, resulting in the slower and sustained release of the drug in 
the epidermis and allowing for sustained residence time.  
In conclusion, the synergistic combination of PGA-FLUO and HA-CP provides 
an elevated reduction in inflammation and, therefore, represents a possible palliative 
treatment of inflammatory skin diseases. Our strategy opens a new horizon in the field of 
localized dermal delivery that can be extended to the conjugation of other therapeutic 
moieties implemented for other aggressive skin diseases, such as cancer. The use of 
polymer/polypeptide therapeutic-based formulations for various skin diseases could 
revolutionize current therapeutic strategies of dermatology, overcoming old challenges, 
and offering new perspectives for the treatment and prevention of dermatological 
conditions. 
IV.4. Materials and Methods 
IV.4.1. Materials 
All organic solvents were of analytical grade purchased from Scharlab and used 
without further purification. All chemicals were of reagent grade and used without further 
purification, purchased from Sigma-Aldrich otherwise stated. Poly-(alpha-L-glutamic 
acid) (Mw: 12,9 kDa, PDI: 1.2, 100 subunits per polymer, PGA100 u) was obtained from 
Polypeptide Therapeutic Solutions SL (Valencia, Spain). Fluocinolone acetonide was 
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purchased from Cymit Quimica S.L. (Barcelona, Spain). Anhydrous N,N-
Dimethylformamide (DMF, ≥99.8% anhydrous) was purchased from Scharlab SL 
(Sentmenat, Spain). Oregon Green 488 cadaverine and Cyanine5.5 were purchased from 
Invitrogen (Spain). Ultrapure water with a resistivity of 18 MΩ cm was used in all 
aqueous preparations (MilliQ water ultrapure). Preparative SEC was performed using 
either Sephadex® G-25 or Sephadex® LH-20, purchased from GE Healthcare Bio-
Sciences AB (Uppsala, Sweden). 
Phenazinemethosulfate (PMS), amphotericin B, and leupeptin were supplied by 
Sigma (Spain). Dulbecco’s Modified Eagle’s Medium (DMEM) with Glutamax was 
purchased from Fisher (Spain). DMEM, phosphate buffer saline (PBS), fetal bovine 
serum (FBS) Medium 200, trypsin, and penicillin/streptomycin were provided from 
Gibco (Spain). 3-(4,5-dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) was supplied by Promega (Spain). Cathepsin B from 
bovine spleen (25 units) was supplied by Sigma Aldrich (Spain). The Raw267.4 
macrophages cell line was supplied by CLS Cell Lines Service (Germany). 
IV.4.2. Physico-Chemical Characterization Methods  
IV.4.2.1. Nuclear Magnetic Resonance (NMR) Spectroscopy 
NMR spectra were recorded at 27°C (300 K) on an Avance III 300 MHz Bruker 
spectrometer equipped with a 5 mm TBI broadband probe or a 300 UltrashieldTM from 
Bruker (Billerica MA, USA). Data were processed with the software Mestrenova (Bruker 
GmbH, Karlsruhe, Germany). Samples were prepared typically at 5 mg/mL in deuterated 
solvents.  
IV.4.2.2. Ultraviolet-Visible (UV-Vis) Spectroscopy  
UV-Vis measurements were performed using V-630 spectrophotometer (JASCO 
Corporation, Spain) at 25°C with 1.0 cm matched quartz cells and with a spectral 
bandwidth of 0.5 nm. The determination of total FLUO content was measured by UV-
Vis spectroscopy. First, a stock solution of FLUO in MilliQ water/ACN (60:40) was 
prepared at 1 mg/mL, to prepare a calibration curve. Samples were diluted using the same 
solution to give a concentration range of 0.1-0.005 mg/mL. Total drug loading of the 
conjugates at different concentrations (0.5, 0.25, 0.1 mg/mL) was determined by 
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measuring the absorbance at 260 nm in a solution of MilliQ water/ACN (60:40). PGA at 
the same concentration range was used as blank. 
IV.4.2.3. Size Exclusion Chromatography (SEC) in Aqueous Media 
For SEC measurements in aqueous media containing 0.1 M NaNO3 and 0.005% 
(w/w) azide as an additive was performed in an AF2000 system from Postnova Analytics 
(Landsberg, Germany). The system was configured to work on SEC mode with an 
isocratic pump (PN1130), an autosampler (PN5300), a refractive index (RI, PN3150), 21 
angle-multi angle light scattering (MALS, PN3621), and an UV-Vis detectors (PN3211). 
A working flow rate of 0.7 mL/min at 30°C was employed with one TSKgel 
G3000PWXL column. Refractive index and Multi-Angle Light Scattering were used for 
detection and Mw determination, calibration of both RI and MALS detectors was 
achieved with well-defined Pullulan (50 kDa) and validation with polymethacrylic acid 
sodium salt (PMASS, 62.5 kDa) standards, purchased from Polymer Standards Service 
(PSS)/Mainz Germany. Dn/dc values for polyglutamates were determined from recovered 
mass, assuming 95 - 100% recovery from the chromatographic column and found to be 
within 0.185 - 0.195. The wavelength used was 268 nm for the polyglutamates containing 
FLUO, and 512 nm for OG-labeled polyglutamates. Finally, 30 μL of a polymer solution 
of 5 mg/mL was injected each time. 
IV.4.2.4. Fluorescence Spectroscopy 
Fluorescence experiments were performed using a FP-6500 spectrofluorometer 
(JASCO Corporation, Spain) at 25ºC with 1 cm quartz cells. Pyrene assay was performed 
as published elsewhere in order to determine the critical aggregation concentration (CAC) 
[28]. In brief, several solutions of the compounds were prepared to cover a wide range of 
concentrations (from 0.004 to 2 mg/mL) to which 3 µL of the pyrene stock solution (0.02 
mg/mL) in acetone was added. Then, all the solutions were placed in vials and were 
incubated in an oven at 37ºC for 2 h in order to evaporate the acetone. After storing the 
samples for 24 h, measurements were carried out. Each excitation spectra was recorded 
from 300 to 360 nm with an emission wavelength of 390 nm. The excitation and emission 
band slits are 5 and 2.5 nm, respectively. Finally, data were expressed by plotting the 
intensity ratio I338/I333 against the concentration to determine CAC value.  
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IV.4.2.5. Transmission Electron Microscopy (TEM) 
TEM images were recorded using a JOEL 2100 transmission electron microscope. 
Samples were applied directly onto carbon film on 200 mesh copper grids. Excess of the 
samples was carefully removed by capillarity, and the grids were immediately stained 
with one drop of 0.1% phosphotungstic acid for 30 s. Excess stain was removed by 
capillary action.  
IV.4.2.6. Dynamic Light Scattering (DLS) 
DLS measurements were performed using a Malvern Zetasizer NanoZS 
instrument (Malvern Instruments Ltd., Worcestershire, UK), equipped with a 532 nm 
laser at a fixed scattering angle of 173°. Solutions were sonicated for 10 min, allowed to 
age for the required time, filtered through a 0.45 μm cellulose membrane filter and 
measured. The samples were dissolved under different conditions (MilliQ water, PBS, 
PB 10 mM) and different concentrations (from 0.02 to 2 mg/mL). Size distribution was 
measured (radius, nm) per triplicate with n > 3 measurements.  
Z-potential measurements were performed at 20ºC using a Malvern Zetasizer 
NanoZS instrument, equipped with a 532 nm laser using disposable folded capillary cells, 
provided by Malvern Instruments Ltd. (Worcestershire, UK). Polymer solutions were 
prepared in 1 mM KCl in MilliQ water. The solutions were filtered through a 0.45 µm 
cellulose membrane filter. Z-potential was measured for each simple per triplicate with  
n >3 measurements.  
IV.4.2.7. High-Performance Liquid Chromatography (HPLC) 
Analytical determination of free drug was performed on a Waters HPLC system 
provided with 2 x 515 binary pumps, autosampler 717 Plus, FLD 2475 and PDA 2996 
(Waters Corporation, S.A, Spain). The measurements were performed using an RP C-18 
Lichrospher analytical column (125 x 4.0 mm) (Scharlab S.L., Barcelona, Spain), with a 
flow rate of 1 mL/min, the volume of injection was 20 µL and using a mobile phase of 
H2O (1% orthophosphoric acid)/ACN (60/40). Detection of FLUO absorbance was 
measured at λ = 239 nm with a retention time between 3.5 - 4.5 min. The calibration curve 
was performed using commercial FLUO, showing a linear response within the 
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concentration range employed (0.001 - 0.1 mg/mL). Chromatograms were treated with 
Empower 2.0 software (Waters Corporation, S.A, Spain). 
IV.4.2.7.1. Recovery of FLUO in a Polymeric Matrix: Liquid-liquid Extraction 
Recovery studies were performed to understand the behavior of the drug in the 
presence of the PGA, in order to evaluate the adequate method of extraction to quantify 
the free FLUO. In the study, four calibration curves were used using the extraction 
treatment: FLUO without treatment (control), FLUO with extraction treatment, FLUO 
with PGA treated, and FLUO and the PGA-FLUO conjugate treated. Liquid-liquid 
extraction was the treatment used to determine the recovery of FLUO content in the 
polymeric matrix. 
PGA-FLUO conjugate was dissolved in PBS/ACN (60:40) solution and extracted 
with 5 mL of isopropanol (IPA)-dichloromethane (DCM) (5:95) solution by mechanical 
stirring with the vortex (3 x 30 s). The upper aqueous layer was carefully removed, and 
the solvent was evaporated under reduced pressure using the speedvac (1:30 h, 80ºC, 0.01 
vacuum). The residue was resuspended in 500 µL of ACN, and the suspension was 
filtered (0.45 µm) into HPLC vials for analysis. Samples were measured per triplicate. 
 Determination of Free FLUO in the Conjugates 
Liquid-liquid extraction was used to determine free drug content; the 
concentration of PGA-FLUO conjugate used was 1 mg/mL. 
 Drug Release Kinetics 
Drug release kinetics of PGA-FLUO conjugates was performed at two different 
pHs (5.5 and 7.4) and also in the presence of cathepsin B. A stock solution was prepared 
in the PBS buffers (2 mg/mL), and in the case of cathepsin B the solution was a mixture 
of 700 µL acetate buffer 20 mM pH=5, 100 µL EDTA 2 mM, 100 µL DTT 5 mM and 
100 µL cathepsin B. The stock was divided into aliquots (50 µL) and were incubated at 
37ºC at different time points (from 0 to 72 h). After the incubation, 10 µL of PBS buffers 
and 40 µL of ACN were added to each sample, in order to have a PBS/ACN (60:40) 
solution. Then, we followed the same methodology for the recovery of FLUO, using the 
liquid-liquid extraction. Finally, the residue was resuspended in 500 µL of ACN, and the 
suspension was filtered (0.45 µm) into HPLC vials for analysis. Samples were measured 
repeatedly (n= 3). 
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IV.4.2.7.2. Extraction and Quantification of FLUO in the Skin 
The permeation of PGA-FLUO conjugate (100 µL of 10 mg/mL solution in water 
and in the HA-CP (1% w/v)) in the skin was evaluated over 24 h in Franz diffusion cells. 
Whole skin was then washed twice with 0.1% PBS-BSA (PBS supplemented with bovine 
serum albumin (BSA)), cut into small pieces and added to 4 mL of DMSO for FLUO 
extraction for 24 h with stirring. Skin samples were then removed and DMSO evaporated 
under reduced pressure using a speedvac (3 h, 80ºC, 0.01 vacuum). Next, the residue was 
resuspended in 500 µL of ACN and sonicated (15 min). Finally, the suspension was 
filtered (0.45 µm) into HPLC vials for analysis. Samples were measured repeatedly (n= 
3).  
IV.4.2.8. Circular Dichroism (CD)  
CD spectroscopy was performed with a J-815 CD spectrometer (JASCO 
Corporation, Spain) using a Peltier thermostated cell holder (PTC-423, JASCO 
Corporation, Spain) with a recirculating cooler (JULABO F250, JASCO Corporation, 
Spain). A nitrogen flow (~2.7 L∙min-1) was led through the spectrometer and controlled 
with a nitrogen flow monitor (Afriso Euro-Index, Germany). The samples were dissolved 
under different conditions (MilliQ water or 10 mM PB) at different concentrations (from 
0.1 to 0.6 mg/mL). Samples were measured repeatedly (n=3) in a quartz cuvette with d= 
0.1 cm.  
IV.4.3. Synthetic Protocols 
IV.4.3.1 Synthesis of Poly-L-glutamate Fluocinolone Acetonide Conjugates 
We aimed to conjugate around 8% molar of FLUO relative to glutamate residues 
as a general synthetic procedure. As an example, to describe the synthesis, we used 200 
mg of PGA. 
PGA100-OH (200 mg, 1.55 mmol) in DMF (5 mL) was added to a two necked flask 
equipped with a stir bar under N2 flow and heated until dissolved. FLUO dissolved in 1 
mL of DMF was added (140.27 mg, 0.3 mmol, 0.2 eq. to glutamic acid units (GAU)) to 
this solution, and the mixture was allowed to stir for ten min. The reaction mixture was 
then cooled in an ice bath and, finally, 1 mL of DMF with DMAP (1.9 mg, 0.0155 mmol, 
0.01 eq. to GAU) and 4 mL DMF with EDAC (89.22 mg, 0.465 mmol, 0.3 eq. to GAU) 
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were added. The mixture was stirred for 72 h under N2 flow at room temperature (r.t.). 
Thin-layer chromatography (MeOH) confirmed the consumption of FLUO. The solution 
was purified by size exclusion chromatography employing either Sephadex® LH-20 
(DMF) and after evaporating the DMF (under vacuum conditions) the residue was 
dissolved with 0.5 M NaHCO3 and repurified using Sephadex
® G-25 (MilliQ water). 
Finally, the resulting aqueous suspension was freeze-dried and the white powder 
characterized (Yield = 60%). 
1H-NMR (300 MHz, D2O) δ 7.42 (s, 1H), 6.38 (s, 2H), 5.58 (d, J = 52.2 Hz, 1H), 5.26 – 
5.07 (m, 1H), 5.01 (s, 1H), 4.33 (d, J = 40.9 Hz, 10H), 3.68 (d, J = 13.9 Hz, 1H), 2.89 (td, 
J = 70.7, 29.2 Hz, 4H), 2.26 (t, J = 21.5 Hz, 16H), 2.05 – 1.81 (m, 15H), 1.63 (s, 1H), 
1.46 (d, J = 23.3 Hz, 3H), 1.30 – 1.09 (m, 2H), 0.81 (d, J = 24.5 Hz, 2H). 
IV.4.3.2 Oregon Green Labeling of PGA-FLUO Conjugates  
70 mg of PGA-FLUO conjugate (0.4183 mmol GAU, 1 eq.) was dissolved in 12 
mL of dry DMF under N2 flow in a round two necked bottom flask fitted with a stirrer 
bar. Then, 2.745 mg of DMTMM.BF4 (8.366 x 10
-3 mmol, 0.02 eq. to GAU) was added 
to the solution and incubated for 10 min at r.t. Finally, 0.01 eq. of the amino dye OG was 
added. The pH was adjusted to 8 by adding ~100 µL of DIEA. The mixture was left 
stirring for 48 h at r.t. and protected from light. The solution was purified by size exclusion 
chromatography employing either Sephadex® LH-20 (DMF) and then the DMF was 
evaporated under vacuum conditions, and then the residue was dissolved with 0.5 M 
NaHCO3 and repurified using Sephadex
® G-25 (MilliQ water). Finally, the resulting 
aqueous suspension was freeze-dried, and the powder characterized. (Yield = 40%). 
The percentage of dye loading in the conjugate was determined by UV-Vis 
spectroscopy. A calibration curve of free dye was performed under the same conditions 
(MilliQ water). To obtain a calibration curve, the free dye was diluted to give a 
concentration range of 0.000025 - 0.000250 mg/mL. The total dye loading of the 




IV.4.4. Biological Evaluation of Polymer-Drug Conjugates 
IV.4.4.1. In Vitro Evaluation 
IV.4.4.1.1. Cell Viability 
To perform the cytotoxicity studies in vitro two cell lines were used: Human 
immortalized non-tumorigenic keratinocyte cell line (HaCaT) was supplied by CLS Cell 
Lines Service (Eppelheim, Germany) and human fibroblasts were supplied by Hospital 
La Fe (Valencia, Spain). The culture media used was high glucose DMEM Glutamax 
(Fisher, Spain) for HaCaT cells and Dulbecco's Modified Eagle's Medium-high glucose 
(Sigma-Aldrich Chemical Co., Spain) for human fibroblasts, both supplemented with 2% 
penicillin/streptomycin and 50 mL of fetal bovine serum (FBS) in a humidified incubator 
(Hucoa-Erlöss S.A., Spain) 5% CO2 and 37°C. 50 μL of cells were seeded in 96-well 
plates at a concentration of 4,000 cells/well in the case of HaCaT cells and 2,000 
cells/well for human fibroblasts. After 24 h, 50 μL of each treatment were added reaching 
a final volume of 100 μL in the well. All the treatments were filtered before adding to the 
well (pore size 0.22 μm). Cells were incubated with samples or controls for 72 h and then 
was performed the MTS assay. For that, 20 μL of the solution of Phenazine Methosulfate 
Minimum 90% (PMS) and the salt of 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethylphenyl)-2-(4-sulfophenyl)-2H tetrazolium (MTS) were added, with a 
dilution 1:20, respectively. After 3 h of incubation, the absorbance was read at 490 nm 
using a Victor2Wallac™ plate reader (Perkin Elmer, Spain). The absorbance values were 
represented as the percentage of cell viability taken as 100% cell viability of untreated 
control cells. The concentrations of linear and star PGA were in a range from 0.02 to 0.5 
mg/mL of polymer, and the concentrations of PGA, FLUO, and PGA-FLUO conjugate 
from 0.0057 to 0.0987 mg/mL FLUO eq. 
IV.4.4.1.2. Cellular Uptake by Flow Cytometry 
Flow cytometry (cell uptake and binding) together with live cell confocal 
microscopy analysis were used to study cellular trafficking of the OG-labeled polymers 
in HaCaT cells. HaCaT cells were seeded in 6-well plates at a density of ~120,000 
cells/cm2 (1 mL cell suspension per well) and allowed to adhere for 24 h. In binding 
experiments conducted at 4ºC, cells were pre-incubated at this temperature for 30 min 
prior to start the experiment. For both experiments, 4ºC and 37ºC, the cathepsin B 
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inhibitor CA-074 (0.4 µL from a solution of 5 µM to reach a final concentration of 2 µM) 
was added 30 min before the addition of PGA-FLUO-OG. Then, 15 µL of OG-labeled 
polymer (were added at different time points from 0 to 27 h) while cells were incubated 
either at 37ºC or 4ºC for each experiment. Finally, cells were placed on ice to inhibit 
energy dependent mechanism and washed twice with cold 0.1% PBS-BSA. Then, 400 µL 
of trypsin was added to detach the cells and 600 µL of culture media was added, and the 
cell pellet was placed in flow cytometer tubes. The fluorescence was then analyzed using 
a fluorescence-activated cell sorting (FACS) caliber cytometer (Becton Dickinson, 
California, USA) equipped with an argon laser (488 nm) and emission filter for 550 nm. 
Data collection involved 10,000 counts per sample, and were analyzed using 
CELLQuestTM version 3.3 software. Data are expressed as a percentage of positive cells. 
Cells incubated without the polymer were used to detect background fluorescence. 
IV.4.4.1.3. Uptake Studies by Confocal Microscopy  
HaCaT cells were seeded in glass in 6-well plates at a density of ~120,000 
cells/cm2 (1 mL cell suspension per well) and allowed to adhere for 24 h at 37ºC. First, 
cathepsin B inhibitor CA-074 (0.4 µL from a solution of 5 µM to reach a final 
concentration of 2 µM) was added 30 min before the addition of the conjugate PGA-
FLUO-OG. Then, 15 µL of OG-labeled polymer was added at different time points from 
0 to 72 h while cells were incubated at 37ºC. 30 min before washing the cells with PBS-
BSA 0.1%, the nuclear marker Hoechst (1 µL from a solution of 5 mM) and the lysosomal 
marker Lysotracker Red (0.75 µL from a solution of 100 mM) were added and incubated 
20 min in order to identify possible co-localizations and therefore establish an endocytic 
pathway. Finally, cells were washed with 0.1% PBS-BSA, and the glass was removed 
and placed on the microscope chamber with 1 mL of fresh media containing 2 µM of CA-
074 inhibitor. Samples were analyzed under the microscope. Images were captured with 
an inverted DM IRE2 microscope equipped with a λ-blue 60 x oil immersion objective 
and handled with a TCS SP2 system, equipped with an Acoustic Optical Beam Splitter 
(AOBS). Excitations were performed with an argon laser ((OG 496 nm), and HeNe laser 
(Lysotracker red 594 nm), and blue diode (Hoechst 405 nm). Images were captured at an 
8-bit greyscale and processed with LCS software (version 2.5.1347a, Leica Germany) 
containing multicolor, macro and 3D components. Control cells that follow the same 
incubation time were also analyzed to establish the autofluorescence, as well as cells 
treated only with Hoechst or Lysotracker red. 
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IV.4.4.1.4. Anti-Inflammatory Activity 
To perform the activity studies in vitro, we used macrophages (Raw264.7 cell 
line), which was supplied by CLS Cell Lines Service (Eppelheim, Germany). The culture 
media used was high glucose DMEM (Fisher, Spain), supplemented with 2% 
penicillin/streptomycin and 50 mL of FBS in a humidified incubator (Hucoa-Erlöss S.A., 
Spain) 5% CO2 and 37°C. 
50 μL of cells were seeded in 96-well plates at a concentration of 6,000 cells/well. 
After 24 h, 50 μL of each individual treatment (LPS from E. coli (5 ng/mL), FLUO (0.49 
ng/mL), PGA-FLUO conjugate (0.49 ng/mL FLUO eq.), and PGA) were added, reaching 
a final volume of 100 μL in the well to evaluate cell viability by MTS assay. At the same 
time, the combination of LPS with FLUO, PGA-FLUO conjugate, and PGA was 
evaluated to assess the anti-inflammatory activity by LUMINEX assay, adding 25 µL of 
each treatment. All the treatments were filtered before adding to the well (pore size 0.22 
μm). Cells were incubated with samples or controls for 72 h and then performed the MTS 
assay. For the subsequent MTS assay, 20 μL of the solution of phenazine methosulfate 
minimum 90% (PMS, Sigma, Spain) and 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethylphenyl)-2-(4-sulfophenyl)-2H tetrazolium salt (MTS, Promega, Spain) 
were added, using a dilution 1:20. After 2 h of incubation, the absorbance was read at 490 
nm using Victor2Wallac™ plate reader (Perkin Elmer, Spain).  
Next, for the quantification of the pro-inflammatory cytokines released to the 
culture media by LUMINEX assay, the 96-well plates were centrifuged 5 min, 22°C, 400 
rcf, and 90 μL of supernatant were collected and frozen until use. Pro-inflammatory 
cytokines levels were measured by LUMINEX multiplex immunoassay (Affymetrix m 
Th1/2/9/17/22/Treg 17plex, eBioscience, Spain). This study was performed using 
LUMINEX 200 equipment (LUMINEX Corporation, USA) and results expressed as a 
percentage of inhibition of each cytokine. 
IV.4.4.1.5. Cathepsin B Activity 
The enzymatic activity of cathepsin B was measured by means of a fluorescence 
reader CLARIOstar®, software version 5.21 R2 from BMH LABTECH (Offenburg, 
Germany). The activity was analyzed using specific fluorescent substrate for this type of 
enzyme, N-CBZ-l-arginyl-l-arginine 7-amido-4-methyl-coumarin (Z-Arg-Arg-AMC) 
0.05 mM. The buffer used was 80 µL of acetate buffer 20 mM pH=5, 10 µL of EDTA 2 
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mM and 10 µL of DTT 5 mM (final volume of 100 µL). Leupeptin (50 µM) was used as 
a negative control. Buffer, buffer with the substrate, and negative control were used as 
controls. Cathepsin B solution (6.25 units) was a mixture of 700 µL acetate buffer 20 mM 
pH=5, 100 µL EDTA 2 mM, 100 µL DTT 5 mM and 100 µL cathepsin B. 10 µL of this 
stock were added to the samples with or without the HA-CP vehicle (1% w/v). The 
reaction mixture (100 μL) was placed in a 96-well fluorescence plate and incubated at 
37°C. The fluorescence was read at time 0 and at 25 min, using excitation and emission 
wavelengths of 360 nm and 460 nm, respectively. Samples were measured repeatedly 
(n=3).  
IV.4.4.2. Ex Vivo Evaluation 
IV.4.4.2.1. Permeation Studies by Franz Diffusion Cells 
Breast skin samples were obtained from healthy women undergoing plastic 
surgery after written informed consent (kindly donated from Hospital La Fe, Valencia, 
Spain). Immediately after excision, the subcutaneous fatty tissue was removed using a 
scalpel. The skin was cut into 4 cm2 pieces, wrapped in aluminum foil and stored at -20ºC 
until use. Permeation study was developed using Franz diffusion cells (Logan Instruments 
Corp., USA).  
Skin samples were fixed between the donor and the receptor chamber, so that 
stratum corneum was placed upwards. The receptor chamber was filled with 8 mL of 0.01 
M PBS pH 7.4, and mixed with a magnetic stirring bar, while the temperature was kept 
at 37ºC. Treatments with 100 µL of 10 mg/mL of linear or star PGA labeled with OG 
applied in water, and PGA-FLUO-OG applied in water or in the HA-CP vehicle labeled 
with Cy5.5 (1% w/v), were applied on the upper area of the skin. Aliquots from the 
receptor chamber (2 mL) were taken at 8 and 24 h, and the liquid was immediately refilled 
with fresh solution. After the permeation study, skin samples were washed twice with 
0.1% PBS-BSA and kept in 4% paraformaldehyde (PFA) for 24 h at r.t. Then, samples 
were washed with 30% sucrose in PBS solution for 24 h at 4ºC. After that, skin samples 
were washed twice with PBS and preserved in a cryopreservation solution (40% 0.1 M 
PB, 30% ethylene glycol, and 30% glycerol) at 4ºC until use. Finally, the samples were 
placed in the optimum cutting temperature (OCT) inclusion medium, and slides of 5 µm 
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were generated via cryostat (version CM1850 UV, Leica, Germany) and samples were 
analyzed by confocal microscopy.  
Images were captured with an inverted DM IRE2 microscope equipped with a λ-
blue 40x oil immersion objective and handled with a TCS SP2 system, equipped with an 
Acoustic Optical Beam Splitter (AOBS). Excitation was performed with an argon laser 
(OG, 496 nm), a blue diode (DAPI, 405 nm), and red diode (Cy5.5, 675 nm). Images were 
captured at an 8-bit greyscale and processed with LCS software (version 2.5.1347a, Leica 
Germany) containing multicolor, macro and 3D components. Control tissue that followed 
the same incubation time with MilliQ water was also analyzed to establish the 
autofluorescence. OG intensity was quantified five times per sample using Image J 
software and expressed as pixels versus the thickness of the skin (µm). Control intensity 
was subtracted in each case. 
IV.4.4.2.2. Tissue Viability and Evaluation of the Anti-Inflammatory Activity of 
PGA-FLUO Conjugates in an Inflammatory Ex Vivo Human Skin Model 
Breast skin samples were obtained from healthy women undergoing plastic 
surgery after written informed consent (kindly donated from Hospital La Fe, Valencia, 
Spain). The skin was cut to approximately 1 cm2 and placed in 6-well plates so that the 
epidermis was exposed to the air and the dermal side was in contact with DMEM medium 
supplemented with 50 mL fetal bovine serum, 5.5 mL penicillin/streptomycin, and 50 µL 
amphotericin B, and the skin was incubated at 37ºC under 5% CO2. The inflammatory 
model was induced by the addition of a combination of a constant concentration of EGF 
(2.5 ng/mL) and 15 µg/mL of LPS from E.coli (InvivoGen, USA) to the culture media, 
and further incubation for 24 h at 37ºC under 5% CO2. The exhaustive characterization of 
the model was explained in Chapter II. 
After inflammatory insult via combined treatment with bacterial LPS and EGF for 
24 h, 3 µL of a solution at 10 mg/mL of PGA, FLUO, PGA-FLUO conjugate applied and 
in the HA-CP vehicle (1% w/v) and HA-CP (1% w/v) were applied topically. After 24 h, 
skin pieces were washed twice with PBS and were introduced in 4 mL of MTT solution 
(2 mg/mL) at 37ºC. MTT assay is a colorimetric assay for assessing cell metabolic 
activity. After 4 h of incubation, skin samples were washed twice with PBS and 
introduced in 4 mL of DMSO, in order to extract the formazan from the skin. After 15 h 
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of extraction, the absorbance was read at 490 nm using Victor2Wallac™ plate reader 
(Perkin Elmer, Spain).  
 
In addition, culture medium was collected under standardized conditions after 24 
h of incubation with the treatments and kept at -80ºC until use. IL-6 concentrations in the 
culture medium were measured by ELISA assay (Invitrogen, Spain). Cytokine 
concentrations were determined according to standard solutions. 
IV.4.4.2.3. Development of a Skin Equivalents Construction Model and Cell 
Viability Assays 
Human skin equivalents were prepared from primary human keratinocytes and 
fibroblasts from juvenile foreskin following circumcision from three different donors 
(EA: 1/081/13, written consent was obtained) as previously described [52, 59]. Negative 
control (solvent control), untreated control, and positive control (sodium dodecyl sulfate 
(SDS) 1%) were studied to ensure the development of the model. PGA, FLUO, PGA-
FLUO conjugate applied in water or in the HA-CP vehicle (1% w/v) and HA-CP vehicle 
(1% w/v) at 5 mg/mL (35 μg/cm2) were applied topically at days 11 and 13. At day 14, 
tissue viability was evaluated by MTT assay. Human skin equivalents were introduced in 
1.8 mL of MTT solution (0.5 mg/mL), and after 4 h of incubation at 37ºC, samples from 
the human skin equivalents were cut and introduced in 1.5 mL of acidic isopropanol 
shaking 3 h in the dark, in order to extract the formazan from the skin. After 3 h of 
extraction, the absorbance was read at 450 nm using Victor2Wallac™ plate reader (Perkin 
Elmer, Spain). 
IV.4.4.2.4. Development of an Inflammatory Skin Equivalents Construction Model 
and Anti-Inflammatory Activity of PGA-FLUO conjugates 
Human skin equivalents were prepared from primary human keratinocytes and 
fibroblasts as previously described [52, 59]. To develop an inflammatory phenotype in 
the skin equivalents emulating characteristics of psoriatic skin in vitro, such as 
hyperproliferation, 20 ng/mL of recombinant TNF-α (eBioscience, Hatfield, UK) were 
added to the culture media on day 10 and 12 to induce skin inflammation. Negative 
control and untreated control were studied to ensure the development of the model. PGA, 
FLUO, PGA-FLUO conjugate applied in water or in the HA-CP vehicle (1% w/v) and 
HA-CP vehicle (1% w/v) at 5 mg/mL (35 μg/cm2) were applied topically at days 11 and 
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13. At day 14, culture media was collected for quantification of IL-6 levels using an 
ELISA assay (Invitrogen, Spain). Cytokines concentrations were determined according 
to standard solutions. The absorbance was read at 450 nm using Victor2Wallac™ plate 
reader (Perkin Elmer, Spain). Cytokine concentrations were determined according to 
standard solutions. 
IV.4.4.3. In Vivo Evaluation 
IV.4.4.3.1. Ethical Considerations 
Animal experiments were performed in accordance with the European 
Communities Council Directive (86/609/ECC) guidelines and by the Spanish Royal 
Decree 1201/2005. All the experimental procedures were approved by the Institutional 
Animal Care and Use Committee and accomplished by accredited and trained staff, 
meeting the animal care rules. All mice were maintained in a specific pathogen free 
facility, under temperature, humidity, and using a 12 h light-dark cycle. Food pellets and 
water were provided ad-libitum during the whole experiments in all cases, and general 
aspect, body weight, grooming conduct, and behavior were evaluated daily from the 
beginning of the experiment to ensure animal wellness.  
IV.4.4.3.2. Optimization of Optimal FLUO Concentration for Psoriatic Mice Model 
IV.4.4.3.2.1. Establishment of Psoriatic Model 
6-week-old male BALB/c mice used for all experimental procedures were 
purchased from Envigo Laboratories Inc. (Spain, EU). One day before the first IMQ 
application, approximately 2x3 cm of the back of the mice was shaved. Psoriasis-like 
symptoms were induced by the daily application of 62.5 mg of commercially available 
IMQ cream (5%) (Imunocare®; Industrial Farmacéutica Cantabria, S.A., Spain) on the 
back and the right ear for seven consecutive days, translating in a daily dose of 3.125 mg 
of the active compound. This dose was empirically determined to cause the most optimal 
and reproducible skin inflammation in mice [60-62]. 
IV.4.4.3.2.1. Safety Evaluation of Treatments 
Seven days after the induction of the disease, mice were split into representative 
groups. Healthy and untreated mice were used as controls (negative and positive control, 
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respectively). Conjugate-based treatments at different FLUO equivalents (0.01, 0.15, and 
0.3 wt% FLUO eq.) were dissolved in the HA-CP vehicle (1% w/v) and immediately 
applied topically in the back and the right ear during five consecutive days. HA-CP 
vehicle was applied as control, following the same methodology. Treatments safety was 
evaluated by tracking body weight every two days compared to the positive control and 
healthy animals. After five days of treatment, mice were sacrificed using a CO2 
atmosphere, and major organs, skin, ears, and blood were extracted for further analysis.  
IV.4.4.3.2.2. Scoring Severity of Skin Inflammation: PASI score  
The anti-psoriatic potential of the formulations was evaluated using an objective 
scoring system based on the clinical Psoriasis Area and Severity Index (PASI). Erythema, 
scaling, and thickening (induration of the skin) were assigned independently on a scale 
from 0 to 4: 0, none; 1, slight; 2, moderate; 3, marked; 4, very marked.  
IV.4.4.3.2.3. Spleen Weight 
After five days of treatments, mice were sacrificed using a CO2 atmosphere, and 
spleen weight was measured, comparing treatments with positive control and healthy 
animals. 
IV.4.4.3.2.4. Ear Thickness 
Ear thickness was measured using a caliper every two days during the treatments 
in comparison with positive control and healthy animals. 
IV.4.4.3.2.5. Histology  
H&E staining was performed in both ears and the back of the mice. After the 
sacrifice, tissues were washed with fresh PBS, carefully dried, weighed, and fixed in 4% 
of PFA for 24 h. Then, PFA was eliminated by successive washing with PBS, and 
common dehydration and paraffin inclusion procedures were performed, leading to 
blocks that were sliced into 5 μm sections. The staining was performed as required (Dako 
Autostainer 48, US), and the slides were assembled with Eukitt. Finally, the slides were 
observed under the microscope, scanned with a Panoramic 250 Flash III slide scanner and 
processed with CaseViewer software (both from (3DHISTECH Ltd, Budapest, Hungary).  
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IV.4.4.3.2.6. Pro-Inflammatory Interleukin Levels in Serum 
The pro-inflammatory interleukin levels were measured in serum. Fresh serum 
was isolated from the blood through centrifugation (4000 rpm, 10 min, 4ºC) and was 
stored at -80oC until use. The quantification of IL-23, INF-γ, and IL-1b levels were 
performed by LUMINEX assay, using a ProcartaPlexTM Multiplex Immunoassay 
according to the manufacturer’s instructions (Invitrogen, Spain). 
IV.4.4.3.3. Evaluation of Anti-Inflammatory Activity of PGA-FLUO Conjugates in 
Psoriatic Mice Model 
IV.4.4.3.3.1. Establishment of Psoriatic Model 
6-week-old male BALB/c mice used for all experimental procedures were 
purchased from Envigo Laboratories Inc. (Spain, EU). One day before the first IMQ 
application, approximately 2x3 cm of the back of the mice was shaved. Psoriasis-like 
symptoms were induced by the daily application of 62.5 mg of commercially available 
IMQ cream (5%) (Imunocare®; Industrial Farmacéutica Cantabria, S.A., Spain) on the 
back and the right ear for seven consecutive days, translating in a daily dose of 3.125 mg 
of the active compound. This dose was empirically determined to cause the most optimal 
and reproducible skin inflammation in mice [60, 62]. 
IV.4.4.3.3.2. Safety Evaluation of Treatments 
Seven days after the induction of the disease, mice were split into representative 
groups. Healthy and untreated mice were used as controls (negative and positive control, 
respectively). Previous studies were conducted to optimize the optimal concentration of 
FLUO, demonstrating that the concentration of 0.15 wt% FLUO eq. had the maximum 
therapeutic potential. Therefore, conjugate-based treatments with 0.15% FLUO eq. were 
applied in the HA-CP vehicle (1% w/v) and in a commercial base cream used for current 
corticosteroids (Cold cream®, Farmacia BOIX, Spain). Free FLUO was dissolved with 
0.5 mL of Hydrolite® (Guinama S.L., Spain) and incorporated in the base cream. HA-CP 
vehicle (1% w/v) and the base cream were applied as controls, following the same 
methodology. All the treatments were immediately applied topically in the back and the 
right ear for five consecutive days. Treatments safety was evaluated by tracking body 
weight every two days compared to the positive control and healthy animals. After five 
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days of treatment, mice were sacrificed using a CO2 atmosphere and major organs, skin, 
ears, and blood were extracted for further analysis.  
IV.4.4.3.3.3. Scoring Severity of Skin Inflammation: PASI score 
The anti-psoriatic potential of the formulations was evaluated using an objective 
scoring system based on the clinical Psoriasis Area and Severity Index (PASI). Erythema, 
scaling, and thickening (induration of the skin) were assigned independently on a scale 
from 0 to 4: 0, none; 1, slight; 2, moderate; 3, marked; 4, very marked.  
IV.4.4.3.3.4. Spleen Weight 
After five days of treatment, mice were sacrificed using a CO2 atmosphere, and 
spleen weight was measured comparing the treatments with positive control and healthy 
animals. 
IV.4.4.3.3.5. Ear Thickness 
Ear thickness was measured using a caliper every two days during the treatments 
in comparison with positive control and healthy animals. 
IV.4.4.3.3.6. Histology 
H&E staining was performed in both ears and the back of the mice. After the 
sacrifice, tissues were washed with fresh PBS, carefully dried, weighed, and fixed in 4% 
of PFA for 24 h. Then, PFA was eliminated by successive washing with PBS, and 
common dehydration and paraffin inclusion procedure were performed, leading to blocks 
that were sliced into 10 μm sections. The staining was performed as required (Dako 
Autostainer 48, US), and the slides were assembled with Eukitt. Finally, the slides were 
observed under the microscope, scanned with a Panoramic 250 Flash III slide scanner and 
processed with CaseViewer software (both from (3DHISTECH Ltd, Budapest, Hungary).  
IV.4.4.3.3.7. Pro-Inflammatory Interleukin Levels in Serum and Tissue 
The pro-inflammatory interleukin levels were measured both in serum and in the 
tissue from the back of the mice. Fresh serum was isolated from the blood through 
centrifugation (4000 rpm, 10 min, 4ºC) and stored at -80oC until use. To performed 
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protein extraction from frozen tissue, the skin was mixed with PBS (pH 7.4) with a 
protease and phosphatase inhibitor cocktail and then treated in an ice bath by Ultra Turrax 
Scatter at 10000 ref/min for 20 min. Immediately after the incubation, the tube was 
centrifuged at 4000 rpm for 20 min at 4°C and supernatants were collected and stored at 
-80oC until use. For LUMINEX assays, IL-23 and INF-γ protein expression in skin lysates 
and serum were quantified with ProcartaPlexTM Multiplex Immunoassay according to the 
manufacturer’s instructions (Invitrogen, Spain). 
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CHAPTER V:  
DEVELOPMENT OF POLYMER CONJUGATES  



























V.1. Antecedents and Background  
The wound healing process aims to re-establish the normal architecture and 
biological activity of damaged tissue [1]. Due to the high incidence rate and the 
exponential increase in the aged population, wound healing has a substantial 
socioeconomic impact worldwide [2]. During the development of this chapter, we focus 
on the treatment of skin wounds and ischemia-reperfusion injury in the heart with 
polymer-drug conjugates as examples of tissue healing therapeutic approaches. 
V.1.1. Skin Wound Healing 
As we have shown throughout this thesis, PGA-drug conjugates can penetrate and 
permeate through the different layers of the skin, even in cases where the skin barrier is 
modified or altered (such as psoriasis, Chapter IV); therefore, they may be used in the 
enhancement of skin regeneration and repair, thereby contributing towards wound 
healing. Wound healing represents a common medical challenge, and exists a rising 
incidence of wound healing-related problems associated with metabolic syndrome (e.g., 
obesity and type II diabetes patients), and aging [3]. The main physiological events in 
wound repair can be classified into three stages that overlap the repair process: the 
inflammatory stage, the proliferative stage, and the remodeling stage [4, 5] (Figure V. 1). 
Wound healing involves the complex interaction of several biological and 
molecular processes associated with tissue regeneration. Tissue damage triggers the onset 
of the inflammatory stage of wound repair; at this stage, components of the coagulation 
cascade, inflammatory pathways, and immune system become activated to minimize 
blood/fluid losses and infection. Meanwhile, a platelet plug composed of platelets, 
fibronectin, vitronectin, and thrombospondins forms at the injury site to create a scaffold-
like structure into which various cells types, such as leukocytes, neutrophils, 
keratinocytes, fibroblasts, and endothelial cells, infiltrate [4]. Two to three days after the 
onset of tissue damage, monocytes migrate from the blood vessels to the lesion area and 
differentiate into macrophages. These cells act as antigen-presenting cells and collaborate 
with the neutrophils in the phagocytosis process to eliminate foreign materials and 
damaged cells, and also participate in the synthesis and release of pro-inflammatory 
cytokines [6, 7]. 
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 The proliferative stage occurs between two to ten days after tissue damage and 
reduces the injured tissue area by creating a viable epithelial barrier to the epithelialization 
process by stimulated keratinocytes. The closure of the wound and restoration of the 
vascular system (via angiogenesis) also occurs during this stage, with macrophage-
stimulated differentiation of fibroblasts into myofibroblasts [8] facilitating wound 
closure.  
The remodeling stage begins after two to three weeks of tissue damage and can 
last for over a year. During this stage, endothelial cells, macrophages, and myofibroblasts 
apoptosis halts the wound healing processes [9], thereby creating an avascular and 
acellular mature wound [10]. After six to twelve months, matrix metalloproteinases 
excreted by different cells promote the replacement of the collagen III component of the 
acellular matrix synthesized in the proliferative stage with the more robust collagen I [11]. 
Additionally, a marked decrease of angiogenesis, blood flow, and metabolic activity in 
the wound is also observed. 
 
Figure V. 1: Stages of wound repair: (a) inflammatory stage, (b) proliferative stage, and (c) 
remodeling stage. Adapted from [9]. 
Traditional therapies for wound healing treatment have included naturally 
occurring products such as plants or animal-derived products (such as honey) due to their 
anti-inflammatory, antimicrobial, and cell-stimulating properties [12]. However, more 
recently developed therapies (e.g., the use of skin substitutes, growth factors, or 
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dressings) have significantly improved wound treatment [13]. The avoidance of wound 
contamination represents the primary function of wound dressings [14]; however, they 
can also act as platforms to deliver bioactive molecules to the wound site and promote 
tissue regeneration. Incorporated bioactive drugs can enhance the wound healing process 
directly by promoting the removal of necrotic tissue or indirectly by avoiding/treating 
infections in the wound area and dampening inflammatory responses [3]. 
 Bioactive molecules that modulate inflammatory responses and promote skin 
wound healing include the family of omega-3 polyunsaturated fatty acids (PUFA) [15-
19]. Docosahexaenoic acid (DHA), a 22-carbon omega-3 fatty acid with six cis-double 
bonds, represents the most abundant and highly unsaturated PUFA in tissues (primarily 
in the brain and retina) [20, 21]. DHA is commonly obtained from fish oil, in particular 
from plasma, tissue, and cellular membranes [22]. 
 Dietary studies positively associated DHA with the prevention of numerous 
human diseases, including cancer [23-25], cardiovascular diseases [26-29], and 
Alzheimer’s disease [30, 31], amongst others [32]. In terms of wound repair, a range of 
studies have reported the beneficial role of DHA [16, 33]. Lu et al. revealed that 
endogenous DHA accelerated tissue repair by acting as a substrate for the synthesis of 
14S,21R-dihydroxy-DHA, a compound that enhances both reepithelization and wound 
area closure. Wound-resident activated macrophages promote the activity of 12-
lipoxygenase and p450, catalyzing the conversion of DHA into 14S,21R-dihydroxy-DHA 
[34]. In 2011, a study confirmed deficiency in 14S,21R-dihydroxy-DHA production in a 
diabetic wound healing mouse model, increasing the importance of the topical application 
of DHA to chronic skin wounds [33]. 
Importantly, DHA exhibits anti-inflammatory activity through various 
mechanisms of action and, therefore, could also represent a potential therapeutic for 
psoriasis [35-37] (to be further explored in our models, Chapter IV, in a near future). 
DHA can act as a substrate for the production of some anti-inflammatory molecules, such 
as the resolvins (metabolic byproducts of omega-3 fatty acids) [38-40]. DHA also 
modifies the expression of some pro-inflammatory cytokines and mediators, such as 
cyclooxygenase-II (COX-2) and TNF [22, 38, 41, 42]. Interestingly, recent studies have 
discovered the presence of a membrane receptor for DHA, G-protein-coupled receptor 
120 (GPR120), which inhibits TLR4 and TNF receptor 1 (TNFR1)-induced activation of 
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the IkB kinase (IKK) [43]. As these factors represent potential enhancers of metabolic 
inflammation [44], DHA may promote a general reduction in inflammatory activity.  
 Recent studies have also described an effect of DHA on endothelial cell function. 
De Caterina et al. employed cultured human endothelial cells activated by pro-
inflammatory cytokines to evaluate DHA-modulated endothelial activation. Interestingly, 
DHA treatment resulted in the reduced expression of vascular cell adhesion molecule 1 
(VCAM-1), intercellular adhesion molecule 1 (ICAM-1), E-selectin, and pro-
inflammatory cytokines such as IL-6 and IL-8 [45, 46]. DHA also modifies cell 
membrane features [47] and the organization and composition of the membrane 
microdomains [48-50], specifically in lipid rafts (areas with high concentrations of 
cholesterol and sphingolipids) [51]. 
 Of note, several factors, including oxygen, light, elevated temperatures, and 
irradiation can provoke lipid oxidation, structure destabilization, and reduced activity of 
PUFAs [52]. Lipid oxidation gives rise to various unstable products, creating a mixture 
of intermediate and secondary products that include free radicals and hydroperoxides. 
These products also can be oxidized into aldehydes and ketones, for example, which can 
produce several adverse effects [53]. Furthermore, PUFAs display some limitations 
regarding their incorporation into various formulations, as they can only be completely 
solubilized into formulations with at least one oil phase. Therefore, there exists a growing 
effort to improve stability and overcome the limitations associated with PUFAs through 
innovative delivery methods.  
 The use of nanoemulsions and liposomes represent the most commonly employed 
methods to include fatty acids such as PUFAs in topical treatments. As an example, 
Marinosomes® are liposomes composed of polyunsaturated fatty acids such as 
eicosapentaenoic acid (EPA) and DHA obtained from natural marine lipid extracts [54]. 
Jung et al. used a newly developed emulsification method, layer-by-layer (LbL) 
deposition, to encapsulate the omega-3 fatty acids present in fish oil. Excitingly, this study 
established improved skin permeability of LbL emulsions compared to free fatty acids by 
Franz diffusion cells using a method described by Sonavane et al. [55] with some 
modifications [56]. Yang et al. developed a nanoemulsion loaded with algae oil (rich in 
DHA) and coffee oil, to study the inhibitory effect on UVA-radiation induced skin 
damage in mice and melanoma cell growth. In vitro cytotoxicity assay of nanoemulsions 
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in melanoma cells revealed effective inhibition of cell growth with an IC50 value of 26.5 
µg/mL and cell cycle arrest at the G2/M phase. Moreover, in vivo results demonstrated 
that a nanoemulsion dose of 0.1% coffee oil-algae oil reduced several characteristics 
parameters after UVA-damaged skin, such as trans-epidermal water loss, skin erythema, 
melanin formation, and subcutaneous blood flow [57].  
However, topical application presents with certain limitations, including a 
requirement for aqueous and oily phases to incorporate fatty acids. To overcome these 
limitations, we proposed the application of polymer conjugation.  
In this project, we used a type of DHA composed of two chains containing 12 
double bonds, called didocosahexaenoic acid (diDHA), in order to achieve adequate 
bioresponsive linking chemistry with our carriers. Specifically, we assessed the potential 
for a PGA-conjugated form of diDHA using an ester linker (PGA-diDHA conjugates) 
that promotes stability, solubility in water and allows its incorporation in aqueous 
formulations, such as hydrogels. 
V.1.2. Heart Tissue Damage by Induced Ischemia-Reperfusion Injury 
Cardiovascular diseases (CVD) currently represent a significant cause of mortality 
across the world; an estimated 22 million people will die from CVD in 2030 [58]. 
Interestingly, the use of PUFAs as therapeutic agents to treat CVD has grown 
exponentially in recent years. Specifically, DHA protects the heart against myocardial 
ischemia-reperfusion (I/R)-induced injury [59], entailing both morbidity and loss of 
quality of life in patients [60]. Ischemia, or the lack of oxygen in the myocardial vascular 
territory, cause irreversible damage to the myocardium by inducing necrosis and 
apoptosis of cardiomyocytes [61]. However, subsequent reperfusion with oxygenated 
blood provokes tissue damage, inflammation, and oxidative stress in the area, leading to 
cardiomyocyte death. This process decreases contractile activity and induces alterations 
to the heart wall, thereby generating cardiac dysfunction [62, 63]. Preventing cell death 
during the reperfusion process represents a promising approach for the reduction of 
secondary effects following the implementation of treatment after an ischemic heart 
disease. Of note, recent studies have demonstrated that dietary supplementation with fish 
oil or direct intravenous DHA infusion can reduce arrhythmias in I/R animal models [64, 
65], myocardial infarct size [66-68], and cardiac dysfunction [69-71].  
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For this reason, after exploring skin wound healing application, in the second part 
of this chapter we also studied the ability of the PGA-diDHA conjugates to reduce and 
prevent damage caused by I/R during the cardiac ischemic process, through a 
collaboration with the laboratory of Dr. Pilar Sepúlveda (Hospital La Fe, Valencia, 
Spain). We aimed to enhance the already known properties of diDHA upon polymer 
conjugation by decreasing the damage associated with the I/R process. Mainly, by 
diminishing the effect of blood flow during the reperfusion process not only by a physical 
effect (adhesion of PGA-diDHA to the endothelium) but also by enhancing the anti-
inflammatory and healing properties of diDHA triggering its controlled and sustained 
release at the injury site. 
IV.2. Results and Discussion 
V.2.1. Synthesis and Characterization of Poly-L-Glutamate-Didocosahexaenoic 
Acid Conjugates  
We prepared a family of PGA-diDHA conjugates following well-established 
synthetic procedures [72]. We attached diDHA to the polypeptidic backbone employing 
an ester linker through an esterification reaction using DMTMM·BF4 [73] and DMAP as 
a catalyst (Scheme V. 1). We conjugated different diDHA loadings to PGA, creating a 
broad family of conjugates that exhibit different physico-chemical properties.  
 
Scheme V. 1: Synthetic procedures for PGA-diDHA conjugate synthesis. 
We started from a PGA of an average molecular weight of 41.3 kDa (273 units of 
glutamic acid) and proceed with the conjugation of diDHA achieving the desired family 
of PGA-diDHA conjugates with mol% loading ranging from 2 to 9 mol%, as determined 
via 1H-NMR (namely, PGA-diDHA2.2, PGA-diDHA6.4, and PGA-diDHA9.1 
conjugates). We optimized the synthetic methodology, which proved reproducible and 
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yielded the desired products with high purity as also revealed via 1H-NMR (60% yield). 
While we observed a broadening of the bands after diDHA conjugation to PGA, the 
characteristic peaks of the parent drug at 5.5 - 5 ppm were retained (Figure V. 1A). We 
calculated the backbone modification by 1H-NMR, comparing the integration for the 
alkenyl diDHA protons (5.5 - 5 ppm) to that of the PGA backbone (4.5 - 4 ppm). Indeed, 
we revealed the integrity of the diDHA signals throughout the conjugate, as evidenced by 
the prevalence of the associated peaks at 5.5 - 5 ppm, 3 - 2.5 ppm, and 1 - 0.5 ppm within 
the conjugate (Figure V. 1B).  
 
Figure V. 1: (A) 1H-NMR approach to diDHA loading quantification (mol%) by means of relative 
integration (alkenyl diDHA protons 5.5 - 5 ppm vs. -CH at PGA backbone 4.5 – 4 ppm) in the 
PGA-diDHA conjugate (5 mg/mL D2O). (B) diDHA signals were maintained after the 
conjugation to the polymeric backbone, ensuring the protection of the drug during the synthesis 




In order to achieve the different diDHA loading in the conjugates the same 
synthetic methodology was implemented demonstrating the robustness of the synthesis 
(Figure V. 2).  
 
Figure V. 2: 1H-NMR spectra in D2O of PGA-diDHA conjugates with different loading 
demonstrating conjugation efficiency and purity. 
 
Figure V. 3: UV-Vis spectra of OG labeled PGA-diDHA conjugates. (A) Calibration curve of 
OG at 495 nm. (B) UV-Vis spectra of the OG calibration curve. (C) UV-Vis spectra of PGA-
diDHA6.4-OG conjugate as representative example. 
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In the case of the conjugates labeled with Oregon Green (OG), we also calculated 
the backbone modification by 1H-NMR (integration of the PGA -CH at 4.5 - 4 ppm vs.  
aromatic OG protons from 6.7 to 8.1 ppm) yielding as result 1.9 mol% OG in all the 
conjugates. We further verified loading efficiency by assessing the UV-Vis absorbance 
at 495 nm compared to a standard curve of free OG, which provided a similar result (2 
mol% OG) (Figure V. 3). 
Table V. 1 summarizes the most relevant physico-chemical parameters of the 
synthesized PGA-diDHA conjugates. We further confirmed diDHA loading determined 
by 1H-NMR using the triglyceride assay, finding diDHA loadings of 1.6, 9.5, and 14.7 
diDHA/PGA for PGA-diDHA2.2, 6.4, and 9.1, respectively. The differences compared 
with the results by 1H-NMR could derive from the degradation of the alkene bonds by 
means of several factors, including peroxidation or hydrolysis. Of note, the size 
assessments of the conjugates by DLS measurements (in number) revealed that diDHA 
loading plays an important role: higher diDHA loading generated conjugates with smaller 
sizes. The measurements by DLS in terms of intensity reflects the different aggregation 
behavior for the synthesized conjugates revealing much larger aggregates for the 
intermediate diDHA loading. Deeper physico-chemical studies on conjugate 
conformation by SAXS and/or SANS techniques are required to fully understand this 
behavior (for preliminary data in this direction see section V.2.3.). 
Table V. 1: Physico-chemical characterization of PGA-diDHA conjugates. a. Diameter by DLS 
in MilliQ water by number (2 mg/mL) b. Diameter by DLS in MilliQ water by intensity (2 
mg/mL) c. Polydispersity index (PDI) as determined by DLS d. Critical concentration of 
aggregation (CAC) by pyrene assay e. diDHA loading (mol%) by 1H-NMR f. diDHA loading 
(mol%) by triglyceride assay g. Free diDHA (wt% of the total drug loading) by FPLC. 
 
All conjugates displayed a negative Z-potential close to -50 mV, in good 
agreement with reported data in the literature for similar systems [74], due to the 
contribution of PGA. Moreover, we detected free diDHA content of <0.15 wt% of the 
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total drug loading in all the conjugates tested, as determined by FPLC, demonstrating the 
purity of the conjugates. 
V.2.2. Enhanced Solubility and Stability upon diDHA Conjugation 
diDHA displays very low aqueous solubility (forming a solid gel visible at the tip 
of the Eppendorf tube), likely due to diDHA autopolymerization upon contact with water. 
However, conjugation of diDHA to PGA significantly increases water solubility, as 
shown for PGA-diDHA-OG conjugate in Figure V. 4A. Conjugation also protects 
diDHA from oxidative damage, as evidenced by a 1H-NMR degradation study that 
compared the depletion of signal from the alkene groups to an internal standard over 28 
days (Figure V. 4B).  
 
Figure V. 4: Increased stability and solubility of PGA-diDHA. (A) Increased solubility in water 
of PGA-diDHA conjugates (yellow staining = OG labeled PGA-diDHA). Free diDHA forms gels 
on contact with water, creating an insoluble mass stuck to the bottom of the tube (clear gel). (B) 
Degradation over time of diDHA and PGA-diDHA conjugates as assessed by 1H-NMR for 28 
days (n=3). (C) Degradation over time of diDHA and PGA-diDHA conjugates by MDA assay 
(n=3). Asterisks indicate statistically significant differences after ANOVA analyses followed by 
Bonferroni’s post hoc tests, mean ± SEM. In all cases, we considered differences to be significant 
when p***<0.001; p**<0.01; p*<0.05. 
After one day, free diDHA degraded by 30 - 40%, while PGA-diDHA conjugates 
maintained their alkene bond integrity and degraded by less than 5%. Encouragingly, at 
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day 28, diDHA degraded by 50%, while PGA-diDHA displayed only 10% degradation, 
demonstrating that PGA conjugation stabilizes and protects diDHA. 
We confirmed the stabilizing effect through the malondialdehyde (MDA) lipid 
peroxidation assay (Figure V. 4C). Independently of the diDHA loading in the 
conjugates, we detected <5 mol% MDA/diDHA for all PGA-diDHA conjugates at room 
temperature (r.t.) after one month, while free diDHA samples provided >100 mol% 
MDA/diDHA after only one week, and >200 mol% MDA/diDHA after one month. 
Overall, these findings suggest that PGA conjugation could significantly enhance the 
shelf-life of diDHA and the stabilization of the molecule. The differences between the 
results of the MDA assay and 1H-NMR assays could derive from the various means of 
degrading alkene bonds, including peroxidation, hydrolysis, and polymerization, 
therefore deeper studies should be performed to fully understand the cause of the 
differences. 
V.2.3. Self-assembling Behavior of PGA-diDHA Conjugates 
 
Figure V. 5: Physico-chemical characterization of PGA-diDHA conjugates. (A) Size 
measurements of PGA-diDHA by DLS in PB 10 mM and water. (B) Correlation coefficients of 
each PGA-diDHA by DLS. (C) TEM images of PGA-diDHA at 2 mg/mL.  
We studied the behavior of the PGA-diDHA conjugates in solution, creating an 
amphiphilic system with appropriate hydrophobic-hydrophilic (diDHA-PGA) balance, 
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enabling the self-assembly behavior into larger nanometer-sized objects [74].  We 
characterized the synthesized conjugates using a battery of techniques. First, we measured 
the sizes of selected PGA-diDHA conjugates in PB 10 mM and water by DLS (Figure 
V. 5A), discovering adequate quality criteria and correlation coefficients (Figure V. 5B). 
In both media, we observed a relationship between diDHA loading and the size of the 
conjugates; the size decreases as diDHA loading increases, with values of 100 nm to 20 
nm for PGA-diDHA9.1 and PGA-diDHA2.2, respectively. In agreement with the above-
mentioned data (Table V.1). This phenomenon may be intimately related to the 
hydrophilic-lipophilic ratio in the conjugates. As expected, looking at solution 
conformation of our nanoconjugates, as the lipophilic part (diDHA) increases, elevated 
compaction occurs, thereby causing a reduction in size. This finding agrees with the 
results obtained by TEM images that confirmed the existence of nanosized spherical 
aggregates (Figure V. 5C).  
We next performed a pyrene assay to determine the critical aggregation 
concentration (CAC) of the conjugates, which suggested that the self-assembly of PGA-
diDHA conjugates was triggered mainly due to hydrophobic interactions. As shown in 
Figure V. 6, the presence of hydrophobic pockets within the assemblies allowed the 
determination of the CAC using a pyrene probe. Of note, diDHA loading modifies the 
capacity of nanoconjugate self-assembly; PGA-diDHA9.1, 6.4, and 2.2 exhibit CACs of 
2.84 µM, 3.96 µM, and 28.87 µM, respectively. This difference in the self-assembly 
capacity of the conjugates directly relates to the range of sizes obtained according to 
diDHA loading.  
 
Figure V. 6: CAC determination for PGA-diDHA conjugates by pyrene assay. 
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We next determined free diDHA content by FPLC to ensure the safety and purity 
of the synthesized conjugates (Figure V. 7). The presence of free diDHA in the 
conjugates can trigger adverse reactions, as well as undesirable biological activity. For 
this reason, after the optimization of the synthesis of the PGA-diDHA conjugates, the 
purification process plays an essential role. After an exhaustive purification by means of 
dialysis, free diDHA content was determined up to a maximum of 0.15 wt% of the total 
diDHA loading in all the conjugates, thereby proving the purity and overall drug loading 
to secure further biological evaluations (see also Table V.1).  
 
Figure V. 7: Free diDHA content in the PGA-diDHA conjugates by FPLC. (A) Chromatograms 
of the diDHA calibration curve. (B) Chromatogram of free diDHA from PGA-diDHA conjugates. 
In summary, conjugation of the highly hydrophobic fatty acid diDHA to PGA 
results in amphiphilic PGA-diDHA conjugates that self-assemble into spherical 
nanosized objects driven by hydrophobic interactions among diDHA residues, therefore, 
diDHA loading drives nanoconjugate solution conformation with the greatest core 




V.2.4. Drug Release Kinetics and Conformation of PGA-diDHA Conjugates 
In order to demonstrate diDHA sustained release from the polymeric carrier, we 
studied drug release kinetics by FPLC under hydrolytic conditions, given the pH-labile 
nature of the ester bond. We performed this study only for those conjugates that presented 
promising results in the in vitro/in vivo biological evaluation in both the skin and the I/R-
cardio models (see section V.2.5 and V.2.6). The selected conjugates will be evaluated 
in an in vivo wound healing model in the near future and from the I/R model are currently 
being tested in a swine model (Dr. Sepúlveda, Hospital La Fe, Valencia, Spain).  
We incubated the selected conjugates (PGA-diDHA6.4 and PGA-diDHA2.2) at 
37ºC in hydrolytic conditions: pH 5.5 (lysosome) and 7.4 (blood) up to 72 h, discovering 
a small but sustained diDHA release, with values around 5% and 3% for PGA-diDHA6.4 
and PGA-diDHA2.2, respectively. Unexpectedly considering our physico-chemical 
characterization regarding CAC and size, diDHA release from the PGA-diDHA6.4 
conjugate was found to be two-fold faster than that from PGA-diDHA2.2 conjugate, both 
at pH 5.5 and pH 7.4, most probably due to the different aggregation behavior seen in 
both conjugates. Furthermore, our data indicates a faster drug release at pH 7.4 (as in the 
case of PGA-FLUO conjugates - see Chapter IV for more details) compared to the acidic 
pH. In the case of PGA-diDHA6.4, we obtained 5 and 4.5% of free diDHA, and for PGA-
diDHA2.2 we obtained a 3 and 2.5% of free diDHA at pH 7.4 and 5.5, respectively 
(Figure V. 8A). In the case of the PGA-diDHA2.2 at both pHs, we observed a sustained 
diDHA release over the first 24 h of incubation after a rapid diDHA release, followed by 
an increased release up to 72 h. This plateau may be explained in terms of size, the 
presence of different species (aggregates) in solution, and the exposure of the drug; the 
conjugate PGA-diDHA6.4 presents smaller size by number but higher size by intensity 
(analyzed by DLS) than PGA-diDHA2.2 conjugate, indicating that PGA-diDHA6.4 
displays different species in solution, presenting larger aggregates. Thereby, in the PGA-
diDHA2.2 conjugate the drug could be found in a more compressed form within the 
polypeptidic system, provoking a more impeded exposure of the drug and therefore a 
more sustained release would be obtained over time. As mentioned above, a deeper 
understanding on solution conformation for PGA-diDHA conjugates by SAXS, SANS,  





Figure V. 8: Drug release kinetics of PGA-diDHA2.2 and PGA-diDHA6.4 conjugates by FPLC. 
(A) diDHA release kinetics at pH 5.5 and 7.4. (B) Chromatograms of released diDHA from PGA-
diDHA conjugates (n=3). Asterisks indicate statistically significant differences after ANOVA 
analyses followed Bonferroni’s post hoc tests, mean ± SEM. In all cases, we considered 
differences to be significant when p***<0.001; p**<0.01; p*<0.05. 
To understand these results for a pH labile ester linker, we next sought to analyze 
the spatial arrangement of the drug within the polymer-drug conjugate and the resulting 
assembled nanocarrier to further explore drug release characteristics. We analyzed the 
conjugates by circular dichroism (CD) as a function of PGA-diDHA conjugate 
concentration and different pHs that mimic the different environments that conjugates 
encounter following topical administration (Figure V. 9).  
At pH 7.4, 100% molar side chains in PGA are presented as carboxylates, yielding 
a full random coil conformation - a more accessible and flexible structure that favors the 
access to cleavable linker and release the drug. However, at pH 5.5, protonation of PGA 
side chains represents roughly 50% molar of the overall carboxylates, as derived from the 
pKa of linear PGA reported in the literature [75]. The protonation induces a partial 
random coil to alpha-helix conformation transition, thereby generating a much more rigid 
270 
 
and compact structure that inhibits access to the linker and drug release. This pH-
dependent secondary structure transition could explain the kinetics of diDHA release in 
both conjugates. 
 
Figure V. 9: Secondary structure of PGA-diDHA6.4 conjugates at pH 7.4 and 5.5 as determined 
by circular dichroism. 
V.2.5. PGA-diDHA Treatment of Skin Wound Healing 
V.2.5.1. Cell Viability Studies with PGA-diDHA Conjugates 
We performed cell viability assays using immortalized human keratinocytes 
(HaCaT cells) and human dermal fibroblasts after 72 h of treatment with increasing doses 
of free diDHA or PGA-diDHA conjugates (0.37 - 23.75 ng/mL diDHA equivalents (eq.)) 
(Figure V. 10). While we failed to observe cell toxicity with PGA-diDHA conjugates at 
the concentrations used, treatment with free diDHA from 2.97 ng/mL led to significant 
decreases in cell viability in both cell types.  
These results revealed that in addition to providing stability and protection against 




Figure V. 10: Cell viability assays in human fibroblasts (left) and keratinocytes (HaCaT) cells 
(right) after 72 h of treatment with diDHA or PGA-diDHA conjugates (n=3). Asterisks indicate 
statistically significant differences after ANOVA analyses followed by Bonferroni’s post hoc 
tests, mean ± SEM. In all cases, we considered differences to be significant when p***<0.001; 
p**<0.01; p*<0.05. 
V.2.5.2. Enhanced Cell Migration by PGA-diDHA Conjugates 
The scratch assay evaluates the capacity of compounds to modulate cell migration, 
acting as a proxy for wound healing potential [76, 77]. Following scratch formation in a 
human dermal fibroblast cell culture, we directly added the treatments (diDHA and PGA-
diDHA conjugates) to the cell culture medium and compared the capacity of free diDHA 
compared to PGA-diDHA conjugates to enhance the migration of the cells at 24 h post-
treatment (Figure V. 11). For this study, we used the highest non-toxic concentrations 
from cell viability assays (2.97 ng/mL diDHA eq.). As controls we included an untreated 
sample and PGA for better comparison. Interestingly, while diDHA, PGA-diDHA2.2, 
and PGA-diDHA9.1 treatment failed to significantly alter cell migration and proliferation 
compared to controls, treatment with PGA-diDHA6.4 induced ~20% increase in 
fibroblast migration, suggesting that diDHA loading significantly influences conjugate 




Figure V. 11: Scratch assay using human dermal fibroblasts. Quantification of the percentage of 
migration of the fibroblasts after 24 h of treatment with PGA, PGA-diDHA conjugates, and 
diDHA (n=3).  
V.2.5.3. PGA-diDHA Permeation into the Epidermis 
We evaluated the penetration of PGA-diDHA-OG labeled after 24 h of incubation 
in human skin explants using Franz diffusion cells. For this study, we used the maximum 
and minimum diDHA loading in the conjugates (PGA-diDHA9.1-OG and PGA-
diDHA2.2-OG) to explore the differences in skin penetration upon diDHA loading. After 
fixation and tissue processing, we captured confocal images to assess skin penetration. 
The results suggest that the conjugate with low diDHA loading (PGA-diDHA2.2-OG) 
can reach the viable epidermis, although the PGA-diDHA9.1-OG conjugate mainly 
accumulated in the stratum corneum (Figure V. 12A). We next quantified OG intensity 
by Image J software after the permeation studies, corroborating the results obtained by 
confocal microscopy. In general, the data obtained revealed significantly higher PGA-
diDHA2.2-OG intensity compared to the PGA-diDHA9.1-OG in all skin layers, 
encountering the most remarkable difference in the viable epidermis (Figure V. 12B). It 
was clear that diDHA loading determines skin penetration, whereas PGA-diDHA9.1-OG 
mainly remains in the stratum corneum, PGA-diDHA2.2-OG efficient found her path up 
to the viable epidermis, our desired skin layer to trigger the therapeutic response. Most 
probably due to the greater exposure of diDHA to the cells due to a less compact conjugate 




Figure V. 12: Permeation studies of PGA-diDHA-OG conjugates in human skin by Franz 
diffusion cells. (A) Confocal images of PGA-diDHA2.2-OG and PGA-diDHA9.1-OG conjugates 
after 24 h of permeation. (B) Quantification of OG intensity by Image J software in the stratum 
corneum (SC) and the viable epidermis (n=5). Asterisks indicate statistically significant 
differences after ANOVA analyses followed by Bonferroni’s post hoc tests, mean ± SEM. In all 
cases, we considered differences to be significant when p***<0.001; p**<0.01; p*<0.05. 
Moreover, we studied the capacity of PGA-diDHA-OG conjugates to cross the 
whole skin, quantifying the signal of OG in the receptor chamber acting as a proxy for 
the passage of our conjugates/drugs into the circulatory system. We analyzed 2 mL from 
the receptor chamber at 8 and 24 h of study by Franz diffusion cells and quantified the 
OG signal at 495 nm in the UV-Vis spectrophotometer (Figure V. 13). When we 
compared results with a negative control using MilliQ water, we failed to observe any 
OG signal, indicating that conjugates failed to penetrate through the skin and therefore 
could be unlikely to reach the circulatory system and induce undesirable side effects. 
Thus, these data provide evidence regarding the safety for topical application of 




Figure V. 13: UV-Vis spectra of the aliquots from the receptor chamber after 8 and 24 h of 
permeation in human skin using PGA-diDHA-OG conjugates by Franz diffusion cells.  
V.2.6. PGA-diDHA Treatment of Ischemia-Reperfusion (I/R) Injury 
As mentioned previously, several studies have demonstrated a role for DHA in 
the protection of the heart against myocardial ischemia-reperfusion (I/R)-induced injury. 
Hence, we studied the ability of our PGA-diDHA conjugates to reduce and prevent 
damage caused by I/R. For this purpose, we employed the family of PGA-diDHA 
conjugates following well-established synthetic procedures, described above, which we 
subsequently biologically evaluated in vitro and in vivo. 
V.2.6.1. Enhanced Cell Viability after diDHA Conjugation In Vitro  
We evaluated cell viability and the capacity of the PGA-diDHA conjugates to 
reduce damage caused by I/R in vitro using murine H9C2 cell line (myoblasts). We 
assessed the effect of PGA-diDHA conjugates on cell viability by MTS assay to 
determine the optimum concentration for our cell models. We added PGA, PGA-
diDHA2.2, PGA-diDHA6.4, PGA-diDHA9.1, and diDHA at 0.2, 2, 10, and 20 µg/mL 
diDHA eq. for 72 h (Figure V. 14). PGA, PGA-diDHA2.2, and PGA-diDHA6.4 did not 
exhibit adverse effects on cell viability; however, PGA-diDHA9.1 decreased cell viability 
by 30% at 10 and 20 µg/mL. Additionally, free diDHA revealed a cytotoxic effect at 2, 
10, or 20 µg/mL, but not at 0.2 µg/mL. These data confirmed that conjugation of diDHA 




Figure V. 14: Cell viability assays in H9C2 cells after 72 h of treatment with PGA, diDHA, or 
PGA-diDHA conjugates. Asterisks indicate statistically significant differences after ANOVA 
analyses followed by Bonferroni’s post hoc tests, mean ± SEM. In all cases, we considered 
differences to be significant when p***<0.001; p**<0.01; p*<0.05. 
We next assessed the capacity of PGA-diDHA conjugates to reduce the damage 
caused by I/R injury in vitro using the lactate dehydrogenase (LDH) assay, which is 
widely used to study cell damage (higher amounts of LDH secretion correlates with more 
severe cellular damage). In this study, we assessed the amount of LDH in the culture 
medium after 72 h of exposition to PGA, PGA-diDHA2.2, PGA-diDHA6.4, PGA-
diDHA9.1, and free diDHA at the same concentrations used for cell viability assays, 
compared to control cells (1% LDH release). This experiment reflects the importance of 
the diDHA availability, as although non-significant differences were observed, there is a 
clear trend on possible cell damage recovery at 0.2 µg/mL for free diDHA although an 
increase in concentration reverts such effect due to possible cytotoxicity as shown before 
(Figure V.14). In the case of the conjugates, the same effect is observed but at different 
drug concentration as it is clearly correlated with the drug release kinetics profile (Figure 
V. 15). Apoptosis and autophagy studies as mean of cell death/recovery with these diDHA 
derivatives have been also performed with much more significant results than those 
obtained with LDH, as it seems mitochondria-mediated cell death is the molecular 
mechanism followed. PGA-diDHA6.4 conjugate revealed the higher prevention of cell 
death in vitro after an I/R injury (data included in the PhD thesis of Sandra Tejedor, Dr. 
Sepúlveda Lab., Hospital La Fe, Valencia, Spain), and also the presence of PGA-
diDHA2.2 triggered a recovery trend.  
Based on the promising results in vitro, we moved to the in vivo experiments with 
the conjugates that revealed the best therapeutic potential: PGA-diDHA2.2 and PGA-



























diDHA6.4. As PGA-diDHA9.1 clearly displayed cytotoxic effects at high concentration 
against H9C2 cells we did not further consider it for in vivo experiments.  
 
Figure V. 15: LDH release to the culture medium in H9C2 cells after 72 h of treatment with PGA, 
diDHA, or PGA-diDHA conjugates. Results obtained were normalized with values obtained from 
control cells. Data were obtained from three independent experiments by triplicate and presented 
as mean ± SEM.  
V.2.6.2. PGA-diDHA6.4 Treatment Decreases Myocardial Infarct Size in an I/R 
Model In Vivo 
 We evaluated the selected PGA-diDHA conjugates in vivo in a rat I/R model to 
assess the protective capacity of conjugates on cardiomyocytes. We split rats into 
different groups and induced acute myocardial infarction (AMI) as described in the 
materials and methods. We treated the control group with PBS, and we used a negative 
group without I/R-induced injury (sham or placebo surgery). Based on previous results 
in vitro, we decided to test PGA-diDHA2.2 and PGA-diDHA6.4 conjugates at 10 µg/mL 
diDHA eq. We stained representative pictures of heart slices with the redox indicator 
2,3,5 triphenyl tetrazolium chloride (TTC) after the surgical procedure (Figure V. 16A). 
Figure V. 16B depicts the differences between infarct sizes observed. Following the I/R 
procedure and PBS injection as control, we observed an infarct size of 28.32 ± 5.57%. 
We observed a non-significant reduction in infarct size in the group treated with PGA-
diDHA2.2, obtaining values similar to the control (23.43 ± 1.91%); however, we 
discovered significantly lower tissue damage in the group treated with PGA-diDHA6.4 
conjugate (11.99 ± 3.75%). These data suggest that PGA conjugation of diDHA has 
beneficial effects regarding the treatment of AMI through a reduction in the required dose 
of diDHA and an increase in its therapeutic efficiency. Also, this effect is concentration 


























dependent, and in this case a higher loading resulted in a greater therapeutic output most 
probably due to the higher diDHA bioavailability at the site of action (see drug release 
kinetics studies, section V.2.4). 
 
Figure V. 16: PGA-diDHA6.4 conjugate decreases myocardial infarct size in an I/R model in 
vivo. (A) Representative pictures of TTC staining in heart slices determined the effect of the 
different experimental procedures on myocardial infarct size. (B) Myocardial infarct size 
expressed as the percentage of area at risk. Sham group without I/R (n=4), control group treated 
with PBS (n=4), PGA-diDHA2.2 (n=6), and PGA-diDHA6.4 (n=5). Results were presented as 
mean ± SEM and analyzed by ANOVA. All groups are compared with the I/R condition 
(*p<0.05). 
V.3. Conclusions  
The use of diDHA provides several advantages in the tissue healing due to its 
ability to promote the reepithelization and closure of the wound area and its anti-
inflammatory activity. To improve the physico-chemical characteristics of diDHA and, 
therefore, the effectiveness of the treatment, we successfully synthesized and 
characterized a new family of PGA-diDHA conjugates. We discovered that diDHA 
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loading determines the final conjugate solution conformation, including size and the 
critical concentration of aggregation giving a more compact constructs upon increasing 
drug loading, which is also a key feature modulating drug release kinetics. Our analyses 
demonstrated that PGA conjugation enhanced diDHA stability by protecting the lipid and 
reducing degradation over time while also increasing its aqueous solubility. 
Moreover, PGA conjugation to diDHA led to a marked improvement in dermal 
cell viability when compared to the free drug, most probably due to the reduction of the 
diDHA degradation subproducts. Of note, diDHA loading also represents a crucial 
parameter towards achieving an adequate biological activity; migration and skin 
penetration studies revealed that lower diDHA loadings prompted better therapeutic 
activity, thereby promoting enhanced closure of the wound and skin penetration.  
These results lay the groundwork for polymer conjugation as an effective means 
to diminish or avoid drug degradation and adverse effects. Moreover, the use of 
polyglutamates as a carrier enhances the skin penetration of conjugated drugs, as has been 
demonstrated in previous chapters of this Thesis, which also contributes to the 
effectiveness of the treatment. Future studies will focus on developing a diabetic rat 
model to evaluate the proliferative and anti-inflammatory activity of conjugates with the 
low-medium diDHA loading. 
Looking at I/R-induced damage applications, our results showed that diDHA 
loadings in the conjugate play a key role in the final biological activity and more 
importantly, PGA-diDHA6.4 conjugate has the best therapeutic effects under I/R 
condition in vitro and in vivo in comparison with free diDHA in terms of safety as well 
as therapeutic efficiency.  
Infusion of nanoconjugates and free diDHA in an in vivo I/R rat model showed 
that heart infarct size was significantly reduced when PGA-diDHA6.4 was administrated 
before reperfusion in comparison with free diDHA at the same dose. Collectively, our 
data showed that PGA-diDHA6.4 could be effective in mitigating I/R-induced injury 





V.4. Materials and Methods 
V.4.1. Materials 
All analytical grade organic solvents and anhydrous N,N-Dimethylformamide 
(DMF, ≥99.8% anhydrous) were purchased from Scharlab S.L. (Spain) and used without 
further purification. Poly-(alpha-L-glutamic acid) (Mw: 41.3 kDa, PDI: 1.2, 273 subunits 
per polymer) was obtained from Polypeptide Therapeutic Solutions S.L. (Spain). 
Didocosahexaenoic acid (diDHA) was purchased from Nu-Chek Prep, Inc. (Elysian, MN, 
USA). Oregon Green 488 cadaverine was purchased from Invitrogen (Spain). Ultrapure 
water with a resistivity of 18 MΩ cm was used in all aqueous preparations (MilliQ water). 
Phenazine methosulfate (PMS) was supplied by Sigma (Spain). Dulbecco’s Modified 
Eagle’s Medium (DMEM) with Glutamax was purchased from Fisher (Spain). DMEM, 
phosphate buffer saline (PBS), fetal bovine serum (FBS) Medium 200, trypsin, and 
penicillin/streptomycin were provided from Gibco (Spain). (3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) was 
supplied by Promega (Spain). 
V.4.2. Physico-Chemical Characterization Methods  
V.4.2.1. Nuclear Magnetic Resonance (NMR) Spectroscopy 
NMR spectra were recorded at 27°C (300 K) on a 500 MHz Bruker spectrometer 
(Billerica, US). Data were processed with the software Mestrenova (Bruker GmbH, 
Germany). Samples were typically prepared at 5 mg/mL in deuterated solvents.  
V.4.2.2. Ultraviolet-Visible (UV-Vis) Spectroscopy 
UV-Vis measurements were performed using V-630 spectrophotometer (JASCO 
Corporation, Spain) at 25°C with 1.0 cm matched quartz cells and with a spectral 
bandwidth of 0.5 nm. Determination of total OG content was measured by UV-Vis 
spectroscopy. To obtain a calibration curve, free dye was diluted in MilliQ water to give 
a concentration range of 0.000250 – 0.000025 mg/mL. The total dye loading of the 
conjugates at different concentrations (0.5, 0.25, 0.1 mg/mL) was determined by 
measuring the absorbance of the samples at 495 nm in MilliQ water. 
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V.4.2.3. Fluorescence Spectroscopy 
Fluorescence experiments were performed using a JASCO FP-6500 
spectrofluorimeter (JASCO Corporation, Spain) at 25ºC with 1cm quartz cells. Pyrene 
assay was performed as published elsewhere to determine the critical concentration of 
aggregation (CAC) [78]. In brief, polymers were dissolved and diluted ranging from 0.44 
- 240 M in PBS with a final volume of 1 mL, to which 3 µL of the pyrene stock solution 
(0.02 mg/mL) in acetone was added. Then, all solutions were placed in vials and were 
incubated at 37ºC for 2 h to evaporate acetone. The solutions were then allowed to rest 
overnight at r.t. and then transferred into a 1 mL quartz cuvette, and the excitation spectra 
from 300 - 360 were recorded with emission set to 390 nm on the spectrofluorometer. 
Excitation and emission band slits were set to 5 and 2.5 nm. The I338/I333 fluorescence 
intensity was plotted as a function of logarithmic polymer concentration. The I338/I333 
ratio increased steadily with increasing polymer concentration and became sigmoidal in 
the crossover region. The CAC was determined at the intersection of the horizontal 
tangent line through points of low polymer concentration and the tangent line of the curve 
at the inflection point. 
V.4.2.4. Transmission Electron Microscopy (TEM) 
TEM images were recorded using a JOEL 2100 transmission electron microscope. 
Samples were applied directly onto carbon film on 200 mesh copper grids at 2 mg/mL. 
Any excess of the sample was carefully removed by capillary action, and the grids were 
immediately stained with one drop of 0.1% phosphotungstic acid for 30 s. Excess stain 
was removed by capillary action.  
V.4.2.5. Dynamic Light Scattering (DLS) 
DLS measurements were performed using a Malvern ZetaSizer NanoZS 
instrument (Malvern Instruments Ltd., UK), equipped with a 532 nm laser at a fixed 
scattering angle of 173°. Solutions were sonicated for 10 min and allowed to equilibrate 
for the required time, filtered through a 0.45 μm cellulose membrane filter, and then 
measured. The samples were dissolved in MilliQ water and 10 mM PB. Size distribution 
by number and intensity (diameter, nm) were measured in triplicate. 
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Z-potential measurements were performed at 20ºC using a Malvern ZetaSizer 
NanoZS instrument (Malvern Instruments Ltd., UK), equipped with a 532 nm laser using 
disposable folded capillary cells. Z-potential was measured for the highest concentration 
of each polymer (2 mg/mL) in 1 mM KCl in MilliQ water. The solutions were filtered 
through a 0.45 µm cellulose membrane filter. Z-potential was measured for each sample 
in triplicate. 
V.4.2.6. Fast Protein Liquid Chromatography (FPLC)  
Analytical determination of the free drug was performed on an ETTAN LC 
equipment (Amersham Biosciences, Spain). The measurements were performed using a 
C-18 LiChrospher analytical column (125 x 4.0 mm) (Scharlab S.L., Spain), with a flow 
rate of 0.7 mL/min, a 15 L loop, and isocratic conditions with 100% acetonitrile (ACN). 
Detection of the alkene bonds of diDHA absorbance was measured at λ = 200 nm. The 
calibration curve was constructed using commercial diDHA, showing a linear response 
within the concentration range employed (0.001 - 0.5 mg/mL). 
 Free Drug Content 
PGA-diDHA conjugates were dissolved in water at 1 mg/mL and lyophilized to 
form a thin film at the bottom of glass vials, protected from light. Then, 300 L of ACN 
was added slowly over the films, and the vials sealed for 30 min. The contents were then 
physically mixed via a glass pipette and vortex to ensure thorough washing of the solid 
polymers. The liquid was then transferred to a new glass container for centrifugation, and 
80 L of the supernatant was filtered (0.45 µm) and injected in the FPLC system. Samples 
were measured repeatedly (n=3). The area for peak(s) from 3.5 - 4 mL were used against 
a standard curve of diDHA to determine the free diDHA in the conjugates. 
 Drug Release Kinetics 
Drug release kinetics of PGA-diDHA2.2 and PGA-diDHA6.4 conjugates were 
performed at two different pHs (5.5 and 7.4). A stock solution of the conjugates was 
prepared in PBS buffer (5 mg/mL) and was divided into 100 µL aliquots; each aliquot 
was then incubated at 37ºC over times ranging from 0 to 72 h. After incubation, the 
samples were lyophilized, the residue resuspended in 500 µL of ACN, and then 
centrifuged 5 min at 10,000 rpm to separate the free drug from the polymer. Finally, the 
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supernatant was evaporated under reduced pressure using the speedvac (1:30 h, 80ºC, 
0.01 vacuum). The final residue was resuspended in 300 µL of ACN and filtered (0.45 
µm) for analysis. Samples were measured in triplicate. The area for peak(s) from 3.5 - 4 
mL were used against a standard curve of diDHA to determine the final free diDHA 
released. 
V.4.2.7. Circular Dichroism (CD)  
CD spectroscopy was performed with a J-815 CD Spectrometer using a PTC-423 
Peltier thermostated cell holder with a JULABO F250 recirculating cooler (All JASCO 
Corporation, Spain). A nitrogen flow (~2.7 L/min) was led through the spectrometer and 
controlled with a nitrogen flow monitor (Afriso Euro-Index, Germany). Samples were 
dissolved in MilliQ water or 10 mM PB, and employed at different concentrations (0.01- 
0.4 mg/mL). Samples were measured in triplicate in a quartz cuvette with d = 0.1 cm. 
V.4.2.8. Stability Over Time by NMR Analysis 
1H-NMR was used to track the oxidation of fatty acids. Samples were prepared as 
follows: PGA-diDHA conjugates (PGA-diDHA2.2, PGA-diDHA6.4 and PGA-
diDHA9.1) were dissolved at 10 mg/mL in D2O and transferred to an NMR tube. To 
these, an insert with 1 mg/mL of 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) in 
D2O was added. Free diDHA was dissolved at 10 mg/mL in MeOD with 0.03% of 
tetramethylsilane (TMS) as the internal standard. The NMR tubes were capped, sealed 
with parafilm to prevent evaporation, and placed in the dark, wrapped in foil. At each 
time point, samples were analyzed by 1H-NMR on a Bruker 500 MHz spectrometer 
(relaxation delay time = 10 seconds, 500 scans) and the spectra analyzed using TopSpin 
3.5 pl 7 software. To calculate the percentage of degradation, the integration of the 
internal standard was set to 1, and then the alkenyl peaks for diDHA from 5.66 - 5.17 
ppm at each time point were compared to the integration in the same region at day 0. 
V.4.2.9. Stability Over Time by Malondialdehyde Colorimetric Assay 
Malondialdehyde (MDA) formation was evaluated over time to assess the 
protective function of PGA conjugation on the prevention of lipid peroxidation by 
diDHA. PGA-diDHA conjugates were dissolved at 4 mg/mL in 10 mM PB pH 7.4 (-
NaCl, -Mg2+, -Ca2+) and free diDHA in ethanol. Both were allowed to incubate at r.t., 
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capped and sealed with parafilm, and protected from light. At each time point (one day, 
one week, two weeks, and one month), an aliquot was taken from each sample, and MDA 
levels were quantified via the TBARS (thiobarbituric acid reactive substance) Lipid 
Peroxidation Assay Kit (Sigma Aldrich, Spain). Briefly, 50 L of sample or standard 
were mixed with 300 L TBA solution and heated at 95C for 1 h, the solutions were then 
cooled for 5 min, and fluorescence monitored at 530/590 (Ex/Em) using a 
Victor2Wallac™ plate reader (Perkin Elmer, Spain). 
V.4.2.10. Quantitative Determination of the Triglyceride Content in the PGA-
diDHA Conjugates 
Total triglyceride (TG) content in the conjugates was quantified using a 
LabAssayTM Triglyceride kit (Wako Chemicals GmbH, Germany), which is based on the 
enzymatic GPO-DAOS method [79]. Briefly, a calibration curve was constructed using 
concentrations of glycerol ranging from 0 to 134.62 nmol. PGA-diDHA conjugates were 
dissolved at 15 mg/mL in MilliQ water and 50 µL of the samples were added to 250 µL 
of color reagent containing chromogen substrate (prepared according to the assay kit 
instructions). The mixture was incubated at 37ºC for 5 min, and the absorbance was 
measured at 590 nm using a Victor2Wallac™ plate reader (Perkin Elmer, Spain). TG 
content was determined according to standard solutions. 
V.4.3. Synthetic Protocols 
V.4.3.1 Synthesis of Poly-L-Glutamate Didocosahexaenoic Acid Conjugates 
PGA (100 mg, 3 mol, 273 eq. GAU, 1 eq.) was dissolved in 10 mL dry DMF in 
a 100 mL round bottom under an inert atmosphere. DMTMM·BF4 (19.0 mg, 0.06 mmol, 
20.0 eq.) was dissolved in 1 mL dry DMF under nitrogen and added dropwise to the PGA 
solution. A catalytic amount of DMAP was added in 1 mL dry DMF, and the solution 
was stirred for 30 min. diDHA (27.6 mg, 0.04 mmol, 13.6 eq.) was dissolved in 1 mL dry 
DMF (0.3 ppm BHT added) and the pH adjusted to 8 with N,N-Diisopropylethylamine 
(DIEA). The solution was protected from light and allowed to stir at r.t. for 3 days until 
all diDHA had reacted, as visualized by thin-layer chromatography (TLC) (80:20:1 
hexanes:ether:acetic acid, retention factor (Rf): Rf (diDHA) = 0.2 and Rf (PGA) = 0.1). 
The pH was adjusted as necessary to pH 8, and the solution precipitated into cold diethyl 
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ether. The precipitate was then rinsed (with vortexing) three times with ether. Then, the 
precipitate was suspended in water, and the pH was adjusted to 8 with sodium 
carbonate/bicarbonate buffer pH 10. This solution was then dialyzed (MWCO 3000) 
protected from light against sodium carbonate/bicarbonate buffer pH 10 for 12 h followed 
by MilliQ water to remove salts. The purified product was then lyophilized and stored 
under an inert atmosphere at -20C protected from light.  
V.4.3.2 Oregon Green Labeling of PGA-diDHA Conjugates 
PGA (600 mg, 0.02 mmol, 273 eq. GAU, 1 eq.) was dissolved in 100 mL dry 
DMF in a two-neck round bottom flask under nitrogen atmosphere. DMTMM·BF4 (23 
mg, 0.07 mmol, 4.1 eq.) and a catalytic amount of DMAP were added in 10 mL additional 
dry DMF and the solution allowed to stir for 30 min. OG (23 mg, 0.05 mmol, 2.7 eq.) was 
added to the reaction mixture in 10 ml dry DMF, protected from light. The pH was 
adjusted to 8 with DIEA and stirred for three days. The reaction mixture was then either 
purified or further modified with diDHA. For example, for 5 mol% diDHA modification, 
additional DMTMM·BF4 (38 mg, 0.12 mmol, 20.5 eq.) and catalytic DMAP in 10 mL 
DMF were added to one third of the crude reaction mixture for 30 min, followed by the 
addition of diDHA (55 mg, 0.08 mmol, 13.6 eq.). The pH was again adjusted to 8 with 
DIEA and allowed to react for three days. At the end of the reaction, the pH was adjusted 
to pH 8, and the solution precipitated into cold diethyl ether. The precipitate was then 
rinsed (with vortexing) three times with ether. Then, the precipitate was suspended in 
water, and the pH was adjusted to 8 with sodium carbonate/bicarbonate buffer pH 10. 
This solution was then dialyzed (MWCO 3000) protected from light against sodium 
carbonate/bicarbonate buffer pH 10 for 12 h followed by MilliQ water to remove salts. 
The purified product was then lyophilized and stored under an inert atmosphere at -20C 
protected from light.  
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V.4.4. Biological Evaluation of PGA-diDHA Conjugates 
V.4.4.1. Skin Wound Healing 
V.4.4.1.1. In Vitro Evaluation 
V.4.4.1.1.1. Cell Viability 
To carry out the in vitro cytotoxicity studies, two cell lines were used: human 
immortalized non-tumorigenic keratinocytes (HaCaT cells), supplied by CLS Cell Lines 
Service (Germany), and human fibroblasts supplied by Hospital La Fe (Valencia, Spain). 
High glucose DMEM Glutamax (Fisher, Spain) was used for keratinocyte culture and 
DMEM (Gibco, Spain) for fibroblast culture; both were supplemented with 2% 
penicillin/streptomycin and 50 mL of FBS in a humidified incubator (Hucoa-Erlöss S.A., 
Spain) at 5% CO2 and 37°C.  
For the cell viability assays, 50 μL of cells were seeded in 96-well plates at a 
concentration of 4,000 cells/well for HaCaT cells and 2,000 cells/well for human 
fibroblasts. After 24 h, 50 μL of each treatment was added, reaching a final volume of 
100 μL. All treatments were previously filtered (pore size 0.22 μm). Cells were incubated 
with samples or controls for 72 h before performing MTS assay. For this assay, 20 μL of 
PMS and MTS (1:20) solution were added. After 3 h of incubation, absorbance values 
were captured at 490 nm using a Victor2Wallac™ plate reader (Perkin Elmer, Spain). The 
absorbance values were represented as the percentage of cell viability relative to the 100% 
cell viability of untreated control cells. The concentrations of PGA, diDHA, and PGA-
diDHA conjugates were in a range from 0.37 to 23.75 ng/mL diDHA eq. 
V.4.4.1.1.2. Scratch Assays 
Human fibroblasts were seeded in a 24-well plate at a concentration of 75,000 
cells/well. After 24 h, simple scratch wounds were made with a white Gilson pipette tip 
in all wells, culture media was removed, and treatments were applied at a 2.97 ng/mL 
diDHA eq. in 400 µL of media. All treatments were previously filtered (pore size 0.22 
μm). A Leica DMI6000 automatic inverted microscope (Leica, Germany) was used to 
follow the migration of the cells, taking pictures every half hour for 24 h. Finally, the 
reduction in scratch wound area compared to time 0 was calculated. 
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V.4.4.1.2. Ex Vivo Evaluation 
V.4.4.1.2.1. Visualization of Dermal Penetration 
Breast skin samples were obtained with informed consent from healthy women 
undergoing plastic surgery (kindly donated by Hospital la Fe, Valencia, Spain). 
Immediately after excision, the subcutaneous fatty tissue was removed using a scalpel. 
The skin was cut into 4 cm2 pieces, wrapped in aluminum foil and stored at -20ºC until 
use. Permeation study was developed using Franz diffusion cells (Logan Instruments 
Corp., USA). The skin was fixed between the donor and the receptor chamber, so that 
stratum corneum faced upwards. The receptor chamber was filled with 8 mL of 0.01 M 
PBS pH 7.4 and mixed with a magnetic stirring bar while the temperature was kept at 
37ºC. The skin was placed between the chambers and 100 µL of a solution of 10 mg/mL 
of PGA-diDHA2.2-OG and PGA-diDHA9.1-OG in water were topically applied to the 
skin surface. 2 mL sample were taken from the receptor chamber at 8 and 24 h for further 
analysis by UV-Vis and immediately refilled with fresh solution. After 24 h, skin samples 
were gently rinsed twice with 0.1% PBS-BSA and incubated in 4% paraformaldehyde 
(PFA) for 24 h at r.t. Then samples were washed with 30% sucrose in PBS and retained 
in said solution for 24 h at 4ºC. Finally, skin samples were washed twice with PBS and 
preserved in a cryopreservation solution (40% 0.1 M PB, 30% ethylene glycol and 30% 
glycerol) at 4ºC until use. Finally, skin samples were included in the optimum cutting 
temperature inclusion medium, and slides of 5 µm were performed with the cryostat 
version CM1850 UV (Leica, Germany). 
V.4.4.1.2.2. Confocal Microscopy 
The permeation of the fluorescent labeled-conjugates by Franz diffusion cells was 
evaluated by confocal microscopy. Excitation was performed with an argon laser ((OG, 
496 nm) and blue diode (Hoechst, 405 nm). Images were captured at an 8-bit greyscale 
and processed with LCS software version 2.5.1347a (Leica Germany) containing 
multicolor, macro, and 3D components. Control tissue that follows the same incubation 
time with MilliQ water was also analyzed to establish the autofluorescence. OG intensity 
was quantified five times per sample using Image J software and expressed as pixels 




V.4.4.2. Ischemia-Reperfusion Injury 
V.4.4.2.1. In Vitro Evaluation 
H9C2 cells were seeded on 96-well plates and were treated with increasing 
concentrations of PGA, diDHA, and PGA-diDHA conjugates, using 0.2, 2, 10, and 20 
µg/mL diDHA eq. for 72 h in 190 μL of culture medium. Then, 100 μl of the culture 
medium were taken for LDH activity measurement, following the recommended protocol 
(Roche, Spain). Triton-treated cells were used as a positive control of the assay. The 
absorbance of LDH activity was measured at 490 nm using a Victor2Wallac™ plate 
reader (Perkin Elmer, Spain).  
Cell viability was determined using the MTS assay (CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay, Promega, USA). Cells were supplemented with 
MTS solution (10 μL/well) and incubated for 3 h at 37°C. Then, the absorbance was 
recorded at 490 nm using a Victor2Wallac™ plate reader (Perkin Elmer, Spain). 
V.4.4.2.2. In Vivo Evaluation 
Adult male Wistar rats (Charles River Laboratories, Inc., US) weighing 350 – 
400 g were housed in a standard vivarium with free access to food and water. All 
procedures were approved by institutional ethical and animal care committees. Before 
experiments, animals were randomized into experimental groups. Rats were anesthetized 
intraperitoneally with fentanyl (Acost-Comercial Generis Pharma, S.L., Spain) at 0.05 
mg/kg and by inhalation with Sevorane (Abbot, Spain). Once animals were anesthetized, 
intubation was carried out to ensure proper anesthesia during the procedure. Later, the 
left paw was tied to feel the heart beating. The left chest area was sterilized, and a 
thoracotomy was performed. For myocardial ischemia, the left anterior descending 
coronary artery was occluded with a silk suture as previously described [80]. Different 
treatments at 10 µg/mL diDHA eq. (PGA-diDHA2.2 and PGA-diDHA6.4) were prepared 
in PBS and were injected after 15 min of ischemia. PBS alone was injected in control rats, 
and the sham group was used as a negative control. 
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Topical administration represents the main route to attain local therapeutic activity 
of bioactive agents due to its affordability compared to other administration routes (e.g., 
intravenous and intramuscular administration) enhancing patient compliance and 
clinician acceptance [1]. The principal body sites explored that benefit from topical drug 
administration include the skin, vagina, eyes and nose, but also other organs, as the heart, 
could be reach by means of devices that act as a reservoir and are capable to enhance drug 
transport through the endothelium.The main challenge of the topical administration of 
various therapeutics is the requirement to bypass specific biological barriers to achieve a 
required concentration of a given therapeutic agent at the desired site of action for a 
duration that would allow optimal pharmacological activity [2].  
The skin represents the main biological barrier present in the human body, 
controlling the exchange of molecules between the body and the environment; however, 
this protective system also diminishes the penetration of therapeutic agents [3]. In 
particular, the nanoporosity and composition of the stratum corneum represent the most 
significant obstacles for therapeutics to surpass [4] leading to low drug bioavailability 
and efficacy. These deficiencies have led to the administration of higher concentrations 
of therapeutic agents to achieve a desired level of activity, but also to the development of 
complex formulations that enhance skin penetration of the therapeutic to the required skin 
layer. Nanosized drug delivery systems represent an exciting means to safely increase 
drug penetration into the skin [5-7] and maintain a prolonged and constant drug release 
rate at the desired site of action [8]. 
In this thesis we focused on the topical administration of advanced therapeutics  
mainly for skin pathologies (Chapter III and IV), but we have also begun to explore a 
local administration approach that aims to diminish the consequences of 
ischemia/reperfusion (I/R) injury in the heart (Chapter V). We developed our new 
advanced therapeutics using a polymer therapeutics-based approach: the conjugation of 
active agents to a biodegradable and biocompatible polypeptide scaffold to create novel 
nanosized drug delivery systems that improve drug penetration through the skin or 




To this end, we followed the strategies described below:  
(1) The use of biodegradable and biocompatible polymeric carriers, mainly 
polypeptide-based derivatives that permit chronic treatment via topical 
application while avoiding bioaccumulation and any undesirable side-effects. 
(2) The rational design of the final polypeptide-drug conjugates alone and in 
combination with polypeptide-base penetration enhancers, to enhance the 
activity and promote the attainment of therapeutic drug concentrations at the 
desired place of action. 
(3) An exhaustive physico-chemical characterization of the synthesised 
conjugates to correlate features with the biological activity. 
(4) The use of preclinically relevant models of disease, including ex vivo human 
skin models and an in vivo psoriatic model. 
Polymer-drug conjugates, a subtype of polymer therapeutics, offer advantages 
when compared to other nanomedicines that favor drug skin penetration [9-11]. These 
properties include: (1) chemical stability and controlled physico-chemical features due to 
the presence of a covalent linker between the drug and the polymer carrier, (2) solubility 
of hydrophobic drugs in aqueous media, (3) sustained and site-specific release of drugs 
via rationally designed bioresponsive linkers, and (4) the capacity to load drug 
combinations or add targeting moieties due to polymer multivalency [12]. Herein, we 
have achieved proof of concept regarding the benefits of the implementation of polymer 
therapeutics-based approaches for topical administration in pathologies such as psoriasis 
or wound healing. 
Psoriasis is a common inflammatory chronic disease mediated by the immune 
system with a predominantly cutaneous involvement [13]. There are several clinical 
phenotypes of psoriasis that are classified based on the characteristics of the disease, 
including patient age at disease onset, degree of skin involvement, morphologic pattern, 
and anatomical location [14]. Scaly skin, erythematous plaques, and inflammatory cell 
infiltration characterize plaque psoriasis, the most prevalent type of psoriasis [15, 16]. In 
recent years, the immune response involved in the onset of the disease has been 
extensively investigated, uncovering the relative importance of the Interleukin (IL)-
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23/IL-17 axis [16, 17]. The current development of anti-psoriatic therapeutics, mainly IL-
17 and IL-23 inhibitors, focuses on systemic treatments that target the immune system 
[17]. However, topical treatment with corticosteroids remains one of the most widely 
employed treatments for approximately 80% of patients affected with mild to moderate 
psoriasis [18]. Corticosteroids induce anti-inflammatory, antiproliferative, 
immunosuppressive, and vasoconstrictive effects through binding to intracellular 
corticosteroid receptors and the modulation of pro-inflammatory cytokine gene 
transcription [19]. 
However, many topical corticosteroids that are currently employed or under 
assessment in clinical trials lack adequate physico-chemical properties (e.g., solubility) 
and suffer from local cutaneous (e.g., skin atrophy and acne) and systemic side effects 
(e.g., osteoporosis, diabetes and weight gain) that limit their clinical use [20]. These 
effects correlate with the high doses required and the elevated frequency of applications 
and have been noted for both high and reduced potency corticosteroids. Therefore, any 
advanced therapeutic approaches that allow a reduction in dose and the avoidance of 
systemic circulation of corticosteroids could significantly enhance treatment efficacy and 
patient compliance.  
The application of nanomedicines as advanced therapeutics in the field of topical 
and transdermal delivery of active compounds [21-25] and immunotherapy [26] is 
currently in exponential growth. Liposomes have been the most used carriers for skin 
delivery, although their large sizes and heterogeneous size distribution limit their 
efficiency when acting as skin permeation enhancers [27, 28]. The application of 
controlled polymerization techniques and the tailoring of critical nanocarrier parameters, 
such as size and Z-potential, can significantly enhance the penetration of active 
substances into the skin, as has been demonstrated for polypeptide-based nanostructures 
[29, 30]. Furthermore, the mode of the drug encapsulation/entrapment [31] or polypeptide 
carrier-conjugation [32, 33] significantly influences the site of drug release and kinetic 
profile of drug release. Although currently underexplored for skin delivery, rationally-
designed bioresponsive linkers as part of a nonmedicinal approach can optimize the 
therapeutic output of topical treatment by enhancing efficiency and reducing side effects 
[34, 35]. Finally, the vehicle used for the administration of a given therapeutic may also 
have an essential synergistic effect; formulations with an optimal interaction between the 
vehicle and the therapeutic agent can enhance penetration and hydration of the skin [36].  
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We developed healthy and inflammatory ex vivo human skin models and establish 
an in vivo psoriatic murine model with the hope of understanding the complex pathology 
and histological features of psoriasis (Chapter II). These models also provide a useful 
platform to confirm advanced anti-inflammatory and anti-psoriatic therapeutics. 
Moreover, the ex vivo human skin model allows the evaluation of therapeutics in a more 
realistic setting than those in in vitro assays. 
During the development of the inflammatory ex vivo skin model, we assessed 
tissue viability after the induction of inflammation by treatment with LPS and EGF, 
finding maintained tissue viability at each time and concentration evaluated. 
Histomorphologic analysis of the skin samples with H&E staining and the Ki67 and 
Ck5/6 markers confirmed that treated skin maintained its structure, viability, and 
proliferation capacity in response to the inflammatory insult. Of note, the skin mimicked 
certain features of the psoriasis, including induced epidermal thickness and acanthosis, in 
good agreement with other reports [37, 38]. We also assessed the inflammatory model 
through the quantification of pro-inflammatory cytokines released into the culture media 
(e.g., IL-1b, TNF-α, INF-γ, and IL-6), and then employed this model to evaluate the safety 
and the anti-inflammatory activity of our newly developed family of drug conjugates in 
Chapter IV. However, the absence of a full immune response in this ex vivo human skin 
represents a significant limitation in the modeling of autoimmune diseases, such as 
psoriasis. Therefore, the information from in vivo preclinical mouse models can 
complement the ex vivo models with regards to the understanding of the immune 
mechanisms contributing to disease development and reflect the critical features of the 
human disease [39]. 
With this in mind, we subsequently developed an imiquimod (IMQ)-induced 
model of skin inflammation in immunocompetent (BALB/c) mice for the preclinical 
study of psoriasis. Although the main limitation of the IMQ model relates to the duration, 
this acute model does not represent a chronic disease [40], this model remains relevant 
and widely employed as it mimics the histopathological characteristics of inflamed skin 
and induces a systemic inflammatory response [41]. We developed this model by 
applying IMQ cream daily to the mouse back and ear for seven consecutive days, 
following the timing reported in other studies [41-43]. After this point, we evaluated the 
histological characteristics of the mice for ten days to determine the best time for further 
studies into the application of anti-psoriatic treatments.  
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We employed different methodologies to assess disease progression. We 
monitored mouse body weight measurements to ensure the safety of the treatment, 
demonstrating that after the application of the treatments the animals maintain and even 
recover weight. At the gross morphological level, we used the PASI score [44] to evaluate 
itching, erythema, scaling, and skin thickness on the back of the mice, revealing a 
maximum level at day seven which remained for up to five days later. We also assessed 
the increase in epidermal thickness by H&E staining on the back and treated ear, revealing 
marked epidermal hyperplasia and hyperkeratosis compared to the control group at day 
seven that was maintained up to five days after. In the case of the treated mouse ear, we 
corroborated the increase in epidermal thickness via caliper measurements every two 
days. Therefore, our mouse model demonstrated the same histopathologic changes as 
observed in human psoriasis [45]. Of note, we discovered a significant enlargement of 
the spleen after the application of IMQ cream, corroborating the results of previous 
studies [41, 46, 47]. The enlargement was maintained for five days after the last 
application of IMQ, correlating this phenomenon with the increase in pro-inflammatory 
cytokine synthesis observed in tissue and serum. In both cases, we observed a significant 
induction of the pro-inflammatory cytokines that play a crucial role in the onset of 
psoriasis such as IL-23, INF- γ, and TNF-α [48]. These findings corroborated the results 
obtained by other authors using the topical administration of IMQ as a trigger for the 
disease [41, 43, 49].  
We also discovered the importance of the appropriate vehicle to transport 
polymer-drug conjugates into the skin during the development of this thesis [50]. Of note, 
penetration through the skin relies on the combination of the three factors: skin features, 
the physico-chemical characteristics of the polymer-drug conjugate (in this case), and the 
vehicle. Vehicles should possess sufficient residence time on the skin to allow a 
controlled and sustained release of the drug to provide a therapeutic dose, and also should 
enhance patient compliance [51-53]. Importantly, a universal vehicle does not exist, and 
so, vehicle formulation should consider the specific physico-chemical properties of the 
nanomaterial employed to maximize drug release across the skin. 
 For this reason, we used a novel biodegradable hyaluronic acid-poly-L-glutamate 
cross-polymer vehicle (HA-CP; Yalic®) as a penetration enhancer (developed in 
collaboration with Polypeptide Therapeutic Solutions S.L.). The rationale for the 
development of this penetration enhance lies in the properties of hyaluronic acid (HA), 
300 
 
whose use in dermal applications has increased in recent years [54-56] (Chapter III). We 
implemented a synthetic methodology to synthesize the cross-linked HA using PGA and 
lysines as cross-linkers, following well-established methodologies [57, 58]. The 
degradation of the HA-based materials in the presence of hyaluronidase revealed a more 
rapid degradation for linear HA compared to the cross-linked vehicle. These findings 
support the results obtained in a hydration study in human volunteers, in which the HA-
CP vehicle prolonged and improved the skin hydration over time compared to linear HA.  
 The biological evaluation in vitro in keratinocytes and fibroblasts cells 
demonstrated that the cross-polymer maintained cell viability when compared to linear 
HA. Moreover, safety assessments of HA-CP in an ex vivo human skin model (see 
Chapter II for more details) revealed the maintainance and even improvement of tissue 
viability after 72 h of treatment, thereby demonstrating suitability for topical applications. 
We also studied the capacity of a fluorescently-labeled HA-CP cross-polymer to penetrate 
the skin by Franz diffusion cells, demonstrating that the HA-CP can significantly 
penetrate the viable epidermis when compared to linear HA, which remains mainly in the 
stratum corneum, in good agreement with previous studies [59, 60]. Also, we evaluated 
the properties of HA-CP as a skin penetration enhancer by evaluating its role as a vehicle 
for the delivery of a family of amphiphilic block copolymers of different nature, using 
PPhe and PBG with different degree of polymerization. We demonstrated that the 
presence of Phe as an amino acid in the polymer chain, as well as the critical micelle 
concentration (CMC) and the encapsulation efficiency (E.E) of a fluorophore (Dil) as a 
model hydrophobic drug drove changes in the nanocarrier solution conformation. 
Micelles composed by the Phe-based block copolymers possessed a higher tendency to 
form micelles (lower CMC) and a lower capacity to encapsulate Dil than the BG-based 
block copolymers. Finally, we confirmed the ability of the HA-CP cross-polymer to 
enhance the penetration of all the micelles through to the viable epidermis while avoiding 
problems related to systemic exposure. 
Therefore, we have demonstrated the suitability of a novel biodegradable cross-
polymer (HA-CP) for topical applications as a vehicle to increase the penetration of 
nanocarriers. Encouraged by this approach, we used this vehicle for the application of the 
PGA-FLUO conjugate as a treatment for psoriasis, aiming to improve the penetration of 
PGA-FLUO into the skin. Within Chapter IV of this thesis, we conjugated the poorly 
water-soluble corticosteroid, fluocinolone acetonide (FLUO), to a water-soluble poly-L-
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glutamic acid (PGA) polymer via an ester bond (PGA-FLUO), to bypass the noted 
limitations of drug treatment and provide more controlled and sustained release of FLUO 
within the epidermis. We also validated the anti-psoriatic activity of PGA-FLUO using 
both preclinically-relevant ex vivo (including human-derived models) and an in vivo 
psoriatic model (described in Chapter II). 
We synthesized PGA-FLUO conjugates using well-established methodologies 
[61] and then characterized them using a full battery of physico-chemical techniques, 
ensuring identity and purity. We discovered self-assembly behavior of the conjugates in 
aqueous environments, creating assemblies with a hydrodynamic radius of 40 - 100 nm 
and a highly negative Z-potential value (-50 mV) by DLS measurements. We 
corroborated a globular nanoassembly for PGA-FLUO by TEM, in agreement with other 
systems based on PGA with similar structures which revealed spherical shapes around 
100 nm [62]. Drug release kinetics at relevant pHs (7.4 and 5.5) revealed higher drug 
release at pH 7.4 than a pH 5.5, an unexpected result due to higher degradability of the 
ester bond under acidic conditions, as previously reported [63-65]. However, this 
phenomenon could be explained by the different solution conformation of the conjugate 
at different pHs, which at pH 7.4 presented a random coil structure meanwhile at pH 5.5 
a alpha-helix structure, more compact and less accessible than the random coil. We also 
studied the physico-chemical characteristics as well as the drug release kinetics of the 
conjugate in the HA-CP vehicle; the conjugate maintained the same size and globular 
shape and displayed a slower and more sustained release compared to the conjugate in 
PBS buffer. These results suggested that the application of the conjugate in the HA-CP 
vehicle promotes a more controllable and sustained release at the desired place of action, 
spacing the necessary doses to achieve the desired therapeutic effect. 
Biological evaluation in vitro revealed that our newly developed PGA-FLUO 
conjugate maintained/enhanced skin cell viability (keratinocytes and fibroblasts) when 
compared to the unconjugated drug. Moreover, cell internalization of a fluorescently-
labeled conjugate in keratinocytes studied by flow cytometry and confocal microscopy 
demonstrated an energy-dependent endocytic uptake and a clear colocalization with 
lysosomes. We also studied the anti-inflammatory activity of the conjugate in LPS-
induced macrophages to evaluate alterations in the secretion of pro-inflammatory 
cytokines. Unexpectedly, we discovered that conjugation enhanced the anti-inflammatory 
capacity of free FLUO. Importantly, during permeation studies in human skin by Franz 
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diffusion cells, we observed a considerable increment in the amount of the fluorescently-
labeled conjugate that reached deeper epidermal layers when applied within the HA-CP 
vehicle than applied in water.   
We corroborated the in vitro findings in two ex vivo models: an optimized 
inflammatory ex vivo human skin model and a reconstructed inflammatory skin 
equivalent model [66]. In both models, we demonstrated the safety of PGA-FLUO and 
the improved ability to reduce the secretion of the pro-inflammatory cytokine IL-6 from 
the skin when compared to the free FLUO.  
Moreover, in vivo proof of concept of the anti-psoriatic activity of our conjugate 
has been achieved in our preclinical IMQ-induced psoriatic mouse model (details in 
Chapter II). Histological comparisons with free FLUO in cream demonstrated that PGA-
FLUO applied in cream produced a more significant reduction in epidermal thickness, 
both in the IMQ-treated back and ear of the mouse model. Remarkable, the group treated 
with PGA-FLUO in the HA-CP vehicle revealed a marked reduction of epidermal 
thickness, compared with healthy animals. These results could be explained due to a 
synergistic effect between the conjugate and the vehicle, promoting an improvement in 
the controlled release of the drug and its permanence in the viable epidermis while also 
improving skin hydration in healthy volunteers (see Chapter III for more details). 
Systemic analyses provided similar results to the localized histological analyses: PGA-
FLUO applied in cream provided a more significant reduction of the release of pro-
inflammatory cytokines related to psoriasis disease (IL-23 and IFN-γ) in serum and tissue 
compared to free FLUO. Of note, treatment with PGA-FLUO within HA-CP provided 
the best results compared to all other treatment modalities. In agreement with these 
results, we observed the same trend in spleen weight reduction, perhaps due to the 
decrease in the synthesis of pro-inflammatory cytokines [41]. Importantly, treatment with 
PGA-FLUO within HA-CP returned spleen weight in psoriatic model mice to that of 
healthy controls.  
 In conclusion, the rationally designed PGA-FLUO conjugate combined with an 
optimized HA-CP vehicle may represent an effective strategy for the treatment of 
psoriasis. This combination provides specific characteristics and advantages compared to 
other nanocarriers; firstly, the conjugation of the drug allows the better controlled of the 
drug release kinetics in the specific skin layer, and secondly, the use of the HA-CP vehicle 
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promotes the penetration of the conjugate into the skin, as well as improves the 
characteristics of the psoriatic skin, such as hydration and dryness. These results lay the 
groundwork for future studies and development of new anti-psoriatic treatments, using 
other types of drugs or drug combination. 
As we have demonstrated during this thesis, PGA-drug conjugates can penetrate 
and permeate through the different layers of the skin, even in cases where the skin barrier 
is altered, such as in the case of psoriasis; therefore, they may find use in the enhancement 
of skin regeneration and repair, thereby contributing towards wound healing. Encouraged 
by these results, we also studied the potential of polymer-drug conjugates to enhance the 
treatment of skin wounds and ischemia-reperfusion injury in the heart. 
Chronic wounds are considered a silent epidemic that affects between 1 - 2% of 
the population in developed countries [67, 68]. Several therapeutic agents have 
demonstrated the capacity to promote skin wound healing, including the family of omega-
3 polyunsaturated fatty acids (PUFAs), especially docosahexaenoic acid (DHA), due to 
its anti-inflammatory properties [69, 70] and the capacity to modify endothelial cell 
function [71, 72]. In Chapter V, we implemeneted a type of DHA composed of two 
chains containing 12 double bonds called diDHA, to develop advanced therapeutics 
towards the treatment of chronic wounds. 
Lipid oxidation of these fatty acids can compromise the implementation of these 
compounds by destabilizing the molecule and decreasing the intrinsic activity [73]. To 
enhance the stability of diDHA, we proposed the generation of a family of PGA-diDHA 
conjugates formed through an ester bond in the hope of protecting the drug from 
degradation and increasing skin wound healing activity. To this end, we synthesized, 
characterized, and biologically evaluated a family of PGA-diDHA conjugates with 
different diDHA loadings (2.2, 6.4, and 9.1 mol%) (Chapter V). diDHA conjugation led 
to increased solubility in water, stability (as evidenced by 1H-NMR), and decreased lipid 
peroxidation of diDHA over time (as evidenced by the malondialdehyde colorimetric 
assay). We also discovered a self-assembly behavior of the conjugates in aqueous 
environments, as occurred with other polymer-drug conjugates developed in this thesis 
due to the hydrophilic-lipophilic ratio. PGA-diDHA conjugates possessed a 
hydrodynamic radius between 20 and 100 nm, in good agreement with the results 
obtained by TEM images, thereby confirming the existence of a globular nanoassembly 
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[62]. Of note, we observed smaller conjugate sizes with higher diDHA loading, results 
related to the critical concentration of aggregation values, which are smaller in conjugates 
with higher diDHA loadings. Moreover, as in the case of the PGA-FLUO conjugates 
(Chapter IV), we discovered a slightly higher drug release kinetics at pH 7.4 than at pH 
5.5 – an unexpected phenomenon that again could be explained by the different 
conformation of the conjugate at different pHs, with overall accessibility higher at pH 
7.4. 
Concerning the biological evaluation, cell viability assays in vitro revealed that 
PGA-diDHA conjugates enhanced skin cell viability (keratinocytes and fibroblasts) and 
maintained nearly complete viability in response to the concentrations evaluated. Of note, 
unconjugated diDHA causes cellular toxicity at higher concentrations, demonstrating that 
diDHA conjugation improved drug stability and decreased cell toxicity in vitro. 
Moreover, in an in vitro scratch assay in fibroblasts, to evaluate the capacity of the 
conjugates to enhance the migration and proliferation into the wounded monolayer, only 
the conjugate with medium diDHA loading (PGA-diDHA6.4) showed a 20% of 
improvement in cell migration compared to control.  
As a topical application, we also assessed the capacity of fluorescently labelled 
PGA-diDHA conjugates with different diDHA loadings (2.2 and 9.1 mol%) to penetrate 
into the human skin by Franz diffusion cells, revealing that the conjugate with lower 
diDHA loading can penetrate deeper into the viable skin, a finding that could be explained 
by saturation of the skin with higher diDHA loadings. Of note, we failed to observe any 
signal in the receptor chamber that could indicate that the conjugate remains in the 
epidermis without reaching the bloodstream and allowing adverse effects on a systemic 
level. 
Encouraged by the successful application of PGA-diDHA conjugates in vitro, 
further studies will be focused on the in vivo evaluation of the selected conjugates in 
diabetic rats, since the biological evaluation revealed that the diDHA loading in the 
conjugate determines the final biological activity.  
Finally, we also demonstrated the ability of the PGA-diDHA conjugates to 
enhance the healing process following damage to the heart produced by I/R associated 
with acute myocardial infarction (AMI) in collaboration with the group of Dr. P. 
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Sepúlveda (Hospital La Fe, Valencia, Spain). In vitro evaluation using a lactate 
dehydrogenase assay revealed that PGA-diDHA6.4 conjugate reduced heart cell damage 
in comparison with free diDHA. Infusion of nanoconjugates and free diDHA in an in vivo 
I/R rat model showed a significant reduction in infarct size following PGA-diDHA6.4 
administration before reperfusion in comparison with free diDHA at the same dose (12 
% vs. 28% infarcted area with or without treatment, respectively). Moreover, 
intracoronary infusion of PGA-diDHA6.4 nanoconjugate after 90 min of ischemia in a 
swine model before reperfusion limited edema and decreased the area in risk seven days 
after experimental infarction as assessed by cardiac magnetic resonance and histological 
analysis (data included in the Ph.D. thesis of Sandra Tejedor at the laboratory of Dr. Pilar 
Sepúlveda).  Collectively, our data established the potential use of PGA-diDHA6.4 in 
mitigating I/R-induced injury, thereby providing a new therapeutic agent for future 
clinical studies. 
In summary, we believe that the results reported in this thesis support the 
development of polypeptide-based conjugates as an effective strategy for the local 
delivery of therapeutic agents and the treatment of a range of conditions. 
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During the development of this Thesis, we demonstrated the applicability of 
polymer therapeutics as platform technology to topically administer bioactive agents or 
drugs for the treatment, among others, of skin disorders such as psoriasis or wound 
healing.  
Herein, we highlight the main conclusions resulting from this work: 
 
1. We have developed ex vivo human skin models using human skin explants from 
donors as a useful tool to validate polymer-based treatments. We established a 
healthy skin model as well as an inflammatory skin model by treating the explants 
with a combination of LPS and EGF. 
 
The established ex vivo models have been validated as relevant preclinical models 
of disease for skin disorders. We evaluated tissue viability both in the healthy and 
in the inflammatory model by means of MTT assay as well as by 
immunohistochemistry, and several inflammatory markers were also used to 
analyze the inflammatory process. Finally, we detected the modulation of the 
release of pro-inflammatory cytokines to the culture media, demonstrating the 
inflammatory effect produced by the combined action of LPS and EGF.  
 
2. We have characterized a preclinically relevant acute psoriatic mice model for 
testing and validating the polypeptide-based therapies developed. By topical 
application of imiquimod (IMQ) cream, we triggered the intrinsic characteristics 
of the psoriasis disease. We evaluated for ten days the progression and 
maintenance of the disease, by assessing the morphology of the skin using PASI 
score and also H&E staining, focusing on specific parameters of the disease, such 
as the epidermal thickening. We also studied the increase in spleen weight after 
the application of IMQ, correlated with the synthesis of cytokines. Finally, we 
identified specific pro-inflammatory cytokines related to the human disease both 
in tissue and in serum. 
 
3. To improve and optimize the penetration of nanocarriers through the skin, we 
have developed and fully characterized a hyaluronic-poly-L-glutamate cross-
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polymer (HA-CP) vehicle (composed by hyaluronic acid (HA) and poly-L-
glutamic acid (PGA) cross-linked through lysine moieties). We validated and 
demonstrated its properties as skin penetration enhancer by means of its use with 
a family of amphiphilic block copolymers of different nature and consequently 
different solution conformation, thereby modulating the final skin permeation 
enhancement. Changes in the nanocarrier solution conformation were driven by 
the presence of Phe as aminoacid in the polymer chain, as well as the polymer size 
among other features.  
 
4. We have developed a family of polymer-drug conjugates, based on the 
biodegradable carrier poly-L-glutamic acid (PGA), incorporating a corticosteroid 
(fluocinolone acetonide) by means an ester bond for the topical treatment of 
psoriasis. An exhaustive characterization using several techniques were employed 
to fully characterize our conjugates in relevant solutions, establishing a relation 
between the structure and their biological activity. 
 
5. In vitro evaluation of the developed conjugates in relevant skin cell lines revealed 
the absence of toxicity up to the concentrations tested. Cellular internalization and 
anti-inflammatory activity studies demonstrated the ability of the conjugates to 
penetrate into the skin cells and maintain the anti-inflammatory activity of the 
drug once conjugated to the PGA. 
 
6. Ex vivo evaluation of the conjugate alone or applied in the HA-CP vehicle as 
penetration enhancer demonstrated its presence in the viable epidermis. 
Moreover, using two ex vivo models, our developed inflammatory ex vivo human 
skin model and a reconstructed inflammatory skin equivalents model (in 
collaboration with Freie Universität Berlin, Prof S. Hedtrich), we demonstrated 
the enhanced activity of the conjugate to reduce the release of IL-6 compared to 
the free drug. 
 
7. In vivo evaluation in our established psoriatic mice model demonstrated the anti-
inflammatory/anti-psoriatic efficacy and safety of our conjugate compared to the 
free drug demonstrating the importance of the use of adequate linking chemistry 
315 
 
in order to control drug release kinetics in the adequate skin layers. Of note, the 
conjugate applied in the HA-CP vehicle revealed enhanced activity and 
effectiveness, demonstrating also the importance of the selection of an appropriate 
vehicle to improve the penetration through the skin. HA-CP showed high 
hydration properties which synergizes with the anti-inflammatory effects of the 
corticosteroid conjugate, resulting in a significantly improved therapeutic 
approach for psoriasis. 
 
8. Finally, we have developed a new family of polymer-drug conjugates, using PGA 
as a carrier, incorporating different loadings of an omega 3 fatty acid (diDHA) by 
means of an ester bond for the topical treatment of wound healing. We thoroughly 
studied the physico-chemical characteristics of the conjugate optimizing diDHA 
loading, and the in vitro biological evaluation revealed its suitability for wound 
healing applications, enhancing the closure of the wound.  
 
9. The family of PGA-diDHA conjugates were validated in vivo in a wound healing 
scenario using an ischemia-reperfusion (I/R) model in collaboration with Hospital 
La Fe (Dr P. Sepúlveda) clearly showing the advantages of polymer conjugation. 
Infusion of the conjugates and free diDHA in an in vivo I/R rat model showed that 
infarct size was significantly reduced when PGA-diDHA6.4 was administrated 
before reperfusion in comparison with free diDHA at the same dose. Collectively, 
our data showed that PGA-diDHA6.4 could be effective in mitigating I/R-induced 
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1. Introducción y antecedentes de la Tesis  
 
La administración local de agentes bioactivos representa la principal vía de 
administración para lograr una actividad terapéutica local debido a su idoneidad y 
asequibilidad en comparación con otras vías de administración, como la intravenosa e 
intramuscular, lo que mejora el cumplimiento del tratamiento por parte del paciente y la 
aceptación por parte del clínico [1]. Los principales lugares del cuerpo que pueden 
beneficiarse de la administración local son la piel, la vagina, los ojos o la nariz, pero 
también otros órganos, como el corazón, a los que se puede llegar mediante dispositivos 
que actúan como reservorio y son capaces de mejorar el transporte del fármaco a través 
del endotelio. El principal reto de la vía de administración tópica es sortear eficientemente 
las barreras biológicas para lograr una concentración óptima del agente terapéutico en el 
lugar de acción deseado, durante el tiempo necesario para llevar a cabo la actividad 
farmacológica [2]. 
 
La piel es el órgano más extenso del cuerpo humano, por lo que representa la 
principal barrera biológica del cuerpo frente a amenazas externas [3]. La piel está 
compuesta por distintas capas, divididas principalmente entre la epidermis y la dermis. 
Esta complejidad fisiológica ejerce una protección a nuestro organismo, sin embargo, 
también evita la penetración de agentes terapéuticos cuando se administran de forma 
tópica, y por tanto su efectividad se encuentra limitada. Además, muchos de los 
medicamentos tópicos actualmente utilizados o en ensayos clínicos carecen de las 
características físico-químicas adecuadas para su administración a través de la piel. Por 
este motivo, actualmente se están desarrollado varias estrategias para mejorar las 
propiedades físico-químicas de los agentes terapéuticos de acuerdo con las características 
del sitio de acción deseado, mejorando la administración tópica así como la estabilidad 
de los fármacos. Algunos métodos incluyen la utilización de profármacos [4] o el 
desarrollo de nanomedicinas mediante la conjugación de agentes terapéuticos a diferentes 
portadores con características específicas [5]. Dichas nanomedicinas protegen al agente 
terapéutico frente a la degradación prematura y también interactúan con varios 
componentes de la piel, incrementando su penetración a través de las diferentes capas de 




Los portadores de tamaño nanométrico son especialmente útiles para la 
administración pasiva de agentes terapéuticos, induciendo el tránsito a través de la piel 
sin necesidad de aporte de energía o de receptores específicos. Algunos de los 
nanotransportadores más utilizados son las nanopartículas, los liposomas, las 
micropartículas, los nanocristales, los polímeros, los niosomas, los dendrímeros, entre 
otros [8, 9].  
En esta Tesis se describe un enfoque específico de la nanomedicina mediante la 
utilización de Polímeros Terapéuticos [10], cuyo principal objetivo en este trabajo es 
aumentar la penetrabilidad de los agentes bioactivos a través de la piel, mejorar sus 
propiedades físico-químicas y liberar el fármaco de una manera controlada en la capa de 
la piel específica. Los Polímeros Terapéuticos engloban una amplia variedad de sistemas 
macromoleculares, presentando la mayoría una estructura común basada en un enlace 
químico (covalente) entre el agente(s) bioactivo y el transportador polimérico que es 
soluble en medio acuoso. Las principales ventajas de la conjugación de fármacos a los 
transportadores poliméricos se pueden resumir en: (i) mayor solubilidad en medios 
acuosos, (ii) control sobre el tamaño final del conjugado (tamaño nanométrico), (iii) 
protección del agente terapéutico contra la degradación por enzimas proteolíticas o 
absorción celular inespecífica, (iv) prevención o reducción de la agregación, la 
inmunogenicidad y la antigenicidad, (v) farmacocinética modificada tanto a nivel celular 
como incluso subcelular y (vi) liberación controlada y sostenida del fármaco en el lugar 
de acción específico gracias a los enlaces polímero-fármaco biosensibles en presencia de 
condiciones específicas [11]. Además, el desarrollo de nuevos Polímeros Terapéuticos 
basados en la utilización de polímeros biodegradables y biocompatibles, como los 
aminoácidos, supone un avance frente a las limitaciones que presentan otros polímeros 
que no son biodegradables [12]. En esta Tesis, nos centramos en la utilización de 
poliglutamatos (PGA) para llevar a cabo la conjugación de fármacos, basándonos en los 
buenos resultados obtenidos en ensayos clínicos del conjugado PGA-paclitaxel 
(OpaxioTM) para el tratamiento de varios tipos de cáncer [13]. 
Cabe destacar que la correcta selección del vehículo para la administración de 
estos polímeros es un parámetro crítico para favorecer la eficacia y la aceptabilidad de las 
formulaciones tópicas, ya que la permeabilidad a través de las diferentes capas de la piel 
está modulada y relacionada con las propiedades del vehículo utilizado [14], por lo que 
las propiedades físico-químicas del vehículo condicionan su efecto sobre la piel. Por ello, 
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en este trabajo se propone la utilización de un nuevo vehículo basado en el ácido 
hialurónico [15, 16], para favorecer la penetración de estos polímeros a través de la piel.  
En esta Tesis nos hemos centrado en la administración tópica de terapias 
avanzadas validando una nueva plataforma de administración de fármacos a nivel tópico 
basada en la utilización de Polímeros Terapéuticos, principalmente para patologías de la 
piel (como la psoriasis o la cicatrización de heridas), pero también hemos explorado 
ligeramente un enfoque de administración local para disminuir el daño de la lesión por 
isquemia/reperfusión (I/R) en el corazón. 
 
2. Objetivos de la investigación  
 
La presente tesis doctoral se centra en el desarrollo de plataformas poliméricas 
para la administración de fármacos de manera tópica como nuevos enfoques de 
tratamiento, por ejemplo, para trastornos de la piel, como la psoriasis y la cicatrización 
de heridas. El desarrollo de nuevos conjugados poliméricos debe basarse en enfoques 
sintéticos bien establecidos así como  en el diseño racional de los conjugados, seguido de 
una caracterización físico-química exhaustiva y una evaluación biológica completa en 
modelos preclínicos relevantes, con el objetivo de avanzar hacia un posible escenario 
clínico. 
Este objetivo general puede resumirse en los siguientes objetivos específicos: 
1. Desarrollo y caracterización exhaustiva de modelos de piel humana ex vivo sanos 
e inflamatorios, así como un modelo preclínico de psoriasis en ratones, ambos como 
plataformas para evaluar y validar terapias avanzadas basadas en polipéptidos. 
(Capítulo II) 
 
2. Síntesis, caracterización físico-química completa y evaluación biológica de nuevos 
materiales a base de ácido hialurónico reticulado y polipéptidos (solos o en 
combinación) como portadores capaces de mejorar la penetración de fármacos a 
través de la piel. (Capítulo III) 
 
3. Diseño, síntesis y caracterización físico-química exhaustiva de conjugados de 
ácido poli-L-glutámico y corticosteroides para el tratamiento tópico de la psoriasis. 
Optimización de la química de conjugación y evaluación biológica para lograr una 
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prueba de concepto para mejorar la actividad antiinflamatoria y antipsoriásica 
después de la conjugación. (Capítulo IV)  
 
4. Diseño, síntesis, caracterización físico-química exhaustiva y evaluación biológica 
en modelos preclínicos relevantes de una familia de conjugados de ácido poli-L-
glutámico para los trastornos de cicatrización de heridas (incluida la cicatrización 
de heridas en la piel y en el tejido cardíaco). (Capítulo V) 
 
3. Metodología  
3.1. Materiales e instrumentación 
3.1.1. Materiales 
Todos los reactivos y disolventes utilizados durante el desarrollo de la presente 
Tesis fueron de grado analítico o superior, sin purificación adicional (a no ser que se 
indique lo contrario en el correspondiente apartado). Generalmente, las reacciones 
llevadas a cabo en disolventes orgánicos se realizaron bajo atmósfera inerte de nitrógeno 
o argón. El agua utilizada era desionizada, presentando una conductancia menor que 0.06 
μS (agua milliQ). 
Los métodos más empleados para llevar a cabo la purificación de los conjugados 
poliméricos fueron principalmente la cromatografía por exclusión de tamaño, utilizando 
resina Sephadex® LH-20 medium (disolventes orgánicos) o Sephadex® G-25 medium 
(fase acuosa). Además, se utilizó la diálisis (con membranas de 3, 30 kDa) y la 
ultrafiltración (Vivaspin®).  
Los animales de experimentación utilizados en la Tesis, se adquirieron en Envigo 
Laboratories Inc. (España). Se utilizaron ratones machos de 6 semanas de la cepas 
BALB/c OlaHsd. 
3.1.2. Instrumentación 
Espectroscopía de Resonancia Magnética Nuclear (RMN): Los espectros de 
RMN se llevaron a cabo en un sistema Bruker Advance AC 300 (Billerica MA, USA) 
utilizando al menos 5 mg de compuesto, temperatura ambiente y disolventes deuterados. 




Espectroscopía Ultravioleta-Visible (UV-Vis): Los espectros fueron adquiridos 
en un espectrofotómetro Jasco V-630 (JASCO Corporation, Spain) a 25˚C con celdas de 
cuarzo de 1 cm y ancho de banda de 0.5 nm.  
Espectroscopia por dicroísmo circular: Se llevó a cabo en un espectrómetro J-
815 CD Spectrometer equipado con un soporte de celda termostatizado (PTC-423), un 
refrigerante (JASCO Corporation, Spain) y flujo controlado de nitrógeno (~2.7 L.min-1) 
(Afriso Euro-Index, Germany). Las muestras se midieron en agua MilliQ, PB 7.4 y a 
diferentes pHs (7.4 y 5.5) para polímeros en la forma sal sódica. Las medidas se realizaron 
en cubetas de cuarzo, de d= 0.1 cm y por triplicado.  
Dispersión de Luz Dinámica (DLS): Las medidas tanto de tamaño de partícula 
como de potencial Z se realizaron a 25˚C en un dispositivo Malvern Zetasizer Nano ZS 
equipado con un láser (532 nm), utilizando un ángulo de dispersión fijo de 90˚ (Malvern 
Instruments Ltd., UK). La celda utilizada fue DTS 1070. Para las medidas de tamaño, el 
tiempo de equilibrado fue de 0 min con atenuación automática. El índice de refracción 
del disolvente (agua) fue 1.330 y, por lo tanto, la viscosidad fue 0.8872. Para el análisis 
de los diferentes polímeros se utilizó el índice de refracción del látex de poliestireno 
(1.590). Cada muestra se midió tres veces con 10 submedidas. 
Cromatografía de permeabilidad en gel en medios acuosos: Las mediciones en 
medios acuosos que contienen 150 mM de NaNO3, se realizaron utilizando 5 mM de 
tampón fosfato (PB) a pH 5 y 0.005 % (p/p) de azida sódica como aditivo en un sistema 
AF2000 de Postnova Analytics (Landsberg, Germany). El sistema fue configurado para 
funcionar con una bomba isocrática (PN1130), un muestreador automático (PN5300), un 
índice de refracción (RI, PN3150), 21 ángulos múltiples de dispersión de luz (MALS, 
PN3621) y detectores ultravioleta-visible (UV-Vis) (PN3211). La columna utilizada fue 
TSKgel G6000PWXL, empleando un caudal de trabajo de 0.8 mL/min a 30°C. El índice 
de refracción y la dispersión de luz multiángulo se utilizaron para la detección y la 
determinación del peso molecular.  
Microscopía Electrónica de Transmisión (TEM): Las imágenes se adquirieron 
en un microscopio de transmisión electrónica EM 410 Philips. Para su preparación, las 
muestras se adsorbieron en rejillas de cobre recubiertas por una película de carbón de 200 
mallas. Seguidamente, se realizó una tinción de contraste negativo con una disolución de 
ácido fosfotúngstico al 0.1%.  
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Victor2 WallacTM para medidas de absorbancia o fluorescencia: Para 
determinar absorbancias o fluorescencias se utilizó un equipo Victor2 WallacTM 1420 
(Perkin Elmer, Spain) utilizando placas de 96 pocillos y las correspondientes longitudes 
de onda (emisión/excitación) propias de cada compuesto. 
  Cromatografía líquida de alta eficacia (HPLC): La determinación analítica de 
la cantidad de fármaco libre y la cinética de liberación de los fármacos se realizó en un 
sistema HPLC Waters (Waters Corporation, S.A, Spain) provisto de bombas binarias 
2x515, automuestreador 717 Plus, FLD 2475 y PDA 2996. Las medidas se realizaron 
utilizando una columna analítica RP C-18 Licrospher (125x4.0mm) (Scharlab S.L., 
Spain). Los cromatogramas fueron tratados con el software Empower 2.0 (Waters 
Corporation, S.A, Spain).   
Microscopía Confocal: Las imágenes fueron adquiridas con un microscopio 
(invertido) láser confocal Leica, modeloTCS SP8 AOBS (Leica Microsystems 
Heidelberg and MBH, Germany). Todas las imágenes se adquirieron bajo las mismas 
condiciones y se analizaron mediante el software de Leica LAS AF Lite (Leica 
Microsystems Heidelberg and MBH, Germany). 
3.2. Métodos más relevantes 
3.2.1. Protocolos de síntesis 
Síntesis de un polímero entrecruzado de ácido hialurónico (HA) y ácido poli-
glutámico (PGA): Paralelamente se preparan cuatro soluciones: HA (100 mg, 0.249 
mmol, 1 eq.) (solución A) y PGA (2.6 mg, 0.017 mmol, 0.07 eq.) (solución B) se 
disuelven por separado en agua destilada. (C) DMTMM·Cl utilizado como agente de 
acoplamiento (44 mg, 0.159 mmol, 0.6 eq. a ácidos carboxílicos totales) se disuelve en 
agua destilada. La sal de clorhidrato de L-lisina (1.5 mg, 0.008 mmol, 0.03 eq. a ácidos 
carboxílicos totales) se disuelve en agua destilada. A continuación, la solución B se 
agrega a la A, seguidamente se agrega C y se mezcla, ajustando el pH a 7 con unos pocos 
microlitros de 1 M NaOH. La solución se agita durante 15 minutos. A continuación, se 
añade D y se ajusta el pH a 8.5 con unos pocos microlitros de 1 M NaOH. La mezcla se 
deja reaccionar durante toda noche a temperatura ambiente. Tras ello, el producto es 
purificado por diálisis usando Vivaspin®, utilizando una membrana MWCO de 30 kDa. 
En primer lugar, el producto se lava con 5 mM tampón fosfato (PB) utilizando un pH de 
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7.5, y seguidamente, se lava con agua destilada. La solución final es liofilizada, 
obteniendo un polvo blanco.  
 
Síntesis general de los copolímeros en bloque a partir de polietilenglicol 
(PEG): La síntesis de los copolímeros en bloque compuestos por PEG-poliaminoácido 
se efectúa ajustando la relación [monómero]/[iniciador] para obtener el grado de 
polimerización deseado. Brevemente, el monómero NCA (3.923 mmol, 10 eq.) se pesa 
en un tubo de Schlenk, equipado con una barra de agitación y secado a 80ºC en un horno 
durante al menos 24 h antes de comenzar la reacción. El tubo es purgado con ciclos de 
argón/vacío, y el monómero se disuelve en 4 mL de DMF seco. A continuación, el 
macroiniciador MeO-PEG-NH2 se pesa en un vial, se purga con argón y se disuelve en 1 
mL de DMF seco. Tras ello, la solución iniciadora se agrega a la solución de monómero, 
manteniéndose la atmósfera de argón a 4ºC bajo agitación vigorosa durante 3 - 4 días. 
Finalmente, la mezcla de reacción se vierte sobre más de 50 mL de Et2O, y el precipitado 
obtenido se filtra y lava con Et2O adicional. Tras ello, se realiza una purificación adicional 
mediante suspensión en THF y precipitación sobre el exceso de Et2O, se filtra y se seca 
bajo la corriente de N2. 
 
Marcaje con Cyanine 5.5 (Cy5.5) para estudios de internalización en piel: El 
marcaje con Cy5.5 se realizó mediante la conjugación a los materiales basados en el HA 
mediante enlace tipo amida. Brevemente y a modo de ejemplo, HA-CP (100 mg, 0.249 
mmol, 1 eq.) se disuelve en agua destilada. Paralelamente, el agente de acoplamiento 
DMTMM·Cl (3.4 mg, 0.012 mmol, 0.05 eq) se disuelve en agua y la solución de 
DMTMM·Cl se añade a la solución HA-CP, ajustando el pH a 7 con unos pocos 
microlitros de 1 M NaOH. La activación del acoplamiento del ácido carboxílico a través 
de DMTMM·Cl se lleva a cabo durante 30 minutos. A continuación, se añade la solución 
de Cy5.5 (1.8 mg, 0.003 mmol, 0.01 eq.) previamente preparada en una mezcla de 
H2O:DMSO (1:1), y se ajusta el pH a 8.5 con unos pocos microlitros de 1 M NaOH. La 
solución azul resultante de la reacción de conjugación se deja actuar durante 72 horas a 
temperatura ambiente. Tras ello, el producto se purifica por diálisis usando Vivaspin® 
(MWCO 30 kDa). El producto se debe lavar con 5 mM PB a un pH de 7.5, y seguidamente 




El contenido de Cy5.5 se determinó por espectroscopia UV-Vis, con filtro de excitación 
de 680 nm de longitud de onda y filtro de emisión de 595 nm a través de una curva de 
calibrado previa. 
 
Protocolo para la conjugación de Acetónido de Fluocinolona (FLUO) al 
PGA: La conjugación se llevó a cabo para alcanzar alrededor de un 8% molar de FLUO 
en relación con los residuos de glutamato, a través de enlaces tipo éster. Como ejemplo 
para describir la síntesis, utilizamos un lote de 200 mg de PGA. 
Brevemente, en un matraz provisto con un agitador magnético y una entrada y salida de 
nitrógeno, se agrega PGA en forma ácida (200 mg, 1.55 mmol) y se disuelve en DMF 
anhidro (5 mL) bajo atmósfera de nitrógeno. Seguidamente, se agrega FLUO (140.27 mg, 
0.3 mmol, 0.2 eq. a unidades de ácido glutámico) disuelto en 1 mL DMF y se permite que 
la mezcla se agite durante diez minutos. Tras ello, la mezcla de reacción se enfría en baño 
de hielo, y se agrega 1 mL de DMF con DMAP (1.9 mg, 0.0155 mmol, 0.01 eq. a unidades 
de ácido glutámico) y 4 mL de DMF con EDAC (89.22 mg, 0.465 mmol, 0.3 eq. a 
unidades de ácido glutámico). La mezcla se deja reaccionar durante 72 horas. La 
cromatografía de capa fina (MeOH) confirma el consumo de FLUO. La solución final se 
purifica mediante cromatografía de exclusión de tamaño utilizando Sephadex® LH-20 y 
después de evaporar el DMF (en condiciones de vacío) el residuo se disuelve con 0.5 M 
NaHCO3 para pasarlo a forma sal y volver a purificarlo con Sephadex® G-25. 
Finalmente, la suspensión acuosa resultante se liofiliza obteniendo un polvo blanco. 
 
 
Marcaje con Oregon Green (OG) 488 Cadaverina para estudios de 
internalización celular y en piel: El marcaje con OG se realizó mediante la conjugación 
al conjugado polímero-fármaco o al polímero mediante enlace tipo amida. Brevemente, 
siguiendo el protocolo descrito para la síntesis del conjugado PGA-FLUO, después de 
agregar el PGA y el fármaco disueltos en DMF, se añaden 2.745 mg de DMTMM.BF4 
(8.366x10-3 mmol, 0.02 eq.) a la solución y se deja transcurrir durante diez minutos a 
temperatura ambiente. A continuación, se añaden 0.01 eq. del fluoróforo OG y se ajusta 
el pH a 8 mediante la adición de DIEA.  La mezcla se deja reaccionar durante 48 horas a 
temperatura ambiente y protegida de la luz. Tras ello, el disolvente es eliminado a vacío, 
y el producto se disuelve con 0.5 M NaHCO3 para pasarlo a forma sal. Finalmente, se 
procede a su purificación mediante los métodos estándar de diálisis, Sephadex® G-25 o 
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precipitación ácido-base. Finalmente, la suspensión acuosa resultante se liofiliza 
obteniendo un polvo naranja. 
El contenido de OG se determinó por espectroscopia UV-Vis, con filtro de excitación de 
490 nm de longitud de onda y filtro de emisión de 535 nm a través de una curva de 
calibrado previa. 
3.3. Ensayos In vitro 
Degradaciones con Catepsina B: La biodegradabilidad de varios conjugados 
polímero-fármaco en presencia de la enzima lisosomal catepsina B fue evaluada in vitro. 
Brevemente, se prepararon disoluciones de 2 mg/mL de polímero en tampón acetato (para 
3 mg de polímero, 700 μL de tampón acetato 20 mM, pH 6, 100 μL de EDTA 2 mM, 100 
μL de DTT 5 mM). A continuación, se añadieron 6.25 unidades de catepsina B disueltas 
en 100 μL de tampón acetato pH 6, 20 mM. Las mezclas se mantuvieron a 37°C bajo 
agitación, y se tomaron alícuotas a diferentes tiempos (0, 0.5, 1, 3, 6, 10, 24, 30, 48 y 72 
horas). La concentración de fármaco liberada en cada tiempo de estudio se analizó 
mediante HPLC. 
Cultivos celulares: Las células HaCaT (CLS Cell Lines Servic, Germany) se 
cultivaron en medio DMEM Glutamax alto en glucosa (Fisher, Spain) mientras que los 
fibroblastos humanos (Hospital La Fe, Spain) y la línea celular Raw264.7 CLS Cell Lines 
Service, Germany) se cultivaron en medio DMEM (Sigma-Aldrich Chemical Co., Spain). 
Los medios de cultivo fueron complementados con un 2% de penicilina/estreptomicina y 
50 mL de suero fetal bovino (FBS). Las células se mantuvieron a 37°C en atmósfera con 
un 5% de CO2. En las 3 líneas celulares, el medio se renovó cada 2 - 3 días y se pasaron 
al menos una vez por semana cuando se alcanzó el 80% de confluencia. 
 
Ensayos de viabilidad celular (MTS): Las células se sembraron en placas 
estériles de 96 pocillos a una concentración de 4000 células/cm2 para HaCaT, 2000 
células/cm2 para los fibroblastos y 6000 células/cm2 para Raw264.7. Después de la 
siembra, las placas se incubaron durante 24 horas y transcurrido ese tiempo se añadieron 
los tratamientos (previamente filtrados con un filtro de 0.22 μm). Transcurridas 72 horas 
de incubación, se añadió 20 μL de la mezcla MTS/PMS (20:1) a cada pocillo, y la placa 
se incubó durante 3 horas más (2 horas en el caso de Raw264.7) en oscuridad. 
Transcurrido este tiempo, la densidad óptica de cada pocillo se midió 
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espectrofotométricamente a 490 nm utilizando el equipo Victor2 WallacTM  (Perkin Elmer, 
Spain). Los valores de absorbancia se representaron como porcentaje de viabilidad celular 
tomando como 100% de viabilidad celular células control no tratadas. 
 
Internalización de los conjugados marcados con OG mediante citometría de 
flujo: Las células HaCaT fueron sembradas en placas de 6 pocillos a una densidad de 
células de 118751 células/cm2, y se incubaron durante 24 horas. El estudio se realizó 
transcurridas las 24 horas tanto a 4°C como a 37°C. Para el experimento a 4°C, las células 
se pre-incubaron a esa temperatura durante 30 minutos antes de empezar el experimento. 
Para ambas temperaturas, 30 minutos antes de añadir el compuesto a estudiar, se añadió 
0.4 μL de una solución de 5 μM de inhibidor de catepsina B CA-074 (alcanzando una 
concentración final de 2 μM). Seguidamente, se añadieron 15 μL de una solución del 
conjugado marcado con OG a diferentes tiempos (0 a 27 horas), tanto a las células 
incubadas a 37°C como a 4°C. Tras ello, las placas se colocaron en hielo, las células 
fueron lavadas dos veces con PBS-BSA 0.1% y se añadieron 400 µL de tripsina para 
levantar las células. Finalmente, las células se resuspendieron en 600 µL de medio celular 
y se depositaron en tubos de citometría de flujo. El pellet se analizó con el citómetro de 
flujo Becton Dickinson FACS Calibur cytometer (California, USA) equipado con un láser 
de argón (488 nm) y filtro de emisión de 550 nm. Los datos se expresaron en porcentaje 
de células positivas. Se utilizaron células incubadas sin polímero para eliminar la 
fluorescencia de fondo. 
 
Internalización celular por microscopía confocal: Las células fueron incubadas 
en las mismas condiciones que para citometría de flujo, pero la siembra se realizó sobre 
un cristal para recoger posteriormente las muestras y analizarlas mediante microscopía 
confocal. Al igual que en la citometría de flujo, primero se añadió el inhibidor de 
catepsina B (misma cantidad que para citometría) 30 minutos antes de la adición del 
conjugado marcado con OG. Seguidamente, se añadieron 15 μL de una solución del 
conjugado marcado con OG a diferentes tiempos (0 a 72 horas) y las células se incubaron 
a 37°C. 30 minutos antes de efectuar el lavado de las células con PBS-BSA 0.1%, se 
añadió el marcador nuclear (Hoetch, 1 μL de una disolución 5 mM) y lisosomal 
(Lysotracker Red, 0.75 μL de una disolución 100 μM). Finalmente, las células se lavaron 
con PBS-BSA al 0.1%, y el cristal fue acoplado a una cámara para microscopía con medio 
nuevo, conteniendo 2 μM de CA-074. Las imágenes fueron capturadas con un 
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microscopio DM IRE2 invertido, excitando con los láseres de argón (OG 496 nm), HeNe 
(Lysotracker Red 594 nm) y diodo azul (Hoetch 405 nm). 
 
Evaluación de la actividad antiinflamatoria en Raw264.7: Se sembraron 50 μL 
de células en placas de 96 pocillos a una concentración de 6000 células/cm2. Después de 
24 horas, se evaluó la combinación de 25 µL de lipopolisacárido (LPS) de E. coli (5 
ng/mL) para inducir la síntesis de citoquinas proinflamatorias, junto con 25 µL de cada 
tratamiento: FLUO libre (0.49 ng/mL), PGA-FLUO (a los mismos equivalentes de FLUO 
libre) y PGA. Todos los tratamientos fueron filtrados antes de añadirlos al pocillo (tamaño 
de poro 0.22 μm). Las células fueron incubadas con muestras o controles durante 72 
horas. Tras ello, las placas de 96 pocillos fueron centrifugadas durante 5 minutos, a 22°C 
y 400 rcf, y 90 μL del sobrenadante fueron recogidos y congelados hasta su uso. Para la 
cuantificación de citoquinas proinflamatorias se utilizó un ensayo LUMINEX® (kit 
Affymetrix m Th1/2/9/9/17/22/Treg 17plex, eBioscience, Spain). Este estudio se analizó 
mediante el equipo LUMINEX 200 (LUMINEX corporation, USA), y los resultados se 
expresaron como porcentaje de inhibición de cada citoquina. 
 
3.4. Ensayos Ex vivo 
3.4.1. Estudios de penetración a través de piel humana mediante celdas de difusión 
de Franz 
Las muestras de piel se obtuvieron de mujeres sanas que se sometieron a cirugía 
plástica (reducciones de pecho) después del consentimiento informado por escrito (piel 
cedida por Hospital La Fe, Valencia, Spain). Inmediatamente después de la escisión, se 
eliminó el tejido graso subcutáneo con un bisturí. La piel se cortó en trozos de 4 cm2, se 
envolvió en papel de aluminio y se almacenó a -20ºC hasta su uso. El estudio de 
penetración a través de la piel humana se desarrolló utilizando las celdas de difusión de 
Franz (Logan Instruments Corp., EE.UU.).  
La piel fue fijada entre el compartimento donador y el receptor, de modo que el 
estrato córneo se colocó hacia arriba. La cámara receptora se llenó con 8 mL de PBS 0.01 
M, pH 7.4 y se mezcló con una barra agitadora magnética, mientras que la temperatura 
se mantuvo a 37ºC. Se colocó la piel entre las celdas y se aplicó en el compartimento 
donador 100 µL del tratamiento de estudio marcado con el fluoróforo correspondiente, a 
una concentración de 10 mg/mL, para poder observar su penetración a través de la piel 
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mediante microscopia confocal. Además, se tomaron alícuotas del compartimento 
receptor  a tiempo 0, 8 y 24 horas (dependiendo del estudio realizado). Los 2 mL de la 
muestra tomada se rellenaron inmediatamente con solución fresca. Después de 8 o 24 
horas de ensayo, las muestras de piel se lavaron dos veces con PBS-BSA 0.1% y se 
mantuvieron en paraformaldehído (PFA) al 4% durante 24 horas a temperatura ambiente. 
A continuación, las muestras se lavaron con un 30% de sacarosa en solución de PBS, y 
se mantuvieron en ella 24 horas a 4ºC. Finalmente, las muestras de piel se lavaron dos 
veces con PBS y se conservaron en una solución de criopreservación (40% PB 0.1 M, 
30% etilenglicol y 30% glicerol) a 4ºC hasta su utilización. A continuación, las muestras 
de piel se incluyeron en el medio de inclusión de temperatura de corte óptima (OCT) y se 
realizaron cortes de 5 µm con el criostato (versión CM1850 UV, Leica, Alemania), para 
analizar las muestras finalmente mediante microscopía confocal. Los núcleos celulares 
fueron marcados con DAPI para diferenciar las distintas capas de la piel. Las imágenes 
se capturaron con un microscopio DM IRE2 invertido equipado con un objetivo de 
inmersión en aceite λ-blue 40x y se manipularon con un sistema TCS SP2, equipado con 
un divisor de haz óptico acústico (AOBS). La excitación se realizó con un láser de argón 
(OG, 496 nm), diodo azul (DAPI, 405 nm) y diodo rojo (Cy5.5 o Dil, 675 nm). Las 
imágenes se procesaron con el software LCS (versión 2.5.1347a, Leica, Alemania). 
También se analizó el tejido control, el cual siguió el mismo tiempo de estudio utilizando 
como tratamiento agua MilliQ para establecer la autofluorescencia. Además, utilizando 
el programa Image J se realizaron medidas de la intensidad de fluorescencia para cada 
fluoróforo (cuantificando 5 veces por muestra), y el resultado se expresó en píxeles frente 
al grosor de la piel (µm). La intensidad del control fue restada en cada caso. 
 
3.4.2. Viabilidad del tejido y evaluación de la actividad antiinflamatoria de los 
conjugados en un modelo de inflamación en piel humana ex vivo 
Las muestras de piel se obtuvieron de mujeres sanas que se sometieron a cirugía 
plástica (reducciones de pecho) después del consentimiento informado por escrito (piel 
cedida por Hospital La Fe, Valencia, Spain). Inmediatamente después de la escisión, se 
eliminó el tejido graso subcutáneo con un bisturí. La piel fue cortada aproximadamente 
en 1 cm2 y se colocó en unas rejillas metálicas situadas en placas de 6 pocillos, de modo 
que el la dermis estaba en contacto con el medio de cultivo DMEM, complementado con 
50 mL de suero fetal bovino, 5.5 mL de penicilina/estreptomicina y 50 µL anfotericina 
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B, quedando la epidermis expuesta al aire. El modelo de piel se incubó a 37ºC y 5% de 
CO2. El modelo inflamatorio fue inducido mediante la adición de una combinación de 2.5 
ng/mL de factor de crecimiento epidérmico (EGF) y 15 µg/mL de LPS de E. coli al medio 
de crecimiento durante 24 horas (ver Capítulo II para más detalles). 
Después de 24 horas en cultivo, se aplicaron los tratamientos.  El control negativo 
y el control no tratado fueron evaluados para asegurar el desarrollo del modelo. 3 µL de 
una solución a 10 mg/mL de los tratamientos bajo estudio fueron aplicados tópicamente 
durante 24, 48 o 72 horas (según experimento). Después de este tiempo, las muestras de 
piel se lavaron dos veces con PBS y se introdujeron en 4 mL de solución de MTT (2 
mg/mL) a 37ºC. Después de 4 horas de incubación, las muestras de piel fueron lavadas 
dos veces con PBS e introducidas en 4 mL de DMSO, para extraer el formazán de la piel. 
Después de 15 horas de extracción, la absorbancia fue leída a 490 nm usando el lector de 
placas Victor2Wallac™. 
Finalmente, para cuantificar los niveles de citoquinas proinflamatorias secretadas 
por la piel, se recogieron los medios de cultivo en condiciones estandarizadas después de 
cada tiempo de tratamiento, y se conservaron a -80ºC hasta su uso. Las concentraciones 
de IL-6 se midieron mediante el ensayo ELISA (Invitrogen, Spain) y se determinaron de 
acuerdo con las soluciones estándar. 
3.5. Ensayos In vivo 
3.5.1. Consideraciones éticas 
Los experimentos con animales se realizaron de acuerdo con las directrices del 
Consejo de la Comunidad Europea (86/609/CCE) y con el Real Decreto español 
1201/2005. Los procedimientos experimentales realizados durante esta Tesis fueron 
aprobados por el comité institucional sobre el cuidado y uso de animales, así como 
realizados por personal acreditado y capacitado. Los ratones utilizados se mantuvieron 
durante todo el proceso en una instalación libre de patógenos específicos (SPF), a una 
temperatura y humedad específica, y bajo un ciclo de luz-oscuridad de 12 horas. Además, 
como alimento se proporcionó pienso estandarizado libre de alfalfa y agua ad-libitum. 
Durante los estudios, se evaluó el aspecto y comportamiento general, la conducta de 




3.5.2. Establecimiento de un modelo murino de psoriasis mediante la aplicación de 
la imiquimod en forma de crema 
Ratones machos BALB/c (BALB/cOlaHsd) de 6 semanas de edad fueron 
utilizados para todos los procedimientos experimentales. Un día antes de la primera 
aplicación de imiquimod (IMQ) en forma de crema, se afeitó aproximadamente 2x3 cm 
de la parte posterior de los ratones. Los síntomas similares a los de la psoriasis fueron 
inducidos por la aplicación diaria durante 7 días consecutivos de 62.5 mg de crema de 
IMQ disponible comercialmente (5%) (Imunocare; Industrial Farmacéutica Cantabria, 
S.A., Spain) tanto en la espalda como en la oreja derecha, lo que se traduce en una dosis 
diaria de 3.125 mg del compuesto activo. Después de los 7 días de aplicación, la 
progresión de la enfermedad se estudió durante 10 días más, para evaluar los días 
adecuados para añadir los tratamientos posteriores asegurando el mantenimiento de la 
enfermedad. Después de este periodo, los animales fueron sacrificados utilizando una 
atmósfera de CO2 y los órganos de interés fueron aislados y evaluados. 
3.5.3. Evaluación de la actividad antipsoriática de los conjugados poliméricos 
Mediante estudios previos se establecieron 7 días de aplicación de la crema de 
IMQ y 5 días de tratamiento con los polímeros sintetizados. Por lo tanto, siete días 
después de la inducción de la enfermedad, los ratones fueron divididos en grupos 
representativos. Se utilizaron ratones sanos y sin tratar como control negativo y positivo, 
respectivamente. Se realizaron estudios previos para optimizar la concentración óptima 
equivalente de FLUO, seleccionando 0.15% equivalentes de FLUO para realizar el 
experimento con todos los tratamientos. Los conjugados se disolvieron en nuestro nuevo 
vehículo de ácido hialurónico entrecruzado con PGA (HA-CP) al 1% (ver Capítulo III 
para más detalles), y en una crema base (Cold cream®, Farmacia BOIX, Spain). La FLUO 
libre se disolvió con 0.5 mL de Hydrolite® (Guinama S.L., Spain) y se incorporó a la 
crema base. El vehículo HA-CP y la crema base se aplicaron también como control, 
siguiendo el mismo procedimiento. Todos los tratamientos fueron inmediatamente 
aplicados tópicamente en la espalda y en la oreja derecha del ratón durante 5 días 
consecutivos desde la última aplicación de la crema de IMQ. La seguridad de los 
tratamientos se evaluó mediante el seguimiento del peso corporal cada dos días desde el 
principio del experimento en comparación con los animales sanos. El grosor epidérmico 
de las orejas fue medido antes de cada tratamiento cada 2 días desde el inicio del 
experimento. Además, durante todo el estudio se utilizó la escala PASI para evaluar 
333 
 
visualmente parámetros presentes en la enfermedad, como eritema, descamación de la 
piel y grosor epidérmico (relacionado con el endurecimiento de la piel). Después de los 5 
días de tratamiento, los ratones fueron sacrificados utilizando una atmósfera de CO2 y se 
extrajeron los órganos principales, la piel, las orejas y la sangre para su análisis posterior. 
El peso del bazo se midió al final del experimento usando para ello una balanza de 
precisión. En estudios posteriores se evaluó el grosor epidérmico de la piel de la espalda 
y de la oreja mediante histología hematoxilina-eosina, así como los niveles de citoquinas 
proinflamatorias relacionadas con la enfermedad (IL-23 y INF-γ) tanto en tejido como en 
suero.  
4. Resultados  
 
4.1. Desarrollo de modelos relevantes para la evaluación de nanomedicinas: modelo 
de inflamación en piel humana ex vivo y un modelo murino de psoriasis (Capítulo 
II). 
La psoriasis es una enfermedad cutánea inflamatoria crónica, autoinmune, 
genéticamente heterogénea y específica de los seres humanos [17]. Durante la última 
década, nuestro conocimiento sobre el desarrollo y la patogénesis de la enfermedad ha 
aumentado, lo que ha promovido al desarrollo de modelos ex vivo e in vivo precisos que 
favorezcan la comprensión de los mecanismos genéticos e inmunológicos que 
contribuyen al desarrollo de la enfermedad. Por lo tanto, cualquier modelo desarrollado 
debe reflejar las características críticas de la enfermedad humana y responder de manera 
similar a los tratamientos previamente desarrollados [18]. 
A lo largo del presente trabajo de Tesis, se presenta una caracterización detallada 
de dos modelos ex vivo (piel sana e inflamada) y un modelo in vivo de ratones psoriásicos. 
Estos modelos han sido empleados para evaluar la seguridad de los conjugados 
sintetizados, así como su actividad antiinflamatoria; el modelo inflamatorio ex vivo nos 
ha servido como plataforma para hacer un primer cribado de la actividad antiinflamatoria 
de los conjugados polímero-fármaco, para posteriormente evaluar en el modelo in vivo de 
psoriasis los que ofrezcan un mejor potencial terapéutico. 
 
El modelo ex vivo de inflamación en piel humana desarrolla características 
histológicas similares a la enfermedad humana, como por ejemplo el engrosamiento de la 
capa epidérmica de la piel, manteniendo la estructura y viabilidad de las células de la piel. 
Además, la inducción de la inflamación en la piel ha promovido la liberación de 
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citoquinas proinflamatorias al medio de cultivo, permitiendo la evaluación de la 
capacidad antiinflamatoria de los conjugados. 
 
Por otra parte, el desarrollo de un modelo agudo de psoriasis en ratón ha 
reproducido fielmente las características más descriptivas de la patología humana. 
Nuestras investigaciones han permitido evaluar la progresión y el mantenimiento de la 
enfermedad con el paso del tiempo. Este modelo se caracteriza por presentar 
características intrínsecas de la enfermedad humana tanto en la espalda como en la oreja 
del ratón, como enrojecimiento y descamación de la piel, así como engrosamiento 
epidérmico. Asimismo, hemos identificado características distintivas de este tipo de 
modelo inducido por la aplicación de IMQ en forma de crema, como es el aumento de 
tamaño del bazo [19-21], el cual está íntimamente relacionado con la síntesis de 
citoquinas proinflamatorias, ya que se encuentran elevadas tanto en suero como en tejido. 
 
Por lo tanto, estos modelos presentan características similares a la enfermedad 
humana, ofreciendo una plataforma útil para poder evaluar terapias antiinflamatorias y 
antipsoriáticas. 
 
4.2. Desarrollo de un nuevo material a base de ácido hialurónico (HA) entrecruzado 
con ácido poli-L-glutámico (PGA) el cual potencia la penetración a través de la piel 
en comparación con HA lineal (Capítulo III). Manuscrito en preparación 
Como se ha discutido anteriormente en varios capítulos de este trabajo de Tesis, 
las características físico-químicas tanto de las nanomedicinas así como del vehículo en el 
que se apliquen a nivel tópico van a condicionar la penetración a través de la piel. La 
utilización de vehículos basados principalmente en el ácido hialurónico (HA) [22], ha 
demostrado su idoneidad para aplicaciones dérmicas y cosméticas [16]. 
A lo largo de este capítulo de Tesis, hemos diseñado una nueva plataforma de 
administración tópica, basada en la utilización del HA como base biodegradable para 
nuestro vehículo. Este vehículo llamado ácido hialurónico-poli-L-glutamato (HA-CP) 
está compuesto por el entrecruzamiento de dos polímeros biodegradables, HA y PGA, a 
través de L-lisina.  
Utilizando metodologías bien establecidas, pudimos llevar a cabo la síntesis del 
vehículo HA-CP, el cual fue caracterizado mediante una exhaustiva caracterización 
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físico-química utilizando una batería de técnicas, como RMN y cromatografía de 
exclusión por tamaño (SEC). Los resultados obtenidos mediante RMN revelaron que 
nuestro material entrecruzado presentaba mayor peso molecular y radio hidrodinámico 
que el HA lineal, sugiriendo que la reacción de entrecruzamiento se había desarrollado 
con éxito. Además, mediante los estudios realizados por SEC, cabe destacar que la 
población de aminas libres se ve disminuida con la progresión de la reacción, mientras 
que la viscosidad se ve aumentada, debido a la formación de enlaces tipo amida que 
promueven la reacción de entrecruzamiento del HA-CP. Además, se pudo observar una 
disminución progresiva del pH de la reacción como consecuencia de la liberación de 
protones en cada formación del enlace amida. 
 Además, estudiamos en profundidad las características del biomaterial HA-CP 
como vehículo para aplicaciones tópicas en la piel. Se realizó un estudio de degradación 
por SEC en presencia de la enzima hialuronidasa [23], comparando el biomaterial HA-
CP con HA lineal, demostrando que nuestro nuevo vehículo presentaba una degradación 
mucho más lenta, constante y sostenida a lo largo del tiempo, debido principalmente a las 
diferentes conformaciones estructurales de ambos materiales. Además, estudios de 
penetración a través de la piel revelaron que nuestro biomaterial HA-CP es capaz de 
alcanzar en mayor medida la epidermis que el HA lineal, el cual se encuentra 
principalmente en el estrato córneo, como ya demostraron otros autores [24]. Por último, 
ensayos de hidratación en voluntarios humanos demostraron que a tiempos largos de 
estudio nuestro HA-CP fue capaz de prolongar y mejorar la hidratación de la piel en 
comparación con HA. 
Como hemos podido corroborar en este trabajo, el entrecruzamiento del HA con 
el PGA modifica las características físico-químicas del HA y favorece la penetración del 
biomaterial a través de la piel. Por ello, nuestro último esfuerzo se centró en estudiar la 
capacidad de nuestro vehículo como potenciador de la penetración de diferentes 
transportadores, como micelas polipeptídicas. Para la síntesis de estas micelas, se 
sintetizaron diferentes copolímeros utilizando polietilenglicol (PEG) como parte 
hidrofílica y como parte hidrofóbica se utilizó poli-fenilalanina (PPhe) y poli-bencil-L-
glutamato (PBG) con diferentes grado de polimerización (10, 20, 40). La caracterización 
físico-química de estas micelas reveló que las que poseían mayor grado de polimerización 
(40) precipitaban en solución, probablemente debido a un desequilibrio de la relación 
hidrofílica y lipofílica, por lo que fueron descartadas del estudio. Los copolímeros PEG-
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PBG mostraron unos valores de concentración micelar crítica más altos que los derivados 
de PEG-PPhe, indicando que los copolímeros de PEG-PPhe tienen un comportamiento 
más compacto en solución acuosa. Además, estos resultados fueron corroborados 
mediante cromatografía por exclusión de tamaño en medio orgánico (GPC), en los cuales 
los copolímeros basados en PPhe presentaron un fuerte comportamiento de agregación en 
comparación con PBG. Por último, las 4 micelas presentaron un tamaño entre 12 y 30 
nm, lo cual coindice con las imágenes de microscopio electrónico de transmisión (TEM). 
 Así pues, estudiamos la penetración de las micelas marcadas con el fluoróforo Dil 
embebidas en el vehículo HA-CP a través de piel humana. Este estudio nos permitió 
demostrar la capacidad de nuestro vehículo para mejorar la penetración de las micelas a 
través de la piel, y por tanto, resaltar su utilización como vehículo para posibles 
aplicaciones tópicas de nanomedicinas. 
4.3. Diseño racional de conjugados basados en poliglutamatos, incorporando un 
corticosteroide para el tratamiento de la psoriasis (Capítulo IV, manuscrito en 
revisión (Journal of Controlled Release)). 
 
A lo largo de este capítulo de Tesis, hemos diseñado un nuevo conjugado 
polímero-fármaco incorporando el corticosteroide acetónido de fluocinolona (FLUO). El 
objetivo de esta conjugación es mejorar la penetración del fármaco a través de la piel y 
que su liberación se lleve a cabo de manera controlada y sostenida en la epidermis.  
Para desarrollar este conjugado, se ha empleado una química optimizada, dotando 
al conjugado de un enlace sensible al pH (éster) para obtener una liberación controlada 
del fármaco. El conjugado PGA-FLUO presentaba un tamaño hidrodinámico constante 
con valores alrededor de 100 nm en todos los medios acuosos evaluados mediante 
dispersión dinámica de luz (DLS). Además, descubrimos que el conjugado era capaz de 
autoensamblarse en nanoestructuras mayores debido al balance hidrofílico-hidrofóbico, 
presentando una morfología esférica mediante TEM. Adicionalmente, se comprobó que 
el pH de la solución acuosa utilizada (pH 7.4 o 5.5) induce un cambio significativo en la 
cinética de liberación del fármaco y su estructura secundaria, influyendo por tanto en la 
disposición interna del fármaco en el esqueleto polipeptídico, tal y como pudimos 
observar tras los análisis llevados a cabo por cromatografía líquida de alta eficacia 
(HPLC) y dicroísmo circular (CD). La distinta estructura secundaria del conjugado parece 
modificar accesibilidad al fármaco, por lo que se ve favorecida su liberación a pH 7.4, del 
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mismo modo que se favorece el acceso de la enzima proteolítica catepsina B. Además, la 
liberación del fármaco una vez el conjugado se aplica en el vehículo HA-CP es más 
sostenida y constante en el tiempo, característica clave a la hora de controlar la actividad 
biológica en la epidermis. 
 La evaluación biológica del conjugado PGA-FLUO in vitro en líneas celulares de 
la piel demostró su internalización en los queratinocitos y colocalización en los lisosomas. 
Además, se comprobó la capacidad antiinflamatoria del conjugado en macrófagos 
estimulados con LPS, ya que el conjugado presentaba una mayor disminución de los 
niveles de citoquinas proinflamatorias en comparación con el fármaco libre. Estudios de 
penetración a través de la piel nos permitieron demostrar la presencia del conjugado en la 
epidermis, aumentando su cantidad si el conjugado se aplicaba con el vehículo HA-CP. 
Además, en dos modelos ex vivo de inflamación (definidos en el Capítulo II), se 
demostró nuevamente la mejoría de la capacidad antiinflamatoria del conjugado 
comparado con el fármaco libre, mediante la disminución de la liberación de IL-6. Por 
último, debemos destacar que la presencia del vehículo HA-CP en la aplicación del 
conjugado resultó en una mayor disminución de los niveles de IL-6. 
 Finalmente, el conjugado fue validado in vivo en un modelo murino de psoriasis 
(definido en el Capítulo II). En este modelo, se comparó la actividad del fármaco libre 
frente al conjugado, ambos aplicados en crema. Los resultados demostraron una mayor 
capacidad antipsoriática del conjugado, reduciendo parámetros significativos de la 
enfermedad como el engrosamiento epidérmico, el tamaño del bazo (un ~60% de 
reducción de peso del bazo con respecto al control positivo) y los niveles de citoquinas 
proinflamatorias características de la enfermedad (INF-γ y IL-23) en suero y tejido. Es de 
destacar que el grupo tratado con el conjugado aplicado en el vehículo HA-CP demostró 
una mayor capacidad de reducción de todos los parámetros estudiados en comparación 
con el conjugado aplicado en crema, alcanzando niveles similares a los controles sanos. 
Mediante este estudio se demostró nuevamente una mejora de la actividad del 
conjugado frente al fármaco libre. Además, la administración del conjugado en nuestro 
vehículo HA-CP presentó en todos los casos un mayor efecto terapéutico, probándose la 
importancia de la correcta administración de los conjugados a nivel tópico mediante la 
elección de vehículos que promuevan su penetración a través de la piel. 
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4.4. Diseño racional de conjugados basados en poliglutamatos, incorporando un 
ácido graso omega 3 para mejorar la cicatrización de heridas y disminuir el daño 
producido por isquemia/reperfusión (I/R) en el corazón (Capítulo IV). Manuscrito en 
preparación 
Tras la mejora terapéutica obtenida mediante la conjugación de fármacos al PGA 
para aplicaciones tópicas, durante este capítulo de Tesis se desarrolló una nueva familia 
de conjugados poliméricos con una estructura similar, incorporando distintas cargas de 
un ácido graso omega 3, llamado ácido docosahexaenoico (DHA), el cual ha demostrado 
eficacia terapéutica para en la cicatrización de heridas [25-27]. Para este trabajo, 
utilizamos DHA con dos cadenas poliinsaturadas, al que llamamos diDHA, para 
favorecer la conjugación al PGA. La conjugación se efectuó mediante un enlace tipo éster 
sensible al pH, con el objetivo de mejorar la estabilidad y actividad del diDHA. 
La síntesis de los conjugados fue previamente optimizada facilitando la 
conjugación de distintas cargas de diDHA al polímero (2.2, 6.4 y 9.1 mol%). Hemos 
demostrado que la conjugación al PGA mejoró la solubilidad del diDHA en medios 
acuosos, así como su estabilidad y protección durante el tiempo, independientemente de 
la carga de diDHA en los conjugados. Mediante estudios de RMN pudimos evidenciar 
que después de 28 días de estudio, el diDHA sufrió una degradación de un 50%, mientras 
que los conjugados PGA-diDHA sólo mostraron un 10% de degradación, y además, estos 
estudios fueron corroborados mediante ensayos de peroxidación de lípidos. 
Adicionalmente, hemos demostrado que la carga de diDHA en los conjugados condiciona 
las propiedades físico-químicas del mismo, ya que a mayor carga de diDHA el conjugado 
presenta tamaños más pequeños y valores de concentración de agregación crítica 
menores, tras los análisis llevados a cabo mediante DLS y fluorímetro.  
 
La familia de conjugados obtenida fue evaluada in vitro, en dos líneas celulares 
de la piel, demostrando una citotoxicidad del 100% el fármaco libre a las mayores 
concentraciones testadas, en comparación con los conjugados que mantuvieron el 100% 
de viabilidad celular a todas las concentraciones testadas. Además, en un estudio de cierre 
de herida en fibroblastos, el conjugado con carga intermedia de diDHA (PGA-diDHA6.4) 
favoreció el cierre de heridas respecto al diDHA libre. Por último, estudiamos la 
capacidad de penetración de los conjugados con mayor y menor carga de diDHA 
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marcados con OG (PGA-diDHA2.2-OG y PGA-diDHA9.1-OG) a través de la piel, 
demostrando que menores cargas de diDHA favorecen su penetración.  
Basándonos en estos resultados, realizamos el estudio de liberación de fármaco 
con los conjugados con menor carga de diDHA, en el que comprobamos que la liberación 
de diDHA en el conjugado con carga intermedia (PGA-diDHA6.4) era casi el doble en 
comparación con el conjugado con carga baja (PGA-diDHA2.2) (5% y 3% de diDHA 
liberado, respectivamente). Mediante estos estudios también comprobamos que a pH 7.4 
la liberación era mayor que a pH 5.5, y al igual que ocurría con otros conjugados 
desarrollados durante esta Tesis (Capítulo IV), observando cambios conformacionales a 
cada pH mediante CD. 
Tanto los resultados experimentales en el modelo de cierre de herida como el 
estudio de la penetración a través de la piel, indicaron que los dos conjugados más 
efectivos eran los que presentaban una menor carga de diDHA (PGA-diDHA2.2 y PGA-
DHA6.4) debido a sus características físico-químicas. Estos resultados sientan las bases 
para realizar estudios posteriores in vivo de rata diabética, en el cual se validarán estos 
dos conjugados y se evaluará su capacidad para favorecer la proliferación celular y 
disminuir la inflamación en la zona de la herida. 
Finalmente, también demostramos la capacidad de los conjugados PGA-diDHA 
para mejorar el proceso de curación tras el daño al corazón producido por I/R asociado a 
infarto agudo de miocardio (IAM). La evaluación in vitro utilizando un ensayo de lactato 
deshidrogenasa reveló que el conjugado PGA-diDHA6.4 redujo el daño a las células 
cardíacas en comparación con el diDHA libre. Además, la infusión de los conjugados y 
diDHA libre en un modelo in vivo de I/R en ratas mostró que el tamaño del infarto se 
redujo significativamente cuando se administró PGA-diDHA6.4 antes de la reperfusión, 
en comparación con el diDHA libre en la misma dosis (12 % vs 28% de área infartada 
con o sin tratamiento, respectivamente). En conclusión, nuestros datos mostraron que la 
conjugación del diDHA podría ser un tratamiento efectivo para mitigar la lesión inducida 
por I/R. 
5. Conclusiones  
Durante el desarrollo de esta Tesis hemos demostrado la aplicabilidad de los 
polímeros terapéuticos como una nueva plataforma de administración tópica de diferentes 
agentes bioactivos o fármacos para el tratamiento, entre otras, de enfermedades de la piel, 
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como la psoriasis o la cicatrización de heridas. A continuación, destacamos las principales 
conclusiones de este trabajo: 
1. Se han desarrollado modelos ex vivo de piel humana utilizando explantes de piel 
a partir de donantes, como una herramienta útil para validar los tratamientos 
basados en polímeros. Hemos establecido un modelo de piel sana así como un 
modelo inflamatorio tratando los explantes con una combinación de LPS y EGF. 
Los modelos ex vivo establecidos han sido validados como modelos preclínicos 
de enfermedad relevantes para los trastornos de la piel. La viabilidad de la piel fue 
evaluada en ambos modelos mediante ensayo MTT e inmunohistoquímica, y 
varios marcadores inflamatorios también se utilizaron para analizar el proceso 
inflamatorio. Finalmente, se detectó la modulación de la liberación de citoquinas 
proinflamatorias en el medio de cultivo, demostrando el efecto inflamatorio 
producido por la acción combinada de LPS y EGF. 
2. Se ha caracterizado un modelo agudo de ratón psoriásico preclínicamente 
relevante, en el cual poder testar y validar las terapias basadas en polipéptidos que 
han sido desarrolladas. Mediante la aplicación tópica de una crema compuesta por 
imiquimod (IMQ), desarrollamos las características intrínsecas de la enfermedad 
de la psoriasis. Se evaluó durante 10 días la progresión y el mantenimiento de la 
enfermedad, mediante la valoración de la morfología de la piel utilizando la 
puntuación PASI y también la tinción H&E, centrándonos en parámetros 
específicos de la enfermedad, como el engrosamiento epidérmico. También se 
estudió el aumento del peso del bazo tras la aplicación de IMQ, el cual está 
relacionado con la síntesis de citoquinas. Finalmente, identificamos varias 
citoquinas proinflamatorias específicas relacionadas con la enfermedad humana, 
tanto en tejido como en suero. 
3. Para mejorar y optimizar la penetración de los nanoportadores a través de la piel, 
hemos desarrollado y caracterizado completamente un nuevo vehículo basado en  
un polímero entrecruzado de ácido hialurónico-poli-L-glutamato (HA-CP) 
(compuesto por ácido hialurónico (HA) y ácido poli-L-glutámico (PGA) 
entrecruzados a través de fragmentos de lisina). Además, validamos y 
demostramos sus propiedades como potenciador de la penetración mediante su 
uso con una familia de copolímeros en bloque anfifílicos de diferente naturaleza 
341 
 
y consecuentemente presentando una conformación en solución diferente, 
modulando así la mejora de la permeación cutánea. Los cambios en la 
conformación de los portadores fueron impulsados por la presencia de Phe como 
aminoácido en la cadena de polímeros, así como por el tamaño del polímero, entre 
otras características.  
4. Se ha desarrollado una nueva familia de conjugados polímero-fármaco, basados 
en el ácido poli-L-glutámico (PGA) como portador biodegradable, el cual 
incorpora un corticosteroide (acetónido de fluocinolona) mediante una unión tipo 
éster para el tratamiento tópico de la psoriasis. Se empleó una exhaustiva 
caracterización utilizando varias técnicas para caracterizar plenamente nuestros 
conjugados poliméricos en soluciones relevantes, estableciendo una relación entre 
la estructura y la actividad biológica. 
5. La evaluación in vitro de los conjugados desarrollados en líneas celulares 
relevantes de la piel reveló la ausencia de toxicidad hasta las concentraciones 
probadas. Los estudios de internalización celular y actividad antiinflamatoria 
demostraron la capacidad de los conjugados para penetrar en las células de la piel 
y mantener la actividad antiinflamatoria del fármaco una vez se encuentra 
conjugado al PGA. 
6. La evaluación ex vivo de los conjugados solos o aplicados en el vehículo HA-CP 
(como potenciador de la penetración) demostró su presencia en la epidermis 
viable. Además, utilizando dos modelos ex vivo, nuestro modelo de inflamatorio 
ex vivo de piel humana y un modelo reconstituido de inflamación a partir 
equivalentes cutáneos (en colaboración con la Freie Universität Berlin, Prof. S. 
Hedtrich), demostramos que el conjugado presentaba mayor capacidad para 
reducir la liberación de IL-6 en el medio de cultivo, en comparación con el 
fármaco libre. 
7. La evaluación in vivo en nuestro modelo de ratón psoriásico demostró la eficacia 
antiinflamatoria/antipsoriásica y la seguridad de nuestro conjugado en 
comparación con el fármaco libre, verificando la importancia del uso de una 
química de enlace adecuada para controlar la cinética de liberación de los 
fármacos en las capas cutáneas adecuadas. Cabe destacar que el conjugado 
aplicado en nuestro novedoso vehículo HA-CP reveló una mayor actividad y 
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eficacia, demostrando la importancia de un vehículo adecuado para mejorar la 
penetración a través de la piel. HA-CP mostró altas propiedades de hidratación 
que se sinergizan con los efectos antiinflamatorios del conjugado, resultando en 
un enfoque terapéutico significativamente mejorado para la psoriasis. 
8. Finalmente, se ha desarrollado una nueva familia de conjugados poliméricos, 
utilizando PGA como portador, incorporando diferentes cargas de un ácido graso 
omega 3 (diDHA) por medio de un enlace éster para el tratamiento tópico de la 
cicatrización de heridas. Las características físico-químicas del conjugado fueron 
estudiadas a fondo, y la evaluación biológica in vitro reveló su idoneidad para 
aplicaciones de cicatrización de heridas, mejorando el cierre de la herida.  
 
9. La familia de conjugados PGA-diDHA fue validada en un escenario de curación 
de heridas in vivo utilizando un modelo de isquemia-reperfusión (I/R) en 
colaboración con el Hospital La Fe (Dr. P. Sepúlveda) mostrando claramente las 
ventajas de la conjugación a polímeros. La infusión de los conjugados y el diDHA 
libre en un modelo in vivo de I/R en rata mostró que el tamaño del infarto se redujo 
significativamente cuando se administró el conjugado PGA-diDHA6.4 antes de la 
reperfusión en comparación con el diDHA libre a la misma dosis. En conclusión, 
nuestros datos demostraron que el conjugado PGA-diDHA6.4 podría ser efectivo 
para mitigar la lesión inducida por I/R, proporcionando así un nuevo agente 
terapéutico para futuros estudios clínicos. 
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